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Foreword
This volume comes at an especially important time. PCP continues
to be a significant problem in the U.S. with reports of epidemic
levels of use in certain localities. Since 1978, NIDA has sup-
ported a substantial research program on this drug. The results
of these studies demonstrated the biological and behavioral tox-
icity of PCP. Furthermore, PCP abuse presents a considerable haz-
ard not only to the abuser, but to those in social contact with
him/her. Particularly disconcerting were reports concerning the
widespread occurrence of PCP-induced psychoses and neurological
deficits and the number of PCP-abusing pregnant women.
In view of this, NIDA felt that it was important to convene a con-
ference and prepare a monograph on a wide variety of issues relat-
ing to PCP. The present volume represents input from the preclin-
ical, clinical, and epidemiological programs of the Institute. It
is hoped that this state-of-the-science report on the basic bio-
logical mechanisms underlying PCP's action and current, as well as
potential, treatment approaches to PCP abuse will prove useful to
both researchers and health care personnel. This monograph also
serves to document, once again, the harmful effects of PCP and
should be useful in the development of specific prevention pro-
grams.
I would like to express my appreciation to Dr. Doris Clouet who
undertook to organize the conference and edit the monograph while
a Visiting Scientist at NIDA.
Marvin Snyder, Ph.D.




Since the last Technical Review on phencyclidine (PCP) held by the
National Institute on Drug Abuse was published in the NIDA
Research Monograph series in 1978, there has been an explosion of
new knowledge about drug actions in brain, including those of
phencyclidine and related compounds, and during the same period, a
new epidemic of PCP abuse has arisen in a few population centers
in the country, resulting in greater clinical expertise in treat-
ing PCP abuse and PCP psychoses. In reports published in this
Monograph, based on a Technical Review that was held May 7-9,
1985, at NIDA, both basic and clinical aspects of PCP abuse are
discussed in detail by leading experts in each area.
In the first section of the Review, the basic neurobiology of PCP
was emphasized. Studies on the binding of PCP to specific recep-
tor molecules in brain have been confounded by the presence of two
types of PCP-binding molecules. GUNDLACH reported that he was
able to distinguish a PCP-binding site from an opiate-binding site
that also binds PCP. The two sites had different localizations in
brain and produced different behaviors. ZUKIN also separated the
two receptors and reported on the early development of the PCP
receptor in brain. He described the isolation from brain of a
substance that reacts specifically with the PCP receptor.
O'DONAHUE has isolated a naturally occurring peptide from brain
that can produce responses similar to PCP when administered to
animals. The results are reminiscent of the early studies of the
opiopeptides that interact with opiate receptors and produce
effects like narcotic drugs when administered to animals.
The binding of PCP to its receptor initiates a series of coupled
neurochemical events eventually leading to the expression of be-
havior. One such coupling reaction was described by BLAUSTEIN as
a blockade of transmembrane channels that transport K+ into the
neuronal cells. Since K+ movements are part of the process of
neurotransmission between neurons, this effect of PCP may explain
the results of studies by MARWAH and by JOHNSON, in which several
neurotransmitter systems were shown to be involved in the actions
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of PCP. BUTERBAUGH also involved the K+ channel in the dose-
dependent convulsant and anticonvulsant actions of PCP. MORETON
elaborated on the specific electrophysiological responses to PCP
administration. JACOBSON has synthesized many components related
to PCP, one of which, metaphit, was able to bind at the PCP recep-
tor and display responses similar to PCP itself. CONTRERAS showed
that metaphit had a dose-dependent effect on ataxia in rats acting
like both agonist and antagonist.
OWENS has prepared antibodies to PCP in goats. When administered
to mice the PCP levels in blood rose tenfold as an antibody-bound
form that was readily excreted in urine. BROWNE tested the self-
administration by rats of 1,000 compounds related (and not relat-
ed) to PCP, some of which produced PCP-like effects. One compound
that was self-administered prevented the entrance of PCP into
brain. BALSTER gave a general review of the effects produced by
PCP in laboratory animals and showed that some effects were simi-
lar to those produced by amphetamine , some to barbiturates, and
some to antipsychotics. This response profile makes PCP a unique
drug that stands alone in its complex effects and toxicity.
An epidemiological report by CRIDER showed high PCP abuse in Los
Angeles, the Baltimore-Washington area and New York City, with
part of the increase due to higher use by inner-city black males.
WISH reported that urine tests on prison admissions show a high
use of PCP, alone or in combination with alcohol and cocaine, in
the New York City prison population. Signs of brain damage and
motor impairment were found by LEWIS in PCP users subjected to a
battery of psychological and motor tests. These subjects did not,
in general, have toxic responses to PCP, raising the question of
whether the symptoms preceded drug use. Many legal questions
arise from incidents occurring while the PCP user is under the
drug's influence or during psychotic episodes, including acts
committed by police or others trying to restrain the psychotic
individual. LERNER described three such cases that went to trial.
In the last section, clinicians discussed the treatment strategies
for PCP abusers. MCCARRON described the presenting symptoms in
prison admissions or emergency room admissions of over 1,000 PCP
abusers with PCP toxicity. She divided responses in adults into
four major patterns and suggested treatment for each group of
symptoms. GORELICK explored the reasons for choosing PCP for use
in a population entering a V.A. Hospital. The feelings of power,
invulnerability, and great strength, followed by dysphoria, were
the principal reasons. HOWARD showed the unfortunate condition of
babies born to mothers using PCP. The babies at birth were
smaller than usual, shaking and unconsolable. Some motor and
mental deficits were seen in some of these babies after 6 months
and 5 years. FRAM stated that the most successful treatment of
middle-class adolescent PCP abusers was in a peer-group meeting
attended daily. PAUL LUISADA of the Northern Virginia Institute
of Psychiatry summed up the Technical Review meeting in a masterly
fashion, blending basic and clinical reports into a coherent
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whole. Unfortunately, this off-the-cuff summary was not recorded
for publication.
Selecting from these presentations those that will prove most
useful in the future, either clinically or mechanistically, is not
easy. However, the potential value of some studies may be men-
tioned: (1) the separation and characterization of two PCP recep-
tors; (2) the discovery of a naturally occurring brain substance
with which PCP competes; (3) the synthesis of a long-lasting PCP
analog; and (4) the successful preparation of antibodies to PCP.
Clinically, we may mention: (1) the discovery that motor and psy-
chological deficits are found in PCP abusers; (2) the categoriza-
tion of responses in man to psychosis-producing doses of PCP,
which has led to different treatment regimes depending on the
group of presenting symptoms; and (3) the relative success of
peer-group therapy programs in treating adolescent and young adult
PCP abusers.
The editor would like to thank the participants, all of whom
provided timely and complete reports in their areas of expertise,
and Dr. J. Michael Walsh (Division of Clinical Research) and
Nicholas J. Kozel (Division of Epidemiology and Statistical.
Analysis) who cochaired the Technical Review. Special thanks
go to Dr. R. Stanley Burns, who made a major contribution by
suggesting suitable clinical investigators.
Doris H. Clouet, Ph.D.
Neuroscience Research Branch
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Characterization of Phencyclidine
and Sigma Receptor-Binding Sites
in Brain
Andrew L. Gundlach, Brian L. Largent, and Solomon H. Snyder
INTRODUCTION
Introduced in the late 1950s as a dissociative anesthetic, phen-
cyclidine (PCP) has since become a major drug of abuse. PCP has
strong, centrally mediated behavioral effects in animals and man
and influences many different neuronal systems. PCP inhibits the
uptake and increases the release of monoamines in brain (Smith et
al. 1977; Doherty et al. 1980; Vickroy and Johnson 1983; Marwaha
1982; Johnson and Snell, this volume), interacts with cholinergic
(Aronstam et al. 1980; Maayani et al. 1974) and serotonergic
(Nabeshima et al. 1984) systems and antagonizes the neuronal stim-
ulation caused by the excitatory amino acid, N-methyl aspartate
(Anis et al. 1983). PCP may produce a general enhancement of neu-
rotransmitter release by blocking voltage-sensitive potassium
channels (Blaustein and Ickowicz 1983; Blaustein et al., this
volume) and thus might act at several different loci.
Several groups have described specific receptor binding sites for
PCP in brain, with a pharmacological selectivity consistent with
effects of PCP and PCP analogues in animal behavioral tests
(Vincent et al. 1979; Zukin and Zukin 1979). Classical neuro-
transmitters and neuropeptides fail to interact with 3H-PCP bind-
ing sites. However, recently, a putative endogenous ligand for
PCP receptor sites has been described (Quirion et al. 1984;
DiMaggio et al., this volume; Sircar and Zukin, this volume).
Psychotomimetic effects of certain opioids in man (Keats and
Telford 1964; Haertzen 1970) and unique behavioral effects of
these drugs in animals have suggested the existence of specific
receptor sites, designated sigma receptors (Martin et al. 1976).
Many pharmacological and behavioral effects of the "sigma benzo-
morphans," such as N-allylnormetazocine (SKF-10,047) and cyclazo-
tine, are not blocked by opioid antagonists, such as naloxone or
naltrexone (Iwamoto 1981; Cowan 1981; Vaupel 1983; Young and
Khazan 1984), suggesting that these drugs interact at sites very
different from more classical opiate receptors. Furthermore,
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other studies have suggested that the ability to produce "sigma"
or psychotomimetic-like behavioral effects resides more in the (+)
isomer of drugs such as SKF-10,047, with the (-) isomer being much
weaker or inactive (Brady et al. 1982; Slifer and Balster 1983;
Katz et al. 1985). This stereoselectivity is opposite to that at
opiate receptors.
Assays of tritium-labeled (+) and (-) SKF-10,047 binding to brain
membranes have suggested that the two isomers bind to distinct
sites with different pharmacological profiles and regional distri-
butions (Martin et al. 1984). Other behavioral and biochemical
studies have suggested a commonality of effects of the sigma opi-
oids and PCP and have suggested that these common actions are
mediated through a common receptor binding site (Zukin and Zukin
1981; Shannon 1983). However, the regional distribution and phar-
macology of (+)3H-SKF-10,047
sites labeled with 3
labeled sites appears to differ from
H-PCP (Tam 1983; Tam 1985; Martin et al.
1984).
3-(3-Hydroxyphenyl)-N-(1-propyl)piperidine (3-PPP) produces behav-
ioral and biochemical effects in animals that are consistent with
its having agonist actions at dopamine autoreceptors (Hjorth et
al. 1981; Hjorth, et al. 1983; Arnt et al. 1983). However, in
vitro assays reveal 3-PPP as a weak inhibitor of dopamine release
and tyrosine hydroxylase activity, mechanisms thought to be under
dopamine autoreceptor control (Sminia and Mulder 1983; Markstein
and Lahaye 1983; Haubrich and Pflueger 1981; Mulder et al. 1985).
Recently, specific binding sites in brain for (+) 3H-3-PPP have
been described (Largent et al. 1984). These apparently nondopami-
nergic binding sites have a distinctive pharmacological profile
and regional distribution
tor sites labeled with (+)3H-SKF-10,047
similar to that of putative sigma recep-
(Tam 1983; Tam 1985;
Martin et al. 1984).
This study compares the pharmacological specificity and autoradio-
graphic lotcalization of binding sites in brain for (+)3H-SKF-
10,047, (+) 3H-3-PPP and 3H-TCP (1-[l-(2-thienyl) cyclohexyl]
piperidine), a PCP analogue that labels PCP receptor sites with
high affinity (Vignon et al. 1983). Equilibrium-saturation and
drug-inhibition binding studies using rat brain homogenates reveal
that (+)3H-SKF-10,047 binds to two sites on brain membranes and
that (+)3H-3-PPP and 3H-TCP are selective radioligands for the
high and low affinity (+)3H-SKF-10,047 labeled sites respectively.
Autoradiographic studies reveal a similar distribution of (+)3H-3-
PPP and high affinity (+)3H-SKF-10,047 binding sites and the dif-
ferential localization of these and 3H-TCP (PCP-receptor) sites.
CHARACTERISTICS OF (+)3H-3-PPP, (+)3H-SKF-10,047 AND 3H-TCP
BINDING
Binding studies were carried out as previously described (Largent
et al. 1984), except that in experiments utilizing (+) 3H-SKF-
10,047 or 3H-TCP the incubation buffer was Tris pH 8.0 at a
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concentration of 5 mM rather than 50 mM, as used in (+)3H-3-PPP
studies. All three ligands bind saturably and with high affinity
to rat brain membranes. (+)3H-3-PPP binds with an apparent disso-
ciation constant (KD) of 30 nM to a maximal number of binding
3H-TCP
sites (Bmax) equal to 30 pmol/g wet wt (Largent et al. 1984).
(0.5 - 50 nM) binds to a single population of sites with a
KD of 8 ± 1 nM and a Bmax of 44 ± 4 pmol/g wet wt (n = 4). Compu-
ter-assisted analysis of saturation data suggests that (+)3H-SKF-
10,047 labels two sites in brain membranes with KD values of 42 ±
12 and 615 ± 430 nM and Bmax values of 18 ± 7 and 80 ± 25 pmol/g
wet wt (n = 5) (see figure 1). In the presence of haloperidol (5
µM), a potent inhibitor of high affinity (+)3H-SKF-10,047 binding
(see figure 2), (+)3H-SKF-10,047 labels a single low affinity site
(KD, 300 ± 24 nM) with a Bmax of 74 ± 18 pmol/g wet wt (n = 3).
PHARMACOLOGY OF (+)3H-3-PPP, (+)3H-SKF-10,047 and (+)3H-TCP
BINDING
The drug specificity of sites labeled by (+)3H-3-PPP has been ex-
tensively described previously (Largent et al. 1984) with binding
being potently inhibited by haloperidol, phenothiazines such as
perphenazine and psychotomimetic opioids such as pentazocine, SKF-
10,047, and cyclazocine (see table 1). Stereoselectivity for dif-
ferent isomers of drugs at the binding site is seen for 3-PPP and
many opioid derivatives, with the (+) isomer being a more potent
inhibitor than its corresponding (-) isomer. However, little
stereoselectivity occurs for isomers of PCP-like drugs, with dex-
oxadrol and levoxadrol having similar potency (see table 1).
Furthermore, other potent PCP analogues have very low affinity for
(+) 3H-3-PPP labeled sites (data not shown).
3H-TCP binding is inhibited potently by PCP and is stereoselec-
tive, with the potency of dexoxadrol exceeding that of levoxadrol
by a factor of 400, in contrast to that seen at (+)3H-3-PPP
labeled Sites. Benzomorphans differ widely in their potency
against 3H-TCP binding with (+)SKF-10,047 being eight-fold more
potent than pentazocine, a reversal of their relative potencies at
(+)3H-3-PPP labeled sites. Haloperidol and (+)3-PPP are very weak
inhibitors of 3H-TCP binding (see table 1).
The drug inhibition profile of (+)3H-SKF-10,047 binding is similar
in many ways to that of (+)3H-3-PPP binding, but has some impor-
tant differences. While pentazocine and SKF-10,047 are both
potent inhibitors of (+)3H-SKF-10,047 binding, haloperidol and
(+)3H-3-PPP inhibit only a portion of total specific (+)3H-SKF-
10,047 binding with high potency (see figure 2 and table 1). If
(+)3H-SKF-10,047 binding is measured in the presence of 5µM
haloperidol to block binding to the haloperidol/(+)3-PPP-sensitive
sites, the drug specificity of the remaining specific binding is
similar to that for 3H-TCP binding (see table 1). The decreased
potency of pentazocine and the higher potencies of phencyclidine
and dexoxadrol against (+)3H-SKF-10,047 binding, relative to
their potencies at (+)3H-3-PPP sites, merely reflects the
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contribution of the low-affinity PCP-like sites to the total spe-
cific (+)3H-SKF-10,047 binding (see table 1). Although overall
IC50 values are given in table 1, inhibition of (+)
3H-SKF-10,047
binding by drugs such as phencyclidine and pentazocine is consist-
ent with displacement of binding from two sites (see figure 2).
FIGURE 1. Scatchard plot of equilibrium-saturation binding of
(+)SKF-10,047 to rat brain membranes. Membranes were
incubated with 8 nM (+)3H-SKF-10,047 and various con-
centrations (1 - 64,000 nM) of (+)SKF-10,047 for 45
min at room temperature. Results  are  from a  s ingle
exper iment  and values  are  the  average  o f  dupl icate
determinat ions . Lines indicate the high (K D  45 nM;
Bm a x  22 pmol/g) and low (K D  110 nM; Bm a x  86 pmol/g)
affinity components of total specific b i n d i n g .  A l s o
shown is  the  computer-generated  curve  o f  best  f i t  for
t h e  d a t a  p o i n t s .
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FIGURE 2. Drug inhibition of (+)3H-SKF-10,047 binding to rat
brain membranes. The data shown are from a typical
experiment and represent the mean of duplicate de-
terminations, replicated twice. Lines represent
computer generated curves of best fit for drug dis-
placement from one site (haloperidol ,  Ki 4 nM) or
two sites (pentazocine , Ki values 13 and 1550 nM;
phencyczidine , Ki values 31 and 457 nM).
AUTORADIOGRAPHIC LOCALIZATION OF (+)3H-3-PPP, (+)3H-SKF-10,047 AND
3H-TCP BINDING SITES
Studies of the regional distribution of (+)3H-3-PPP binding sites
in brain homogenates reveals highest levels in the hindbrain, mid-
brain, cerebellum, and hypothalamus, with lower levels in cerebral
cortex, corpus striatum, and olfactory tubercle. Similar studies
reveal high levels of (+)3H-SKF-10,047 binding site in hypothal-
amus, midbrain, pons, and medulla (Tam 1985), while 3H-PCP binding
is highest in hippocampus and cerebral cortex (Zukin and Zukin
1979). Autoradiographic studies provide details of these binding
site localizations and alloy a better comparative analysis of the
structures labeled by each 3H-ligand. Slide mounted brain sec-
tions (8 microns) were incubated with 5 nM (+)3H-3-PPP, 10 nM
(+)3H-SKF-10,047, or 5 nM 3H-TCP for 45 minutes at room tempera-
ture, washed in buffer for the appropriate amount of time, rinsed
in water, and dried. Autoradiograms were produced by apposing the
labeled brain sections to tritium-sensitive film for 3 to 5 weeks
at 4°C.
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TABLE 1. Drug inhib i t ion  o f  spec i f i c  b inding of various  3 H-
l igands  to  s igma and PCP receptor  s i tes  in  brain
IC5 0  (nM)
( + ) 3 H - S K F - 1 0 , 0 4 7
Drug ( + ) 3 H - 3 - P P P ( + ) 3 H - S K F - 1 0 , 0 4 7 ( +  5 µ H  h a l o p e r i d o l ) (+ ) 3H-TCP
(+)SKF-10,047 3 4 0  ± 30 7 5 + 3 375 + 30 420 ± 7
( - ) S K F - 1 0 , 0 4 7 1350 ± 110 8 9 5  ± 175 530 ± 25 840 ± 35
(+)3 -PPP 30 ± 2 49 + 6 * >100,000 >100,000
H a l o p e r i d o l 2 ± 1 5 ± 1 *
2 3 ± 2 8 5  ±
>50,000 >50,000
P e n t a z o c i n e 2 50 1520 ± 220
P h e n c y c l l d i n e 7 1 0  ± 3 3 0  ± 48 ± 12
3 , 2 0 0
85 40 63 ± 6
Dexoxadro l 1880 ± 510 569 ± 140 46 ± 9 42 ± 5
L e v o x a d r o l 2080 ± 490 3790 ± 70 9 , 5 0 0 17,000
NOTE: Membranes were Incubated with 10-12 concentrations of drug and 2-4 nM
(+)3H-J-PPP, 8-10 nM (+)3H-SKF-10,047, or 1-3 nM 3H-TCP respectively. T h e
IC50 (concentration that inhibited 50% of specific binding) was calculated
using an iterative curve fitting program (McPherson 1983). Nonspecific
binding was determined in the presence of 1 µM haloperidol for (+)3H-3-PPP,
100µM PCP for (+)3H-SKF-10,047, and 100 µM (+)SKF-10,047 for 3H-TCP.
*IC50 values for (+)3-PPP and haloperidol against the portion of specific (+)
3H-
SKF-10,047 binding displaceable by these drugs.
(+)3H-3-PPP labels a number of different areas in the brain, in-
cluding a major group of structures associated with the limbic
system, and another with the brainstem motor-regulatory system.
Binding sites are concentrated in the pyramidal cell layer of the
hippocampus and the granular layer of the dentate gyrus, with low-
er levels in the remaining hippocampal areas (see figure 3). Most
of the cerebral cortex has low levels of binding, but the pyra-
midal cell layer of the pyriform cortex and a superficial layer of
the cingulate cortex have higher levels. The hypothalamus, septal
nuclei, diagonal band, and central grey also display high amounts
of (+)3H-3-PPP binding sites. Likewise several cranial nerve
nuclei, reticular, and pontine nuclei all have high levels of
binding. In the cerebellum the Purkinje and granule cell layers
are heavily labeled, while high levels are also seen in the deep
cerebellar nuclei and vestibular nuclei (see figure 4).
The distribution of 3H-TCP labeled sites is similar to that de-
scribed previously for 3H-PCP (Quirion et al. 1981). Binding is
densest in cortical regions, the strata oriens and radiatum of the
hippocam us and the molecular layer of the dentate gyrus (see
figure 3). There is negligible binding over the pyramidal cell
layer of the hippocampus and the granular layer of the dentate
gyrus. Moderate levels of binding sites are present in thalamic
areas, the corpus striatum, nucleus accumbens, olfactory tubercle,
septum, and interpeduncular nucleus, while low levels are found
throughout the cerebellum, pons-medulla, midbrain, and hypothal-
amus (see figures 3 and 4).
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FIGURE 3. Autoradiograms of (+)3H-3-PPP, (+)3H-SKF-10,047 and 3H-
TCP binding s i tes  in  coronal  sect ions  o f  guinea  p ig
b r a i n . Increased  gra in densi ty  i s  indicated  by
increased  whiteness  in  the  photograph.  Distr ibut ion
of  (A) (+) 3 H-3-PPP s i tes ,  (B)  (+) 3 H-SKF-10,047 s i t es ,
(C) 3H-TCP sites. Nonspec i f i c  b inding o f  each  l igand
was not  s igni f icant ly  above  f i lm background to  y ie ld
an image at a comparable exposure. Cingulate  cortex ,
CC; dentate gyrus, DC; hippocampus, Hi (pyramidal
C e l l  l a y e r ,  a r r o w s ;  S t r a t u m  o r i e n s ,  a s t e r i s k s ) ;  v e n -
tra l  thalamus,  VT;  zona incerta ,  Zi . (Bar = 2 mm).
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FIGURE 4. Autoradiograms of (+)3H-3-PPP, (+)3H-SKF-10,047
a n d 3H-TCP binding sites at the level of the midbrain
(A-C) and cerebellum/hindbrain (D-F). (+)3H-3-PPP
binding i s  h ighest  in  the  pont ine  nucle i  and centra l
grey  (A) ,  over  the  Purkinje  and granular  layers  o f
the  cerebe l lum and to  crania l  nerve  nucle i  (D) .  The
distr ibut ion o f  (+) 3 H-SKF-10.047 b indina  s i t es  i s
s imilar  to  that  for ,  (+) 3 H-3-PPP (B,E) .  Very  low
levels  o f  3 H-TCP assoc iated  ara ins  are  found at  the
leve l  o f  the  cerebe l lum and pons-medul la  (C,F) .
Central  grey ,  CG;  cerebe l lum,  Purkinje  ce l l  layer ,
arrows; e n t o r h i n a l  c o r t e x ,  E C ;  f a c i a l  n u c l e u s ,  F n ;
pont ine  nuc le i  Pn; Superior colliculus, SC;  vestibu-
tar  nucle i ,  Ve .  Bar  = 2  mm.
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In several brain areas the distribution of (+)3H-SKF-10,047 bind-
ing sites is strikingly similar to that of (+)3H-3-PPP labeled
sites.
PPP
Structures labeled by both (+)3H-SKF-10,047 and (+)3H-3-
(but not by 3H-TCP) include the pyramidal cell layer of the
hippocampus, the granular layer of the dentate gyrus, the Purkinje
cell layer of the cerebellum, cranial nerve and pontine nuclei,
the central grey, the zona incerta and hypothalamic areas, among
others (see figures 3 and 4). Additionally, (+)3H-SKF-10,047
labels to some extent certain brain areas labeled heavily by 3H-
TCP, but not by (+)3H-3-PPP. These include the thalamus, olfacto-
ry tubercle, and nonpyramidal layers of the hippocampus. One com-
plicating methodological problem associated with (+)3H-SKF-10,047
binding to brain slices is the somewhat low affinity of specific
binding and high levels of nonspecific binding of the ligand,
which makes interpretation of the autoradiograms more difficult.
Initial attempts to examine sites labeled by (+)3H-SKF-10,047
which are lower affinity and not labeled by haloperidol or (+)3H-
3-PPP, failed to produce visually convincing images. However,
depletion of the concentrated binding over the pyramidal cell
layer of the hippocampus, Purkinje cell layer of the cerebellum,
and cranial nerve nuclei was apparent (data not shown). Likewise,
examination of (+) 3H-SKF-10,047 binding in the presence of a drug
selective for PCP sites should give further confirmation of the
similarity of high affinity (+)SKF-10,047 and (+)3-PPP/haloperidol
labeled sites.
CONCLUSIONS
These studies have implications for research on both PCP and psy-
chotomimetic opioids, as well as perhaps dopaminergic function. A
major finding, which goes against previous suggestions, is that
PCP and psychotomimetic opioid binding sites in brain are not
identical with regard to pharmacology or distribution, at least
when examined in an in vitro system. The benzomorphan, (+)SKF-
10,047, labels at least two populations of nonopiate sites in
brain. Sites for which (+)SKF-10,047 has higher affinity have a
characteristic pharmacology having high affinity and selectivity
for benzomorphans, haloperidol, and (+)3-PPP (this study, see also
Martin et al. 1984; Tam 1985). Their distribution can be visual-
ized autoradiographically, revealing high levels in hypothalamus,
midbrain, cerebellum, pons, and medulla. Overall, the pharmacol-
ogy and distribution of (+)3-PPP labeled sites and high affinity
(+)SKF-10,047 sites are very similar, suggesting that these drugs
at least label the same receptor-binding site complex, although
there is not, as yet, conclusive evidence that they label the
exact same site on the molecule. Further studies examining pos-
sible allosteric interactions and agonist-antagonist roles of the
two types of drug are required to decide this issue.
The relative selectivity of drugs such as haloperidol for the
higher affinity (+)SKF-10,047 labeled sites allowed the determina-
tion of the pharmacological profile of the low affinity sites,
which was very similar to that of 3H-TCP labeled sites. PCP and
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PCP analogues had high affinity for the haloperidol-insensitive
(+)SKF-10,047 binding, and stereoselectivity for dexoxadrol over
levoxadrol was greater than that seen against total specific
(+) 3H-SKF-10,047 binding.
Although PCP has high affinity for 3H-TCP labeled sites, it also
has moderate potency against (+)3H-3-PPP and (+)3H-SKF-10,047
binding, suggesting that it may still have pharmacological activi-
ty at these sites, in vivo, when present at appropriate concentra-
tions. This may explain the apparent contradiction between these
in vitro results, revealing different binding sites for these two
groups of drugs and differences in distribution of these sites,
and the evidence cited in the introduction to this study, from in
vivo behavioral and biochemical studies, which demonstrates common
actions of PCP ard psychotomimetic opioids. For example, the num-
ber and regional concentration of PCP binding sites in the pons-
medulla and hypothalamus is lower than that of (+)SKF-10,047 (and
(+)3-PPP) sites in these same areas. Yet both SKF-10,047 and PCP
produce effects-on cardiovascular parameters (Vaupel 1983), pre-
sumably through central actions at cardiovascular regulatory loci
in these brain areas. Furthermore, in light of the common psy-
chotic effects of PCP and SKF-10,047, it is possible that sites
that are labeled by both PCP (TCP) and (+)SKF-10,047 such as in
nonpyramidal cell areas of the hippocampus and in cortex may rep-
resent at least some of the sites at which these drugs mediate
these effects. However, it is also possible that sites labeled
with high affinity by (+)SKF-10,047 (and (+)3-PPP) throughout the
brain, particularly in the hippocampus, hypothalamus, and brain-
stem reticular formation, are "psychotomimetic sites."
Experiments based on our results could be conducted to test the
physiological and pharmacological relevance of these findings.
Autoradiographic mapping studies should assist future work towards
this end, as they provide new information that allows "site-
directed experiments." The examination of the effects, in vivo
and in vitro, of sigma and/or PCP drugs on biochemical, physiolog-
ical, and behavioral parameters in discrete brain areas will best
improve our knowledge of the true sites and mechanisms of action
of PCP-like and psychotomimetic opioid drugs.
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Ratna Sircar and Stephen R. Zukin
Phencyclidine (1-[1-phenylcyclohexyl]piperidine HCl; PCP) and its
active derivatives produce unique behavioral effects in animals
and psychotomimetic effects in humans. Drugs of this class have
been demonstrated to bind saturably, reversibly, and with high af-
finity to specific binding sites in brain (Hampton et al. 1982;
Quirion et al. 1981; Sircar and Zukin 1983; Vincent et al. 1979;
Zukin and Zukin 1979). These sites have been shown to exhibit a
characteristic heterogeneous regional distribution pattern
(Quirion et al. 1981; Sircar et al., submitted for publication;
Zukin and Zukin 1979) distinct from that of any other receptor
type.
A variety of evidence suggests that PCP-like drugs and sigma
opioids may bring about their common behavioral effects via activ-
ation of the same receptors. The existence of sigma opioid recep-
tors was postulated by Martin to account for the behavioral phar-
macology of the drug N-allylnormetazocine (SKF-10,047) and related
benzomorphans, such as cyclazocine, which can produce psychosis in
humans and "canine delirium," tachycardia, and tachypnea in ani-
mals (Martin et al. 1976). Sigma opioid receptors differ from mu,
delta, and kappa receptors in terms of ligand selectivity. Speci-
fic sigma receptor ligands, such as (+)SKF-10,047, have very lit-
tle affinity for mu, delta, or kappa receptors (Zukin et al.
1984), while prototypic mu, delta, and kappa opioids exhibit lit-
tle or no affinity for sigma opioid receptors (Zukin and Zukin
1981a). Sigma opioid receptors labeled by 3H-cyclazocine (ibid.)
or 3H-(-)SKF-10,047 (Zukin et al., submitted for publication) in
homogenate binding studies under conditions blocking radioligand
access to mu, delta, and kappa opioid receptors do, however, ex-
hibit a ligand selectivity pattern in which not only sigma opioids
but also PC and its derivatives are active. Similarly, receptors
labeled by 3H-PCP exhibit high affinity for sigma opioids (Zukin
et al. 1983). Regional distributions of 3H-PCP and 3H-cyclazocine
homogenate binding are similar (Zukin and Zukin 1981a). Behavior-
al studies utilizing the drug discrimination paradigm (Shannon
1981; Shannon 1982; Teal and Holtzman 1980; Holtzman 1980; Brady
et al. 1982; Katz et al. 1985) have demonstrated cross-generaliza-
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tion between PCP derivatives and sigma opioids. Such biochemical
and behavioral findings have suggested the hypothesis that the
sigma opioid and PCP receptors may represent the same entity
(Zukin and Zukin 1981b; Quirion et al. 1981).
A problem in previous studies of sigma opioid receptors has been
that racemic or (-) sigma opioid isomers interacted at multiple
opioid receptor sites, requiring special blocking techniques to
permit targeting of sigma receptors (Zukin and Zukin 1981b). The
(+) isomers of sigma opioids, essentially devoid of mu, delta, and
kappa activity (Zukin et al. 1984), thus seemed the ligands of
choice for studies of sigma opioid receptors. This report docu-
ments the binding characteristics of 3H-(+)SKF-10,047 to rat and
mouse brain.
Among PCP derivatives, TCP (N-(1-[2-thienyl]cyclohexyl)piperidine)
has been shown to be more potent than PCP itself (Vincent et al.
1979; Zukin and Zukin, 1979). In homogenate binding studies 3H-TCP
binds to brain PCP receptor sites more potently than 3H-PCP
(Vignon et al. 1983). Such findings raise the possibility that
3H-TCP might prove a superior molecular probe of PCP/sigma opiate
receptors.
In this chapter, the binding characteristics of the prototypical
sigma opioid H-(+)SKF-10,047 are described, and the quantitative
localization patterns of bits binding sites in brain are compared
with those of 3H-PCP and 3H-TCP, the prototypic PCP receptor
ligands, to address the questions of the extent and nature of
PCP-sigma opioid receptor commonalities, and which radioligands
constitute the best molecular probes of brain PCP/sigma opioid
receptors.
CHARACTERIZATION OF 3H-(+)SKF-10,047 BINDING IN RAT BRAIN
Specific binding of 3H-(+)SKF-10,047 proved saturable with respect
to increasing radioligand concentration. Scatchard analysis of
3H-(+)SFK-10,047 binding gave a curvilinear plot suggestive of mul-
tiple 3H-(+)SKF-10,047 binding sites or cooperativity of binding.
Computer-assisted analysis (Munson and Rodbard 1980) revealed the
best fit to be to a two-site model with apparent KD values of 3.6
nM and 153 nM, and BMax values of 40 fmol and 1.6 pmol/mg protein
for the apparent high- and low-affinity binding sites, respec-
tively. Scatchard analysis of complete binding isotherms in each
of the four dissected brain regions (hippocampus, frontal cortex,
cerebellum and pons-medulla) similarly gave curvilinear plots,
which, in each case, displayed a good fit to a two-site model. For
each of these regions, as well as for the whole-brain preparation,
a valid fit to a one-site model could not be obtained (Sircar and
Zukin, in press).
3H-(+)SKF-10,047 binding was also measured in the presence of 100
nM haloperidol. This approach yielded a Scatchard plot in which
the density of the apparent high-affinity sites was decreased by
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greater than 90 percent (to 0.5 fmol/mg protein) relative to the
value obtained in the absence of haloperidol, while the density of
the apparent low-affinity binding sites showed little alteration
(1.08 pmol/mg protein). This finding suggested that the curvilin-
ear Scatchard plot was the result of independent interactions
of 3H-(+)SKF-10,047 with two distinct binding sites. To test this
hypothesis, ligand selectivities of the two apparent classes of
sites were characterized. The rank order of potency (PCE>dexoxa-
drol>PCP>pentazocine>ketamine>levoxadrol) of ligands for displace-
ment of 100 nM 3H-(t)SKF-10,047 from the predominant lower-affin-
ity sites (in the presence of 100 nM haloperidol) was similar to
that reported for displacement of 3H-PCP (Zukin and Zukin 1979;
Zukin et al. 1983). By contrast, the rank order of drugs inhibit-
ing the binding of 3H-(+)SKF-10,047 to the higher-affinity site
(haloperidol>dexoxadrol>pentazocine>PCP>levoxadrol) proved dis-
tinct from the pattern for PCP receptors.
CHARACTERIZATION OF 3H-(+)SKF-10,047 BINDING SITES IN MOUSE BRAIN
To assess possible species specificity of our findings, 3H-(+)SKF-
10,047 binding was carried out in mouse brain. Scatchard analysis
of the binding data resulted in a biphasic Scatchard plot similar
to that observed in rat brain. Computer-assisted analysis of the
apparent two-site fit of the binding data yielded apparent KD val-
ues of 4 and 227 nM, and BMax values of 86 fmol and 3.8 pmol/mg
protein, respectively. As in the rat, 100 nM haloperidol signifi-
cantly reduced the high-affinity site while leaving
ity site unaffected.
 the low-affin-
Our finding of two distinct 3H-(+)SKF-10,047
binding sites in mouse as well as rat brain is at variance with a
recent study (Martin et al. 1984), which had reported mouse brain
to possess a homogeneous population of haloperidol-sensitive 3H-
(+)SKF-10,047 binding sites. It may be that our extending the
binding isotherm to higher radioligand concentrations (500 nM for
our study as opposed to 100 nM for Martin et al.) was responsible
for revealing the lower-affinity PCP/sigma opioid receptors.
VISUALIZATION OF PCP/SIGMA OPIOID RECEPTORS BY LIGHT HICROSCOPY
AUTORADIOGRAPHY
The quantitative distribution patterns of PCP/sigma opioid recep-
tors identified here from 3H-TCP autoradiograms(Sircar and Zukin,
in press), 3H-(+)SKF-10,047 autoradiograms and 3H-PCP autoradio-
grams (Sircar et al., submitted for publication) were remarkably
similar (table l), and resembled the qualitative pattern of 3H-PCP
binding sites previously reported (Quirion et al 1981). Hippocam-
pus was the most heavily labeled region in all 3 autoradiograms
(figure 1). Dentate gyrus and hippocampal fields CA1 and CA2 were
noticeably darker than hippocampal field CA3 in PCP, TCP and
(+)SKF-10,047 autoradiograms. Distinct laminar patterning in the
hippocampus was seen with PCP and TCP, while lamination was less
distinct in the case of (+)SKF-10,047. Diencephalic structures
manifested moderate to low amounts of binding. In the thalamic
region, the intermediodorsal nucleus had the highest concentration
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of both 3H-PCP and 3H-(+)SKF-10,047 binding, while in the hypo-
thalamus the dorsomedial nucleus had the highest levels of both.
Midbrain/pontine areas also showed moderate to low levels of 3H-
PCP and 3H-(+)SKF-10,047 binding. The superficial layer of the
superior colliculus was substantially darker than the deeper lay-
ers.
both 3H-PCP and 3H-(+)SKF-10,047 binding was the interpeduncular
Another region in this area showing high concentrations of
nucleus. Cerebellym had moderate levels of PCP binding, but fair-
ly high levels of 3H-(+)SKF-10,047 binding. In comparison, there
were significantly lower levels of 3H-TCP binding in central gray,
TABLE 1. Receptor density values obtained from autoradiograms
l a b e l e d  w i t h 3H-PCP, 3H-TCP and 3H-(+)SKF-10,047 in
rat brain
Receptor Density (fmol/mg Tissue)
Anatomical Region PCP TCP (+)SKF-10,047
Hippocampus 296 91
CA 1 284 104
CA 2 272 105
CA 3 225 66
Dentate 378 111
Dorsomedial hypothalamus 284 40
Superior colliculus 260 65
Interpeduncular n. 248 40
Frontal cortex 225 83
Basolateral amygdaloid n. 225 42
Substantia nigra 225 1 4
Central gray 213 26
Nucleus accumbens 177 52 94
Cerebellum 154 47
Locus coeruleus 154 46
Striatum 154 46 94
Pons reticular formation 12 8

















NOTE: 20-Micron sectlons from specific regions of rat brain were prepared and in-
cubated with 10 nM H-PCP (49.9 Cl/mnol), 5 nM 3H-TCP (58.2 Cl/mmol) and 10
nM 3H-(+)SKF-10.047 (25.5 Cl/mmol) respectively. Sections were juxtaposed
against trltlum-sensltlve film along with tritium standards, and-optical
densities determined (Geary and Wooten 1983: Kuhar 1982: Sircar and Zukin.
in press; Tempel et al. 1984). Optical density values from different brain
regions were converted to receptor densities (nCl/mg tissue) using the
tritium standards. The receptor density values have been expressed in




Values represent mean readings from six sections for each region, derived
from two Independent experiments. Readings have been normalized to nonspe-
cific binding and to blank tissue.
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FIGURE 1. Anatomical distrubtion of 3H-PCP, 3H-TCP,
and 3H-(+)SKF-10,047 bindings in rat brain
NOTE: Brain sections are at the level of bregma -3.8 mm of the rat
brain atlas (paxinos and Watson 1982). 20-Micron thick coro-
nal sections of frozen rat brain were cut, thaw-mounted onto
gelatin-coated slides, and incubated with (a) 10 nM 3H-PCP
(49.9 Ci/mmol) for 45 minutes; (b) 5 nm 3H-TCP (58.2 Ci/mM)
for 1 hour; (c) 10 nM 3H-(+)SKF-10,047 (25.5 Ci/mmol) for 1
hour. Adjacent sections were incubated with the same radio-
ligand concentrations, but in the presence of 1,000-fold ex-
cess of nonlabeled PCP, TCP or (+)SKF-10,047, respectively,
for nonspecific binding. Sections were washed, dried, and
exposed to tritium-sensitive film for 2 to 6 weeks. Note the
dense labeling in CA1, CA2, and dentate gyrus of the hipo-
campus with all three radioligands. TeUnlike PCP and TCP,
(+)SKF-10,047 labeled stratum pyramidale.
substantia nigra, dorsomedial hypothalamus, and interpeduncular
nucleus. PCP is known to bind very weakly to mu opiate receptors
(Vincent et al. 1978) but this property is not related to its dis-
criminative stimulus behavioral effects or to its interaction with
PCP/sigma opiate receptors. Areas such as central gray, substan-
tia nigra, and interpeduncular nucleus are known to be rich in mu
opiate receptors (Herkenham and Pert 1982). The fact that 3H-TCP
does not bind significantly in these areas suggests that, besides
being a more potent analog of PCP than PCP itself (Vignon et al.
1983), it may also be a more specific PCP/sigma opioid receptor
ligand, devoid of significant cross-activity at other classes of
receptors.
The remarkable similarity in the regional distribution of binding
sites for the arylcyclohexylamines PCP and TCP and those of the
chemically unrelated benzomorphan (+)SKF-10,047 supports the
hypothesis that PCP derivatives and sigma opioids may act via a
common receptor site. The sigma opioid/PCP receptors are concen-
trated primarily in the limbic areas of the brain, including hip-
pocampus, amygdala, striatum, and frontal cortex--regions that are
involved in higher nervous functions, including memory, emotion,
and behavior (Kimura 1958; Milner 1968). Autoradiograms obtained
with 3H-(-)SKF-10,047 in the presence of mu and delta blockers
(Zukin et al., Submitted for publication are generally similar to
those obtained with 3H-( +)SKF-10,047 or 3H-PCP. By contrast
to 3H-PCP, 3H-TCP, and 3H-(+)SKF-10,047 autoradiograms, 3H-
(-)SKF-10,047 autoradiograms show striosomes in the striatum and
denser labeling in central gray, locus coeruleus, and nucleus
accumbens, whereas hippocampus showed a lower relative concentra-
tion of 3H-(-)SKF-10,047 binding. 3H-(-)SKF-10,047 may thus label
not only sigma opioid/PCP receptors, but also residual mu opioid
receptors and other binding sites as well, perhaps including the
haloperidol-sensitive sites described above. The differences be-
tween the autoradiographic patterns of 3H-PCP and 3H-(+)SKF-10,847
binding in the present study probably arise from the fact that 3H-
PCP, which gives a Scatchard analysis indicative of a single high-
affinity site in binding studies (Vincent et al. 1979; Zukin and
Zukin 1979; Quirion et al 1981; Mendelsohn et al. 1984) reveals
the pattern of its homogenous class of PCP/sigma opioid receptors
in autoradiograms, while 3H-(+)SKF-10,047, which we have shown in
this study to bind to two independent sites, reveals the auto-
radiographic pattern of the pattern of PCP/sigma opioid receptors
plus that of the haloperidol-sensitive binding sites.
Our results suggest that the numerically predominant 153 nM 3H-
(+)SKF-10,047 site represents the PCP opioid receptor. The much
less abundant haloperidol-sensitive 3.6 nM 3H-SKF-10,047 binding
site that we have described appears to represent the same entity
as a class of sites reported by several other groups utilizing di-
verse strategies, including use of
3H-SKF-10,047 in the presence
of etorphine (Su 1982); 3H-ethylketoSyclazocine
ence of excess naloxone (Tam 1983);
(EKC) in the pres-
3H-(+)SKF-10,047 or (+)3H-
haloperidol in guinea pig brain (Tam and Cook 1984); (+)3H-3-PPP
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(3-(3-hydroxyphenyl)-N-(1-propyl)piperidine) or 3H-haloperidol
(Largent et al. 1984); 3H-EKC or 3H-SKF-10,047 in cultured NCB20
cells (McLawhon et al. 1981; West et al. 1983); and 3H-(+)SKF-
10,047 in mouse brain (Martin et al. 1984). The pattern of areas
where we have found relatively higher 3H-(+)SKF-10,047 than 3H-PCP
binding, including central gray and cerebellum, is consistent with
areas enriched in (+)3H-3-PPP binding (Largent et al. 1984). As
noted above, the latter radioligand labels sites identical to the
haloperidol-sensitive 3H-(+)SKF-10,047 sites but distinct from
3H-PCP sites (ibid.). The behavioral significance of the halo-
peridol-sensitive (sigma) sites remains unknown. The striking
PCP-like behavioral effects of (+)SKF-10,047 thus appear to be
mediated at the haloperidol-insensitive sites, as well as at halo-
peridol-sensitive sites.
Because of its interactions with multiple binding sites, 3H-
(+)SKF-10,047 does not appear to be the ideal ligand for labeling
PCP/sigma opioid receptors in binding assays. While its interac-
tion with the non-PCP/sigma opioid sites can
sion of haloperidol in the incubation medium,
be blocked by inclu-
3H-TCP, which binds
exclusively and more potently to the nonhaloperidol-sensitive sig-
ma opioid/PCP receptors (Vignon et al. 1983; Sircar and Zukin, in
press), is clearly preprable to
3H-(+)SKF-10,047 for targeting
these sites. Indeed, 3H-TCP appears to be the best ligand of
PCP/sigma opioid receptors currently available.
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Isolation and Identification of an
Endogenous Ligand for the
Phencyclidine Receptor
Debora A. DiMaggio, Patricia C. Contreras, Remi Quirion,
and Thomas L. O’Donohue
CLASSIFICATION OF OPIOID RECEPTORS
Opioid receptors comprise a heterogenous group that can be divided
into at least four biochemically and topographically distinct sub-
types, designated mu, kappa, sigma, and delta. Martin et al.
(1976) proposed the existence of mu, kappa, and sigma opioid re-
ceptors based on observed differences in pharmacological profiles
of drugs seen with variably selective opioid agonists and
antagonists. Other groups have provided evidence for the delta
subtype (Hughes et al. 1975).
The mu opioid receptor has been extensively characterized (Lord et
al. 1976; Lord et al. 1977; Chang et al. 1979; Chang and
Cuatrecasas 1981). Classical opioid effects, such as analgesia
induced by morphine and its congeners, are thought to be mediated
by the mu opioid receptor, which preferentially binds the levo-
rotatory isomer. This stereoselective binding of the (-) enanti-
omer, which has greater analgesic and respiratory depressant
properties than the (+) isomer, strongly supports the physio-
logical relevance of specific mu opioid receptors. Delta recep-
tors have also been well characterized (Simantov 1978). These
opioid receptors are believed to be involved in reward processes
and seizure. From the evidence available for kappa receptors
(Kosterlitz and Paterson 1980, Chang and Cuatrecasas 1979), it
appears that these sites are involved in mediating analgesia and
sedation. Finally, it has been postulated that sigma receptors
are involved in mediating the psychotomimetic actions seen with
some of the benzomorphans, PCP, and PCP analogs (Quirion et al.
1981a).
INTERACTION OF OPIOID RECEPTORS WITH ENDOGENOUS PEPTIDE LIGANDS
The mu, kappa, and delta opioid receptors have been found to
interact with endogenous peptide ligands that share certain phar-
macologic properties with opioid drugs. These peptide ligands are
derived from at least three different prohormones located in both
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the central and peripheral nervous systems and also in the endo-
crine system.
Delta receptors are relatively selective for two related penta-
peptides, methionine enkephalin and leucine enkephalin (met- and
leu-enkephalin), which were isolated from porcine brain (Hughes
1975). Both met- and leu-enkephalin inhibit electrically induced
contractions of guinea pig ileum, an effect that mimics those
effects seen with opioid drugs, and is naloxone reversible. The
enkephalins are processed posttranslationally from proenkephalin,
and secreted from central and peripheral neurons and endocrine
cells in the adrenal medulla.
Neurons in the brain and spinal cord process peptides derived from
prodynorphin; these peptides appear to be kappa-preferring
ligands. Dynorphin 1-13 was isolated from porcine pituitary by
Goldstein et al. (1979). This pituitary opioid peptide contains
within its sequence leu-enkephalin, which appears to be one of the
products of posttranslational processing (Zamir et al. 1985;
Palkovits et al. 1983). Dynorphin 1-13 is 700 times more potent
than the enkephalins in inhibiting electrical contractions in
guinea pig ileum longitudinal muscle (Goldstein 1979).
The third prohormone from which opioid peptides are derived is
pro-opiomelanocortin, which yields a number of nonopioid and
opioid peptide products (O'Donohue and Dorsa 1982). Of these
products, beta-endorphin, an untriakontapeptide isolated from
camel pituitary gland by Li and Chung (1976)) is thought to
interact primarily with mu and delta receptors.
EVIDENCE OF SPECIFIC PCP BINDING SITES
In recent years, a number of groups have reported the presence of
a class of high-affinity binding sites for phencyclidine (1-(1-
cyclohexylphenyl)piperidine, PCP), a dissociative anesthetic with
psychotomimetic properties. This binding was shown to be satur-
able, reversible, and selective (Vincent et al. 1979; Zukin and
Zukin 1979; Quirion et al. 1981a; Vignon et al. 1982), as well as
stereospecific (guirion et al 1981b). Furthermore receptor
densities using 3H-PCP (Quirion et al. 1981a) and 3H-TCP (N-(1-(2-
thienyl)cyclohexyl)3,4-3(H)piperidine, (Contreras et al., sub-
mitted for publication) to label the binding sites were reported
to be highest in cortical regions and hippocampus, indicating that
the distribution of PCP binding sites correlates well with the
psychotomimetic properties of the drug. The pharmacological rele-
vance of the PCP receptor is supported by the fact that only those
drugs with PCP-like properties in vivo, such as SKF-10,047 (N-
allylnormetazocine),
binding of
cyclazocine, PCP, and PCP analogs inhibit the
3H-PCP in vitro (Quirion et al. 1981a). Although PCP
appears to bind to muscarinic and mu opioid receptors with very
low affinity (Vincent et al. 1979), its action on these receptors
is not compatible with its pharmacological profile (Vincent et al.
1979). Binding of PCP to the PCP receptor is not antagonized by
25
mu, delta, or muscarinic receptor ligands (Vincent et al. 1979).
Finally, good correlation exists between the ability of PCP
analogs to bind to the receptor and pharmacological potency as
measured by a number of assays, including the rotarod assay
(Vignon et al. 1982) and stereotypy (Contreras et al., submitted
for publication).
Because the psychotomimetic benzomorphans, classed as sigma opi-
oids, inhibit binding of 3H-PCP and show PCP-like actions in sev-
eral behavioral assays, it has been suggested that PCP and sigma
opioids act through the same binding sites. However, recent work
by a number of investigators (Su 1982; Tam 1983; Martin et al.
1984; Contreras et al., in press) indicate that PCP binding sites
and sigma opioid sites may be distinct due to differences in drug
selectivity and regional distribution.
ENDOGENOUS LIGAND FOR THE PCP/SIGMA RECEPTOR
The presence of highly specific and selective binding sites for
PCP in brain strongly supported the presence of an endogenous lig-
and for these receptors. Quirion et al. (1984) and O'Donohue et
al. (1983) have reported the isolation of an endogenous factor
from preparative scale porcine brain acid extracts that inhibited
the binding of 3H-PCP in rat brain membranes. This paper summa-
rizes those previous findings , and extends the data on this
endogenous factor which has now been purified to homogeneity and
has been given the name alpha-endopsychosin.
EXTRACTION AND PURIFICATION OF ALPHA-ENDOPSYCHOSIN
Porcine brains (200) were obtained from Gwaltney Co. and homoge-
nized at 4 °C in five volumes of acid solution (Bennett et al.
1979) consisting of trifluoroacetic acid, formic acid, hydro-
chloric acid, and sodium chloride. Following centrifugation, the
homogenate was extracted 1:1 with petroleum ether. The resulting
supernatant (60 liters) was then filtered using a Minitan Ultra-
filtration System, and chromatographed in a series of runs using
preparative and semipreparative liquid chromatography followed by
several analytical reverse phase high pressure liquid chromatogra-
phy steps. Figure 1 provides an overview of the purification
procedure. Throughout the purification, a binding assay using 3H-
PCP and rat brain membranes was used to assess the progress of
this procedure.
ENZYMATIC INACTIVATION
The effects of various enzymes on the activity of HPLC fractions
that inhibited 3H-PCP binding were investigated. As shown in
table 1, pronase (0.5 µg/ml), carboxypeptidase A (0.1 unit/ml),
and trypsin (3.0 g/ml) markedly decreased the potency of 10 n
units of PCP-like activity. No significant change in activity was.
seen when fractions were incubated with alpha-chymotrypsin.
Boiled enzymes did not alter the ability of active fractions to
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inhibit the binding of 3H-PCP to its receptor. These data suggest
that the endogenous material is a protein or peptide.
FIGURE 1. Purification scheme of alpha-endopsychosin
TABLE 1. Effects of various enzymes on the activity of HPLC
fractions which inhibited 3H-PCP binding
Treatment
Control (Boiled Active Enzyme
Enzyme) n Unit n Unit PCP-
PCP-Like Activity Like Activity
Pronase 8.9 ± 1.4 0
Trypsin 8.1 ± 1.6 2.3 ± 0.7
-Chymotrypsin 7.7 ± 1.4 5.4 ± 1.0
Carboxypeptidase A 8.8 ± 1.3 3.1 ± 0.6
NOTE: 10 n units of PCP-like activity were incubated with various concentrations
of active or inactive (boiled at 80 °C for 10 min) enzymes. The remaining
activity was then evaluated by the 3H-PCP binding assay. One unit of ac-
tivity is equivalent to 1 mole of PCP. Mean ± SEM of three determinations.
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GEL FILTRATION STUDIES
Supernatants were chromatographed over a column of Sephadex G-10,
G-25, and G-50, and aliquots of collected fractions were assessed
for their ability to displace 3H-PCP from binding sites in rat
brain preparations. Results indicated that the endogenous materi-
al has a molecule weight of about 3,000.
SELECTIVITY AND SPECIFICITY OF ACTIVE FRACTIONS
As Shown in table 2, a comparative dose of 10 n units of PCP-like
activity inhibited 3H-PCP binding in rat brain membranes, but did
not inhibit binding of 3H-dihydromorphine, 3H-D-ala2-D-leu5-
enkephalin, 3H-ethylketocyclazocine, 3H-diazepam, or 3H-neuro-
tensin. These results indicate that the active material is
specific and selective from PCP receptors, as binding to the mu,
delta, and kappa opioid receptors was unaffected, as was binding
to benzodiazepine and neurotensin receptors.
Aliquots of fractions from an intermediate chromatography step
were assayed for their ability to inhibit 3H-PCP receptor bind-
ing. The endogenous material inhibited binding of 3HPCP to rat
brain membranes and did so in a dose-related fashion, but did not
displace 3H-SKF-10,047 in a separate binding study. Similarly, no
displacement of 3H-dexoxadrol or 3H-haloperidol from rat brain
preparations was apparent with aliquots taken from these same
fractions.
TABLE 2. Effect of endogenous 3H-PCP displacing material on the
spec i f i c  b inding o f  var ious  l igands
Specific Binding
Ligand














2474 304 2435 347
2691 ± 237 2831 ± 352
7211 ± 315 7337 ± 366
1817 ± 207 1901 ± 291
Remaining specific binding (CPM) after incubation in presence of 10 n units of
PCP-like activity as determined in a binding assay.
+p<0.001
NOTE: One unit of activity is equivalent to 1 mole of PCP. Mean ± SEM of at
least three determinations, each In triplicate.
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REGIONAL DISTRIBUTION OF ACTIVE MATERIAL IN RAT BRAIN
The distribution of 3H-PCP-displacing material correlated well
with PCP receptor densities. Highest concentrations of endogenous
material can be found in hippocampus and cortex, while relatively
little material is detectable in striatum and brainstem (table 3).
TABLE 3. Distribution of the endogenous PCP-like material (as
measured in a PCP receptor assay) in porcine brain
Region
N Units PCP Equivalents/g
Wet Weight
Hippocampus 6.91 ± 1.31
Frontal cortex 5.80 ± 1.15
Cerebellum 1.27 ± 0.78
Striatum 0.12 ± 0.08
Brainstem 0.08 ± 0.04
BIOLOGICAL PROPERTIES OF PCP-LIKE FRACTIONS
Active fractions tested for electrophysiological actions on hippo-
campal and cortical cells mimicked the actions of PCP (Quirion et
al. 1984). Iontophoresis of PCP inhibited spontaneous cortical
and hippocampal cell firing, as did micropressure ejection of the
PCP-like material. Fractions that did not possess PCP-like
actions had no effect on spontaneous neuronal activity.
Similarly, using a behavioral paradigm where unilateral injection
of PCP into substantia nigra induces contralateral turning behav-
ior (Quirion et al. 1984), PCP-like fractions also mimicked the
actions of PCP, producing significant rotational behavior contra-
lateral to the injection site. Once again, inactive fractions
elicited no response in this test. These two in vivo experiments
demonstrate that the endogenous material is anagonist relative to
PCP.
CHEMICAL CHARACTERIZATION OF PCP-LIKE MATERIAL
Figure 2 shows the elution profiles of several neuropeptides and
the PCP-like material. When the PCP-active fractions were re-
chromatographed over a flatter gradient and in a different solvent
system, it was clear that bombesin- and substance P-immunoreactiv-
ity no longer coeluted with the PCP-like material.
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Figure 3 shows the final chromatogram and activity profile of
purified alpha-endopsychosin. The first peak contained most of
the PCP displacing activity as measured by its ability to inhib-
it 3H-PCP. An aliquot of the most active material was hydrolyzed
in acid and the amino acid composition was determined using OPA
detection. It was determined that the peptide contained approxi-
mately 26 amino acids, in close agreement with the molecular
weight predicted by Sephadex gel filtration studies. N-terminal
analysis revealed that the peptide was blocked at this site. The
nature of this blockade is yet to be determined. Studies are
under way to determine the amino acid sequence of the peptide.
FIGURE 2. Panel A: Elution  pattern of endogenous PCP-like mate-
r i a l  f r o m  f r a c t i o n a t e d  p o r c i n e  b r a i n . A c t i v i t y  i s
expressed  in  terms o f  equivalents  o f  PCP required  to
inhibit 3H-PCP bindina to rat brain membranes. One
u n i t  o f  a c t i v i t y  i s  e q i v a l e n t  t o  1  m o l e  o f  P C P .
Panel B: Act iv i ty  pro f i l es  o f  bombes in ,  neuropept ide
Y, and substance p from the same HPLC fractions.
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FIGURE 3. Chromatogram and e lut ion pattern o f  the  puri f i ed
m a t e r i a l
DISCUSSION
The existence of high affinity and stereoselective binding sites
for PCP, a dissociative anesthetic with psychotomimetic proper-
ties, has been demonstrated in brain by a number of groups
(Vincent et al. 1979; Zukin and Zukin 1979; Quirion et al. 1981a;
Vignon et al. 1982). The identification of these PCP receptors in
central nervous tissue suggested the existence of an endogenous
ligand specific for these pharmacologically relevant binding
sites. We have identified what appears to be a selective peptide
ligand for the PCP receptor from porcine brain acid extracts and
have named this compound alpha-endopsychosin due to its similarity
in pharmacology to PCP. We have assigned the alpha designation to
this peptide, since it is the first endogenous PCP ligand to be
identified, and activity profiles of fractionated porcine brain
show that other fractions are also PCP-active, although they do
not appear to be as potent as the fraction characterized. This
putative ligand for the PCP receptor, which is regionally distrib-
uted throughout the CNS and inhibits 3H-PCP binding in rat brain
membranes, appears to be an agonist relative to PCP, as indicated
by its actions in electrophysiological and behavioral tests. The
peptide appears to be selective for PCP receptors, since it does
not interact with mu, kappa, or delta opioid receptors; nor does
it interact with a number of other peptide binding sites.
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Furthermore, the distribution of this peptide is compatible with
PCP receptor densities, with highest concentrations of both ligand
and receptor in areas that could be relevant to the psychoto-
mimetic properties of PCP. Amino acid analysis of an aliquot of
the purified fraction shows the peptide to contain at least 26
residues. Because the peptide is blocked at the N-terminus,
enzyme fragments have been generated and purified over HPLC for
sequence determination.
Without a specific PCP antagonist, it cannot be stated unequiv-
ocally that the endogenous ligand and PCP act at the same receptor
to induce specific electrophysiological and behavioral actions.
The discovery of specific PCP antagonists will facilitate complete
characterization of the PCP-endogenous ligand system. Along this
line of investigation, Rafferty et al. (in press) have reported
the discovery of an acylating agent which specifically reacts with
PCP receptors. This agent effectively blocks PCP-induced stereo-
typic behavior and electrophysiological actions in rats (Contreras
et al. 1985). an effect that has been shown to be the result of
PCP receptor-binding. It will be interesting to study the effects
of this specific acylating agent on the interaction of PCP recep-
tors with the endogenous ligand.
Although PCP affects several ion channels (Aguayo et al. 1982;
Albuquerque et al. 1980) and numerous neurotransmitter systems, it
is believed to exert its psychotomimetic effects via interaction
with a specific receptor. It has been suggested that PCP receptor
sites are actually sigma opioid sites, since SKF-10,047 and
Syclazocine, sigma opioid psychotomimetics, inhibit the binding of
3H-PCP to membranes in vitro.
hibit binding of
PCP analogs have been shown to in-
3H-cyclazocine and 3H-SKF-10,047 (Quirion et al.
1981b). Furthermore, sigma opioids generalize to PCP stimulus In
drug discrimination paradigms (Brady et al. 1982; Shannon 1981).
and PCP has been shown to generalize to sigma opioid stimulus
(Shannon 1983). However, Contreras et al. (1985) have shown that
Metaphit, an acylating agent specific for PCP receptors, inhibits
PCP-induced stereotypy but does not inhibit stereotyped behavior
typically seen with cyclazocine treatment. In addition, evidence
exists that suggests that PCP, SKF-10,047, and cyclazocine do not
bind to a homogenous population of receptors (Contreras et al., in
press). Recent work presented by a number of investigators (Su
1982; Tam 1983; Martin et al. 1984; and Contreras et al., in
press) also indicates that, due to differences in regional distri-
bution of drug selectivity, PCP receptors and sigma opioid sites
represent different binding sites. Largent et al. (1984) have
shown that sites labeled with 3H-PPP (3-(3-hydroxyphenyl)-N-(1-
propyl)piperidine) are specific for sites that are distinct from
PCP sites. Finally, Pilapil et al. (in press) have delineated a
binding profile for dexoxadrol, a putative sigma agonist, that is
distinct from PCP binding. In this light, it is particularly
interesting to note that the PCP-like peptide inhibits binding of
3H-PCP but not of 3H-(+)SKF-10,047, 3H-dexoxadrol or 3H-halo-
peridol. The endogenous ligand for the PCP receptor may therefore
32
be a far more selective ligand than any of the synthetic
compounds.
A controversial issue concerns whether PCP/sigma opioids are in
fact opioids at all, as their "sigma" psychotomimetic actions are
not antagonized by naloxone. The three known opioid peptide pre-
cursors share marked structural homology in that they all contain
multiple cysteine residues in the N-terminal region, they are all
approximately the same size, and they all contain an enkephalin
sequence (Douglass et al. 1984). It will be interesting to see
whether alpha-endopsychosin is the peptide product of a distinct
yet similar prohormone. If so, then perhaps alpha-endopsychosin
and PCP binding sites may belong to the superfamily of opioid pep-
tides and receptors.
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and Roger G. Sorensen
INTRODUCTION
Phencyclidine (1-[1-phenylcyclohexyl] piperidine; "PCP"; "angel
dust") is a major drug of abuse in the United States. It is a
particularly interesting pharmacological tool because it induces a
toxic confusional psychosis in man that reproduces many of the
primary symptoms of schizophrenia (Domino and Luby 1981). The
precise mechanism of action is not known, but many studies suggest
that the complex behavioral syndrome elicited by PCP is a conse-
quence of altered central synaptic transmission (Petersen and
Stillman 1978). PCP is known to bind with high affinity to brain
membranes (Vincent et al. 1978: Zukin and Zukin 19791: however,
the physiological activity of these receptors has not-yet been-
elucidated, nor have these receptors been identified. One effect
of low concentrations of PCP is a blockade of a portion of the
potassium-stimulated 86Rb efflux from rat brain presynaptic nerve
terminals (synaptosomes) (Albuquerque et al. 1981; Albuquerque et
al. 1983; Blaustein and Ickowicz 1983). These studies led to the
suggestion that PCP may selectively block certain potassium chan-
nels, and that this effect might account for the behavioral action
of the drug (Albuquerque et al. 1981; Albuquerque et al. 1983;
Blaustein and Ickowicz 1983).
ferent fractions of 86Rb efflux from synaptosomes (Bartschat and
Recently, we succeeded in separating four pharmacologically-dif-
Blaustein 1985a; Bartschat and Blaustein 1985b), which correspond
to four different types of K channels. Submicromolar to micro-
molar concentrations of PCP and behaviorally-active congeners
selectively block one of these channels--a voltage-regulated, non-
inactivating (or very slowly inactivating) K channel in nerve
terminals. The rank order of potency for block of these K chan-
nels paralleled both the relative ability of these agents to pro-
duce characteristic behavioral deficits in rats (Shannon, 1983),
and their ability to displace 3H-PCP from its high affinity bind-
ing sites in brain (Vincent et al. 1978; Zukin and Zukin 1979;
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Sorensen and Blaustein 1985a). In view of the enhanced neuro-
transmitter release that would be expected to accompany block of
presynaptic K channels (Llinas et al. 1976), this mechanism could
explain the PCP-induced "dopamine storm" (Rappolt et al. 1980).
Such altered synaptic transmission at central synapses may under-
lie the disordered behavior characteristic of PCP intoxication.
The aforementioned observations imply that the high affinity PCP
binding sites in the brain are K channels. Therefore, as a prel-
ude to the eventual isolation and characterization of these PCP
"receptors"/K channels, we employed a tritiated photo affinity
analogue of PCP, m-azido-3H-PCP (3H-Az-PCP) to label rat brain,
synaptic membrane proteins. The results indicate that this ana-
logue binds specifically to two membrane polypeptides of a parent
MR 80,000 and 95,000 Daltons (Sorensen and Blaustein 1985b).
IDENTlFICATION OF K CHANNELS IN SYNAPTOSOMES WITH TRACER 86Rb
EFFLUX
Rb efflux from synaptosomes loaded with 86Rb was used to assess
the K permeability of the nerve terminals under "resting" condi-
tions, and under conditions in which the terminals were depolar-
ized by elevating the external
half-life 36 times longer than 42K,
k concentration, [K]o. With a
86Rb is a suitable tracer for
K because (Bartschat and Blaustein 1985a; Bartschat and Blaustein
1985b): (1) Rb, like K, is accumulated by synaptosomes via a
metabolically active, ouabain-sensitive route; (2) Rb permeates
most neuronal K channels nearly as well
(3) synaptosomes preloaded with both
as does K itself; and
42K and 86Rb have qualita-
tively similar K and Rb effluxes.
Voltage-regulated K channel activity in synaptosomes was measured
as described in the figure 1 legend. For further details, see
Bartschat and Blaustein (1985a).
[K]o; open circles in figure 1),
Under "resting" conditions (5 mM
86Rb efflux was about 0.3 to
0.4%/sec (component "R"), which corresponds to a resting K per-
meability of 2.4x10-7cm/sec (Bartschat and Blaustein 1985a). Rb
efflux under these conditions probably reflects the mechanism(s)
responsible for the normal K permeability of the resting
terminals.
Depolarization of the synaptosomes with Ca-free media containing
100mM K increased 86Rb efflux (figure 1, open squares); two
kinetically and pharmacologically distinct K conductances could be
discerned. Between 1 and 4 seconds, Rb efflux was linear and was
2.2 to 2.4%/sec (component "S"). Extrapolation of Rb efflux to
the
of 86Rb efflux (component "T").
ordinate ("zero time") exposed an additional, rapid component
Component T reflects a distinct K
channel that, unlike component S, appeared to inactivate in less
than 1 second (Bartschat and Blaustein 1985a).
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FIGURE 1. Time course  o f
8 6 Rb e f f lux from synaptosomes ; t h e
NOTE:
e f f e c t  o f  P C P
Synaptosomes were prepared as described (Krueger et al. 1979), were equil-
ibrated with
late tracer 86Rb (20 µCi/ml in PSS) at 30 °C for 30 minutes. PSS contained
hysiologlcal salt solution (PSS). and were allowed to accumu-
(mM): KCI, 5; NaCl, 145; MgCI2, 2; glucose, 10; HEPES buffer, 10, titrated
to ph  7.4 with NaOH; Na2 HPO4,  0.5; and unlabelled RbCI, 0.1. Aliquots
(30 µl) of the synaptosomal suspension were then pipetted onto glass fiber
filters, were washed free of extracellular tracer, and then exposed to
efflux media for various lengths of time (1 to 4 seconds). Efflux was ter-
minated by rapid addition of “stopping solution” containing the K channel
blockers tetraethylamnonium (145 mM) and tetrabutylamnonium (5 mM), but no
NaCl or KCI. Suction was rapidly applied, and the filters and filtrates
were counted by Iiquid scintillation spectroscopy; Rb efflux was expressed
as:
The efflux medium was similar to the loading medium; however, In exper-
iments involving elevated [K]o, K replaced Na mole-for-mole. When drugs
were tested, they were Included In the wash media facilitate equilibra-
tion with the synaptosomes. Symbols correspond to Rb efflux in: 5 mM
K ( 0), 100 mM K (control; ), 100 mM K + 10 µM PCP ( ). or 100 mH K +
100 µM PCP . The data points are the means of six determinations.
The components of 86Rb efflux indicated in the figure represent: R = Rb
efflux in 5 mH K media (expressed in %/sec); S = Rb efflux between 1 and 4
seconds (%/set) in K-rich media minus component R; T = K-dependent incre-
ment (%) In Rb efflux when S is extrapolated back to zero time. SV =
component of S that is blocked by PCP; SR = PCP-lnsensltive portion of
component S.
Inclusion of Ca in the efflux media enhanced 86Rb efflux in 100 mM
[K]o but not 5 mM [K]o (data not shown). This Ca-dependent 
86Rb
efflux (component "C") appears to be a manifestation of TEA-sensi-
tive, Ca-regulated K channels (Bartschat and Blaustein 1985a;
Bartschat and Blaustein 1985b).
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Pharmacological evidence indicates that components R, S, T, and C
correspond to distinct classes of K channels (Bartschat and
Blaustein 1985a; Bartschat and Blaustein 1985b). Component T is
blocked by low concentrations of 4-aminopyridine (4-AP); component
C is selectively blocked by micromolar quinine sulfate, but not by
4-AP. Components R and S are much less sensitive to both drugs.
EFFECTS OF PCP ON K CHANNELS IN SYNAPTOSOMES
To determine which of these K channels are inhibited by PCP, this
drug was tested for its ability to block the various components of
Rb efflux. In the experiment of figure 1, the effects of 10 µM
PCP (closed circles) and 100 µM PCP (closed squares) were examined
d e p r e s s e d
in nominally Ca-free solutions. In 100 mM [K]o medium, 10 µM PCP
86Rb efflux through S by about 35 percent, but had neg-
ligible effect on component T. Increasing PCP to 100 µM had no
additional effect on S, but blocked component T by about 45 per-
cent. Although not shown here, component R and the Ca-dependent
component, C, were virtually unchanged by 100 µM PCP.
The dose-response curves for the effects of PCP on components S
and T are illustrated in figure 2. Note that low doses of PCP se-
lectively blocked a portion (about one-third) of component S (SV);
higher doses inhibited T, as well, with but little additional ef-
fect on S.
FIGURE 2. PCP dose-response curves for the inhibition of compo-
nents  S  ( ) and T ( )
NOTE: The data points are the means of 4 determinations, ± SEW. SimiIar results
were obtained in 3 other experlments.
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EFFLUX COMPONENT S CAN BE DIVIDED INTO TWO FRACTIONS, SR AND SV,
WITH DIFFERENT PROPERTIES
Before trying to interpret this partial inhibition of S by PCP, we
need to consider the influence of membrane potential on the 86Rb
efflux. To obtain information about the relationship between com-
ponent S and membrane potential, we measured S (increase in the
slope of 86Rb efflux between 2 and 4 seconds) as a function of
[K]o in the efflux solution, in the absence of drug. These data
are shown in figure 3 (solid circles); the calculated depolariza-
tion, due to increasing [K]o, is given in the upper abscissa
scale.
FIGURE 3. Effect of PCP on 8 6Rb efflux component S
NOTE: The magnitude of component S at the indicated [K] was expressed as the
slops of the least squares line fitting Rb efflox°between 2 and 4 seconds
for control (•) and 100 µM PCP-containing solution (o). The dotted line Is
the expected contrlbutlon of the "resting” K permeablllty (R) to component
S due to electrodiffusion effects (i.e., SR) when the synaptosomes are de-
polarized to the level lndicated In the upper abscissa (also see Bartschat
and Elsusteln 1985a). The data points are the means of 4 determinatlons.
As discussed previously (Bartschat and Blaustein 1985a), depolar-
ization of
flux of  86Rb through the "resting" K permeability (component R),
the terminals should increase the driving force for ef-
even if there is no increase in conductance (i.e., no voltage gat-
ing of R). The magnitude of this calculated electrodiffusion com-
ponent of 86Rb efflux through the "resting" K conductance, denoted
as SR, is shown as the dotted line in figure 3 (also see figure 6c
in Bartschat and Blaustein 1985a). The difference between this
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dotted line (fraction SR) and the solid line (component S) presum-
ably represents the voltage-regulated fraction of component S,
denoted as SV.
THE EFFECT OF PCP ON 86Rb EFFLUX THROUGH COMPONENT S
If two different types of K conductances contribute to component
S, we might anticipate that some drugs will affect the two conduc-
tances differently. Indeed, the dose-response curves for inhibi-
tion of S by tetra-alkylamines and 4-AP appear to be biphasic
(Bartschat and Blaustein 1985a), which is consistent with this
prediction. The obviously biphasic dose-response curve for PCP
inhibition of component S (figure 2, open circles) provides fur-
ther evidence for this view.
Note that the magnitude of component S measured as a function of
[Klo in the presence of 100 µM PCP (figure 3, open circles) cor-
responds very closely to the calculated magnitude of SR (figure 3,
dotted line). These data clearly indicate that components SR and
Sv are different. Component SV
voltage-regulated, noninactivat
apparently is a manifestation of
ing K channels, and is blocked
selectively by low concentrations of PCP. Since the "resting" 86Rb
efflux is unaffected by these conc
we would not expect PCP to affect
entrations of PCP (not shown),
86Rb efflux component SR if this
flux is mediated by the resting K conductance, as described.
The concentration of PCP that inhibits SV by 50 percent (IC50) is
about 1 µM (figure 2, open circles). This is within the range of
doses that produce confusional psychosis (0.1 to 1.0 mg/kg, corre-
sponding to about 0.1 to 1 µM) (Burns and Lerner 1981). Higher
concentrations of PCP induce convulsions and coma (Burns and
Lerner 1981). Assuming that block of the K channels corresponding
to SV does cause the behavioral deficit, it is important to con-
sider the possibility that block of only a small fraction of these
K channels may be sufficient to induce behavioral change.
THE EFFECTS OF PCP ANALOGUES ON COMPONENT Sv
If the behavioral activity of PCP is related to its block of pre-
synaptic K channels (Albuquerque et al. 1981; Albuquerque et al.
1983; Blaustein and Ickowicz 1983), PCP-like analogues should
block these same K channels with a rank order of potency that
parallels their relative in vivo psychotomimetic activity. One of
the most behaviorally potent PCP-like agents is TCP (1-[1-(2-
thienyl)-cyclohexyl] piperidine) (Shannon 1983). Figure 4 illus-
trates the dose-response curves for the block of components S and
T by this drug. The data indicate that TCP is a more potent
blocker of Sv than is PCP (figure 2). TCP blocked component T
only at high concentrations (>1O-5 M), and in this respect was
approximately equivalent in potency to PCP (figure 2).
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FIGURE 4. Dose-response curve illustrating the effects of the PCP
analogue  TCP on components  ( ) and T (o)
NOTE: The experiment was carried out as described in the figure 1 legend. The
data points are the means of 6 determinations.
Figure 5 compares the ability of PCP and two of its congeners,
meta-amino-PCP (m-NH2-PCP)
block component S. All
and meta-nitro-PCP (m-NO2-PCP), to
three drugs selectively blocked Sv, but
with very different affinities. The rank order of potency for
block of Sv by these three drugs and TCP (figure 4) was: TCP, m-
NH2-PCP>PCP>m-NO2-PCP. This same sequence was observed when these
agents were examined in various behavioral impairment paradigms
that have been used to assess the psychotomimetic liability of
these and related agents (Albuquerque et al. 1981; Shannon 1983;
Aguayo et al. 1984). In contrast, all of these agents blocked T
only at higher concentrations (IC5O's=100-500 µM; data not shown).
The similarity between the relative potency of block of Sv by PCP-
like drugs and the effects of these drugs in the behavioral
impairment paradigms strongly supports the view that blockade of
voltage-regulated, noninactivating K channels may be directly
involved in the psychotomimetic actions of these drugs.
THE EFFECTS OF "SIGMA OPIATES" ON COMPONENT SV
Several "sigma opiates," which differ structurally from PCP, are
known to induce a PCP-like toxic psychosis, and to displace PCP
from rat brain membranes (Zukin 1982; Hampton et al. 1982;
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FIGURE 5. The e f f ects  o f  the  PCP (  ), m-NH2-PCP (o), and m-NO2-
P C P  ( ) on component S
NOTE: The experiments were carried out as described in the figure 1 legend. The
data points are the means of SiX determinations.
Mendelsohn et al. 1984; Murray and Leid 1984). Of particular in-
terest are several stereoisomer pairs of "sigma opiates," one
isomer of which produces PCP-like behavioral effects and displaces
bound 3H-PCP more potently than the other. These agents should be
especially well suited for a test of the hypothesis mentioned in
the preceding section, namely, that induction of the PCP-like be-
havioral deficit can be correlated with block of SV.
We examined the
opiates" on 86Rb efflux in synaptosomes in the presence of 10 µM
effects of three such stereoisomer pairs of "sigma
naloxone (to avoid classical opiate effects). Our data show
(Bartschat et al. 1985) that dexoxadrol blocks Sv at one-
thousandth the concentration of its stereoisomer, levoxadrol;
(+)NANM (N-allyl-normetazocine or SKF-10,047) is tenfold more
potent than (-)NANM; and (-)cyclazocine is two- to threefold more
potent than (+)cyclarocine. This stereoselectivity for block of
SV closely parallels the effects of these stereoisomers in behav-
ioral and binding experiments (table 1). Furthermore, block of Sv
occurs at nano- to micromolar concentrations of the more potent
"sigma opiates"-- comparable to the concentrations at which PCP and
its more potent congeners act.
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TABLE 1. Comparison o f  act ions  o f  s tereoisomer pairs  o f  "s igma
















IDENTIFICATION OF THE RAT BRAIN PCP RECEPTOR
The aforementioned results are consistent with the view that the
rat brain PCP/"sigma opiate" high-affinity receptor is associated
with the voltage-regulated, noninactivating K channels in the pre-
synaptic terminals. Thus, we reasoned that the elucidation of the
molecular composition of this PCP "receptor" might provide direct
information about the subunit composition of these K channels.
This could also prove to be a very useful first step in the effort
to purify and characterize the channel protein. To label and
identify the brain PCP receptor, we synthesized a tritiated photo
affinity analogue of PCP, m-azido-3H-phencyclidine (3H-Az-PCP)
(Haring and Kloog 1984). This photolabile ligand binds with high
affinity (K0.5 0.9 µM) to the rat brain PCP receptor (Sorensen
and Blaustein 1984) As illustrated by the fluorogram in figure
6, when rat brain sinaptic membranes were incubated with 3H-Az-PCP
and irradiated, several polypeptides incorporated the label. How-
ever, when excess unlabelled PCP was added before the samples were
irradiated, incorporation of the label was markedly reduced in
only two of the polypeptides, MR=80 kD (80,000 Daltons; P80) and
95 kD (P95). respectively. P95 was labelled more heavily than
P80, and may, therefore, include the primary PCP binding site;
however, we have not yet ruled out the possibility that P80 is a
product of proteolytic cleavage (Sorensen and Blaustein 1985b).
Covalent labelling of these two polypeptides was also specifically
blocked by other PCP analogues such as TCP, by some K channel
blockers (4-AP and tetrabutylammonium ions), and stereoselectively
by certain PCP-like "sigma opiates" (dexoxadrol >> levoxadrol)
(not shown). The latter results parallel the ability of these
ligands to displace 3H-PCP from rat brain membranes and to block
86Rb efflux component Sv in synaptosomes (Sorensen and Blaustein
1985a; Bartschat et al. 1985).
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FIGURE 6. Fluorogram showing the covalent attachment of 3H-Az-PCP
to rat  bra in  synapt ic  membrane  polypept ides
NOTE: Synaptic membranes were incubated in the dark for 60 minutes at 0 °C in
either 54 mM3Tris-HEPES (A) or 5 mM sodium phosphate (B) buffers at pH 7.0,
with 1.0 µM H-Az-PCP, without (-) or with (+) a five hundredfold excess of
unlabelled PCP. The samples were then Irradiated with 366 nm UV light for
15 minutes (irradiation at 254 nm UV light for 5 minutes gives similar re-
sults) to pnotolyze the Az-PCP. The membranes were solubilized in sodium
dodecyl sulfate (SDS) dissociation buffer overnight. and subjected to SDS-
polyacrylamide gel electrophoresis. The resulting geIs were impregnated
with “Fluore-Hance” (RPI, Mt. Prospect, III.) dried, and exposed to Kodak
X-Omat AR film for several weeks to obtain fluorographic patterns of the
labelled polypeptides. Several polypeptldes that incorporate label are
lndlcated as PN where N is defined as the apparent molecular weight (kD) of
the polypeptlde x 10-3. Molecular weight standards are also Indicated.
The acetylcholine receptor (AChR) of Torpedo electric organ is
also a PCP "receptor." However, this nicotinic AChR has about
one-tenth the affinity for PCP than that of the rat brain PCP re-
ceptor [K0.5 0.3 µM , versus  4-6 µM for Torpedo (Heidmann et
al. 1983; flaring et al. 1984)]. Moreover, the nicotinic AChR has
subunits of MR<66 kD, and these are the subunits that are specifi-
cally labelled with 3H-AZ-PCP in the Torpedo electroplax membranes
(Heidmann et al. 1983; Haring and Kloog 1984; Haring et al. 1984).
These data indicate that the nicotinic AChR-PCP receptor differs
from the rat brain PCP receptor. Furthermore, our findings are
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consistent with the view that the rat brain PCP receptor is the
voltage-regulated, noninactivating K channel in the nerve termi-
nals, and that this channel consists of at least two subunits of
MR=80 kD and 95 kD.
HOW DOES PCP PRODUCE ITS BEHAVIORAL EFFECTS?
The
of 86Rb efflux component SV,
striking correlation between behavioral potency and block
for PCP analogues and the stereo-
isomer pairs of "sigma opiates," provides strong circumstantial
evidence that the K channel block may underlie the behavioral
effects of these drugs. Block of K channels at the nerve tetmi-
nals should prolong the nerve action potential and thereby enhance
Ca entry into the terminals. This would in turn, alter synaptic
transmission by increasing Ca-dependent neurotransmitter release;
virtually all neurotransmitter types might be affected, depending
upon the distribution in the brain of these PCP-sensitive, volt-
age-regulated K channels. Such disruption of synaptic transmis-
sion at central synapses could induce the disordered behavior that
is characteristic of PCP intoxication. Thus, our observations may
provide the physiological link between the binding of PCP to its
high-affinity receptor in the brain and the ultimate behavioral
effects of PCP intoxication.
It should be pointed out that PCP analogues also have a prominent
postsynaptic action: they block the channels associated with the
nicotinic cholinergic receptors (Albuquerque et al. 1981;
Albuquerque et al. 1983). However, many of the analogues that
display potent antinicotinic activity are behaviorally inactive
(Albuquerque et al. 1983), whereas our data demonstrate that there
is a direct relationship between block of certain presynaptic K
channels and behavioral potency; the stereoselective effects of
the "sigma opiates" are particularly striking in this regard
(table 1). This supports the view that presynaptic K channels are
the primary sites of action of these drugs in the brain. More-
over, our data indicate that the voltage-regulated, noninactivat-
ing K channels may be the high-affinity PCP binding sites, and
that PCP may be a useful ligand to help identify and isolate these
K channels.
The behavioral effects of PCP have been associated with excessive
release of a wide variety of neurotransmitters: in particular, a
massive dopamine release may underlie some of the most prominent
symptoms of PCP intoxication (Rappolt et al. 1980). Our results
readily explain the genesis of such an effect, because activation
of presynaptic K channels is one of the primary factors that in-
fluences Ca entry into nerve terminals and Ca-dependent transmit-
ter release by limiting action-potential duration and regulating
excitability.
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There is ample precedent for a modulatory role of K channels in
behavior. The K channel blocker, 4-AP, selectively blocks compo-
nent T (Bartschat and Blaustein 1985a). prolongs nerve action
potentials, and enhances neurotransmitter release (Llinas et al.
1976). In man, intoxication with this agent may lead to dissocia-
tive behavior, agitation, confusion, convulsions, and coma (Spyker
et al. 1980). However, the behavioral aberrations induced by 4-AP
differ qualitatively from those induced by PCP. This implies that
block of various types of presynaptic K channels may modify behav-
ior and mental activity; however, the precise nature of the behav-
ioral manifestations is likely to depend upon the specific type of
K channel that is affected.
In man, PCP intoxication causes a profound perceptual and cogni-
tive disturbance that resembles the primary symptoms of schizo-
phrenia (Domino and Luby 1981). According to the popular
"dopamine hypothesis," the positive symptoms (e.g., thought dis-
order and delusions) of schizophrenia are associated with an
excessive release of dopamine (by an unknown mechanism). These
symptoms can often be curtailed by treatment with neuroleptics,
agents that block dopamine receptors (Seeman 1980). However, the
negative symptoms (e.g., flattened affect and anhedonia) are not
alleviated by the neuroleptics, and are likely to be associated
with other, nondopaminergic pathways (Crow 1980). PCP intoxica-
tion reproduces both the positive and negative symptoms of schizo-
phrenia (Domino and Luby 1981). In view of the evidence that
schizophrenia may be an inherited disorder (Kety et al. 1978), and
that neurotransmitter pathways other than dopaminergic pathways
may be involved in producing some of the behavioral aberrations
(Hornykiewicz 1982; Henn 1983), recent findings (Albuquerque et
al. 1981; Albuquerque et al. 1983; Blaustein and Ickowicz 1983)
raise the possibility that the inherited defect could involve a
primary alteration in the ion channels responsible for the mainte-
nance of normal electrical activity in the nervous system. For
example, a defect in K channel activation could lead to prolonga-
tion of action potentials at nerve terminals and, thus, to exces-
sive release of a wide variety of neurotransmitters, including
dopamine.
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Mechanisms in the Actions of
Phencyclidine-Like Drugs
Kenneth M. Johnson and Lawrence D. Snell
INTRODUCTION
Although there is good evidence that administration of phencycli-
dine (PCP) to rodents alters the synthesis, metabolism, release,
or reuptake of several neurotransmitters, including serotonin,
norepinephrine, GABA, acetylcholine (ACh), and methionine enkepha-
lin, most of the research in this area has been on dopamine (DA).
The reasons underlying the interest in DA are several. Perhaps
the most important is the similarity seen by most investigators
between schizophrenia and PCP-induced psychosis in humans. This
has been coupled with the observation that PCP-induced stereotypy,
locomotor activity, and rotational behavior can be blocked by
antischizophrenic agents that are DA receptor antagonists. The DA
connection has been strengthened substantially by studies from
several laboratories showing that PCP, like amfonelic acid, en-
hances DA synthesis and release, and blocks its subsequent re-
uptake (Johnson 1983). However, because of the complexity of the
neuronal systems subserving even relatively simple behaviors such
as stereotypy or circling behavior in rats with unilateral de-
struction of the nigrostriatal dopaminergic pathway, it is possi-
ble that the dopaminergic properties of PCP are not the primary
factors that underlie these behavioral properties. One of the
primary goals of the studies presented here was to determine the
relevance of the known dopaminergic properties of PCP to the
ipsilateral turning produced by PCP administration to rats.
Another characteristic of PCP which has been studied with great
interest over the last 5 years, is the ability of PCP to produce a
discriminative stimulus in monkeys, rats, and pigeons. As dis-
cussed elsewhere in this volume, by Browne, the discriminative
stimulus properties of PCP are shared not only by other members of
the arylcycloalkylamine class, but by psychotomimetic benzo-
morphans and substituted dioxolanes. The structure-activity
relationships (SAR) within and between these classes are virtually
identical to those found when studying the displacement of 3H-PCP
from its binding site in rat brain membranes. This correlation
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between the behavioral and binding data suggests that this binding
site could be part of a physiologically relevant receptor.
Although some progress is being made toward the identification of
an endogenous ligand for this receptor (DiMaggio et al., this
volume), many questions remain unanswered. For example, on what
kinds of neurons are these receptors located? What is their
function? How is this function carried out? A more specific
question, which we sought to answer, was whether facilitation of
DA release or blockade of its reuptake could be mediated by an
action at this receptor.
One of the difficulties in the pharmacological analysis of drug-
induced behavior is that the same behavior may be affected in a
similar fashion by a variety of drugs. For example, PCP-induced
turning is inhibited by alpha-methyl-p-tyrosine (an inhibitor of
tyrosine hydroxylase) and arecoline (a muscarininc agonist)
(Finnegan et al. 1976). Similarly, PCP-induced behaviors are
facilitated by amphetamine (Balster and Chait 1978) and physostig-
mine (Finnegan et al. 1976). Thus, behaviors such as turning,
which are thought to be largely mediated in the striatum, are
somewhat difficult to analyze because of the balance between
cholinergic and dopaminergic neurons in that area (Pycock et al.
1978). That balance may be influenced considerably by the excita-
tory (presumably glutamatergic) input from the cortex. The poten-
tial importance of this input was revealed by studies that showed
that PCP and several drugs with PCP-like discriminative stimulus
properties selectively antagonized spinal neuron excitation by N-
methyl-D-aspartate (NMDA), an agent believed to selectively acti-
vate one of three putative glutamate receptors (Lodge et al. 1982;
Berry et al. 1984a; Berry et al. 1984b). In addition, this labo-
ratory recently reported that PCP potently inhibited NMDA-induced
ACh release from the rat striatum (Snell and Johnson 1984; Snell
and Johnson, in press). Therefore, another goal of the studies
reported here was to determine whether ACh release could be influ-
enced by PCP, either by virtue of its ability to release DA or by
antagonism of glutamate, in a way that was correlated with turning
behavior. By using the SAR approach, we also hoped to determine
whether PCP/sigma receptors might be mediating any of the effects
we observed on DA or ACh function in the striatum.
METHODS
Male Sprague-Dawley rats (200-300 gm) were used in all experi-
ments. Dopamine uptake was measured using the accumulation of
tritium into a striatal synaptosomal fraction in the presence of
an MAO inhibitor following a 5-minute incubation period with
10 nM 3H-DA at 37 °C. Uptake at 2 °C was used as a control for
uptake by diffusion and was subtracted from uptake at 37 °C.
Other details have been published previously (Johnson and Snell
1985).
To measure the spontaneous efflux of DA, we preincubated striatal
slices (0.4 mm) in a modified Tyrode's buffer containing pargyline
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and 10 nM 3H-DA for 30 minutes. Slices were loaded into plexiglas
superfusion chambers (0.4 ml) and superfused with buffer at a con-
stant rate of 0.7 ml/min. Superfusate was collected in 5-minute
fractions and radioactivity estimated by liquid scintillation
spectrometry. Fractional release was calculated as the percent of
radioactivity in each fraction, relative to that which was in the
slice at that time (radioactivity in the slice was counted at the
end of the experiment). Fractional release reached a stable base-
line of about 1 percent after 30 minutes of superfusion. Drugs
were added in various concentrations 15 minutes later, for a peri-
od of 15 minutes. Drug-induced increases in spontaneous 3H-DA
efflux were estimated by subtracting the average of the fraction
before addition of drug and the fraction collecting 25 minutes
after the removal of drug from each of the eight fractions in
between. This technique is published in detail elsewhere (Snell
et al. 1984).
The effects of various PCP-like drugs on K+ and NMDA-induced ACh
release were studied in a similar superfusion paradigm. KCl (30
mM) was used as a depolarizing stimulus as previously described
(Leventer and Johnson 1983). As with K+ stimulation, in the study
of NMDA-induced ACh release, slices were loaded with 3H-choline
(50 nM) and then superfused
(to prevent the reuptake of
with buffer containing hemicholinium-3
3H-choline formed from the extra-
neuronal hydrolysis of newly synthesized and released 3H-acetyl-
choline), until a stable baseline was reached (60 minutes).
Superfusion was continued and the collection of 3-minute fractions
was begun. Buffer containing test drug or vehicle was added 9
minutes prior to the addition of an excitatory amino acid (usually
1 mM NMDA) for 2 minutes. Fractional release over baseline was
estimated in a manner similar to that described above for 3H-DA
release. This paradigm was slightly modified to allow the study
of NMDA-induced 3H-DA release as well.
The effect of PCP-like drugs was also studied in vivo. In these
experiments, the ability of these drugs to enhance haloperidol-
induced DA metabolism was assessed by measuring DA and homovanil-
lic acid (HVA) concentrations in the striatum. In this paradigm,
saline or drug was administered (SC) immediately after the admin-
istration of 0.1. mg/kg haloperidol. The rats were killed 45
minutes later, and DA and HVA levels were estimated fluorometri-
tally (Snell et al. 1984).
Turning behavior in rats was measured after unilateral administra-
tion of 8 µg of 6-hydroxydopamine into the substantia nigra.
Details of the injection procedure and experimental protocol were
described in Johnson and Snell, 1985.
In order to determine the potential correlation between any of
these variables and affinity for the PCP/sigma receptor, we deter-
mined the concentration of these drugs required to displace spe-
cific binding of 3H-PCP to rat cortical membranes (Johnson and
Snell 1985). In other experiments, we determined the effect of
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NMDA on the affinity and binding site density by Scatchard
analysis, as described in the note with table 4.
RESULTS
Turning Behavior
All the drugs tested in these experiments were administered (IP)
at doses ranging from 3 to 10 mg/kg (except for ketamine, which
was tested at 10, 30, and 100 mg/kg). All the rats used had
previously turned contralaterally in response to 0.05 mg/kg apo-
morphine HCl. Net ipsilateral rotations were counted in two
consecutive 15-minute bins, immediately following drug (or saline)
administration.
PCP produced a dose-related increase in ipsilateral turning, as
reported previously (Fessler et al. 1979). However, the effects
of N-ethyl-phenylcyclohexylamine (PCE) and ketamine were related
to dose in an inverse manner. This inverse dose-relationship was
apparent in both 15-minute periods, and appeared to be due to a
general motor incapacitation. With PCE, ipsilateral posturing was
apparent, but hindlimb coordination was grossly impaired. Keta-
mine, on the other hand, seemed to reduce turning by virtue of
gross sedation (after 100 mg/kg, the rats were totally akinetic).
N-Allylnormetazocine (NANM) produced results virtually identical
with those of PCP (about 25 turns in the first 15-minute period
after 10 mg/kg). Cyclazocine was a little more potent than PCP,
and etoxadrol was more potent than cyclazocine, although turning
was impaired by ataxia at the higher dose of each. Neither keto-
cyclazocine nor ethylketocyclazocine (EKC) produced any signifi-
cant rotation at the doses tested. If these drugs are ranked for
effectiveness in the first 15-minute period (without regard to
dose), one obtains the following rank: PCE, etoxadrol > cyclazo-
tine, NANM, PCP > ketamine >> EKC, ketocyclazocine (Johnson and
Snell 1985).
The ineffectiveness of the latter two kappa agonists suggested
that this effect might be partially mediated via the PCP/sigma
receptor. To test this notion further, we utilized three related
pairs of drugs, each of which has one member that is more potent
than the other in displacing 3H-PCP from its binding site, and in
eliciting PCP-like responding in rats trained to discriminate PCP
from saline. These data are shown in table 1. In the first 15
minutes following administration, 1-[1-(napthyl)cyclohexyllpiperi-
dine, (m-NH2-PCP), dexoxadrol and (-) cyclazocine induced signif-
icant ipsilateral turning, while their counterparts, 1-[(m-
nitrophenyl)cyclohexyl]piperidine, (m-NO2-PCP), levoxadrol, and
(+) cyclazocine did not. (-) Cyclazocine and m-NH2-PCP caused
significant ataxia, as evidenced by reduced turning rates in the
second 15-minute time period. Ataxia produced by dexoxadrol and
etoxadrol (data not shown) was less severe. Although (-) cyclazo-
cine was clearly more effective than (+) cyclazocine in the first
15-minute period, it was somewhat less active than (+) cyclazocine
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TABLE 1. Effect of some PCP-like drugs on turning behavior
Drug
Net Ipsilateral Turns
Mg/ Kg (N) O-15 Min 15-30 Min
m-NH2-PCP 10 (3) 63 ± 2 1_+l
m-N02-PCP 10 (3) 8.0 ± 3.5 5.3 ± 2.9
Dexoxadrol 10 (6) 50 ± 15* 105 ± 17**
Levoxadrol 10 (6) 4.0 ± 1.0
(6) ±
2.5 ± 1.5
(-) Cyclazocine 5 48 13* 11 ± 6.0
(+) Cyclazocine 5 (3) 6.3 ± 5.3 19 ± 0.9**
*Slgniflcantly different from the turning rate produced by 0.9% NaCl (6.8 ± 2.1).
**Slgniflcantly different from the turning rate produced by 0.9% NaCl (5.0 ± 1.1);
P<.05 (Mann-Whitney U test).
in the second time period. This was probably due to the greater
ataxia produced by the (-) isomer. Thus, the differences between
dexoxadrol and levoxadrol, and between m-NH2-PCP and m-N02-PCP are
obvious, while the difference between the enantiomers of cyclazo-
cine are more subtle, in that each produces turning at different
times following administration. Similar differences between the
enantiomers of dioxadrol and cyclazocine in producing stereotypy




potent, competitive inhibitor of synaptosomal uptake of
3H-norepinephrine, and 3H-serotonin) (Garey and Heath 1976;
Smith et al. 1977). In addition, we found that PCP administration
in vivo resulted in a time- and dose-dependent inhibition of 3H-DA
uptake into striatal slices (Vickroy and Johnson 1980). More
recently, we compared the effects of amphetamine and representa-
tives from each of the three chemical classes known to produce
PCP-like behavioral effects in rats on high-affinity, synaptosomal
uptake of H-DA (Johnson and Snell 1985). IC50 values (x10
-6M)
were as follows: amphetamine
cyclohexylamine (PCE)
(0.06), PCP (O.58), N-ethyl-phenyl-
(9.4), ketamine (24), etoxadrol (38), and N-
allylnormetazocine (NANM or SKF-10,047) (46). Cyclazocine and EKC
were extremely weak inhibitors, producing minimal inhibition even
at 1x10-4 M. Thus, although PCP unquestionably can inhibit DA
reuptake, other drugs with similar behavioral effects (and similar
potency) like PCE, etoxadrol, and cyclazocine are either much
weaker inhibitors or simply lack this property entirely. Further,
the abilities of these drugs to inhibit 3H-DA uptake and to dis-
place 3H-PCP from its binding site in brain membranes were not
significantly correlated (Johnson and Snell 1985).
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Release of 3H-DA
Complete concentration-response curves for representatives from
several chemical classes with PCP-like behavioral properties were
obtained using the in vitro release of 3H-DA from striatal slices
(Snell et al. 1984). Every agent tested produced a significant
increase in spontaneous 3H-DA efflux at 30-100x10-6M. Since none
of the compounds tested appeared to exhibit a maximal effect even
at 1x10-4M, potency was difficult to estimate. In lieu of an
estimate of potency, we report here a simple comparison between
these drugs at the somewhat arbitrary concentration of 1x10-5 M
(table 2). This shows that drugs that are approximately equi-
potent with PCP in producing turning are much less effective at
this concentration than PCP. Further, the differences between
m-NH2-PCP and m-NO2-PCP, and between dexoxadrol and levoxadrol are
insignificant.
Inasmuch as the effects of PCP can be distinguished from those of
amphetamine, at a biochemical level, by measuring the effect of
each on haloperidol-induced DA metabolism, we also determined the
effect of these same drugs, in combination with haloperidol, on
the ratio of HVA to DA, which was used as an index of DA metabo-
lism. In preliminary experiments, 0.1 mg/kg haloperidol increased
the striatal concentration of HVA from 1.20 ± 0.05 µg/g to 2.94 ±
0.26 µg/g while not significantly changing the concentration of DA
(7.95 ± 1.65 µg/g). Thus, the HVA/DA ratio was increased from
0.12 to 0.36 by haloperidol. The data presented in table 2 repre-
sent the percent of the HVA/DA ratio for a haloperidol control
group run the same day for the indicated drug (given immediately
after haloperidol). Amfonelic acid, PCP, and m-NH2-PCP signifi-
cantly enhanced haloperidol-induced DA metabolism as indicated by
an increased HVA/DA ratio. Amphetamine reversed the effect of
haloperidol on HVA/DA, primarily by increasing the concentration
of DA. EKC decreased the HVA level and increased the DA level
significantly. All other drugs tested had no significant effect
on this index of haloperidol-induced DA metabolism.
ACh Release: Depolarization with K+ and Excitatory Amino Acids
The effects of PCP and related compounds on ACh release have been
studied using two modes of depolarization: high K+ and excitatory
amino acids. Both modes result in Ca++-dependent release, but
only the mode of excitatory amino acids is sensitive to tetrodo-
toxin, suggesting that excitatory amino acids elicit an action
potential that is requisite for ACh release. Using K+ (30mM KCl)-
stimulated AC release as the dependent variable, we found that
PCP (3-10x10-6M) and amphetamine (1x1O-6M) inhibited release by 17
to 28 percent, in a manner that was reversible by haloperidol
(Leventer and Johnson 1983). We postulated that PCP inhibited K+-
stimulated ACh release via a release of DA. Later, we found that
(+) NANM and EKC, but not (-) NANM or morphine, also inhibited K+-
stimulated release. This was reversed by naloxone as well as by
haloperidol (Leventer and Johnson 1984). This led us to amend our
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hypothesis to include the possibility that PCP was acting through
delta or possibly kappa opiate receptors to release DA, which then
inhibited ACh release. Although an action at these sites has not
been ruled out, it is apparent from our work with (+) and (-) NANM
and EKC that DA release is probably not a relevant intermediate
(table 2) (Snell et al. 1984).
TABLE 2. Comparative effects of several aryLcycLoalkylamines,
benzomorphans, and substituted dioxolanes on striatal








Amphetamine 34.0 ± 3.7
Amfonelic acid 5.9 ± 0.5
PCP 8.9 ± 1.4
PCE 0.53 ± 0.19
Ketamine 0.44 ± 0.28
m-NH2-PCP 4.14 ± 0.55
m-NO2-PCP 2.68 ± 0.29
NANM 0.91 ± 0.33
EKC 0.47 ± 0.15
Etoxadrol 0.68 ± 0.28
Dexoxadrol 0.86 ± 0.25













*All drugs were administered at a dose of 10 mg/kg (except ketamine, dexoxadrol,
and levoxadrol, which were used at 30 mg/kg).
**At 1x10-5 each of the drugs tested, except ketamine and etoxadrol, signiflcant-
ly enhanced release above buffer controls (-0.38 ± 0.23).
***Significantly different from haloperidol control (p<0.05, Student’s t-test).
Since there is a cortico-striatal glutamatergic pathway that pro-
vides excitatory input onto both dopaminergic terminals and choli-
nergic interneurons, we followed the lead of Lodge and coworkers
(Lodge et al. 1983), and determined the effect of PCP on gluta-
mate-stimulated ACh and DA release. We found that glutamate-
induced release of ACh was mediated primarily through a glutamate
receptor subtype characterized by a selective affinity for the
antagonist 2-aminophosphonovalerate (2-APV) and the agonist, NMDA.
ACh release induced by NMDA is apparently mediated by a Mg++-gated
conductance, as 1.2mM MgCl2 inhibited ACh release stimulated by
NMDA by about 80 percent. Release induced by the prototypic ago-
nists of the other receptor subtypes (quisqualate and kainate)
were unaffected by physiologic concentrations of Mg++. PCP in-
hibited ACh release induced by NMDA, but not that induced by
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quisqualate or kainate. Since PCP enhances the spontaneous efflux
of DA, and DA is known to inhibit ACh release, we examined the
possibility that DA release may be involved in the inhibition of
NMDA-induced ACh release by PCP. We believe that it is not
involved, for the following reasons: (1) the concentrations of
PCP required to inhibit NMDA-induced release of ACh are at least
one-thirty-third of those required to elicit DA release, (2) DA
antagonists such as haloperidol, chlorpromazine, and clozapine do
not reverse the inhibition of ACh release by PCP, and (3) drugs
like etoxadrol, which have little or no potency as indirect DA
agonists, are potent inhibitors of NMDA-induced ACh release. The
concentration of several representatives from the drug classes
with PCP-like behavioral properties required to inhibit NMDA-
induced ACh release by 50 percent are shown in table 3.
























*N.D. = not determined
Two points need to be emphasized concerning the data on ACh
release. First, PCP, etoxadrol, and cyclazocine are very poten t ,
being effective in the same range in which they compete with 3H-
PCP for binding to the PCP/sigma receptor recognition site.
Second, the rank order potency of these drugs in this preparation
correlates very highly with their ability to compete for 3H-PCP
binding sites (r=0.98, unpublished observation) and to mimic the
discriminative stimulus and reinforcing properties of PCP
(Balster, this volume; Browne, this volume). In addition, using
a single concentration of 1x10-7M, we found that the paired drugs
shown in table 1, which produced significant ipsilateral turning,
significantly inhibited NMDA-induced release. Their inactive
counterpart was also inactive at this concentration in inhibiting
ACh release.
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In other experiments, we found that PCP also inhibited ACh release
induced by the amino acid transmitter candidates, L-glutamate and
L-aspartate. Release of ACh by these amino acids had a similar
Mg++sensitivity to that induced by NMDA, suggesting an action of
these amino acids on the N-type receptor. No inhibition of re-
lease by PCP could be seen in the presence of Mg++.
Although inhibition of NMDA-induced DA release by all the drugs
studied was one-sixth to one-half that of inhibition of ACh re-
lease (table 3), the rank order potencies and stereoselectivity of
the effect was similar. One major difference, however, was noted
in our characterization of the response of dopaminergic nerves to
excitatory amino acids. That is, the responses to quisqualate and
kainate were inhibited by both Mg++ and PCP. Thus, the receptor
mediating the response of excitatory amino acids is less selective
in that quisqualate and kainate apparently can stimulate N-type
receptors on dopaminergic terminals (or other neurons modulating
DA release), to cause the release of DA. Further, even in the
presence of Mg++, PCP (1x10-6M) can inhibit release induced by L-
glutamate, quisqialate, and kainate. This could mean that PCP is
somewhat less selective than one would predict from the ACh re-
lease experiments, or that the presence of Mg++ does not totally
inactivate the conductance channel activated by NMDA on these
neurons. Alternatively, since Mg++ completely abolishes NMDA-
induced DA release, PCP may also block quisqualate and kainate
receptors in this preparation.
Analysis of PCP-NHDA Interactions
Since the actions of PCP and related compounds in blocking the re-
sponse to NMDA appear to be well correlated with their affinity
for the PCP/sigma receptor, we wondered whether NMDA and PCP might
compete for the same binding site. Although glutamate had been
shown not to inhibit 3H-PCP binding (Zukin and Zukin 1979), we
thought that glutamate might not have a very high affinity for the
NMDA (PCP?) receptor.
NMDA on the specific,
The effects of several concentrations of
saturable binding of 3H-PCP at equilibrium
to rat cortical membranes were analyzed according to Scatchard;
the results are shown in table 4.
These data show that NMDA does not compete for 3H-PCP binding
sites at co centrations that elicit significant ACh release
(EC50=5x10
-5M). The apparent competition observed at the higher
concentrations may be irrelevant to this question, as significant
inhibition of the ACh or DA release can be observed using 3x10-5M
MDA. However, the competitive inhibition observed at higher NMDA
concentrations may indicate that NMDA binding can influence the
conformation of the PCP/sigma recognition site via an allosteric
mechanism.
In perhaps a more physiologic assessment of the nature of the PCP-
NMDA interaction, we determined the effect of fixed concentrations
of PCP and a classic NMDA antagonist (2-APV) on both ACh and DA
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release stimulated by increasing concentrations of NMDA. As shown
in figure 1, 2-APY (3x10-4M) produced a parallel shift to the
right in the concentration response curve, while PCP (1x10-7M)
produced a nonparallel shift to the right. This suggests that
TABLE 4. Effect of NMDA on 3H-PCP binding to rat cortex







261 17 6.38 ± 0.16
3x10-3M
376 ± 26 6.21 ± 0.59
515 ± 68 6.66 ± 1.1
NOTE: Each value is the mean ±S.E. of 3 independent experiments,
Ic binding of 3H-PCP (defined as that displaceable by 3x10-5M PCP)
 in which specif-
measured at six concentrations ranging from 10 to 1,000 nM.
FIGURE 1. Effect of 2-APV and PCP on NMDA-induced ACh release
(upper  panel )  and DA re lease  ( lower  panel ) .  Each
point  i s  the  mean ±S.E.  o f  4-7  exper iments .
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PCP is not acting as a competitive inhibitor at the NMDA receptor;
thus, PCP and NMDA probably do not share a common recognition
site. Examination of the effect of PCP on NMDA-induced DA release
(figure 1, lower panel) tends to support this conclusion, but is
compromised somewhat by the slightly nonparallel shift produced by
2-APV. This may be due to the fact that NMDA may partially acti-
vate quisqualate and kainate receptors on those neurons that are
not antagonized by 2-APV.
DISCUSSION
This laboratory, as well as others, has shown unequivocally that
PCP affects a variety of parameters related to neurotransmission
in several neuronal systems. This paper has focused on evidence
for the involvement of dopaminergic, cholinergic, and glutama-
tergic pathways, and evidence of their interactions in the rat
striatum. However, the effects of PCP undoubtedly involve other
neuronal systems in other brain areas. Thus, it must be borne in
mind that the data discussed in this paper cannot possibly account
for the more complex behavioral effects of PCP.
On the other hand, restriction of our experimental paradigms to
the striatum does have some advantages. First, the involvement of
the striatum in locomotor activity, stereotypy, and circling
behavior are relatively well understood on anatomical, physio-
logical, and neuropharmacological grounds. Although these behav-
iors are in no way selectively affected by PCP, the relatively
circumscribed anatomical and physiological substrates underlying
these behaviors make their study seem attractive. Our approach
has been to determine, using structure-activity relationships, the
correlation between circling behavior and a variety of neurochem-
ical indices of transmitter function. Once the structure-activity
relationships have been established for a given parameter, one can
determine the correlation with other behaviors, or with other
measures of biological function, in an attempt to identify cause
and effect relationships. However, the urge to jump from a simple
correlation between a given neurochemical parameter and a more
complex behavior such as drug discrimination should be resisted
until appropriate hypotheses can be constructed and tested.
Another advantage in studying the striatum, with particular empha-
sis on dopaminergic mechanisms, is that we may gain some insight
into the factor underlying the production, by PCP, of schizo-
phrenic symptoms in humans.
In this regard, considerable evidence shows that PCP increases
dopaminergic transmission in the striatum (Johnson 1983) and, more
recently, evidence indicates that DA function is increased in the
mesolimbic and mesocortical pathways as well. For example, PCP
administration has been shown to inhibit the firing of cells found
in the ventral tegmental area (Freeman and Bunney 1984) similar to
that observed in the substantia nigra (Raja and Guyenet 1980).
This effect was reversed by haloperidol. On the other hand, lower
doses of PCP (and NANM) increased cell firing in both areas in a
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manner that is insensitive to haloperidol, suggesting significant
nondopaminergic influences on dopamine cells as well (Freeman and
Bunney 1984). In spite of the fact that PCP is a competitive
inhibitor of 3H-DA uptake, which also enhances impulse-dependent
release of DA (Doherty et al, 1980; Johnson and Oeffinger 1981) in
a manner similar to nonamphetamine stimulants such as amfonelic
acid (Doherty et al. 1980; Vickroy and Johnson 1982), the apparent
increased dopaminergic tone produced by PCP administration may not
be a major factor in behavioral alteration. The major argument in
favor of dopaminergic involvement in PCP-induced behaviors (aside
from the neurochemical data) is that DA antagonists reversed the
behavior. Unfortunately, the effects of DA antagonists on behav-
iors such as stereotypy and turning (which are strongly influenced
by DA) could dampen the behavior by acting at a site distinct from
that of the primary site of PCP action. The very weak dopaminer-
gic properties of drugs like NANM, cyclazocine, and dexoxadrol
(Snell et al. 1984; Johnson and Snell 1985), which elicit turning
behavior (Johnson and Snell 1985; Snell and Johnson, in press) and
stereotypy (Contreras et al. 1984; Contreras et al., this volume),
argue in favor of this interpretation of the haloperidol-induced
inhibition of these behaviors. Haloperidol has also been shown to
antagonize PCP- and NANM-induced increases in locomotor activity
(Iwamoto 1981). Destruction of the nucleus accumbens and ventral
tegmental area with 6-OHDA prevented the increased locomotor
activity produced by PCP, but not that produced by caffeine or
scopolamine (French et al. 1984). Administration of 6-OHDA in
either area resulted in a decrease in the binding site density
found for 3H-PCP. These authors have suggested that PCP and NANM
may induce locomotor activity by interacting with PCP/sigma recep-
tors located presynaptically on terminals of the mesolimbic DA
system (Iwamoto 1981; French et al. 1984). There may, therefore,
be a better case for the involvement of DA in PCP-induced loco-
motor activity than for stereotypy or rotational behavior, but
more detailed SAR studies are need to confirm this.
A final comment on the DA studies reviewed here: although PCP
does act as an indirect DA agonist similar to methylphenidate and
amfonelic acid, the effects are apparently not mediated via an
action on PCP/sigma receptors. This conclusion is based on the
absence of a significant correlation between (1) the effects of
several drugs from three chemical classes on DA reuptake, DA
release, or haloperidol-induced DA metabolism, and (2) either drug
discrimination behavior or affinity for the site labelled by 3H-
PCP. This does not rule out the possibility that nonstriatal
dopaminergic mechanisms are important in the general pharmacology
of PCP and related drugs.
The most interesting aspects of the studies reviewed here are that
the drugs having discriminative stimulus properties similar to PCP
also produce ipsilateral turning; and that this behavior is well
correlated with both affinity for the PCP/sigma receptor and the
ability to inhibit the effects of NMDA on transmitter release in
the striatum. Although inhibition of NMDA-induced DA release was
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not as extensively characterized from an SAR standpoint as was the
inhibition of NMDA-induced ACh release, similar rank order potency
and stereoselectivity were apparent. Since striatal DA neurons
inhibit cholinergic interneurons, blockade of an excitatory input
onto both neurons would effectively cancel any effect on net out-
put from the striatum. However, two points should be considered.
First, the pharmacologic effect in vivo would be dependent on the
endogenous excitatory input (or tone) on these neuronal elements.
That is, if there is very little excitatory input to the dopami-
nergic terminals relative to the cholinergic interneurons, then
the blockade of excitation by PCP would significantly reduce cho-
linergic output. However, the relative excitatory tone on these
nerves is unknown. Second, the two- to sixfold greater potency of
PCP-like drugs on ACh release may relegate the effects on DA
release to secondary importance. If this were not the case, one
might expect to observe an increase in ACh release following
blockade of an excitatory input onto the inhibitory dopaminergic
neurons. We never observed this at concentrations as high as
1x10-6 M PCP. It would appear that the inhibition of ACh release
is most important. This indirect anticholinergic effect could be
the basis for PCP-induced turning in this model.
The global nature of glutamate/aspartate distribution and function
suggests the tremendous potential of this mechanism in other PCP-
induced behaviors. To determine something of the universality of
this phenomenon, we have conducted preliminary studies in several
brain areas. We have found that PCP inhibits NMDA-induced ACh re-
lease from the nucleus accumbens and dendritic DA release from the
substantia nicra. It would be easy to imagine that PCP modulates
excitatory transmission in numerous CNS pathways in addition. How
this occurs at a molecular level is open to speculation. Since
PCP is known to block both Na+ and K+ conductances, and since NMDA
is thought to activate a channel possibly conducting both Na+ and
K+, our working hypothesis is that PCP and glutamate (or aspar-
tate) modulate the same conductance channel. At very high concen-
trations of NMDA, the configuration of the channel and the nearby
PCP/sigma site may be sufficiently altered to account for the
apparent decreased affinity that we observed for 3H-PCP in the
presence of NMDA. At this point, this hypothesis is very tenta-
tive, but it will be actively investigated by our laboratory in
the future.
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INTRODUCTION
Phencyclidine (1-(1-phenylcyclohexyl)piperidine (PCP)) was the
first in a series of arylcycloalkylamines synthesized in an at-
tempt to develop an intravenous general anesthetic agent. The
compound was subsequently found to produce a complex profile of
acute and chronic effects on overt behavior in animals and humans
(Balster and Chait 1976; Domino 1964; Luby et al. 1958) and cen-
tral nervous system function, including convulsions (Chen et al.
1959; Matsuzaki and Dowling 1984; Snyder et al. 1981; Winters
1976). In humans, the acute effects of PCP overdosage implicated
in fatalities include seizures and cardiovascular collapse (Burns
and Lerner 1981)) although the most probable cause of death in
humans (Burns and Lerner 1978) and in animals (Chen et al. 1959;
Hackett et al. 1981) is respiratory depression. The production of
end-state convulsive-like activity at lethal doses is common to
many analogs of PCP, with the possible exception of ketamine
(Mattia et al., this volume). Animals administered PCP or PCP
analogs do not move through a dose-related progression of clonic
followed by tonic-clonic convulsions, as is typical of classical
convulsant compounds. The convulsive-like behavior associated
with high doses of PCP-like agents is superimposed upon a back-
ground of severe overt behavioral disruption, and is probably a
reflection of a more generalized toxic insult to the central nerv-
ous system (CNS) caused by high doses of the compounds.
In contrast to the convulsive-like effects of high doses of PCP
compounds, several models of convulsions have been used to demon-
strate anticonvulsant properties of PCP in a variety of species.
In mice, PCP is effective in antagonizing electroshock- or pentyl-
enetetrazol (PTZ)-induced tonic extensor convulsions and audiogen-
ic seizures (Chen et al. 1959; Chen and Bohner 1961). In dogs,
PCP raises the threshold and decreases the duration of the after-
discharge produced by electrical stimulation of the suprasylvian
gyrus (Domino 1964). In rats, the latency for seizures produced
by fluorothyl is prolonged by PCP (Geller et al. 1981). The doses
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of PCP required to demonstrate anticonvulsant effects are suffi-
cient to cause mild to severe impairment of behavior, but are well
below lethal levels.
The effects of PCP on the amygdala-kindled seizure model have been
reported by Freeman et al. (1982). A 5 mg/kg dose IP results in a
slightly greater than twofold elevation of the threshold for pro-
ducing amygdala-kindled seizures, but has little effect on the
duration of the EEG afterdischarge or motor seizure. This profile
of effects on the amygdala-kindled seizure does not resemble that
of the convulsant compound pentylenetetrazol, which has no effect
on the threshold but prolongs the duration of the EEG and motor
seizure (Bowyer and Albertson 1982). In addition, PCP and keta-
mine are effective in antagonizing seizures kindled by repeated
stimulation of the cerebral cortex (Bowyer et al. 1983).
This laboratory has utilized two approaches to define further the
anticonvulsant properties of PCP. One approach involved a rela-
tively simple convulsant model, pentylenetetrazol-induced convul-
sions. In this model, the administration of ketamine alone, or in
combination with several known anticonvulsants, was tested. Keta-
mine, as a structural analog of PCP, shares many of the pharmaco-
logical properties associated with PCP. The second approach
involved a more complex model, hippocampal-kindled seizures.
Using this model, the ability of PCP, ketamine, and several anti-
convulsants to antagonize hippocampal seizures and elevate seizure
thresholds was tested both before and after kindling.
ANTIPENTYLENETETRAZOL ACTIVITY
Male Dublin-ICR white mice were administered pentylenetetrazol
(dissolved in normal saline) by tail vein infusion. This slow
intravenous infusion of PTZ to mice provided three consistent and
easily measured endpoints for assessing anticonvulsant effects:
(a) an initial clonic body jerk followed by (b) tonic limb exten-
sion, and (c) lethality. Mice were pretreated with ketamine 15
minutes, and anticonvulsants 30 minutes, prior to PTZ infusion.
All drugs were administered by IP injection.
Figure 1 illustrates the dose-dependent effects of ketamine on
these three endpoints. A dose of 20 mg/kg significantly delayed
tonic limb extension but did not protect against the lethality
associated with this severe convulsive response. Higher doses
significantly delayed the initial clonic convulsive response and
prevented tonic limb extension. At these doses, the tonic exten-
sion response was replaced-with the abrupt onset of continuous
clonic limb convulsions, which persisted until death from apparent
respiratory depression. The onset of the continuous clonic con-
vulsions and lethality was also delayed in a dose-dependent
manner, at the higher doses of ketamine.
The profiles of anticonvulsant effects for phenobarbital, pheny-
toin, and trimethadione were also determined in the PTZ model.
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Phenobarbital closely resembled ketamine, but was more effective
in delaying clonic and tonic convulsions (figure 1). In contrast,
phenytoin was effective only in preventing tonic extension convul-
sions and delaying lethality (figure 2). Trimethadione delayed
the clonic and tonic endpoints but did not prevent tonic extension
convulsions or the lethal effect of the tonic convulsion
(figure 2).
FIGURE 1. Effect of phenobarbital and ketamine on pentylenetetra-
zol convulsions
NOTE: Solid lines = clonic convulsions, dashed Iines = tonic extensor convulsions
and dotted lines = lethality. Open circles represent doses preventing
extension and delaying lethality (see text). Data are expressed as mean +
s.e.m., n=6-7 mice per point. *indicates significant difference from con-
trol,
The interaction of ketamine with each of the three anticonvulsant
compounds was also tested. Ketamine, 15 mg/kg, a dose showing no
anti-PTZ effect and causing no overt behavioral changes, potenti-
ated the effect of phenobarbital (20 mg/kg) in delaying the clonic
and tonic convulsive responses and lethality (figure 3). Ketamine
also potentiated the ability of phenytoin (20 mg/kg) to delay
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FIGURE 2. Effects of Phenytoin and Trimethadione on Pentytenete-
trazol convulsions (see legend for figure 1 for
de t a i l s )
lethality (not shown). No interaction was found between ketamine
and trimethadione (2OO mg/kg).
KINDLED SEIZURES
A model of seizures that many consider to resemble human epi-
leptogenesis closely is the kindling model of epilepsy. Kindling
involves the administration of low intensity stimulation to a
specific brain region (e.g., the amygdala) at regular intervals.
Initially, the stimulation produces a synchronous electrical
afterdischarge with no behavioral correlates; however, as kindling
progresses, a stable clonic convulsive response, which is retained
for long periods of stimulation-free time, gradually results
(Goddard et al. 1969). The kindling model provides the unique
opportunity to assess the effect of a compound on the threshold
for initiating a seizure, the initial prekindled seizure, and the
fully kindled seizure. Many anticonvulsant compounds that are
ineffective against the prekindling afterdischarge are very active
in antagonizing some component of the fully kindled seizure.
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FIGURE 3. Interaction between ketamine and phenobarbital against
pentylenetetrazol convulsions
NOTE: Ketamine, 17.5 mg/kg and phenobarbital, 20 mg/kg, were Injected 15 and 30
min., respectively, prior to pentylenetetrarol Infusion. Data are
expressed as mean ± s.e.m., n=5-6 mice per point. *indicates significant
difference from control, P< .05.
We have evaluated the dose-related effects of PCP, ketamine, and
selected anticonvulsant drugs on seizure activity in the hippo-
campal model of kindled seizures. The hippocampal model is partic-
ularly well suited for the study of the anticonvulsant effects of
drugs because of the slow rate of acquisition of the fully kindled
seizure. Electrical stimulation of the dorsal hippocampus ini-
tially evokes a stereotyped sequence of behavior, accompanied by a
characteristic EEG pattern. Repeated electrical stimulation even-
tually results in generalized kindled seizures. This allows the
testing of drugs on the unkindled hippocampal seizure (after-
discharge) to be compared to effects on the fully kindled seizure
in the same rats.
Male, Sprague-Dawley rats were implanted under pentobarbital anes-
thesia with a bipolar electrode in the right dorsal hippocampus
for hippocampal stimulation and recording. Stainless steel screws
were also placed over the contralateral frontal and parietal cor-
tices for recording cortical seizure activity. The electrodes
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were connected to an Ampherol headpiece and the assembly affixed
to the skull with dental acrylic. Ten days later, the threshold
for eliciting hippocampal afterdischarge (AD) was determined with
an ascending series of stimulations (1 second of 60 Hz, biphasic
square-wave pulses of 1 millisecond duration) at 5-minute inter-
vals. At 7-day intervals, the rats were administered either ve-
hicle or drug, and the threshold determined as above. EEG was
recorded (Grass Model 7 polygraph) 2 minutes prior to stimulation,
and continued for 2 minutes following termination of the seizure.
Each rat received a maximum of four drug trials.
The rats were next administered twice daily hippocampal stimula-
tion (2xthreshold) until three consecutive stage V convulsive
responses (Racine 1972) were obtained, indicating that the rats
were fully kindled. The average number of stimulations to achieve
the kindled state was 41.4 ± 2.3 stimulations. Drug effects on
seizure threshold and the kindled seizure were assessed as de-
scribed above for the prekindled seizure.
Effect on Hippocampal Seizures (Prekindling)
The control EEG records in figure 4 illustrate the typical EEG
response produced by hippocampal stimulation in unkindled rats.
An initial afterdischarge is followed by a period of postictal
depression, which is interrupted by a brief episode of rebound
spiking. The effects of PCP and ketamine on the hippocampal sei-
zure are also illustrated in figure 4. Doses of PCP and ketamine
(IP administration, 15 minutes prior to stimulation) causing
equivalent overt behavioral effects were chosen, and produced
nearly identical effects on the hippocampal response. The initial
AD was slightly prolonged, and the period of postictal depression
was shortened, allowing the rebound spiking to appear earlier,
thus decreasing the total seizure duration. Ketamine, at an anes-
thetic dose of 80 mg/kg, resulted in suppression of the rebound
spiking.
Anticonvulsant drugs such as carbamazepine, diazepam, valproic
acid, and phenobarbital also slightly increased the duration of
the initial AD. However, the effects of these drugs on the other
associated seizure events were quite different from PCP and keta-
mine. The effects of carbamazepine and diazepam, typical of the
four compounds, are illustrated in figure 4. These compounds
either suppressed the rebound spiking (diazepam, valproic acid,
and phenobarbital) or lengthened the total seizure duration with
no rebound suppression (carbamazepine).
Effects on Kindled Hippocampal Seizures
The fully kindled hippocampal seizure is quite different from the
prekindled seizure described above. The hippocampal response typ-
ically appears as a continuous AD, with a duration similar to the
total duration of the unkindled response. In other words, the un-
kindled EEG response of initial AD, postictal depression, and
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FIGURE 4. Effect of phencyclidine (PCP) and ketamine (KET) on the
prekindling hippocampal seizure (afterdischarge)
NOTE: The effects of carbamarepine (CBZ) and diazepam (DZP) are Included as
representative of antlconvulsant drugs. Total seizure duration (control)
averaged 110 seconds. See text for details of seizure response.
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rebound spiking is replaced by continuous AD activity. Moreover,
prominent spiking activity is also continuously recorded from the
cerebral cortex, and the characteristic motor seizure responses
occur. Drug effects on the fully kindled hippocampal seizure were
much different from those seen on the prekindled seizure. More-
over, in marked contrast to the effects on the unkindled seizure,
the effects of PCP, ketamine, and the four anticonvulsants on the
kindled seizure were quite similar. PCP, ketamine, and the four
anticonvulsants all significantly decreased the duration of the
hippocampal EEG seizure and reduced the severity of the motor sei-
zures (table 1). However, none of the six compounds, even in
doses resulting in loss of righting reflex, completely prevented
the kindled seizure response. The EEG seizure response was less
sensitive to the drug effects than was the motor convulsive
response.
TABLE 1. Effect of PCP, ketamine and selected anticonvulsants on





























84 ± 9 *
76 ± 1 1 *
119 ± 7
79 ± 4 *





69 ± 1 4 *




31 ± 4 *





















*Indicates significant difference from control, P<.05.
NOTE: Data expressed as mean ± s.e.m., n=4-6 rats per dose.
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Effects on After discharge and Seizure Threshold
PCP, 15 mg/kg, and ketamine, 40 mg/kg, elevated the threshold for
eliciting hippocampal afterdischarge (prekindling) by 61 percent
and 267 percent, respectively (table 2). Valproic acid and carba-
mazepine also elevated the threshold. In contrast, phenobarbital
and diazepam had no effect on the prekindling afterdischarge
threshold, even at doses capable of altering the AD.
TABLE 2. Increased sensitivity of hippocampal seizure threshold
to drug effects following kindling


















267 ± 9 0 *
15 ± 7
61 ± 2 1 *
10 ± 7
7 ± 7
75 ± 29 *
180 ± 26 *
16 ± 13
631 ± 89 **
381 ± 83 **
















*Indicates significant difference from vehicle control before kindling, P<.05.
**Indicates significant difference from prekindling threshold, P<.05.
NOTE: Data expressed as mean ± s.e.m., n=4-6 per dose.
Following the completion of kindling, the seizure threshold was
not significantly different from the prekindling threshold. How-
ever, there was a marked increase in the sensitivity of the
kindled seizure threshold to all drugs except diazepam and the
lower dose of PCP (table 2). The most dramatic increase in
threshold sensitivity was with ketamine, 40 mg/kg. Before kind-
ling, this dose of ketamine elevated the AD threshold by 61 per-
cent; following kindling, this dose elevated the AD and seizure
threshold by 786 percent. In contrast, diazepam, even at a dose
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(8 mg/kg) resulting in marked sedation and akinesia, had no effect
on the kindled seizure threshold.
DISCUSSION
The results demonstrate anticonvulsant properties of PCP and keta-
mine in two quite different seizure models. On the one hand,
ketamine was effective in antagonizing several components of PTZ
activity. Others have previously reported anti-PTZ effects of
ketamine. However, the present results demonstrate that the anti-
convulsant effects of ketamine against PTZ seizures closely resem-
bled the effects of phenobarbital in that both compounds delayed
clonic convulsions and prevented tonic extension. Moreover, a low
dose of ketamine, which alone showed no anticonvulsant effect or
overt behavioral changes, potentiated the anti-PTZ effects of
phenobarbital. These findings suggest that ketamine possesses
selective anticonvulsant properties. The anticonvulsant mechanism
of action for phenobarbital is not known. However, the similari-
ties between ketamine and phenobarbital, and the interaction be-
tween the two compounds, suggest a common mechanism or site of
action.
Although PCP was not included in these experiments using the PTZ
model, PCP has been shown previously to antagonize PTZ convulsions
(see above). Since ketamine and PCP share many common pharmaco-
logical properties, it is reasonable to expect that PCP would show
effects similar to those seen with ketamine. In fact, since these
experiments were done, others have compared the anticonvulsant
effects of structural analogs of PCP. For example, all compounds
tested thus far are active against electroshock-induced convul-
sions, with some analogs more active than PCP or ketamine at be-
haviorally equivalent doses (Mattia et al., this volume). Further
study of the anticonvulsant properties of PCP derivatives may thus
provide clues to anticonvulsant drug mechanisms of action.
On the other hand, the results using the hippocampal seizure model
revealed an interesting profile of anticonvulsant effects for PCP
and ketamine, compared to several classical anticonvulsant com-
pounds. When tested against the unkindled hippocampal seizure,
the effects of behaviorally equivalent doses of PCP and ketamine
were remarkably similar, but differed substantially from the ef-
fects of the anticonvulsant drugs. The compression of the entire
EEG seizure episode to a shorter duration was unique to PCP and
ketamine, and suggests an anticonvulsant effect. Conversely, the
small prolongation of the initial AD episode, and the decreased
duration of the postictal depression, could be reflective of pro-
convulsive influences. There were, however, no other indications
of enhanced seizure activity , such as the appearance of motor con-
vulsions or spread of seizure activity to the cerebral cortex.
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The four anticonvulsant compounds, like PCP and ketamine, pro-
longed the initial AD of the prekindled hippocampal seizure. How-
ever, diazepam, valprok acid, and phenobarbital, unlike PCP or
ketamine, also suppressed the rebound spiking. Carbamazepine
showed an even different profile of effects, causing a marked
prolongation of the initial AD, rebound spiking, and the total
seizure duration. Thus, although the seizure discharge evoked by
hippocampal stimulation was altered in a similar manner by both
PCP and ketamine, the seizure activity responded differently to
the anticonvulsant compounds. Moreover, unlike the results with
the PTZ model, ketamine did not resemble phenobarbital in the
hippocampal model. These differences may be a reflection of the
focal character of the prekindled hippocampal seizure, in con-
trast to the more widespread CNS stimulatlon following PTZ
administration.
During the acquisition of kindled seizures, a progressive recruit-
ment of structures into a network of neuronal circuits capable of
supporting seizures has been described (Engel et al. 1978).
During this process, the changes in seizure discharge and motor
convulsions characteristic of kindling appear. Therefore, the
kindled seizure reflects altered CNS function, and may more
closely approximate the underlying conditions of epileptogenesis.
When the compounds were tested against the fully kindled hippo-
campal seizure, a different pattern emerged. PCP and ketamine now
exerted anticonvulsant effects similar to the four anticonvulsant
compounds. All six agents caused a dose-related reduction of the
duration of the kindled seizure, and decreased the severity of the
motor convulsions. This similarity suggests that kindled epilep-
togenesis is associated with altered substrates or the formation
of additional substrates necessary for the support of seizure
activity. It is possible that it is against these altered or
new substrates that drugs with anticonvulsant properties are
effective.
This speculation is supported by the marked increase in the sen-
sitivity of the seizure threshold to drug-induced elevation
following kindling. Clearly, the process of kindling produces
alterations in the manner in which the existing neuronal circuitry
responds to drug administration. Interestingly, diazepam, at
doses capable of altering both the prekindled and kindled seizure,
had no effect on either the prekindling or kindled seizure thresh-
old. Therefore, the change in sensitivity of the seizure thresh-
old following kindling, while related to other kindling-induced
alterations in brain function, is nonetheless distinct from them.
Further studies of the mechanisms of action by which PCP and keta-
mine alter seizures and thresholds, particularly involving compar-
isons before and after kindling , and with classical anticonvulsant
drugs, may provide clues to mechanisms of epileptogenesis.
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Agonistic and Antagonistic Effects
of PCP-Derivatives and Sigma
Opioids in PCP Behavioral and
Receptor Assays
Patricia C. Contreras, Remi Quirion, and Thomas L. O’Donohue
Phencyclidine (PCP, 1-(1-phenylcyclohexyl)piperidine, angel dust)
was first synthesized in 1957 as an anesthetic by the Parke Davis
pharmaceutical company. PCP is a "dissociative" anesthetic with
minimal respiratory and cardiovascular depression. However, clin-
ical use of PCP was discontinued because it produced post-anes-
thetic hallucinations often lasting more than 12 hours in about 30
percent of patients (Greifenstein et al. 1958). Today, PCP is one
of the most abused drugs, due in part to its ability to elicit
hallucinations, excitation, and feelings of tranquility. PCP can
also produce very violent aggressive behavior and a psychosis that
resembles the acute symptoms of schizophrenia. Thus, it has been
suggested that PCP may be a better drug model for schizophrenia
than amphetamine (Allen and Young 1978). So far, there is no
specific treatment for PCP intoxication or the schizophrenia-like
psychosis because the mechanisms responsible for the effects of
PCP are not known.
It is believed that many of the behavioral effects of PCP are due
to interactions with specific PCP receptors, which were first
characterized by Vincent et al. (1979) and Zukin and Zukin (1979).
These binding sites appear to satisfy many of the criteria for a
PCP receptor because the binding of 3H-PCP to brain homogenates is
reversible, saturable, stereoselective, occurs with a relatively
high affinity (Vincent et al. 1979; Zukin and Zukin 1979; Quirion
et al. 1981a), and has a selective regional distribution (Quirion
et al. 1981b). Furthermore, the binding of 3H-PCP was rapidly in-
activated by heat and destroyed by proteases, indicating that the
PCP receptor is a protein (Vignon et al. 1982). In addition,
serotonin, LSD, benzodiazepines, cholinergic, dopaminergic, and
adrenergic agonists and antagonists did not inhibit the binding
of 3H-PCP. Only drugs that produced PCP-like psychotomimetic
effects--PCP analogs, dexoxadrol, and sigma opioids--were able to
displace the binding of 3H-PCP at low concentrations, which has
led to the suggestion that the PCP receptor is also the sigma
opioid receptor (Quirion et al. 1981b). This possibility is sup-
ported by the Finding that PCP analogs inhibit the binding of
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3H-cyclazocine (Zukin and Zukin 1981), sigma opioids generalize to
PCP stimulus (Shannon 1981; Brady et al. 1982) and conversely PCP
generalizes to many sigma opioids in drug discrimination paradigms
(Teal and Holtzman 1980; Shannon 1983). But these are repasts
showing that differences between the binding of 3H-PCP and 3H-SKF-
10,047 are significant (Tam 1983; Martin et al. 1985).
The relevance of PCP receptors is supported by reports that the
ability of PCP-like drugs to produce PCP-like stimulus in drug
discrimination paradigms (Shannon 1981; Holtzman 1980; Brad and
Balster 1981), produce vasoconstriction (Altura et al. 1983) and
produce ataxia (Vincent et al. 1979; Vignon et al. 1982; Vaupel
et al. 1984) correlates well with their ability to bind to PCP
receptors.
In rodents, PCP produces not only ataxia, but also stereotyped
behavior and hyperactivity. The PCP-induced stereotyped behavior
is thought to be due to changes in serotonergic and dopaminergic
systems (Nabeshima et al. 1983; Martin et al. 1979; Sturgeon et
al. 1981). It is not known whether PCP receptors mediate PCP-
induced hyperactivity or stereotyped behavior or even the effect
on neurotransmitter systems. It is also possible that mu, kappa,
or sigma opioid receptors are involved (Castellani et al. 1982).
The purpose of these studies was to determine whether stereotyped
behavior and ataxia induced by PCP-like drugs and sigma opioids is
mediated by PCP receptors. Also, we wanted to investigate whether
sigma opioid and PCP receptors are the same receptors using behav-
ioral and radioreceptor assays.
COMPARISON BETWEEN INDUCTION OF PCP-LIKE STEREOTYPED BEHAVIOR AND
ATAXIA TO INTERACTIONS WITH PCP RECEPTORS
Using the PCP rating scale for stereotyped behavior and ataxia as
described by Sturgeon et al. (1979), the central effects of PCP
analogs, dexoxadrol, and its levo-isomer, levoxadrol, were deter-
mined. As shown in figure 1, all drugs except the (-) isomers
produced dose-dependent stereotyped behavior. In contrast,
(-)PCMP was equipotent with (+)PCMP in induction of ataxia (figure
2). Furthermore, TCM, which was one-fifth as potent as PCP in the
induction of stereotyped behavior, was as potent as PCP in induc-
tion of ataxia. The ability of PCP-like drugs to bind to PCP re-
ceptors, as measured by their ability to inhibit the binding of
3H-PCP, was determined as described by Contreras et al. (in prepa-
ration). The order of relative potencies of drugs as compared to
PCP was TCP > PCE > PCP = NIPCA > dexoxadrol > (+) PCMP > TCM =
(-) PCMP >> levoxadrol. A comparison of the ability of drugs to
bind to PCP receptors and induce stereotyped behavior (figure 3A)
resulted in a straight line (r=0.98), that intersected the origin.
However, the correlation between a drug's ability to bind to PCP
receptors and to induce ataxia (figure 3B) did result in a good
fit to a straight line (r=0.80) but did not intersect the origin.
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FIGURE 1. Dose-response curves for induction of stereotyped be-
havior. Ratings for each animal were determined 5
minutes after ICY administration of each drug. At
least 21 rats were used to determine each dose-
response curve.
Thus, stereotyped behavior appears to be mediated by PCP recep-
tors, but ataxia appears to be mediated by more than just an
interaction with PCP receptors.
Only the (+) isomer of SKF-10,047, which very weakly inhibited the
binding of 3H-PCP, induced stereotyped behavior. This finding is
consistent with the results of the PCP receptor assay showing that
(+)SKF-10,047 is one-tenth as potent as PCP, but is fivefold more
potent than (-)SKF-10,047 (table 1). However, it was not possible
to determine whether SKF-10,047 was a full agonist because of its
poor solubility in saline. Also, SKF-10,047 produced weaving and
circling behavior that was much less pronounced than that induced
by PCP. In contrast to the results of the assays for stereotyped
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FIGURE 2. Dose-response curves for induction of atazia. Behav-
ioral ratings were determined 5 minutes after drug
administration ICV. At least 21 rate were used to
determine each dose-response curve.
behavior and binding to PCP receptors, the (-) isomer of SKF-0,047
was more potent than the (+) isomer in induction of ataxia.
Stereoselectivity was evident in the assays for stereotyped behav-
ior and PCP receptor interaction, but not in the assay for ataxia
as the (+) isomers of the PCP-like drugs and SKF-10,047 were more
potent than the (-) isomers in induction of stereotyped behavior
and inhibition of binding of 3H-PCP. However, one exception to
this trend is that the (-) isomer of cyclazocine was more potent
than the (+) isomer in industion of stereotyped behavior and in-
hibition of the binding of 3H-PCP.
Since large doses of naloxone (10 and 50 m/kg) did not antagonize
the ability of PCP or cyclazocine to induce stereotyped behavior
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FIGURE 3. Comparison of the relative potency (ED50 of PCP/ED50 of
drug) for induction of (A) stereotyped behavior or
(B) ataxia to the relative potency (IC50 of PCP/IC50
of drug) for inhibition of the binding of 3H-PCP
or ataxia, it is unlikely that mu, kappa, or sigma opioid recep-
tors play a role in mediating these PCP-like behavioral effects.
In addition, naloxone pretreatment did not antagonize the ability
of (-)SKF-10,047 to induce ataxia.
EFFECT OF METAPHIT ON PCP-INDUCED BEHAVIORAL EFFECTS AND PCP
RECEPTORS
Metaphit, (1-(1-(3-isothiocyanatophenyl)cyclohexyl)piperidine), is
a PCP analog that specifically acylates PCP receptors in vitro
(Rafferty et al. 1985). Additional experiments were performed to
determine whether metaphit could acylate PCP receptors in vivo and
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antagonize PCP induction of stereotyped behavior and ataxia. Pre-
treatment of rats with 1 or 2 µmol/rat of metaphit intracerebro-
ventricular (ICV) 24 hours prior to sacrifice, resulted in a 25
percent and 40 percent decrease in the Bmax, but no change in the
Kd of binding of 3H-PCP.
binding of 3H-etorphine or
Metaphit pretreatment did not alter the
3H-spiroperidol. Since the preparation
of the brain homogenates for the binding assays consisted of two
washes and was prepared 24 hours after metaphit pretreatment,
these results demonstrated that metaphit specifically binds irre-
versibly to PCP receptors after in vivo administration.
Metaphit administered alone at doses up to 1 µmol/rat did not pro-
duce any significant behavioral effects. However at doses of 2
µmol/rat and larger, metaphit produced PCP-like stereotyped behav-
ior and ataxia. Thus, metaphit is a very weak PCP agonist. In
addition to acute effects, metaphit produced convulsions, which
were evident between 5 and 24 hours after ICV administration of
2 µmol/rat.
Metaphit administered ICV prior to PCP administered ICV antago-
nized PCP induction of stereotyped behavior and ataxia up to 5
days after metaphit pretreatment. The antagonism of the behav-
ioral effects of PCP by metaphit was dose dependent as is shown in
figure 4. Furthermore, this antagonism by metaphit is specific as
metaphit pretreatment ICV did not antagonize amphetamine-induced
stereotyped behavior and could be prevented by pretreating rats
with PCP just prior to metaphit administration. These results
indicate that acylation of PCP receptors results in decreased
ability of PCP to induce stereotyped behavior.
Since metaphit appears to specifically acylate PCP receptors,
metaphit is a useful tool with which to study the physiological
role of PCP receptors. When metaphit was administered ICV prior
to IP administration of PCP, metaphit antagonized the ability of
PCP to induce stereotyped behavior, but not its ability to induce
ataxia. Thus, it appears that ataxia is mediated by both central
and peripheral mechanisms. It is unlikely that the peripheral
effect of PCP in induction of ataxia is mediated by PCP receptors
as 20 mg/kg of metaphit administered IV only antagonized PCP-
induced stereotyped behavior when PCP was also administered
peripherally.
Cyclazocine and PCP probably do not induce stereotyped behavior
and ataxia through an interaction with the same receptor, as meta-
phit did not antagonize the behavioral effects of cyclazocine.
Yet, cyclazocine was able to displace the binding of 3H-PCP. These
findings are consistent with the finding that metaphit can only
bind irreversibly to about 50 percent of the receptors labeled by
3H-PCP (Rafferty et al. 1985), which indicates that 3H-PCP binds
to more than one type of receptor. Thus, PCP and cyclazocine
probably exert their effects through different receptors.
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FIGURE 4. PCP (ICV) dose-response curves for induction of
(A) stereotyped behavior and (B) ataxia in control
animals ( ) or 24 hours after ICV administration of
1 µmoZ/rat ( ) or 2 µmol/rat ( ) of metaphit
COMPARISON OF THE BINDING OF 3H-PCP, 3H-TCP, 3H-DEXOXADROL AND
3H-(+)SKF 10,047
The question whether PCP and sigma opioids bind to more than one
receptor was studied by comparing the binding and regional distri-
bution of binding sites labeled by 3H-PCP, 3H-TCP,
3H-dexoxadrol,
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and 3H-(+)SKF-10,047. 3H-dexoxadrol, 3H-TCP, 3H-PCP, and 3H-
(+)SKF-10,047 did not bind to mu, kappa, or sigma opioid receptors
or to alpha or beta adrenergic, serotonin, benzodiazepine, or GABA
receptors. Only very large concentrations of cholinergic drugs
displaced the binding of 3H-PCP. Also dopamine, apomorphine,
(+)butaclamol did not inhibit the binding of 3H-PCP. However, the
rank orders of potency for inhibition of binding of 3H-PCP, 3H-
dexoxadrol and 3H-(+)SKF-10,047 by PCP analogs and sigma opioids
were different (table 1). Although the PCP analogs appeared to
bind to the tritiated ligands with about the same degree of poten-
cy, dexoxadrol, levoxadrol, and the sigma opioids varied greatly
in their ability to displace the tritiated ligands. Also, the
difference in potency of the isomers varied depending upon the
tritiated ligand. These results indicate that PCP, (+)SKF-10,047
and dexoxadrol do not interact with a homogenous population of
binding sites.
TABLE 1. Relative potency of drugs for inhibition of binding of3H-PCP, 3H-(+)SKF-10,047 and 3H-dexoxadrol
Relative potency* for
inhibition of the binding of
























































*Relative potency = IC50 of PCP/IC50 of drug for dlsplaclng 8 nM of 3H-PCP,
6 nM of 3H-(+)SKF-10,047, or 7 nH of 3H-deroxadrol.
Another method used to study whether these tritiated ligands bind
to different groups of binding sites was to determine the regional
distribution of binding sites labeled by 3H-TCP and 3H-dexoxadrol.
3H-TCP was used to label PCP receptors because PCP receptors have
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a higher affinity for TCP than for PCP and the degree of non-
specific binding is lower for 3H-TCP than for 3H-PCP. Thus, the
distributiog of binding sites was more clearly defined when
labeled by 3H-TCP than when labeled with 3H-PCP. 3H-TCP appeared
to bind to the same receptors as 3H-PCP because the
potencies for inhibition of binding of 3H-TCP and
order of
3H-PCP by PCP
analogs and sigma opioids were the same. The areas of the rat
brain with the highest density of binding sites labeled by 3H-TCP
were the superficial layers of cerebral cortex, dentate gyrus,
subiculum and hippocampus, with much lower densities of binding
sites in the olfactory bulb, olfactory tubercle, caudate nucleus,
nucleus accumbens, interpeduncular nucleus, periaqueductal gray,
superior colliculus, and cerebellum. Very low densities of bind-
ing sites were found in most of brainstem, spinal cord, and hypo-
thalamus. 3H-dexoxadrol labeled many more areas of the rat brain
than 3H-TCP (Pilapil et al., in press), For example, in the hypo-
thalamus, which was poorly labeled by 3 H-TCP, there was a large
density of binding sites labeled by 3H-dexoadrol (figure 5).
Analysis of the binding sites labeled by H-dexoxadrol in the
hypothalamus and cortex, as measured by displacement curves of 3H-
dexoxadrol by a variety of ligands, indicated that the binding
sites in the cortex and hypothalamus were different (table 2).
The order of drug potencies of the PCP analogs for inhibition of
binding of 3H-dexoxadrol were similar in the cortex and hypothala-
mus, but the order of potency for the isomers of SKF-10,047 were
reversed in the hypothalamus as compared to binding in
This is the same order of potency for the isomers of
the cortex.
3H-SKF-10,047
for induction of ataxia and analgesia (Aceto and May 1983), but
3H-dexoxadrol does not bind to mu, kappa, or sigma opioid recep-
tors as mu, kappa, or sigma opioid ligands did not displace the
binding of 3H-dexoxadrol in the hypothalamus. Haloperidol only
displaced binding of 3H-dexoxadrol in the hypothalamus. Thus, 3H-
dexoxadrol labels more than one kind of binding site.
CONCLUSIONS
These results clearly demonstrate that PCP-like drugs administered
centrally produce stereotyped behavior that is mediated by PCP
receptors. A causal relationship between binding to PCP receptors
and induction of stereotyped behavior is also supported by the
ability of metaphit, which specifically acylates PCP receptors in
vivo, to antagonize induction of stereotyped behavior. The order
of drug potency of PCP analogs and dexoxadrol to induce stereo-
typed behavior is similar to that seen in other studies on the
binding of 3H-PCP (Hampton et al. 1982; Murray and Leid 1984) and
in drug discrimination assays (Shannon 1981; Shannon 1982). Also,
the finding that the (+)SFK-10,047 and (-)cyclazocine were the
more potent isomers in inducing stereotyped behavior and inhibit-
ing the binding of 3H-PCP is consistent with results from drug
discrimination paradigms (Herling et al. 1983; Shannon 1983;
Shearman and Herz 1982). Thus, stereotyped behavior, like drug
discrimination paradigms, is a good behavioral assay for studying
PCP receptor interaction.
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FIGURE 5. Automdiograms of binding sites labeled by (A) 3H-TCP
and (B) 3H-dexoxadrol in coronal sections of rat
brain
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*Relative potency = IC50 of PCP/IC50 of drug for displacing 7 nM of 3H-dexoxadrol.
The results of the assays for ataxia indicate that ataxia is
induced by more than just an interaction with PCP receptors. The
inability of metaphit to antagonize PCP-induced ataxia after
peripheral administration is another indication that interactions
other than with PCP receptors also mediate ataxia.
It is unlikely that mu, kappa, or sigma opioid receptors mediate
ataxia or stereotyped behavior as naloxone did not antagonize the
behavioral effects of PCP or cyclazocine. Also, mu, kappa, or
sigma ligands did not inhibit the binding of 3H-PCP. These re-
sults are consistent with reports that large doses of naloxone or
naltrexone had no effect or minimal effect on the actions of PCP
or SKF-10,047 in drug discrimination paradigms (Teal and Holtzman
1980; Vaupel 1983; Shannon 1982; Shearman and Herz 1982; Herling
et al. 1983). Since most of the studies indicate that mu, kappa,
or sigma opioid receptors do not mediate the behavioral effects of
PCP, it is unclear why Castellani et al. (1982) found naloxone to
antagonize PCP-induced stereotyped behavior and ataxia.
The finding that metaphit did not antagonize (-)cyclazocine
induction of stereotyped behavior or ataxia is evidence that PCP
receptors and sigma opioid receptors are different receptors.
Also, it is clear that 3H-PCP labels more than one binding site
because metaphit can only bind irreversibly to about 50 percent of
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the binding sites labeled by 3H-PCP. It is also evident that 3H-
dexoxadrol, and probably 3H-SKF-10,047, do not bind to a homoge-
nous population of binding sites. The binding sites labeled by
3H-dexoxadrol in the hypothalamus appear to be similar to the
sigma opioid binding sites describ
peridol displaced the binding of
ed by Tam (1983) because halo-
3H-dexoxadrol in this region.
In summary, induction of stereotyped behavior appears to be medi-
ated by PCP receptors, whereas induction of ataxia is due to more
than one mechanism. Metaphit is a useful tool for studying the
role of PCP receptors, as it specifically acylates PCP receptors.
The question whether PCP and sigma opioid receptors are the same
receptors is complicated by the fact that none of the tritiated
ligands used to label PCP and sigma opioid receptors studied binds
to a homogenous population of receptors. However, it does not
appear that sigma opioids and PCP analogs exert their behavioral
effects through a common receptor.
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INTRODUCTION
Phencyclidine (1-(1-phencyclohexyl)piperidine HCl, PCP) is a wide-
ly abused (Petersen and Stillman 1978) psychoactive agent with a
broad spectrum of activity. PCP's effects have been assessed in a
number of diverse experimental protocols producing behavioral,
electraphysiological, and biochemical data (Kamenka et al. 1983;
Domino 1981). Unfortunately, despite its potency in many experi-
mental models, it is not known which of PCP's experimental effects
in these animal models (motor incoordination, analgesia, stereo-
typy, etc.) are most relevant to its pharmacologic and toxic
effects in humans (anesthesia, analgesia, psychosis). This is at
least partially related to the complexity of PCP's actions. For
example, even seemingly simple protocols of gross behavioral ob-
servations of PCP effects can be difficult since stereotypy,
ataxia, and locomotion occur simultaneously, tend to be fragmented
in nature, and compete with each other for expression. Fortunate-
ly, however, a number of phencyclidine analogues (Kalir et al.
1969) and compounds from other chemical classes that possess
phencyclidine-like activity (benzomorphan, benz(f)isoquinoline,
and dioxolane derivatives) are available and will no doubt be
helpful in elucidating PCP's spectrum of pharmacologic activity
and mechanism of action. We propose that these and other com-
pounds that exhibit significant phencyclidine-like activity be
referred to collectively as "phencyclinoids." In order to obtain
useful information on the basic pharmacology of PCP, which may
help to understand its mechanism of action, comprehensive profiles
are being developed for a series of phencyclinoids in several
assays which progress from simpler to more complex. This report
will describe the results of EEG, behavioral, and receptor binding
studies conducted to date.
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METHODS
Animals and Surgical Procedures
Throughout these studies, adult female Sprague-Dawley rats weigh-
ing about 250 gm were used. During experimentation, they were
housed in individual plastic cages. Purina Rat Chow and water
were available ad libitum, and they were maintained under an
automated light cycle with illumination from 6 a.m. to 10 p.m.
daily.
Rats were implanted with indwelling jugular cannulae for intra-
venous (IV) administration of drugs (Weeks and Davis 1964). To
monitor cortical EEG and electromyographic (EMG) activity, respec-
tively, they were also prepared with chronic cerebrocortical
electrodes and temporalis muscle electrodes (Khazan 1975). One
week was allowed for recovery from surgery before experimentation.
Drugs and Drug Administration
The phencyclinoids used in this study are listed in table 1. PCP
analogues were chosen with modifications of the piperidine (PCA,
NMPCA, PCE, NsBPCA, PCPY) or phenyl (TCP and TCPY) ring systems.
Ketamine, also an analogue of PCP, has a piperidine ring replace-
ment and additional modifications at the cyclohexyl and phenyl
rings. SKF-10,047 is a benzomorphan opioid derivative. PCP, its
analogues, and the racemate of SKF-10,047 were obtained from the
National Institute on Drug Abuse. 3H-PCP (49.9 Ci/mmol) was
obtained from New England Nuclear Company for receptor binding
studies. Dextroamphetamine, ketamine, sodium pentobarbital, and
morphine were obtained commercially.













Drugs were prepared biweekly in physiological saline and adminis-
tered via cumulative IV injections. Acute dose-response data were
generated for each drug in one test session by giving each rat a
series of drug injections beginning at 0.1 mg/kg, and then dou-
bling the dose at successive 30-minute intervals. Rats received
bolus injections of 0.5 ml or less saline alone or 0.1 to 0.2 ml
of drug solution flushed with saline through jugular cannulae. In
anticonvulsant studies, intraperitoneal (IP) drug administration
was used. In the EEG studies, a one-quarter logarithmic dilution
was used for ketamine. Doses are expressed as the hydrochloride
salts.
Direct EEG and EEG Power Spectra
Rats were acclimated to the EEG recording cages and connected by
flexible cables through mercury commutators to a Grass Model 7D
Polygraph. The direct EEG was filtered at the polygraph at 35 Hz.
On the day of an experiment, in addition to paper EEG and EMG
recordings, the EEG was collected on FM magnetic tape using a Sony
TC-277-4 quadradial tape recording system in conjunction with a
Model 4 FM recording adaptor. Spectral analysis of the EEG was
performed using the Fast-Fourier-Transformation on digitized data
points from 0 to 25 Hz with the Nicolet Med-80 and Pathfinder I
computers and software. Sampling was performed at the Nyquist
sampling rate of 50 Hz. Sequential spectra were plotted during
saline and cumulative IV drug injections from 0.1 to 12.8 mg/kg.
Utilizing the overt behavioral assessment described below, doses
were chosen that produced behaviorally similar responses. For all
compounds tested, the peak total power and predominant frequency
of 5 or 6 EEG samples of 10- or 12-second duration were averaged
for each dose. To normalize the data, the absolute power values
were converted to root-mean-square (RMS) voltage and expressed
relative to saline quiet awake baseline for each rat; each rat,
therefore, served as its own control.
Overt Behavior
Locomotion, stereotypy, and ataxia were rated via behavioral ob-
servations for all compounds, using behavioral rating scales de-
vised specifically for PCP (Sturgeon et al. 1979). Behaviors were
rated by observing each animal for 1 or 2 minutes at the midpoint
of each 30-minute dosing interval during collection of the EEG.
Spontaneous Locomotor Activity
Spontaneous locomotor activity (SLA) was measured in photocell
activity cages isolated in light- and sound-attenuated boxes.
Each cage contained six infrared photocell beams arranged around
the base of a circular tract. Each interruption of a beam regis-
tered a count on a total-event counter and on a cumulative
recorder. Cumulative IV doses at 30-minute intervals were admin-




The hot plate test with a 55 °C platform was used to measure la-
tency to hindlimb lick at 12 or 18 minutes postinjection in rats.
A maximum latency of 60 seconds was allowed to prevent tissue dam-
age and to enable multiple testing. Drugs were given by cumula-
tive IV injections at 42-minute intervals up to a maximum dose one
unit below the dose which produced rotarod failure.
Rotarod Performance, Righting Reflex, Convulsant Activity, and
Lethality
Rotarod performance, righting reflex, convulsant activity, and
lethality were evaluated in the same rats, which were given saline
followed by cumulative IV drug injections from 0.1 to 51.2 mg/kg
at intervals of 30 minutes. Two-minute rotarod trials at 20 revo-
lutions per minute were conducted at 12 and 18 minutes after
injections, to measure motor coordination. After completion of
rotarod testing, subsequent drug doses were administered to deter-
mine the doses at which loss of righting reflex, motor signs of
convulsant activity, and lethality occurred. The doses producing
the maximal effects on each parameter were recorded.
Pro- and Anticonvulsant Activity
The pro- and anticonvulsant effects of the phencyclinoids were
studied by assessing their ability to increase or decrease the
intensity of electrically-induced convulsions. A 32 mA, 0.2-
second stimulus was delivered via cornea1 electrodes with a
constant-current electroshock apparatus. The shock parameters
were chosen to produce a convulsion intensity of "3" on a five-
point rating scale as follows: 0 = stunned only, 1 = facial and
vibrissae tremor, 2 = clonic forepaw treading, 3 = tonic forelimb
extension, 4 = tonic forelimb and hindlimb extension, and 5 =
death. Thus, both increases and decreases in the convulsion in-
tensity subsequent to drug administration could be observed.
Drugs were given IP in selected doses based on rotarod test
results. The rats received saline and shock on day one, drug and
shock on day three, and saline and shock again on day five. Data
are presented as difference scores in convulsant intensity for
saline versus drug within animals.
Receptor Binding
Displacement binding experiments with 3H-PCP were conducted with
minor modifications of the filtration method described in the lit-
erature (Zukin and Zukin 1979; Vincent et al. 1979; Hampton et al.
1982) in crude tissue preparations of rat whole brain homogenates
in 5 mM Tris-HCl (pH 7.4).
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RESULTS
Direct EEC and EEC Power Spectra
Representations of the direct cortical EEG effects and sequential
l-minute power spectra after cumulative IV doses of 0.4. 0.8, 1.6,
and 3.2 mg/kg PCP are provided in figure 1 (A, B). The direct EEG
and EEG power spectra correlated in a dose-related manner with
PCP's behavioral effects. At 0.4 mg/kg, PCP produced increased
locomotor activity and stereotypy associated with predominant
spectral power in the 5- to 10-Hz range. At 0.8 mg/kg, locomotor
activity and stereotypy intensified and ataxia emerged. In con-
junction with ataxia, high-amplitude slower waves were present and
more power was contained in the 0- to 5-HZ band. At the higher
doses of 1.6 and 3.2 mg/kg, the EEG activity consisted primarily
of high-amplitude, slow-frequency waves superimposed upon back-
ground theta activity. At the highest doses, severe ataxia and
dyskinetic head and forepaw movements occurred in association with
spectral power concentrated in the 0- to 5-HZ band.
Spectral analysis of the EEG effects of PCP and related compounds-
on peak RMS voltage revealed similarities and differences between
the compounds tested. In general, moderate increases in peak RMS
voltage occurred as a function of dose, producing relatively flat
dose-response curves, as shown in figure 2, for 6 of the 10 com-
pounds tested. The N-piperidine derivatives were qualitatively
similar to PCP and differed primarily in that they were less
potent. NMPCA, about one-fourth as potent as PCP, and ketamine,
about one-eighth as potent as PCP, also differed in that the
slopes of their increase in RMS voltages were steeper, and greater
maximal increases were obtained. TCP (data not shown) was most
potent and SKF-10,047 was least potent with respect to effects on
RMS voltage. Despite its PCP-like effects on the EEG, PCA pro-
duced less intense behavioral effects.
Dose-related shifts in predominant EEG frequency for PCP and sev-
eral phencyclinoids are shown in figure 3. For all 10 compounds
tested, there was a shift in predominant EEG frequency into the
theta range across the lower doses , associated primarily with in-
creased locomotor activity and stereotyped behaviors. With fur-
ther increases in dose, PCP and all of its analogues produced
shifts to lower predominant frequencies, which typically fell
between 2 and 4 Hz. As the dose was incremented geometrically,
the lower frequency EEG waves were associated first with ataxia,
then with dyskinetic movements , catalepsy, and possibly seizure
activity. SKF-10,047 also produced ataxia, but was unique in that
it did not cause a shift to a lower predominant frequency and pro-
duced only EEG theta activity at all subconvulsant doses.
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FIGURE 1. The effects of cumulative intravenous PCP on (A) the direct cortical EEG recorded in freely
moving rats, and (B) the associated sequential l-minute EEG power spectra
FIGURE 2. Peak EEG root-mean-square (RMS) voltage from 0-20 hertz
(Hz) as a function of dose for phencyclinoids
PCP produced electrical seizure activity at 12.8 mg/kg IV, EEG
spectra were clearly different from those produced by lower doses
in that fast-frequency, high-amplitude EEG waves occurred and
resulted in a spectral peak at about 15 Hz. EEG activity from 0
to 35 Hz occurred during seizures in contrast to subseizure doses,
which produced EEG with little activity beyond 10 Hz. Generally,
these seizures occurred immediately after IV injections and lasted
1 to 3 minutes. Similar spectra were obtained with NsBPCA (12.8
mg/kg), SKF-10,047 (25.6 mg/kg), and even with ketamine despite
the absence of overt convulsant activity. Motor manifestations of
EEG seizure activity included whole body tremors and vigorous
twitches of the face and vibrissae.
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FIGURE 3. Predominant EEG frequency as a function of dose for
phencyclinoids
Overt Behavior
Dose-response curves for the effects of PCP and several compounds
on locomotion, stereotypy, and ataxia are shown in figure 4 (A, B,
C). PCP increased behavioral rating scores for stereotypy and
ataxia as a function of increasing dose, from 0.2 to 3.2 mg/kg
cumulative IV. For PCP-induced locomotion, behavioral rating
scores increased up to 1.6 mg/kg, and declined at 3.2 mg/kg.
Similar scores were generated for the other compounds over doses
ranging from 0.1 to 12.8 mg/kg. When scores for one behavior
increased, concomitant increases in the scores for each of the
behaviors resulted, making only quantitative differences between
these phencyclinoids observable. Consequently, similar relative
potencies were obtained from consideration of any one of these
three behaviors. The rank order of potency for locomotion,
stereotypy, and ataxia was TCP > PCP = PCPY = TCPY > PCE = NsBPCA
> NMPCA > ketamine = PCA = SKF-10,047. PCE was unusual in that
its potency for ataxia was nearly equal to PCP's, yet it was only
about one-third as potent in inducing locomotion and about two-
thirds as potent for producing stereotypy. TCP was more potent,
TCPY and PCPY were about equipotent, and PCA was less potent than
PCP (data not shown).
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FIGURE 4. Dose-response-curves for the effects of phencyclinoids
on: (A) locomotion; (B) stereotypy; and (C) ataxia.
Overt behaviors were scored using the behavioral
rating scales of Sturgeon et al. (1979).
Spontaneous Locomotor Activity
The relationship between dose and SLA was characterized by an
inverted U-shaped curve for the phencyclinoids tested and dextro-
amphetamine. Geometric increases in cumulative IV doses produced
nearly linear increases followed by decreases in SLA for each
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compound, while repeated saline injections resulted only in dimin-
ished motor activity. Dose-response curves for the rate-increas-
ing effects of the phencyclinoids were similar and are shown in
figure 5. The psychomotor stimulant dextroamphetamine was nearly
equipotent with PCP. All the drugs tested were significantly less
efficacious than PCP (ANOVA, Dunnett's comparison of means, p <
0.05) with respect to peak increases in SLA, regardless of their
potency. For example, PCE was the least efficacious, yet produced
its maximal effect at 0.8 mg/kg, as did PCP. The doses of phen-
cyclinoids producing peak SLA and maximal disruption of rotarod
performance are strongly correlated (r=0.99). Furthermore, a good
correlation (r=0.77) exists between the doses of phencyclinoids
producing peak SLA and maximum EEG theta activity.
FIGURE 5. Dose-response curves for the rate-increasing effects of
phencyclinoids and dextroamphetamine on spontaneous
locomotor activity.
Analgesic Activity
Analgesic data, expressed as ED50 values and their confidence
limits, are summarized in table 2. All 10 compounds possessed
analgesic activity at doses below those inducing severe ataxia.
Ataxia at higher doses prevented accurate measurement of the re-
sponse, resulting in a ceiling effect. The rank order of analge-
sic potency for the phencyclinoids was TCP > PCE > PCP > PCPY =
TCPY > NsBPCA > ketamine > SKF-10,047 > NMPCA > PCA, which varied
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somewhat from their rank order of potency for disruption of
rotarod performance (figure 6A) and effects on SLA (figure 5).
More important, as was also true in the case of SLA, analgesic
potency was distinguished from analgesic efficacy. But, none of
the phencyclinoids was as efficacious as morphine in producing
analgesia.






PCP 18 0.19 (0.10-0.36) 80.9
NMPCA 12 1.69 (0.44-6.50) 68.8
Ketamine 18 0.48 (0.17-1.36) 54.8
NsBPCA
PCE
18 0.23 (0.13-0.38) 50.7
18 0.10 (0.05-0.22) 48.8
PCPY 12 0.20 (0.12-0.31) 32.8
TCP
TCPY
18 0.02 (0.01-0.07) 31.9
12 0.20 (0.12-0.31) 29.8
SKF-10,047 18 1.49 (0.69-3.31) 27.4
PCA 18 3.94 (0.70-22.2) 15.0
Morphine 12 0.48 (0.11-2.07) 98.4
NOTE: ED50 values determined by the method of Litchfield and Wilcoxon (1949).
Rotarod, Righting Reflex, Convulsant Activity, and Lethality
Figure 6 (A, B, C, D) summarizes the data for 10 phencyclinoids
for disruption of rotarod performance, loss of righting reflex,
convulsant activity, and lethality. The rotarod test proved most
useful in differentiating compounds. The rank order of potency
for the disruption of rotarod performance was TCP > TCPY = PCPY =
PCE > PCP = NsBPCA > PCA = NMPCA > ketamine = SKF-10,047. When
the doses producing disruption of rotarod performance were corn-
pared to lethal doses, none of the compounds demonstrated an
exceptional margin of safety. Distinctions between the drugs were
also made via behavioral observations of convulsant effects. Ex-
cept for ketamine, overt motor manifestations of convulsant activ-
ity, including full body extensions and vigorous twitches of the
face and vibrissae, were noted for each compound at high doses.
Since ketamine lacked convulsant activity and was not very potent
in disrupting rotarod performance, it had the largest margin of
safety when these drug properties were considered relative to
lethality. Loss of righting reflex and lethality were less useful
parameters for discriminating between drugs, at least with the
dosing schedule used in this assay.
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FIGURE 6. Histograms depicting doses of PCP and related compounds
which produced: (A) maximal disruption of rotarod
performance; (B) loss of righting reflex; (C) clonic
and/or toxic convulsions; and (D) lethality in rats
(n=6) given cumulative intravenous doses
Pro- and Anticonvulsant Activity
A complete dose-response analysis was generated for PCP for doses
from 0.625 to 20 mg/kg IP (data not shown). PCP exhibited dose-
related anticonvulsant action when day one minus day three differ-
ence scores were compared for all doses tested. When retested
with saline only on day five, no reduction in convulsant severit
or super-sensitive response was observed (day one minus day five),
indicating no carryover drug effect 48 hours after dosing. At
behaviorally equivalent doses, all compounds assayed were clearly
anticonvulsant (table 3). TCP was most potent at the doses
tested. PCA was the most efficacious, and reduced convulsant se-
verity by 2.58 points. As with PCP, none of the other phencycli-
noids had any carryover effects 48 hours after dosing (day one
minus day five).
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Days 1-3 Days 1-5
Saline - 0.42 0.13
PCP 2.500 -0.83* 0.17
10.000 -0.92** 0.17
PCE 1.250 -0.66* 0.83
5.000 -0.75* 0.17
NsBPCA 2.500 -0.75* 0.33
10.000 -0.83* -0.33
PCA 10.000 -0.75* 0.00
40.000 -2.58** 0.17
NMPCA 5.000 -0.83* 0.50
20.000 -1.40* 0.33
PCPY 1.250 -0.75* -0.17
5.000 -0.83* 0.00
TCP 0.625 -0.33* 0.17
2.500 -0.33* 0.33
TCPY 1.250 -0.33* 0.50
5.000 -0.83* 0.50
Ketamine 5.000 -0.50* 0.00
20.000 -0.50* 0.83




NOTE: A mean difference score of zero lndicates no change; a negative score
denotes ant convulsant action; a positive score denotes a proconvulsant
action of the drug. n=6.
Receptor Binding
The binding of 3H-PCP to whole brain homogenates was saturable
and completely displaced by unlabeled PCP at a concentration
1O-5 M. PCP-related compounds displaced 3H-PCP and varied in
of
potency. Although this work is still in progress, preliminary
results indicate a rank order of potency for the displacement of
3H-PCP from its receptor similar to those reported for effects on
EEG, rotarod performance, and SLA.
DISCUSSION
These studies provide pharmacologic profiles of PCP and related
compounds ("phencyclinoids") derived from in vivo and in vitro
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assays relevant to the general pharmacology of this class of
psychoactive agents. While a comprehensive discussion of all the
data is not possible here, several important points can be made
regarding the data and approach employed to study PCP.
Although some EEG data for PCP and/or related compounds can be
found in the literature (Vanderwolf and Leung 1983; Domino et al.
1983a; Domino et al. 1983b; Young et al. 1981; Gerhmann and Killam
1979), no comprehensive EEG studies systematically associated with
behavioral effects of PCP have been reported. In this study,
characteristic EEG effects, produced by PCP, that are dose related
have been described using computer-assisted EEG analysis. At low
doses of PCP, the predominant EEG effect was theta activity (5 to
10 Hz). At moderate doses, the predominant EEG activity consisted
of high-amplitude slow waves (0 to 5 Hz). At high doses, there
was activity over a wider range of frequencies, which was asso-
ciated with seizure-like activity. There were dose-related
behavioral effects that correlated well with the EEG changes.
Characterization of these EEG and behavioral effects enabled rep-
lication and extension of previous descriptions of qualitative and
quantitative differences between PCP and a more limited sample of
related compounds (Mattia and Moreton 1981). The behavioral rat-
ing scales of Sturgeon et al. (1979) were very useful in conjunc-
tion with EEG recordings, since behaviorally equivalent doses
could be selected for EEG comparisons. However, when used alone,
these behavioral rating scales did not permit qualitative differ-
ences in compounds to be observed.
Summarizing the results of the other pharmacologic assays, our
data for the analgesic effects of phencyclinoids are in agreement
with other published data (Itzhak et al. 1981; Itzhak and Simon
1984; Kalir et al. 1978), but extensive analgesic studies of the
analogues have not previously been reported. On the whole, our
results also support existing data for the effects of phencycli-
noids on spontaneous locomotor activity (Lozovsky et al. 1983;
Castellani and Adams 1981), and for their pro- and anticonvulsant
effects (Chen et al. 1959; Snyder et al. 1981; Hayes and Balster
1985; Zimmerman et al. 1985). The rotarod test of motor coordina-
tion, in agreement with other published data (Vaupel et al. 1984;
Vignon et al. 1982; Cone et al. 1984), proved reliable in separat-
ing the compounds with respect to potency. Both quantitative and
qualitative differences were discernible via observations of con-
vulsant activity occurring at higher doses. Measurements of
righting reflex and lethality, however, were less discriminating,
probably because of the narrow range of potencies of the compounds
tested and the use of dose doublings at successive dosing inter-
vals. Given a broader range of potencies, these parameters might
have been more useful. Furthermore, changing the dosing incre-
ments or time interval between doses might enhance the utility of
measuring these parameters during cumulative dosing.
Although still in progress, correlations of PCP receptor binding
with the results of the other assays should prove valuable in
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completing the pharmacologic profiles of the phencyclinoids stud-
ied thus far. Such correlations have already been obtained by
others for rotarod performance (Vaupel et al. 1984; Vignon et al.
1982; Cone et al. 1984), drug discriminations (Shannon 1981). and
catalepsy (Mendelsohn et al. 1984). It may also be possible to
relate various pharmacologic effects of phencyclinoids to PCP
receptor subtypes recently described in the literature (Mendelsohn
et al. 1984; Sethy and McCall 1984).
Although generally similar pharmacologic profiles were obtained
for the phencyclinoids, subtle but perhaps important differences
in these compounds were discernible depending upon the individual
assay employed. For example, ketamine never produced behavioral
convulsions and was least potent with respect to SLA and disrup-
tion of rotarod performance, but was more potent than PCPY, TCPY,
TCP, and PCA in the assessment of analgesic activity. PCA, which
was very effective in decreasing the severity of electroshock con-
vulsions, was not particularly efficacious or potent in other
assays. While PCE was equipotent with PCP in stimulating SLA, it
was least efficacious of all compounds with respect to peak SLA
achieved.
Cumulative dosing schedules are useful and have practical applica-
tion in psychopharmacology (Wenger 1980). The use of the cumula-
tive IV dosing schedule in these studies permitted the full range
of activities for each compound to be observed in a group of
animals in one test session.
In conclusion, these data emphasize the need for multiple assays
to discern differences among compounds otherwise regarded as phar-
macologically more similar than different. Measurements of EEG
and convulsant activity are useful because each permits qualita-
tive and quantitative differences in the compounds to be observed.
SLA and analgesia are also useful tests which provide information
regarding potency and efficacy. Rotarod performance is helpful in
determining potency but this paradigm does not permit differences
in efficacy to be observed. The binding studies should be of use
in relating diverse pharmacologic effects to specific drug recep-
tor interactions. This integrated approach utilizing multiple
assays to develop pharmacologic profiles, as first accomplished by
Chen et al. (1959) for PCP, should help to better define the ago-
nist properties and mechanism of action of the phencyclinoids.
This would facilitate investigations regarding the physiological
consequences and determinants of drug abuse, and contribute to the
search for antagonists, potentially useful research tools, and
therapeutic agents.
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Modulation of Phencyclidine (PCP)
Pharmacokinetics With PCP-
Specific Fab Fragments
S. Michael Owens and Michael Mayersohn
At high doses, phencyclidine (PCP) abuse sometimes leads to a
schizophrenic-like condition as well as violent and destructive
behavior (Lerner and Burns 1978; Fauman and Fauman 1979). As with
most drugs, there is no specific antagonist for reversing effects
from PCP. Therefore, conventional therapy, such as urine acidifi-
cation and forced diuresis. have been the only available treat-
ments (Domino and Wilson 1977; Aronow et al. 1978). Although
these techniques may aid in the elimination of PCP, there are
several criteria which must be met before these approaches can be
considered clinically effective. First, the degree of ionization
of the drug should be alterable within the physiological urine pH
range. Second, the drug needs to have a fairly small volume of
distribution. Finally, the therapy should cause renal excretion
to become a major route of elimination. PCP meets only the first
of these criteria. In both humans and animals, PCP has been shown
to have a very large volume of distribution (i.e., very little of
the drug is present in the blood stream), and to be primarily
eliminated through metabolism (Cook et al. 1982a; Cook et al.
1982b; Woodworth et al., in press). Therefore, a more effective
detoxification procedure is needed.
A promising technique for detoxification of certain drugs is the
use of drug-specific antibody fragments (Fab, the antigen-binding
fragment of IgG). This type of treatment has been shown to re-
verse digoxin and digitoxin toxicity rapidly in both animals and
humans (Lloyd and Smith 1978; Smith et al. 1982). The purpose of
this paper is to discuss the important factors in the use of im-
munotherapy for treating PCP toxicity and to present preliminary
data on the effects of anti-PCP Fab fragments on PCP pharmaco-
kinetics in dogs.
PHARMACOKINETIC CONSIDERATIONS FOR DETOXIFICATION OF PCP BY
IMMUNOTHERAPY
Immunotherapy for drug overdose is a fairly recent medical devel-
opment (Lloyd and Smith 1978; Smith et al. 1979; Smith et al.
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1982). The advantages and disadvantages of choosing immunotherapy
as a treatment for drug toxicity have been reviewed by Colburn
(1980). The reasons for choosing immunotherapy for PCP are based
on two important characteristics of the drug: an extremely large
volume of distribution, and pharmacological effects that are
mediated through reversible binding to a drug/receptor complex.
The large volume of distribution of PCP precludes effective detox-
ification by passive procedures, which are dependent on access to
the drug in the blood stream. For instance, Allen et al. (1985)
have shown that charcoal hemoperfusion of the blood of dogs after
a 5 mg/kg dose of PCP does not affect the pharmacokinetics of PCP,
nor does it alter the pharmacological response to the drug. To
demonstrate the point regarding the large volume of distribution
of PCP, figure 1 illustrates the change in the apparent volume of
distribution of PCP with time, after an intravenous bolus dose of
3H-PCP in one of our control animals (i.e., no antibody was admin-
istered in this experiment).
Fab fragments (M.W. 50,000) have several advantages over IgG (M.W.
150,000) for use as the immunotherapeutic reagent (Smith et al.
1979). The Fab fragments distribute more rapidly and extensively
than intact IgG. In addition, they are catabolized and excreted
earlier than intact IgG. A final important advantage is that the
Fab fragments are less antigenic than the intact IgG.
Even though the Fab fragments can probably distribute throughout
the plasma and interstitial space (i.e., extracellular water)
(Colburn 1980) after intravenous administration, they most likely
will not penetrate directly to sites of action of PCP in the cen-
tral nervous system. Therefore, the effectiveness of the Fab
fragments will depend on a number of interrelated factors. These
factors include the affinity constant of the Fab fragments rela-
tive to other binding sites in the body (i.e., particularly the
PCP neuroreceptor), the binding capacity of the Fab fragments
(i.e., the amount of antibody administered and its affinity for
the drug), and the accessibility of antibody fragments to PCP in
the peripheral compartment, as judged by the magnitude of clear-
ance from the peripheral to the central compartment (see figure
1). The significance of each point will be discussed separately.
Intravenously administered anti-PCP Fab fragments would be expect-
ed to "neutralize" drug effects by decreasing the concentration of
PCP at the site of action (i.e., particularly the PCP neuro-
receptor). Since the antibody fragment may not be able to pene-
trate directly to the sites of action of PCP, it must shift the in
vivo equilibrium of the drug through reversible, high-affinity 
binding. Therefore, the affinity of the Fab fragments for PCP
needs to be much greater than the affinity of in vivo binding
sites for PCP. The highest reported in vivo binding site for PCP
is the PCP neuroreceptor. Vincent et al. (1979) and Quirion et
al. (1981) have reported affinity constants for this binding site
of 4.0x106 M-1 and 2.17x107 M-1, respectively (i.e. Ka or 1/Kd).
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The affinity constant of the Fab fragments we produced for these
studies (discussed below) was approximately 3.0x109 M-1. This
means that the Fab fragments would have about 138 to 750 times
greater affinity for PCP than for the receptor.
FIGURE 1. Change in the apparent volume of distribution of PCP as
a function of time following administration of an
intravenous bolus dose of 3H-PCP (6.4 µg) in a male
dog (19.5 kg)
NOTE: These results are the predicted values of a nonlinear regression fit of the
concentration-time data, calculated according the method of Colburn (1983).
Note that 2 hours after administration of PCP, the apparent volume of dls-
trlbutlon is greater than 95 percent of its maximum value. Thls dog (dog
C) was also used In the anti-PCP Fab fragment studies discussed below. The
inset figure shoes a schematic representation of PCP in the dog as a two-
compartment open model with elimination from the central compartment. The
constants K1 2 and K2 1
constant k10 is the apparent first-order elimination rate constant. The
are the Intercompartmental transfer rate constants.
In addition to having a high affinity, the amount of antibody
administered must be sufficient to reduce the body burden of PCP
below that of toxic levels. Therefore, the effectiveness of a
given dose of Fab fragments depends on its affinity and the amount
of antibody administered relative to the dose of PCP. Since the
affinity of the Fab fragments in the present study was so high
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relative to other binding sites in the body, we felt that an
amount of Fab fragments that was equimolar to the dose of PCP
administered would be sufficient to bring about a favorable re-
distribution of PCP. Obviously, to attain the same level of
binding with a lower or higher affinity antibody, one would need
to administer more or less antibody, respectively.
The magnitude of drug clearance from the peripheral to the central
compartment (figure 1) will govern the rate of drug redistribution
from the peripheral compartment and, therefore, the rapidity with
which a toxic response is reversed (assuming that the site of tox-
icity is within the peripheral compartment and that the effect is
reversible). Unfortunately, there are too few experimental sys-
tems upon which to judge the relative importance of the rate of
redistribution of drugs, in the presence of Fab, in terminating a
toxic response. One such example is digoxin, whose peripheral to
central clearance is relatively slow; yet Fab fragments produce a
rapid and dramatic reversal of toxicity. It is difficult to judge
the significance of that finding within the context of this dis-
cussion, as the toxic effects are probably mediated by action in
both the central and peripheral compartment. However, intravenous
administration of a sufficient amount of Fab fragments, relative
to the dose of PCP, should produce a favorable shift in the equi-
librium between the compartment containing the Fab fragments and
the compartments containing PCP. The pharmacokinetic result of
this shift in equilibrium is a significantly smaller volume of
distribution for PCP. In addition, this should lead to rapid re-
versal of concentration-dependent, receptor-mediated, pharmaco-
logical effects through depletion of drug at the receptor binding
site.
PRODUCTION OF ANTI-PCP ANTIBODY FRAGMENTS
A PCP antigen was produced by coupling the hapten 4-[(1-piperi-
dinyl)cyclohexyl]benzoic acid sulfate 1/4 M hydrate (figure 2) to
bovine serum albumin using 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide HCl in aqueous dimethylsulfoxide at pH 4.0 to 4.5. The
antibodies produced against this antigen have been shown to be
fairly specific for PCP versus PCP metabolites (Owens et al.
1982). Two goats were immunized three times during the first 2
weeks with 1 mg of the antigen emulsified in 1 ml of Freund's com-
plete adjuvant at several subcutaneous sites near regional lymph
centers. Booster injections of 3 mg of antigen were administered
at monthly intervals. The animals were bled 7 days after each
boost. After several months of immunization, the titer and affin-
ity of the antibody response was judged sufficient for use.
The immunoglobulin fraction from each bleed was purified by use of
a recirculating isoelectric focusing (RIEF) technique (Bier et al.
1979). The whole serum was diluted 1:3 with urea, to yield a
final urea concentration of 3 M, and then desalted by electro-
dialysis. The urea was added to prevent precipitation under hypo-
tonic conditions. Ampholine (1 percent w/v, pH 3.5 to 10, LKB
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Instruments, Inc., Rockville, MD) was added, and the proteins were
fractionated using a 10-channel RIEF apparatus. The proteins in
each of the 10 fractions were then dialyzed against large volumes
of phosphate-buffered saline (PBS, pH 7.4). Immunoelectrophoresis
and a radioimmunoassay (RIA) for PCP were used to determine the
RIEF fractions with the greatest purity and anti-PCP activity.
FIGURE 2. Structures of PCP, the hapten used for antigen
production, and come important PCP metabolites
NOTE: The carboxylic acid group of the hapten was coupled to bovine serum albumin
by using a water-soluble carbodiimide reaction.
The active imnunoglobulin fractions from the RIEF separation were
affinity purified using a column containing the hapten covalently
bound to a sepharose bead. After isolation on the affinity
column, the antibody was eluted using glycine HCl and 6 M guani-
dine HCl. The antibody was concentrated and again tested for
activity and purity using the RIA and immunoelectrophoresis. The
IgG-containing samples were then digested with papain by the
method of Porter (1959)) and the Fab fragments were purified by
anion exchange chromatography using DEAE-sephacel (Pharmacia Inc.,
Piscataway, NJ). Based on the results from immunoelectrophoresis,
only Fab fragments were found in the final product.
The affinity and cross-reactivity of the whole serum and Fab
fragments were determined using equilibrium dialysis for the
affinity determination and RIA for the cross-reactivity studies.
The average intrinsic affinity constant (Ko) of the antibody
(Nisonoff and Pressman 1958) changed very little throughout the
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entire purification procedure, The average value was about
3x109 M-1. The cross-reactivity of the whole serum and the Fab
fragments was tested against three important PCP metabolites:
1-(1-phenylcyclohexyl)-4-hydroxypiperidine (PCHP), 1-(1-phenyl-4-
hydroxycyclohexyl)piperidine (PPC, a cis/trans mixture), and 5-[N-
(1'-phenylcyclohexyl)amino]pentanoic acid (PCAPA) (figure 2). The
aminopentanoic acid metabolite PCAPA showed no cross-reactivity
with the antibody. The two monohydroxylated PCP metabolites PCHP
and PPC showed approximately 1 to 7 percent cross-reactivity
(depending on the bleed) before purification and about 13 percent
cross-reactivity after digestion and purification to Fab
fragments. This meant that the highest affinity binding of the
Fab fragments was directed at the PCP molecule, which is known to
be the most toxic form of the drug. However, the binding affinity
for the two metabolites was still fairly high. Since both PCHP
and PPC have been shown to have some pharmacological activity in
animal models (Shannon 1981), this cross-reactivity was not
considered a problem.
ADMINISTRATION OF ANTI-PCP FAB FRAGMENTS TO DOGS
Three male mongrel dogs were used for the Fab experiments. Each
dog was administered a trace dose of 3H-PCP (from 2.42 to 4.86
µg), and 2 hours later they were given a dose of Fab fragments
(0.5 to 1.0 mg), equimolar to the dose of 3H-PCP. The 2-hour
delay period was chosen to allow for the distribution phase of PCP
to be essentially complete (figure 2). We believe that this
procedure provided the most critical test of the ability of the
antibody fragments to modulate the disposition kinetics of PCP.
Earlier or concurrent administration of Fab would not have pro-
vided as useful an indication of the real-life situation in which
a patient comes to the emergency room after taking the drug.
Blood and urine samples were collected from each dog for about 100
hours. Several analytical assays for PCP and total drug were per-
formed to allow a thorough characterization of the pharmacokinetic
profile in each animal. Serum samples were extracted for PCP with
hexane, after adjusting the pH of each sample to greater than 11.5
with 2 N NaOH. The radioactivity in the hexane extract was then
measured by liquid scintillation spectrometry. Each value was
corrected for extraction efficiency and converted to PCP concen-
tration in serum based on the specific activity of the 3H-PCP
(specific activity was approximately 7 Ci/mM). These PCP concen-
trations were used to determine the pharmacokinetics of the parent
drug. An aliquot of serum was analyzed directly for total radio-
activity (PCP plus metabolites) to determine the pharmacokinetics
of the total drug administered. An aliquot of serum was also used
for determination of the change in free fraction before and after
administration of the antibody. This value was determined by
equilibrium dialysis, followed by extraction of each sample after
dialysis (bound and free fractions) with hexane, for determination
of the unchanged PCP concentration. The blood to plasma ratio of
selected samples before and after Fab administration was also
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185-466 0 - 87 - 5
determined by the method of Owens et al. (1983). The amount of
PCP present in the urine was determined after hexane extraction of
each sample. The amount of total drug (parent plus metabolites)
was determined by direct counting of an aliquot of urine. From
these determinations we were able to calculate numerous pharmaco-
kinetic parameters.
EFFECT OF FAB FRAGMENTS ON PCP DISPOSITION IN DOGS
Immediately after administering the anti-PCP Fab fragments, the
PCP concentration in serum increased approximately 17- to 56-fold
within a period of a few minutes (figure 3). The percent unbound
FIGURE 3. Total unchanged PCP concentration (closed symbols and
unbound PCP concentration (open symbols) before and
after anti-PCP Fab fragment administration
NOTE: The dotted Iines at-e used to connect sequential time points. The solid line
is a ilnear regression fit of the log-linear terminal elimination phase.
The unbound PCP concentration was calculated by multiplylng the total un-
changed PCP concentration In serum by the unbound fraction in serum at each
time point. The harmonic means for the terminal elimination half-life for
unchanged total PCP and unbound PCP were virtually the same (3.5 and 3.3
hours, respectively). The arrows indicate the time of Fab administration.
PCP changed from about 50 percent before administration of the
Fab, to less than 1 percent unbound PCP immediately after admin-
istration of the antibody fragments. By about 10 to 11 hours
after administration of the Fab fragments, the unbound PCP was
37.7 percent, 1.4 percent, and 5.8 percent in dogs A, B,and C,
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respectively. Based upon the sensitivity of the analytical meth-
ods and the relatively short half-life of PCP, the unbound frac-
tion could not be measured accurately beyond those times. The
higher than predicted unbound fraction in dog A at the late time
point was not consistent with the blood to plasma ratio at the
same time point. The blood to plasma ratio indicated that the
drug was still highly bound to the antibody. We suspected that
this might be due to a low molecular-weight breakdown product from
the anti-PCP Fab fragments. Therefore, in subsequent experiments,
we used a 3,500 molecular-weight cutoff (MWCO) membrane, instead
of the 12,000-14,000 MWCO membrane.
We did not measure the terminal elimination half-life of the goat
Fab fragments. However, the terminal half-life of sheep Fab frag-
ments in dogs is 16.4 hours (Lloyd and Smith 1978) (recalculated
as the harmonic mean). Assuming the same half-life for the goat
Fab fragments in this study, after 10 hours, 66 percent of the
intact Fab fragments should have remained in the body. By compar-
ison, after 10 hours, only about 14 percent of intact PCP would
remain in the body, based on the average half-life of PCP in the
three dogs (i.e., 3.5 hours). Therefore, the binding capacity of
the Fab fragments should have been in excess of the amount of PCP.
The total radioactivity in serum (PCP and metabolites) increased
significantly after Fab administration (figure 4). This increase
was mostly due to the dramatic increase in unchanged PCP concen-
tration and not due to an increase in metabolite concentration.
FIGURE 4. Total PCP equivalents in serum (PCP plus metabolites)
before and after Fab administration in three dogs
NOTE: The dotted line connects sequential time points. The solid line is a
linear regression fit of the log-linear terminal elimination phase.
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In fact, the PCP metabolite concentration actually decreased for
1 to 2 hours after Fab administration. The PCP metabolite concen-
trations were determined by subtracting the total PCP equivalents
in serum (PCP plus metabolites) from the PCP concentration in
serum at each time point. The most likely explanation for the
temporary decrease in metabolite concentration was that the high
affinity binding of PCP to the Fab fragments temporarily reduced
metabolism, and/or some of the metabolites also bound to the anti-
body and were prevented from further metabolic changes. The
terminal elimination half-life for the total metabolites in the
three dogs was very long (harmonic mean = 62.4 hours). Since the
serum concentration of PCP was near or below our detection limit
by 24 hours after the administration of PCP, this very long termi-
nal half-life was undoubtedly due to one or more PCP metabolites.
Another interesting and important change in the disposition of PCP
was the blood to plasma ratio. This ratio in the dog is normally
about 1.25, and in man is about 0.94 (Owens et al. 1983). This
indicates that there is an approximately equal distribution of PCP
between plasma and red blood cells. From preliminary experiments,
we knew that the Fab fragments were not found in the red blood
cells. Therefore, the degree of success in modifying the
pharmacokinetics of a drug should also be predictable from the
change in the blood to plasma ratio before and after antibody
administration. The blood to plasma ratio after Fab administra-
tion was approximately equal to one minus the hematocrit. This
indicated that the PCP in the vascular compartment was confined to
the plasma space and was prevented from distributing into red
blood cells as it does in the absence of antibody.
The major route of PCP elimination in dogs is through metabolism
(greater than 95 percent) (Woodworth et al., in press). Because
Fab fragments have been shown to be eliminated primarily by the
kidney (Wochner et al. 1967), and since PCP was highly bound to
the Fab in plasma, we expected that the percentage of the dose
eliminated as PCP might increase after Fab administration. This
was not the case. The amount of PCP eliminated in the urine was
1.91 ± 0.45 percent of the total dose, whereas in control studies
the amount was 4.8 ± 3.3 percent (Woodworth et al., in press).
However, the PCP excretion rate did show a temporal increase for a
period of time after the administration of Fab (figure 5). Ochs
and Smith (1977) also found an increase in the percentage of
digitoxin excreted in urine during the first 96 hours after admin-
istration of Fab fragments. They concluded that the antibody
fragments increased the amount of digitoxin appearing in the
urine. Since they collected urine for less than one half-life of
the drug (half-life of digitoxin > 140 hours), they cannot reach
that conclusion. A more complete urine collection (of at least
four half-lives of the drug) might have revealed a similar finding
to ours (we collected urine for greater than seven half-lives).
Our finding is also verified by Butler et al. (1977). Their
initial premise was that, since Fab fragments are cleared primar-
ily by the kidney, and antibody binding to digoxin can be detected
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in urine, the Fab should increase the amount of drug eliminated by
the kidney. However, their data show that the percentage of the
dose appearing in the urine is not different from control values.
Apparently, digoxin and PCP cannot be eliminated bound to the Fab
fragments. Future studies are planned to clarify this aspect of
the influence of Fab on elimination.
FIGURE 5. PCP urinary excretion rate versus the midpoint of the
urine collection time in three dogs
NOTE: Anti-PCP Fab fragments were administered 2 hours after the start of the
experiment.
RELATIVE CHANGES IN PCP PHARMACOKINETICS IN THE PRESENCE OF FAB
Figure 6 summarizes the relative changes in the disposition param-
eters of PCP after administration of anti-PCP Fab fragments.
These data were calculated by the model-independent methods de-
scribed in the text by Gibaldi and Perrier (1982). Since we were
interested in calculating the effect of anti-PCP Fab fragments on
121
FIGURE 6. Relative change in PCP pharmacokinetic parameters
NOTE: The control values (dotted line) are from the data of Woodworth et al. (in
press). Both studies were conducted in our laboratory. The * indicates
that the values are significantly different (p<0.05) from control animals
(n=4). NS indicates that the values were not significantly different
(p>0.05). Even though the unbound Cl for the Fab-treated group was over
twice the control value. It was not significantly different due to a large
variability in this parameter, especially in one dog.
PCP pharmacokinetics, we calculated the changes in the pharmaco-
kinetic parameters based on concentration-time data occurring
after the administration of the antibody fragment. For these
calculations, we had to estimate the amount of PCP remaining at
the time of antibody administration (i.e., 2 hours after PCP
administration). The amount of PCP remaining at 2 hours was
estimated by calculating first the total area under the concen-
tration-time curve in the absence of PCP and then the volume of
distribution in the absence of PCP. The volume of distribution
times the serum concentration just before antibody administration
provided an estimate of the amount of PCP remaining at 2 hours.
When we tested the validity of this calculation with data from the
control animals (Woodworth et al., in press), the pharmacokinetic
values for both clearance and volume of distribution were within 5
percent of the values calculated using the complete set of data.
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The area under the PCP concentration-time curve (AUC) from the
time of antibody administration to the last measured concentration
(Cn) was determined by the trapezoidal rule. The remaining area
from Cn to time infinity was calculated by dividing Cn by the ter-
minal elimination rate constant. By using dose, AUC, and the ter-
minal elimination rate constant, we were able to calculate the
terminal elimination half-life, systemic clearance, and the volume
of distribution. Renal clearance was determined from the total
amount of PCP appearing in the urine, divided by AUC. Unbound
clearances were calculated based on unbound concentrations of
PCP. The control values are from studies performed in our labora-
tory on dogs administered similar radioactive doses (i.e., 2.4 to
6.5 µg of PCP) (Woodworth et al., in press). Only one of the dogs
(dog C) was used in both studies.
The terminal half-life of PCP did not change significantly, rela-
tive to control studies. This reflects the fact that half-life
depends on systemic clearance (Cls) and volume of distribution
(half-life=0.693xV/Cls), and these two independent parameters
changed approximately by the same order of magnitude, thereby pro-
ducing no net change in half-life. The apparent volume of distri-
bution, systemic clearance, and renal clearance (Clr) decreased to
about one-tenth that of controls. This means that PCP was con-
fined to a much smaller compartment after Fab administration, but
was also cleared at a much slower rate. Both changes can be ex-
plained by the high-affinity binding of PCP to the antibody
fragments.
When we calculated systemic and renal clearance based on the area
under the unbound PCP concentration-time curve, we found essen-
tially no change in these parameters compared to the control stud-
ies without antibody (Woodworth et al., in press) (figure 6).
Since the values for PCP clearance in the presence of Fab were
consistent with restrictive clearance, a change in free fraction
at steady-state would be expected to result in a change in total
drug concentration, without a change in free concentration.
Nevertheless, we cannot predict from these data what is happening
to total and free concentrations at the PCP site of action. The
most accurate conclusions about drug disposition data are based on
the system following first-order kinetic processes when an equi-
librium is achieved. How the introduction of a high-affinity
binding site into the body will affect the amount of drug at the
site of action will have to be determined by physiological model-
ing, and ultimately by its effect on the pharmacological response.
CONCLUSIONS AND FUTURE DIRECTIONS
Based on the dramatic changes in volume of distribution and the
free fraction of PCP found in serum, we predict that this form of
therapy has the potential to rapidly reverse the toxicity of PCP,
if sufficient Fab can be administered relative to the dose of
PCP. The most practical method for making large quantities of
antibodies with reproducible properties is through monoclonal
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antibody production (Kohler and Milstein 1975). We are currently
producing large quantities of high-affinity anti-PCP monoclonal
antibody in mouse ascites fluid. In future studies, we plan to
examine the reversal of PCP toxicity in dogs using anti-PCP mono-
clonal antibodies. A major limitation for this kind of therapy is
the amount of antibody needed for treatment. As a starting point,
we plan to use 2 to 4 grams of anti-PCP Fab to reverse the toxici-
ty of a 1 mg/kg dose of PCP in dogs. This total dose of about 15
to 20 mg of PCP is also a fairly high dose for humans; therefore,
the dog should be a realistic model to demonstrate the feasibility
of this method. The major limitations to this procedure are the
cost of the antibody and the possible antigenicity of mouse mono-
clonal antibodies in humans. Outside of the applied nature of
this research, this approach should provide an important tool for
studying fundamental concepts in the area of pharmacokinetics and
pharmacology.
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Joe Marwah and David K. Pitts
Phencyclidine, 1-(1-phenylcyclohexyl) piperidine hydrochloride
(PCP) was introduced in 1957 as a dissociative anesthetic with a
large margin of safety in humans (Domino 1964). Although limited
respiratory depression was a major asset of this compound, certain
side effects, including emergence psychosis and prolonged excita-
tion, made PCP unsuitable for clinical use. Phencyclidine has now
become a major drug of abuse in the United States (Snyder 1980)
and phencyclidine-related deaths are being reported with increas-
ing frequency (Noguchi and Nakamura 1978). Its continued avail-
ability as an animal tranquilizer and its increasing clandestine
production, distribution, and use have contributed to phencycli-
dine's becoming a major public health concern.
PCP can cause CNS stimulation and depression, which vary markedly
depending upon the dose and species employed. The response of
rodents to PCP appears markedly more sympathomimetic than that of
primates (Balster and Chait 1978). Intoxication in humans with
low doses (5 to 20 mg) of PCP resembles an acute confusional state
lasting several hours. Higher doses (greater than 20 mg) can
elicit serious neurological (nystagmus, gait ataxia, muscle rigid-
ity, EEG changes, and stereotypy), cardiovascular (hypertension),
and psychotic (agitation, disorientation, delirium, auditory hal-
lucinations, thought disorders , and paranoid delusions) reactions.
Current treatment of PCP intoxication involves supportive psycho-
logical and medical measures. Similar clinical features between
PCP-induced psychoses and schizophrenia have led investigators to
view PCP intoxication in humans as a heuristic pharmacological
model for schizophrenia. The most compelling evidence that PCP
psychosis resembles schizophrenia is the fact that experienced
psychiatrists have mistaken drug users for schizophrenics, before
the psychiatrists obtained the history of drug use (Snyder 1980).
PCP can both mimic and reactivate schizophrenic psychoses. Some
PCP users have developed classic schizophrenia subsequent to ex-
periencing PCP psychoses. This phenomenon suggests a relationship
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between the pharmacology of PCP and the neurobiology of schizo-
phrenia. PCP has diverse effects on behavior in rodents, depend-
ing on the dose administered. At low doses, PCP has a stimulant
action; at high doses, it has a sedative effect (Chen et al.
1959).
Although the precise mechanism of action of PCP remains obscure,
virtually all known neurotransmitters have been implicated in its
action. Cholinergic (Alburquerque et al. 1980; Maayani et al.
1974), serotonergic (Martin et al. 1979), dopaminergic (Johnson
and Oeffinger 1981; Fessler et al. 1979; Doherty et al 1980;
Sturgeon et al. 1979), and noradrenergic (Marwah 1982; Bayorh et
al. 1983) mechanisms have been implicated as predominant mediators
of PCP effects. Of these, the dopaminergic and noradrenergic
mechanisms have received the greatest attention.
The administration of low doses of PCP to rodents induces hyper-
activity and stereotypy (Chen et al. 1959). The observation that
neuroleptics such as chlorpromazine, haloperidol, and pimozide,
and adrenolytics such as alpha-methyl paratyrosine antagonize
these behavioral effects of PCP suggests that they are mediated by
facilitation of central dopaminergic neurotransmission (Murray and
Horita 1979). The actions of PCP on central dopaminergic neuro-
transmission may be similar to amphetamine. A dose of PCP (2.5
mg/kg) in rats, which has no effects when given alone, enhances
the behavioral effects of 1 and 3 mg/kg of d-amphetamine (Balster
and Chait 1978). PCP, like dopamine, has also been shown to sup-
press plasma prolactin (Bayorh et al. 1983). However, the firm
establishment of an exclusive relationship between dopamine neuro-
transmission and PCP effects is difficult because of the prominent
interactions of this drug with other neurotransmitter systems.
For example, in regions densely innervated by noradrenergic
fibers, PCP is a very potent inhibitor of norepinephrine uptake.
In rats, cocaine, PCP, and ketamine have been shown to enhance the
spontaneous and electrically stimulated overflow of tritium from
occipital cortex slices preincubated with 3H-norepinephrine (Taube
et al. 1975). Ary and Komiskey (1980) showed that PCP blocks the
reuptake of 3H-norepinephrine into synaptosomes. Consroe et al.
(1982) reported that, in rodents, propranolol blocks the stereo-
typy and hyperactivity elicited by PCP. Clonidine and prazosin
have also been reported to block a number of effects of PCP in
various behavioral states. PCP and (+) PCMP, but not (-) PCMP,
increase blood pressure and heart rate and suppress plasma prolac-
tin (Bayorh et al. 1983). These investigators have suggested
that, because of similar stereospecific effects of PCP derivatives
on the cardiovascular system (noradrenergic system) and plasma
prolactin (dopaminergic system), the actions of PCP on both the
dopaminergic and adrenergic systems may be attributed to the same
active conformation of the PCP molecule. In single unit electro-
physiological studies with the noradrenergic locus coeruleus-
Purkinje neuron synapse, PCP has been shown to have prominent
sympathomimetic effects (Marwah, 1982). Use of lesion techniques
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and receptor antagonists revealed that at this synapse PCP acts as
an indirect sympathomimetic in that it causes release and/or
blocks reuptake of norepinephrine. Marked noradrenergic actions
of PCP have also been observed in the cat spleen (Marwah et al.
unpublished)--a noradrenergically innervated tissue. In the cat
spleen, PCP significantly potentiates the effects of nerve
stimulation and exogenous norepinephrine on the contractile
responses of smooth muscle. This potentiation to exogenous nor-
epinephrine, although attenuated, is also observed in denervated
cat spleens, suggesting that PCP in this system exerts both pre-
synaptic and postsynaptic actions.
PCP has also been reported to possess properties that overlap
with the opioid narcotics. These "opiatergic" effects of PCP are
currently attributed to actions of PCP on the sigma "opiate"
receptor. Activation of the sigma receptor by compounds such as
PCP, SKF-10,047 and cyclazocine elicits dysphoria and other
effects. PCP and SKF-10,047, like amphetamine, elicit locomotor
activity through presynaptic dopaminergic mechanisms within the
mesolimbic system (French and Vantini 1984). SKF-10,047 and PCP
have also been shown to produce a biphasic (initial activation
followed by inhibition) action on single dopaminergic neurons in
the substantia nigra (Freeman and Bunney 1984). The actions of
PCP and SKF-10,047 on sigma receptors are poorly antagonized by mu
opiate receptor antagonists such as naloxone. Geller et al.
(1981) showed that PCP, SKF-10,047, and cyclazocine block fluro-
thyl seizures. These effects are not antagonized by naloxone.
However, Glick and Guido (1982) recently reported that PCP can
interact at mu opiate receptors in brain areas controlling
thermoregulatory  processes.
It appears that mechanisms contributing to the psychopharmacology
of PCP are indeed complex. Despite numerous studies, it is not
yet apparent which, if any, of the above actions are responsible
for the behavioral effects of PCP in humans. An increasing number
of reports (Quirion et al. 1983; Vincent et al. 1979; Zukin and
Zukin, 1978) point to the existence of an endogenous "PCP-like"
(probably peptides) ligand. This ligand (angeldustin!) has been
proposed to interact with sigma or "PCP" receptors (Quirion et al.
1981). Since PCP has been demonstrated to interact with numerous
transmitter systems, it is conceivable that the PCP (sigma)
receptor is located at critical (transmitter release modulating)
sites on susceptible neurons. PCP, by virtue of its interaction
with such a receptor, may subsequently affect steps necessary for
transmitter release (or stimulus-secretion coupling). A candidate
for such a step is the calcium channel. This may explain the
rationale for the use of calcium antagonists during PCP intoxi-
cation. The modulation by PCP of calcium channel properties could
be expressed as increased muscular strength (Marwah, 1980, 1982).
Stimulation of the PCP "receptor" may alter fundamental excitabil-
ity processes such as gk+, which in turn could modulate calcium
mobilization (Aguayo et al. 1984).
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If PCP produces its multitude of effects by activating PCP (sigma)
receptors, then chronic exposure to agonists should elicit the
development of tolerance. Tolerance to plasma prolactin suppres-
sion by PCP is observed in rats following daily administration for
28 days (Quirion et al. 1982). Chronic PCP treatment has been
also shown to reduce the number of PCP sites (receptors) in rodent
brains (Quiriun et al. 1983). Behavioral studies have documented
the development of tolerance to and dependence on PCP (Balster and
Woolverton 1980; Flint and Ho 1980). A tolerance syndrome devel-
ops in humans, in which the user is compelled to increase his
intake of drug (Jain et al. 1977).
Despite this wealth of information, numerous questions regarding











What is the endocrine status of chronic PCP users?
Are the analgesic effects of PCP due to its local anesthetic
properties or actions at sigma or perhaps mu receptors?
Is the development of ultrashort-acting (less abused) PCP
derivatives that are good anesthetics and analgesics with
very little respiratory depression possible?
Can a PCP receptor antagonist be developed?
What is the action of PCC (a PCP analog without psychoto-
mimetic effects) on the numerous synapses that PCP affects?
What are the effects of PCP, SKF-10,047, and PCC on other
central noradrenergically innervated synapses?
How does PCP compare with cocaine and amphetamine at the
various neuronal test systems , where PCP has been documented
to have prominent actions?
What could be the reasons for the existence of endogenous
PCP reactive ligands and receptors? Do they produce a
dissociated mental state following severe trauma or stress?
What causes "flashback" psychosis in some individuals who
abstain from further PCP consumption following the initial
dose? Is it residual drug, slow metabolism to a new stable
metabolite, or a "permanent" change in a defined portion of
the CNS?
What are the effects on the developing nervous system after
chronic in utero exposure? Neurophysiological, neurophar-
macological, and neuroanatomical studies should be useful.
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(11) Is the development of tolerance to PCP pharmacokinetic or
pharmacodynamic? Since PCP psychosis may be the result of a
mixed tolerance and/or altered receptor plasticity, this
phenomenon should be investigated at single monoaminergic
neuron test systems.
Management of PCP intoxication would be significantly enhanced if
the physiologic mechanisms of the drug's effects were better
understood. Such knowledge, which could be derived from basic
science studies in animals, might pave the way to the development
of specific pharmacotherapeutic agents in treating acutely and
chronically intoxicated patients. Additionally, such research
might suggest the development of newer anesthetics and analgesics.
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Phencyclidine (PCP), a dissociative anesthetic agent, which is
subject to abuse, produces behavioral effects in man that fre-
quently resemble schizophrenia (Luisada 1978). Manifestations of
persistent psychopathology frequently remain after the acute
effects of PCP have diminished. With PCP, subjects may display
autistic and delusional thinking typical of schizophrenics (Luby
et al. 1959). A more striking link between schizophrenia and PCP
comes from observations of cases in which PCP was given to hospi-
talized schizophrenics (Luisada 1978). After receiving PCP, these
patients showed extreme exacerbation of their psychoses; the reac-
tion persisted for up to 6 weeks. By contrast, LSD produced no
more severe effects in schizophrenics than in normal subjects.
The close resemblance between schizophrenia and PCP-induced psy-
chosis suggests that the behavioral effects produced by PCP might
be useful as a model of psychosis. On this basis, most animal
studies have examined the ability of various agents to modify PCP-
induced hyperactivity and stereotypy. While some studies suggest
that neuroleptics such as haloperidol (Castellani and Adams 1981;
Garey et al. 1980), chlorpromazine, or clozapine (Freed et al.
1980) antagonize the alterations in locomotor activity produced by
PCP, Sturgeon et al. (1981) could find no consistent effects of
neuroleptics on PCP-induced hyperactivity. In man, phenothia-
zines, butyrophenones, benzodiazepines, and cholinesterase inhibi-
tors have been claimed to be partially effective in treating PCP-
induced effects (Burns and Lerner 1976; Showalter and Thornton
1977; Stockard et al. 1976; Luisada and Brown 1976; Dorand 1977;
Castellani et al. 1982). Thus, the fact that antipsychotic agents
do not completely antagonize the actions produced by PCP in man or
animals suggests that the psychotomimetic effects of PCP are prob-
ably mediated by as yet unelucidated neurochemical mechanisms.
In searching for an animal model specific to PCP and PCP-like
agents, the drug discrimination procedure historically has been
used. The use of drugs as discriminative stimuli provides a
sensitive technique for establishing the similarities among
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various agents, and the method is useful for elucidating the mech-
anism of action of psychoactive drugs (Lal 1977; Ho et al. 1978;
Colpaert and Rosecrans 1978; Thompson and Pickens 1971). The
paradigm requires animals to emit different behavioral responses
depending upon differential drug states. For example, following
injections of PCP, rats, pigeons, or monkeys have been required to
press one of two manipulanda in operant conditioning chambers to
receive a food reward. Following injection of the drug vehicle,
the animals are required to press a different lever or button to
receive reinforcement. After a varying number of sessions where
reinforcement is associated with differential responding dependent
upon drug state, animals learn to identify correctly the appropri-
ate response, based on interoceptive stimuli produced by the
drug. The dependent measure in such paradigms is the number of
responses or number of animals "choosing" the "correct" lever in
the absence of reinforcement feedback. If a drug fails to produce
discriminative stimuli, then no evidence of learning is obtained,
and animals respond at chance levels (50 percent of responses on
both levers or 50 percent of animals choosing the correct
lever). By contrast, drugs that readily produce subjective ef-
fects in man--PCP, for example--engender stimulus control in
animals such that nearly 100 percent discrimination accuracy is
often obtained.
The unique aspect of the drug discrimination paradigm is that the
discriminative stimulus properties produced in animals by drugs
tend to show a great deal of pharmacological specificity. Animals
trained to discriminate one type of drug readily identify pharma-
cologically similar agents as producing similar interoceptive
stimuli, while agents from different classifications do not result
in stimulus generalization. For example, in rats trained to dis-
criminate morphine from vehicle, other opiates and opioid peptides
mimic morphine's effects, and narcotic antagonists such as nalox-
one block the discriminative stimulus properties of these agents
(Browne and Fondren 1978). By contrast, stimulants, depressants,
and anesthetics are not perceived as opiates in the discrimination
paradigm.
A number of investigators have examined PCP in drug discrimination
paradigms. Such studies have revealed a number of PCP analogs
that mimic PCP's discriminative stimulus properties (Shannon 1981,
Brady and Balster 1981). In addition, the sigma opiate agonist
SKF-10,047 has been shown to produce stereoselective PCP-like dis-
criminative effects (Holtzman 1980; Brady et al. 1982). While
some studies have suggested generalization to the PCP cue by opi-
ates such as cyclazocine and dextrorphan (Holtzman 1980, Herling
et al. 1981), the PCP cue does not appear to be mediated via mu
opiate receptors, since it was not blocked by narcotic antagonists
(Holtzman 1980). Other attempts to block PCP's discriminative
properties have not been successful, consistent with the fact
that, to date, there is no established PCP antidote. This paper
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will therefore review the data obtained in discrimination para-
digms that have characterized compounds as PCP-mimetics or have
attempted to antagonize PCP's discriminative properties.
AN EXAMPLE OF DISCRIMINATION METHODOLOGY
Adult, male, Sprague-Dawley rats obtained from Charles River Labs
and weighing 200-250 gm on arrival were used. Throughout the
study, the rats were housed individually, with water freely avail-
able. Purina Rat Chow was fed after each experimental session and
on weekends, in quantities adjusted to maintain the rats between
270 and 350 gm throughout the experiment.
Training and testing sessions were conducted in 10 identical iso-
lated Colbourn operant chambers equipped with two levers mounted
on either side of a motor-driven dipper. Reinforcement consisted
of 3-second presentations of 0.2 ml Carnation Slender, a commer-
cial liquid diet food, diluted 1:1 with water. Reinforcement
contingencies and data recording were performed using a Rockwell
AIM 65 microcomputer.
The procedure used was based on the two-lever fixed ratio 10
(FR-10) drug-discrimination protocol, first described by Colpaert
et al. (1975). At 30 minutes prior to the 15-minute session,
phencyclidine HCl (1.0, 1.78, or 3.2 mg/kg, depending upon experi-
mental group) or vehicle (5 percent ETOH: 95 percent water) was
administered SC in a volume of 1.0 ml/kg. Each animal was
required to discriminate the effects of only one dose of PCP from
vehicle. Depending on whether the rat received drug or vehicle,
reinforcement was programmed exclusively on either the left or
right lever. Only responses on the left lever were reinforced
after drug administration, and responses on the right lever were
reinforced after vehicle administration. Sessions were conducted
Monday through Friday under the alternating drug sequence used by
Colpaert et al, 1975): drug-vehicle-vehicle-drug-drug and
vehicle-drug-drug-vehicle-vehicle. To avoid the possibility that
the correct lever for rats previously tested in the chambers could
serve as an olfactory cue, the sequence of treatments on training
days was alternated for successive groups (i.e., half the animals
received vehicle and half received PCP).
For each session, the number of responses emitted before the first
reinforcement was the measure of discrimination accuracy. For ex-
ample, following PCP administration, if a rat made 10 responses on
the left lever before making 10 or more responses on the opposite,
unreinforced lever, then the animal correctly identified the
training condition for that day. Most rats were clearly discrimi-
nating the effects of PCP from vehicle within about 30 training
sessions, as demonstrated by the animals emitting their first 10
responses on the appropriate lever in 9 out of 10 consecutive
sessions.
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In order to determine stimulus generalization profiles for differ-
ent doses of PCP, various other drugs, and drug interactions with
PCP, twice weekly (Wednesdays and Fridays) experimental tests were
interposed between PCP and vehicle maintenance sessions. Experi-
mental treatments were given in the same ETOH:water vehicle
described above in a volume of 1 ml/kg. Unless noted otherwise,
all treatments were given SC 30 minutes prior to a 15-minute
session. The reinforcement scheduling procedure was changed on
experimental test days as follows: the first reinforcement was
programmed after 10 responses were emitted on either lever. The
lever on which 10 responses were first accumulated defined the
animal's "choice" for that test treatment. If it was the left
lever, the animal was said to have selected the drug side, indi-
cating generalization of the treatment to the PCP training condi-
tion; if it was the right lever, the animal was said to have
selected the vehicle side, indicating nongeneralization of the
treatment to the training condition. Following the first re-
inforcement on experimental treatment days, subsequent reinforce-
ments were given on an FR-10 schedule on either lever.
The degree of generalization of the various treatments to the PCP
cue during the experimental sessions is reflected in the percent-
age of animals choosing the lever previously paired with PCP.
Assuming 100 percent discrimination accuracy for both training
conditions, probability estimates for selection of the drug or
vehicle lever can be ascertained from the binomial theorem with an
underlying probability of 50 percent. For example, using the most
frequent test sample size of n=10, if fewer than four rats (40
percent) chose the PCP lever, then the treatment was considered to
be identical with the vehicle condition. If eight or more rats
selected the drug lever, then the treatment was considered identi-
cal to the training dose of PCP with p<.05. Drug choice in the 40
to 70 percent range was assumed to be different from both training
conditions (i.e., not significantly different from 50 percent).
Response rate data were evaluated using paired t-tests. Calcula-
tions of ED50 values for compounds mimicking PCP were obtained by
linear regression analysis.
RESULTS WITH PCP-MIMETICS
After about 30 training sessions, most animals had acquired the
PCP vs. vehicle discrimination, as evidenced by at least 9 out of
10 consecutive sessions during which the rats emitted fewer than
20 responses before the first reinforcement. Following this
acquisition of the discrimination, the animals were tested in a
random order with different doses of PCP. Figure 1 shows the
dose-response profile for PCP discrimination in different groups
of rats trained to discriminate 1.0, 1.78 or 3.2 mg/kg of PCP from
vehicle. At low doses of PCP few, if any, rats chose the lever
previously paired with PCP (i.e., most rats chose the vehicle-
associated lever).
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FIGURE 1. Dose-response curve for rates trained to discriminate
various doses of PCP from vehicle administered 30
minutes before the test. N=10/dos.
As the dose of PCP was increased, more rats generalized the treat-
ment to that produced by the training dose, so that, when tested
with doses comparable to the training condition, essentially all
animals completed their first 10 responses on the PCP-appropriate
lever. At higher doses of PCP, a significant reduction in the
number of responses emitted during the 15-minute session was
observed. The rate of responding in animals trained at the lowest
dose (1.0 mg/kg) appeared to be more sensitive to disruption by
PCP than in those animals trained at higher doses (figure 2).
However, no tolerance to this rate-disrupting effect of PCP was
seen over the course of the experiments.
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FIGURE 2. Dose-response curve for the effects of PCP on response
rates in rats trained to discriminate various doses
of PCP from vehicle. N=10/dose.
Generalization tests indicated that a number of compounds were
able to substitute for PCP (table 1). Ketamine and tiletamine,
which are structurally similar to PCP, produced dose-dependent
effects mimicking PCP. These compounds are interesting examples
of the structural requirements of molecules for PCP-mimetic activ-
ity, demonstrating that neither the piperidine nor the phenyl
moieties are absolutely necessary for activity.
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NOTE: All compounds were administered SC 30 minutes prior to a 15-minute test.
ED50 values for compounds to mimic the effects produced by 1.78 mg/kg of
PCP.
When the animals were tested with dexoxadrol, PCP-mimetic activity
was found to be about one-third that of PCP. This compound is of
interest because its stereoisomer, levoxadrol, was found to be
completely devoid of PCP-mimetic activity at doses as high as 100
mg/kg (table 1). Another example of the stereoselectivity of the
PCP cue is seen with 2-methyl-3,3-diphenyl-3-propanolamine isomers
(2-MDP). Consistent with the original findings by Tang et al.
(1984), the (-) isomer of 2-MDP is a stereoselective PCP mimetic,
with a potency about one-fourth that of PCP (table 1). SKF-
10,047, the prototypical sigma opiate receptor agonist, also
engenders a dose-dependent generalization to the PCP cue. This
compound has been extensively investigated for its discriminative
properties (Shearman and Herz 1982; Teal and Holtzman 1980;
Shannon 1983). and PCP-mimetic activity is exhibited stereo-
specifically by the dextro isomer (Brady et al. 1982).
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TABLE 2. Structure-activity relationship for piperidine analogs






















In addition to the structurally diverse compounds described above,
which can serve as PCP mimetics, analogs of PCP have also been
examined for their ability to support PCP cueing. The most exten-
sive work reported to date has been done in Harlan Shannon's labo-
ratory (Shannon 1981; Cone et al. 1984; McQuinn et al. 1981) and
has demonstrated (1) that the piperidine moiety is not required
since the free primary amine is active; (2) modifications to the
cyclohexyl ring greatly reduce or abolish activity; and (3) in-
creasing the chain length to the phenyl group or replacement with
naphthyl abolishes activity. In addition, table 2 shows that a
number of piperidine modifications can be made and still retain
PCP-mimetic activity.
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In contrast to the generalization observed with PCP-like com-
pounds, a large number of agents that share similar pharmacologi-
cal activities with PCP failed to mimic PCP's discriminative
effects (table 3). Psychomotor stimulants, hallucinogens like THC
and LSD, opiates, cholinergic and anticholinergic agents, as well
as a diverse group of miscellaneous drugs, consistently produced
vehicle choice.
TABLE 3. PCP discrimination. PCP 3.2 mg/kg vs. vehicle.




Amantadine 10. - 32. 0 518
Methylphenidate 3.2 - 32. 12 530
Cocaine 3.2 - 10. 0 65
d-Amphetamine 1.0 - 1.78 0 140
Apomorphine .32 0 400
THC 3.2 - 10. 12 455
Muscimol 1.0 0 476
LSD .1 0 532
Yohimbine 3.2 0 721
Morphine 3.2 0 145
Ketocyclazoclne 3.2 - 56. 25 144
Cyclazocine 3.2 - 32. 12 357
Mecamylamine 1.0 0 572










- 3.2 12 360
3.2 0 602
.1 - .32 12 136
.32 - 1.0 0 141
10. 0 250
3.2 - 10. 12 321
10. 0 309
Cyproheptadine 3.2 - 10. 33 769





















NOTE: A number of compounds failed to generalize to PCP when administered 30
minutes prior to testing. N=at least 8 rats/treatment. Values are the
highest generalization and lowest number of responses obtained over the
dose-range tested.
ATTEMPTS TO ANTAGONIZE PCP DISCRIMINATION
A search for compounds that might block the PCP cue found that
many drugs failed to reverse PCP discrimination to the vehicle
level. Table 4 lists alphabetically the results obtained with
such compounds over the dose range tested. A few agents,
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TABLE 4. PCP discrimination. PCP 3.2 mg/kg vs. vehicle.










































































































































NOTE: Drugs which failed to reduce PCP discriminability below 50 percent. At
least 8 animals/treatment were tested. However, when response level was
suppressed below about 75 responses/15 minutes, a number of animals
frequently failed to complete 10 responses within 15 minutes; their data
were not included.
including doxapram, diazepam, haloperidol, vasopressin, and yohim-
bine, produced a partial antagonism to approximately the 50 per-
cent PCP-choice level. Frequently, however, testing these agents
at higher doses failed to reduce PCP discrimination further and/or
resulted in complete disruption of responding. In contrast to the
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absence of antagonism by these agents or by PCP analogs, we ob-
served that potent, metabolically stable, adenosine analogs were
capable of blocking completely the discriminative properties of
PCP (Browne and Welch 1982). However, subsequent findings in our
laboratory (Browne et al. 1983) indicated that the anti-PCP activ-
ity of adenosine analogs was most likely attributable to disposi-
tional factors retarding PCP absorption into brain. It is of
interest to note that, in contrast to reported antagonism of PCP's
effects in other endpoints (e.g., locomotor activity), there has
been no definitive report of an agent capable of completely
reversing the discriminative properties produced by PCP. Since
there is no known antidote to PCP intoxication in man, the dis-
criminative stimulus assay may be an appropriate model for
screening for such an agent.
In summary, the results presented here confirm and extend previous
findings that PCP can serve as a discriminative stimulus, and that
pharmacologically similar agents such as ketamine, dexoxadrol, and
SKF-10,047 can mimic the PCP cue (Brady and Balster 1981; Brady et
al. 1982; Herling et al. 1981; Holtzman 1980; Shannon 1981). It
is known that PCP exerts a multiplicity of effects on brain mono-
aminergic and cholinergic systems (Ary and Kominskey 1980; Arora
and Meltzer 1980; Ward and Trevor 1981). However, compounds that
activate or attenuate activity of CNS noradrenergic, dopaminergic,
serotonergic, cholinergic, GABAergic, opiate, or benzodiazepine
systems all failed to mimic or block completely the discriminative
effects of PCF. These results indicate that PCP-like agents prob-
ably exert their effects through unique neurochemical mechanisms
distinctly different from other classes of agents. Indeed, it
appears that PCP-like compounds may be acting on specific "PCP
receptors" in brain (Vincent et al. 1979; Marwaha et al. 1981;
Quirion et al. 1981; Zukin and Zukin 1979). Although good corre-
lations between the ability of agents to support PCP cueing and
their ability to displace labeled PCP from binding sites have been
obtained (Zukin and Zukin 1981; Browne and Kozlowski, in prepara-
tion), it remains to be determined whether antagonists of PCP
cueing and receptor binding can be eventually discovered.
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icipated epidemic of phencyclidine
and early 197Os, biomedical and be-
havioral research on this drug expanded by the late 1970s (Balster
and Pross 1978). Partly because of the improved public health
response resulting from this research activity, the PCP epidemic
has been stopped. The major credit for this rapid growth of PCP
research should go to the National Institute on Drug Abuse, NIDA
supported most of these research activities, and took an active
role in disseminating information on PCP (Peterson and Stillman
1978). Also exceedingly important has been NIDA's leadership in
providing PCP and many critically important analogs for research
use. For the last 10 years or so, NIDA has provided nearly all
the PCP utilized by researchers throughout the world. NIDA has
also had an active intramural research program on PCP, leading to
a number of important findings.
As a consequence of the unant
(PCP) abuse in the late 1960s
This update of NIDA's 1978 monograph on PCP provides an opportu-
nity to see what we have learned from this enormous expansion of
PCP research over the last decade. This paper will focus on the
results of behavioral studies. Since the development of PCP as an
anesthetic was discontinued in the 196Os, there have been no labo-
ratory studies of the behavioral effects of PCP in humans, presum-
ably because of potential dangers to the subjects and probable
difficulties in obtaining an IND to give behaviorally active
doses. Thus, most of what we have learned about the behavioral
pharmacology of phencyclidine has been from animal research. This
review will highlight some of the major findings of that research.
It will also examine the implications to be drawn from this re-
search for treatment and prevention of PCP abuse. Some of these
predictions for PCP abuse are consistent with clinical reports.
In other cases, clinical information is incomplete. One goal of
this paper is to suggest some areas where clinicians and clinical
researchers might focus their attention to learn more about the
implications of PCP abuse.
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WHAT IS PCP?
Pharmacologists and epidemiologists have always had trouble clas-
sifying PCP. In early writings, it was classified as an anesthet-
ic because this was its intended use; however, differences in the
pharmacology of PCP and typical general anesthetics are signifi-
cant, as we shall see. Initially, when PCP was abused, it was
often classified as a hallucinogen; early epidemiologic studies
grouped it together with classical hallucinogens such as LSD.
Again, clinical experience and research have demonstrated the
inappropriateness of this classification. Behavioral pharma-
cologists have also been very interested in classifying PCP's be-
havioral effects and comparing them to other drugs of abuse.
Depending upon the effects being examined, PCP has many properties
in common with other drugs; but, on some measures, PCP seems to
represent a unique class of CNS-active drugs.
Amphetamine-Like Effects
A pioneer in studies of the pharmacology of PCP, Graham Chen,
often characterized PCP as a "sympathomimetic anesthetic" (Chen
1973), a curious juxtaposition of terms. However, the two drugs
to which PCP has been most often compared in behavioral research
are amphetamine, or other sympathomimetic stimulants, and pento-
barbital or other classical CNS depressants. PCP clearly has
effects usually associated with both. PCP has many behavioral
effects characteristic of indirect-acting dopaminergic agonists
(Meltzer et al. 1981; Johnson 1983). Among these effects are the
production of amphetamine-like stereotyped behavior (Sturgeon et
al. 1979) and ipsilateral rotation in substantia nigra-lesioned
rats (Kanner et al. 1975). These amphetamine-like actions are
often blocked by antipsychotic drugs. PCP's effects on schedule-
controlled lever pressing for food reinforcement also often appear
similar to those of amphetamine, with large increases in rates of
responding and rate-dependent effects (Balster and Baird 1979;
Brady et al. 1980; Wenger 1976). Although amphetamine-like
effects on operant behavior have been seen in mice, pigeons, and
monkeys, the amphetamine-like stereotyped behavior and hyper-
activity are particularly prominent in rodents. Monkeys exhibit
decreased responsivity, motor incoordination, changes in visual
attention, and, at high doses, a characteristic anesthesia. These
species differences in overt behavioral effects of PCP lead to the
speculation that dopaminergic actions are less prominent in pri-
mate species, possibly including humans.
Nonetheless, the amphetamine-like actions of PCP are of consid-
erable interest for the following reasons. Malfunction of the
dopaminergic system has been implicated as having considerable
importance in schizophrenia. PCP's interactions with this system
may be responsible in large measure for its schizophreniform mani-
festations in humans. Like amphetamines, PCP would be expected to
exacerbate schizophrenia, and users with this or related dis-
orders, or with latent psychiatric diseases, may be at
149
185-466 0 - 87 - 6
considerable risk from taking PCP. This possible connection be-
tween the effects of acute or chronic PCP administration and
schizophrenic diseases has motivated much of the research done
with PCP, since it is very possible that a further understanding
of this drug will provide valuable leads for study of this impor-
tant psychosis (Domino and Luby 1981). Another implication of the
evidence for amphetamine-like effects of PCP is that high-dose PCP
toxicity may have components of amphetamine toxicity. For exam-
ple, hypertensive crises have been reported in PCP overdose
(Eastman and Cohen 1975), and PCP can cause convulsions at high
doses. It is tempting to suggest treating PCP overdose with anti-
psychotic drugs; however, there is also considerable evidence for
differences in the acute toxicity of PCP and amphetamine. The
well-known aggregate toxicity seen with amphetamine in mice does
not occur with PCP (Landauer and Balster 1982). Chlorpromazine,
which antagonizes amphetamine lethality in mice, does not have a
similar protective effect against PCP; indeed, it has additive
toxicity (Landauer et al. 1982). Also, considering that many
antipsychotic drugs lower seizure thresholds and may contribute
anticholinergic effects to those of PCP, it is difficult to find a
clear pharmacological rationale to use antipsychotic drugs rou-
tinely to treat PCP overdose. A final implication of PCP's stimu-
lant properties is that there may be dangerous interactions in the
combined use of PCP and sympathomimetic stimulants such as amphet-
amine and cocaine. PCP has been shown to enhance amphetamine
stereotyped behavior in rats (Balster and Chait 1978). Further
research on this possibility is needed.
Barbiturate-Like Effects
Although PCP was developed as an anesthetic, its profile as an
anesthetic is very different from typical general anesthetics of
the CNS-depressant class (Domino 1964). Nonetheless, PCP has a
number of behavioral and pharmacological effects similar to those
of depressants such as the barbiturates (Balster and Wessinger
1983). PCP has profound motor effects, as evidenced by effects on
rotorod performance and similar measures (Kalir et al. 1969;
Balster 1980). In this production of ataxia, PCP differs consid-
erably from both stimulants and classical hallucinogens. Although
further, more detailed study of the motor effects of PCP is needed
(Ando et al. 1983), it is clear that abusers of PCP would be ex-
pected to exhibit motor signs of intoxication that might contrib-
ute significantly to PCP's behavioral toxicity. Performance of
tasks requiring motor coordination, such as driving an automobile,
would be expected to be significantly disrupted by PCP.
PCP, like barbiturates, also has anticonvulsant effects in various
animal models (Chen et al. 1959; Geller et al. 1981; Hayes and
Balster 1985). Certain convulsants, such as strychnine, are not
antagonized, and PCP has some specificity for tonic rather than
clonic convulsions.
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Perhaps of most clinical significance, PCP very markedly enhances
the effects of classical depressant drugs, including barbiturates
and ethanol (Balster and Wessinger 1983). We have extensively
studied this interaction. and find that quantitatively the inter-
actions can be as large as the interactions among CNS depressants,
a well-established toxic combination. This interaction has been
shown in pigeons, rodents, and primates using a number of differ-
ent behavioral measures (Chait and Balster 1978; Thompson and
Moerschbaecher 1982a; Thompson and Moerschbaecher 1982b; Wessinger
et al. 1982; Woolverton and Balster 1981). Since there is a high
likelihood of combined use of PCP and depressants such as alcohol,
there is a high likelihood that some of the behavioral manifesta-
tions commonly attributed to PCP may be due to combined effects.
Careful histories on concurrent use of depressants such as alco-
hol, barbiturates, or benzodiazepines should be helpful in estab-
lishing the cause of problems encountered during acute PCP
intoxication.
Classical CNS depressants, such as barbiturates and benzodiaze-
pines, have prominent antianxiety effects. In the animal labora-
tory, these drugs increase responding that has been suppressed by
punishment in what are often referred to as conflict procedures.
Because this effect on responding-suppressed-by-punishment is
relatively specific for antianxiety drugs, it is believed to be an
animal model for anxiolytic activity. PCP has potent rate-
increasing effects on responding-suppressed-by-punishment, at
least in pigeons.(Chait et al. 1981), a widely-used species for
studying these types of effects. Although it requires consider-
ably more study, this benzodiazepine-like antipunishment activity
of PCP suggests that it might have antianxiety effects in humans.
These effects may contribute to PCP's attractiveness to abusers.
An interaction between predisposing anxiety disorders and some
forms of PCP abuse warrants further investigation.
Unique Effects of PCP
In spite of the similarities described in the behavioral effects
of PCP to those of stimulants and depressants, users of PCP
describe an intoxication unlike that reported for other drugs of
abuse. PCP appears to have a unique spectrum of subjective
effects: a spectrum that has been characterized by clinical in-
vestigators (Pollard et al. 1965; Siegel 1978). The corresponding
animal behavior model for these effects utilizes a drug discrimi-
nation procedure. Animals are trained to detect whether or not
they have been given a PCP injection and to indicate their condi-
tion by pressing one of two response levers. Another chapter in
this volume (Browne) will consider the research using this para-
digm in detail; however, a few aspects of the findings warrant
mention here.
The discriminative stimulus effects of PCP differ considerably
from those of other drugs of abuse (Poling et al. 1979; Shannon
1981). Animals do not generalize from PCP to other drugs of
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abuse: neither to stimulants, depressants, nor hallucinogens
(i.e., they do not respond as if they had detected PCP). These
data are consistent with the ability of PCP to produce a unique
intoxication in humans, and with its separate classification as
representative of a distinct class of psychoactive drugs. The
public health implications are that the PCP abuse problem would
need specific treatment and prevention approaches. It would be
expected that some PCP abusers would have this as their drug of
choice, and not mix and match PCP with other drugs, as occurs
routinely within drug classes such as opiates and hallucinogens.
Patterns of PCP use and abuse would be expected to be distinctive;
because of its unique effects, PCP might appeal to certain types
of drug users. It is important to recognize that treatment and
prevention strategies developed for other drugs of abuse may be
inappropriate for problems of PCP abuse.
PCP SELF-ADMINISTRATION
Early evidence that PCP had significant abuse potential was the
finding, from behavioral pharmacology research, that PCP would be
self-administered by rhesus monkeys (Balster et al. 1973). In
that study, monkeys with IV catheters could respond on a lever to
receive injections of PCP. They readily acquired this behavior
and self-administered very large doses. This finding has been
replicated and expanded upon in numerous subsequent studies (e.g.,
Balster and Woolverton 1980; Carroll and Meisch 1980; Lukas et al.
1984; Risner 1982). Strong reinforcing properties are typically
obtained only with drugs having significant potential for human
recreational use. One of the interesting findings from PCP self-
administration research is that, given unlimited access to the
drug, monkeys will maintain nearly continuous intoxication. These
results are unlike the pattern of episodic self-administration
typically obtained for stimulants, and more like the patterns
associated with dependence-producing drugs such as the opiates and
depressants. I will have more to say on the dependence properties
of PCP later. These animal results suggest that at least some
segment of PCP abusers would become chronic heavy users with daily
use patterns. Also, unlike the results of self-administration
studies of opiates, where little overt behavioral toxicity is
observed in the animals at self-administered doses, monkeys self-
administer doses of PCP sufficiently high as to cause marked
behavioral effects. In these respects, PCP may more closely
resemble barbiturates and alcohol, with which self-administration,
by animals and human users, results in severely debilitating
doses. Another interesting recent development in PCP self-
administration research is that the oral route is also effective
(Carroll and Meisch 1980). PCP would be expected to have the
potential for both IV and oral abuse, although smoking appears,
currently, to be the most preferred route.
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PCP-LIKE DRUGS
Although PCP has certain unique behavioral properties among drugs
of abuse, behavioral pharmacology research has established that
there are a number of drugs with PCP-like effects. The primary
tool for classifying drugs as PCP-like has been the drug discrimi-
nation procedure, since this is presumably a model of acute sub-
jective effects, and because this is the one behavioral measure
that clearly establishes PCP's uniqueness. One group of drugs
with PCP-like discriminative stimulus effects are chemical analogs
of PCP, other arylcycloalkylamines. Rats or monkeys trained to
detect PCP will readily respond as if they had been given PCP,
when given any of a large number of PCP analogs (Shannon 1981;
Brady and Balster 1981; Solomon et al. 1982). Shannon and co-
workers have made considerable progress toward determining
structure-activity relationships among arylcycloalkylamines and
essential structural requirements for PCP-like effects (Shannon
1983; Cone et al. 1984). A number of these PCP analogs have been
tested for reinforcing properties in IV self-administration stud-
ies (Risner 1982; Lukas et al. 1984). Those that are self-
administered are also identified as PCP-like in drug discrimina-
tion studies; thus, there is an excellent concordance in these
properties. The PCP molecule is a highly versatile one for making
substantial modifications and retaining activity; therefore, many
potentially abusable PCP analogs could be prepared. As of this
writing, only the N-ethyl analog (TCE), the thienyl analog (TCP),
and the pyrrolidine analog have been subject to much abuse, and
have consequently been scheduled under the Controlled Substances
Act. It would appear that many presently uncontrolled analogs
have PCP-like properties. Since animal behavioral research seems
capable of predicting PCP-like abuse potential, perhaps data from
these procedures will be used to regulate some of these analogs
before they are abused.
Ketamine is an arylcyclohexylamine analog of PCP that warrants
special mention. Ketamine is currently marketed as a parenteral
anesthetic for human use, and has many important clinical indica-
tions. In behavioral studies, including drug discrimination and
self-administration studies, ketamine acts very much like PCP. It
is generalized from PCP and is reliably self-administered. It has
also been subject to some abuse, and is presently controlled.
Although it is about one-tenth as potent, and is shorter acting
than PCP, there are little laboratory data showing qualitatively
different effects. Because ketamine is marketed, there has been
more research on it than on other PCP analogs. This research
literature is an important source of information with probable
relevance to PCP.
Among the more important series of discoveries in behavioral
research with PCP are the reports that drugs chemically distinct
from PCP also have PCP-like discriminative stimulus effects.
These drugs are of little immediate clinical significance because
they are all research compounds not easily available to potential
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abusers. On the other hand, the emergence of various classes of
these PCP "biologs" has proven to be of considerable importance to
basic research on PCP's neural mechanisms of action. For example,
the finding that the opioid derivative, N-allylnormetazocine (also
known as SKF-10,047), which was found to have PCP-like discrimina-
tive effects (Shannon 1981), also had affinity for the PCP binding
site (Zukin and Zukin 1979), was very important in establishing a
possible functional significance for this site. Subsequent re-
search has considerably advanced our understanding of the behav-
ioral and biochemical effects of this and other PCP-like opioids
(Brady et al. 1982a; Holtzman 1980; Shannon 1983; Slifer and
Balster 1983; Zukin et al. 1984). Remarkably, a general concord-
ance shows that diverse drugs with PCP-like behavioral effects are
active at the PCP receptor. It would appear that at least one of
the major effects of PCP mediated by this newly-discovered recep-
tor mechanism is its discriminative effect. It is unclear how
many other effects of PCP are mediated through this receptor. One
way to study this is to examine these PCP biologs to determine the
extent of overlap with PCP in their behavioral and pharmacological
properties. It is beyond the scope of this paper to review the
relatively large research literature relating the pharmacology of
certain opioids with unusual "psychotomimetic" effects to the
pharmacology of PCP. Other papers in this volume document the
considerable progress being made in identifying the neural bases
for many of the important behavioral actions of PCP. This basic
research may lead to novel approaches to treatment of PCP abuse
and will contribute substantially to our understanding of brain-
behavior relationships.
In addition to opioid derivatives, drugs from other chemical
classes have been found to have PCP-like discriminative stimulus
effects. The best characterized compounds are 1,3-substituted
dioxolane derivatives such as dexoxadrol and etoxadrol (Brady et
al. 1982b). Each has also been given to humans with evidence of
PCP-like effects (Lasagna and Pearson 1965; Wilson et al. 1970).
This class of compounds is of particular research interest because
it shows stereospecificity of action both behaviorally (Cone et
al. 1984; Slifer and Balster, in press) and in binding to the PCP
receptor (Hampton et al. 1982). Stereospecificity further sup-
ports the hypothesis that PCP's discriminative stimulus effects
are receptor-mediated. The finding that PCP-like effects occur in
a variety of chemical classes, including the opioid and dioxolane
classes described above, as well as some others (Tang et al. 1984;
Zimmerman et al. 1983), suggests that the potential exists for
arylcyclohexylamines to be only the first of many chemically
heterogeneous classes of PCP-like compounds. New compounds may
emerge with differing potential for abuse. On a more positive
side, there is also the possibility that new therapeutic agents
may be developed that will retain some of PCP's desirable effects
but be devoid of its abuse potential (Domino 1981). The labora-
tory procedures to study these new compounds are already relative-
ly well developed. This variety of PCP-like drugs also provides
powerful tools for the basic study of PCP's pharmacology.
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TOLERANCE
There have been a number of laboratory studies of tolerance to the
behavioral effects of PCP. Some of our earlier work on this has
been summarized previously (Balster and Woolverton 1981). The
usual procedure for tolerance studies is to give PCP repeatedly to
subjects trained to perform an operant task. We have given it
daily, or up to four times a day, at behaviorally active doses, in
some cases in escalating doses, to rats and squirrel monkeys. We
routinely find evidence of two- to fourfold shifts in dose-effect
curves, but no more. More recent studies have attempted to deter-
mine the important factors in this tolerance development. Most of
it appears to be accountable for by pharmacological mechanisms,
including some evidence for biodispositional changes (Woolverton
and Balster 1979; Woolverton et al. 1980; Johnson and Balster
1981; Freeman et al. 1984), although, in one study (Woolverton and
Balster 1979), there was some evidence that behavioral factors
(learning to respond while intoxicated) play some role. Practi-
cally speaking, PCP produces relatively modest tolerance develop-
ment. It would be predicted that considerable tolerance would not
be a major characteristic of PCP abusers. The only evidence we
have to the contrary comes, not from direct tolerance studies, but
from studies of IV PCP self-administration. In one of these stud-
ies (Balster and Woolverton 1980), in which rhesus monkeys had
continuous access to relatively high doses, the monkeys often
self-administered over 10 mg/kg/day. These very high doses were
accompanied by behavioral disruption and decreased food intake,
but were tolerated for periods of weeks: food intake often
recovered. Although we have not systematically studied this, I
believe we could not have administered nearly as high daily doses
to naive animals. It is important to keep in mind that these
monkeys were, generally, keeping themselves continuously intoxi-
cated 24 hours a day. Under conditions of unlimited access, very
large tolerance often develops to other drugs as well (Balster and
Woolverton 1982). Thus, this condition--unlimited access--
probably reflects the extreme circumstances favoring tolerance.
It is difficult to imagine human PCP abusers self-administering
this much drug.
DEPENDENCE
In the study described (Balster and Woolverton 1980), of un-
limited-access self-administration of PCP, in which monkeys' very
large daily doses of PCP resulted in blood levels of 100 to 300
ng/ml during periods of over a month, dramatic withdrawal signs
were observed when PCP access was terminated. Signs included
vocalizations, bruxism, oculomotor hyperactivity, diarrhea, pilo-
erection, difficulty remaining awake, tremors, and, in one case,
convulsions. These signs appeared within 8 hours of abstinence
and were most severe at about 24 hours, corresponding to the rapid
decline in plasma PCP levels. To examine this evidence of depend-
ence more fully, high daily doses by continuous IV infusion were
attempted, but, as stated earlier, could not be done without
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difficulty in maintaining the animals in good health. When lower
doses were infused, the observable withdrawal signs were more
subtle and variable.
To study the possibility of dependence upon lower, more reasonable
doses of PCP, a different approach was used (Slifer et al. 1984).
Again, rhesus monkeys were used, but these subjects were first
trained to lever press for their daily ration of food utilizing an
intermittent schedule of reinforcement (FR100). Behavioral meas-
urements were made during four equally-spaced, 30-minute sessions
each day. After the animals were well trained, continuous IV PCP
infusions began through an implanted catheter. The initial dose
was 0.05 mg/kg/hr (1.2 mg/kg/day). As seen in figure 1, this dose
had little effect upon responding for food. The animals appeared
only very mildly intoxicated. When PCP was withdrawn after 10
days, behavior was markedly affected. By 8 hours after the infu-
sion was terminated (response period A on day 11), some animals
completely ceased responding (see figure 1) and behavior recovered
slowly over the next 7 to 9 days. Some mild withdrawal signs were
occasionally observed during the first 24 hours of abstinence, but
the animals appeared normal by after the second day. When PCP was
given to animals in withdrawal, the animals recovered responding,
but were disrupted again as the acute effects wore off.
FIGURE 1. Effects of continuous PCP infusion and withdrawal on
rates of responding for food reinforcement in a
rhesus monkey
NOTE: Response rates in each of tour daily response periods are shown before
(open circles), during (closed circles), and after (open circles) lnfusion
of 0.05 mg/kg/hr PCP for 10 days. PCP was wlthdrawn at the arrow, 2 hours
before the next session where there was no effect. The first session on
day 11 was 8 hours after PCP was withdrawn. The results with this monkey
are similar to the other tour monkeys studied (modified from Slifer et al.
1984). Copyright 1984 Williams and WiIkins.
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We have viewed these withdrawal effects on behavior as evidence of
behavioral dependence on PCP. Behavioral signs have also been re-
ported in human users of PCP during withdrawal (Tennant et al.
1981); however, these instances appear to be relatively rare.
Nonetheless, the relative ease with which a dependence phenomenon
can be produced in monkeys suggests that PCP has a potential for
producing dependence in PCP users, particularly those who use the
drug very frequently. Behavioral sequelae seen in chronic PCP
abusers might be examined as possible manifestations of dependence
as well as of cumulative toxicity.
SUMMARY
This discussion has highlighted only some of the areas of behav-
ioral, pharmacology research with PCP, focusing largely on studies
in our laboratories. Some of the areas touched upon lightly have
been much more extensively investigated (e.g., PCP-like properties
of psychotomimetic opioids). Some areas, such as the search for a
PCP antagonist, have been studied with relatively little success
so far. Two other areas, among many that are worthy of mention,
are the extensive series of studies of the effects of PCP on com-
plex learning procedures, starting with the studies by
Moerschbaecher and Thompson (1980a, Moerschbaecher and Thompson
1980b), and an elegant series of studies on the determinants of
oral PCP self-administration, beginning with the study by Carroll
and Meisch (1980).
Much progress has been made on the clinical implications of behav-
ioral research with PCP, and we are in a much better position to
respond effectively to this public health problem than we were
when it emerged, only a little over 10 years ago. The impetus be-
hind PCP research has come from two directions--from the emergence
of PCP as a drug of abuse with the pressing practical questions
raised by this epidemic, and from the potential that PCP research
has for a fuller understanding of the brain and behavior. Al-
though this discussion has focused on the former, progress toward
the latter goal has been equally, if not more, substantial, and
may have long-term health implications far beyond those presented
by problems of PCP abuse.
REFERENCES
Ando, K.; Johanson, C.E.; Levy. D.L.; Yasillo, N.J.; Holtzman,
P.S.; and Schuster, C.R. Effects of phencyclidine, secobarbital
and diazepam on eye tracking in rhesus monkeys.
Psychopharmacology (Berlin) 81:295-300, 1983.
Balster, R.L. The effects of phencyclidine and three analogues on
motor performance in mice. Pharmacolgy 20:46-51, 1980.
Balster, R.L., and Baird, J.B. The effects of phencyclidine, d-
amphetamine and pentobarbital on spaced responding in mice.
Pharmacol Biochem Behav 11:617-623, 1979.
157
Balster, R.L., and Chait, L.D. The effects of phencyclidine on
amphetamine stereotypy in rats. Eur J Pharmacol 48:445-450,
1978.
Balster, R.L., and Pross, R.S. Phencyclidine: A bibliography of
biomedical and behavioral research. J Psyched Drugs 1O:1-15,
1978.
Balster, R.L., and Wessinger, W.D. Central nervous system depres-
sant effects of phencyclidine. In: Kamenka. J.M.; Domino.
E.F.; and Geneste. P., eds. Phencyclidine and Related Aryl-
cyclohexylamines: Present and Future Applications. Ann Arbor:
NPP Books. 1983. pp. 291-309.
Balster, R.L., and Woolverton, W.L. Continuous access phencycli-
dine self-administration by rhesus monkeys leading to physical
dependence. Psychopharmacology (Berlin) 70:5-10, 1980.
Balster, R.L., and Woolverton, W.L. Tolerance and dependence to
phencyclidine. In: Domino, E.F., ed. PCP (Phencyclidine):
Historical and Current Perspectives. Ann Arbor: NPP Books,
1981. pp. 293-306.
Balster, R.L., and Woolverton, W.L. Unlimited access drug self-
administration in rhesus monkeys. Fed Proc 41:211-215, 1982.
Balster, R.L.; Johanson, C.E.; Harris, R.T.; and Schuster, C.R.
Phencyclidine self-administration in the rhesus monkey.
Pharmacol Biochem Behav 1:167-172, 1973.
Brady, K.T., and Balster, R.L. Discriminative stimulus properties
of phencyclidine and five analogues in the squirrel monkey.
Pharmacol Biochem Behav 14:213-218, 1981.
Brady, K.T.; Balster, R.L.; and May, E.L. Stereoisomers of N-
allylnormetazocine: Phencyclidine-like behavioral effects-in
squirrel monkeys and rats." Science 212:178-180, 1982a.
Brady, K.T.; Bolster, R.L.; Meltzer, L.T.; and Schwertz, D. Com-
parison of phencyclidine and three analogues on fixed-interval
performance in rhesus monkeys. Pharmacol Biochem Behav 12:67-
71, 1980.
Brady, K.T.; Balster, R.L.; and Woolverton, W.L. Discriminative
stimulus and reinforcing properties of etoxadrol and dexoxadrol
in monkeys. J Pharmacol Exp Ther 220:56-62, 1982b.
Carroll, M.E., and Meisch, R.A.  O r a l phencyclidine (PCP) self-
administration in rhesus monkeys: Effects of feeding
conditions. J Pharmacol Exp Ther 214:339-346, 1980.
Chait, L.D., and Balster, R.L. Interaction between phencyclidine
and pentobarbital in several species of laboratory animals.
Comm Psychopharmacol 2:351-356, 1978.
Chait, L.D.; Wenger, G.R.; and McMillan, D.E. Effects of phen-
cyclidine and ketamine on punished and unpunished responding in
pigeons. Pharmacol Biochem Behav 15:145-148, 1981.
Chen, G. Sympathomimetic anesthetics. Can Anaesth Soc J 20:180-
185, 1973.
Chen, G.; Ensor, C.R.; Russell, D.; and Bohner, B. The pharmacol-
ogy of 1-(1-Fhenylcyclohexyl) piperidine HCl. J Pharmacol Exp
Ther 127:241-250, 1959.
Cone, E.J.; McQuinn, R.L.; and Shannon, H.E. Structure-activity
relationship studies of phencyclidine derivatives in rats. J
Pharmacol Exp Ther 228:147-153, 1984.
158
Domino, E.F. Neurobiology of phencyclidine (Sernyl), a drug with
an unusual spectrum of pharmacological activity, Int Rev
Neurobiol 6:303-347, 1964.
Domino, E.F. Phencyclidine and analogues--future directions. In:
Domino, E.F., ed. PCP (Phencyclidine): Historical and Current
Perspectives. Ann Arbor: NPP Books, 1981. pp. 515-527.
Domino, E.F., and Luby, E.D. Abnormal mental states induced by
phencyclidine as a model of schizophrenia. In: Domino, E.F.,
ed. PCP (Phencyclidine): Historical and Current Perspectives.
Ann Arbor: NPP Books, 1981. pp. 4O1-418.
Eastman, J.W., and Cohen, S.N. Hypertensive crisis and death
associated with phencyclidine poisoning. JAMA 231:1270-1271,
1975.
Freeman, A.S.; Martin, B.R.; and Balster, R.L. Relationship
between the development of behavioral tolerance and the bio-
disposition of phencyclidine in mice. Pharmacol Biochem Behav
20:373-377, 1984.
Geller, E.B.; Adler, L.H.; Wonjo, C.; and Adler, M.W. The anti-
convulsant effect of phencyciidine in rats. Psychopharmacology
(Berlin) 74:97-98, 1981.
Hampton, R.Y.; Medzihradsky, F.; Woods, J.H.; and Dahlstrom, P.J.
Stereospecific bindina of 3H-phencyclidine in brain membranes.
Life Sci 30:2147-2154, 1982. 
Hayes, B.H., and Balster, R.L. Anticonvulsant effects of phen-
cyclidine-like drugs in mice. Fed Proc 44:724, 1985.
Holtzman, S.G. Phencyclidine-like discriminative effects of opi-
oids in the rat. J Pharmaco1 Exp Ther 214:614-619, 1980. 
Johnson, K.M. Phencyclidine: Behavioral and biochemical evidence
supporting a role for dopamine. Fed Proc 42:2579-2583, 1983.
Johnson, K.M., and Balster, R.L. Acute chronic phencyclidine
administration: Relationship between biodispositional factors
and behavioral effects. Subst Alcohol Actions Misuse 2:131-142,
1981.
Kalir, A.; Edery, M.H.; Pelah, Z.; Balderman, D.; and Proath, G.
1-Phenylcycloalkylamine derivatives. II. Synthesis and pharma-
cological activity. J Med Chem 12:473-477, 1969.
Kanner, M.; Finnegan, K.; and Meltzer, H.Y. Dopaminergic effects
of phencyclidine in rats with nigrostriatal lesions. Psycho-
pharmacol Comm 1:393-401, 1975.
Landauer, M.L., and Balster, R.L. The effects of aggregation on
the lethality of phencyclidine in mice. Toxicol Lett, 12:171-
176, 1982.
Landauer, M.L.; Woolverton, W.L.; and Balster, R.L. The effects
of chlorpromazine on the lethality of d-amphetamine and phen-
cyclidine in mice. Res Comm Subst Abuse 3:287-295, 1982.
Lasagna, L., and Pearson, J.W. Analgesic and psychotomimetic
properties of dexoxadrol. Proc Soc Exp Biol Med 118:353-354,
1965.
Lukas, S.E.; Griffiths, R.R.; Brady, J.V.; and Wurster, R.M.
Phencyclidine-analogue self-injection by the baboon.
Psychopharmacology (Berlin) 83:316-320, 1984.
159
Meltzer, H.Y.; Sturgeon, R.D.; Simonovic, M.; and Fessler, R.G.
Phencyclidine as an indirect dopamine agonist. In: Domino,
E.F., ed. PCP (Phencyclidine): Historical and Current
Perspectives. Ann Arbor: NPP Books, 1981. pp. 207-242.
Moerschbaecher, J.M., and Thompson, D.M. Effects of phencycli-
dine, pentobarbital, and d-amphetamine on the acquisition and
performance of conditional discriminations in monkeys.
Pharmacol Biochem Behav 13:887-894, 1980a.
Moerschbaecher, J.M., and Thompson, D.M. Effects of d-ampheta-
mine, cocaine, and phencyclidine on the acquisition of response
sequences with and without stimulus fading. J Exp Anal Behav
33:369-381, 1980b.
Petersen, R.C., and Stillman, R.C., eds. Phencyclidine (PCP)
Abuse: An Appraisal. National Institute on Drug Abuse Research
Monograph 21. DHEW Pub. No. (ADM) 78-728. Washington, D.C.:
Supt. of Docs., U.S. Govt. Print. Off., 1978. 313 pp.
Poling, A.D.; White, F.J.; and Appel, J.B. Discriminative stimu-
lus properties of phencyclidine. Neuropharmacology 18:459-463,
1979.
Pollard, J.C.; Uhr, L.; and Stern, E. Drugs and Phantasy: The
Effects of LSD Psilocybin and Sernyl on College Students.
Boston: Little, Brown and Co., 1965. 205 pp.
Risner, M.E. Intravenous self-administration of phencyclidine and
related compounds in the dog. J Pharmacol Exp Ther 221:627-644,
1982.
Shannon, H.E. Evaluation of phencyclidine analogs on the basis of
their discriminative stimulus properties in the rat. J
Pharmacol Exp Ther 216:543-551, 1981.
Shannon, H.E. Discriminative stimulus effects of phencyclidine:
Stucture-activity relationships. In: Kamenka, J.M.; Domino,
E.F.; and Geneste, P., eds. Phencyclidine and Related Aryl-
cyclohexamines: Present and Future Applications. Ann Arbor:
NPP Books, 1983. pp. 311-335.
Siegel, R.K. Phencyclidine, criminal behavior and the defense of
diminished capacity. In: Petersen, R.C., and Stillman, R.C.,
eds. Phencyclidine (PCP) Abuse: An Appraisal. National
Institute on Drug Abuse Monograph 21. DHEW Pub. No. (ADM) 78-
728. Washington; D.C.: Supt. of Docs., U.S. Govt. Print. Off.,
1978. pp. 272-288.
Slifer, B.L., and Balster, R.L. Reinforcing properties of stereo-
isomers of the putative sigma agonists N-allylnormetazocine and
cyclazocine in rhesus monkeys. J Pharmacol Exp Ther 225:522-
528, 1983.
Slifer, B.L., and Balster, R.L. Phencyclidine-like discriminative
stimulus properties of the stereoisomers of dioxadrol. Subst
Alcohol Actions Misuse, in press.
Slifer, B.L.; Balster, R.L.; and Woolverton, W.L. Behavioral de-
pendence produced by continuous phencyclidine infusion in rhesus
monkeys. J Pharmacol Exp Ther 230:399-406, 1984.
Solomon, R.E.; Herling, S.; Domino, E.F.; and Woods, J.H.
Discriminative stimulus effects of N-substituted analogs of
phencyclidine in rhesus monkeys. Neuropharmacology 21:1329-
1336, 1982.
160
Sturgeon, R.D.; Fessler, R.G.; and Meltzer, H.Y. Behavioral rat-
ing scales for assessing phencyclidine-induced locomotor activi-
ty, stereotyped behavior and ataxia in rats. Eur J Pharmacol
59:169-179, 1979.
Tang, A.H.; Cangelosi, A.A.; Code, R.A.; and Franklin, S.R. Phen-
cyclidine-like behavioral effects of 2-methyl-3,3-diphenyl-3-
propanolamine (2-MDP). Pharmacol Biochem Behav 20:209-213,
1984.
Tennant, F.S., Jr.; Rawson, R.A.; and McCann, M.A. Withdrawal
from chronic phencyclidine (PCP) dependence with desipramine.
Am J Psychiatry 138:845-847, 1981.
Thompson, D.M., and Moerschbaecher, J.M. Phencyclidine in combi-
nation with pentobarbital: Supra-additive effect on complex
operant behavior in patas monkeys. Pharmacol Biochem Behav
16:159-165, 1982a.
Thompson, D.M., and Moerschbaecher, J.M. Phencyclidine in combi-
nation with pentobarbital: Supra-additive effects on complex
operant behavior in pigeons. Pharmacol Biochem Behav 17:353-
357, 1982b.
Wenger, G.R. The effect of phencyclidine and ketamine on
schedule-controlled behavior in the pigeon. J Pharmacol Exp
Ther 196:172-179, 1976.
Wessinger, W.D.; Balster, R.L.; and Hayes, B.A. Interactions
between phencyclidine (PCP) and pentobarbital (PB) evaluated in
mice and rats. Fed Proc 41:1541, 1982.
Wilson, R.D.; Traber, D.L.; Barratt, E.; Creson, D.; Schmitt, R.;
and Allen, C.R. Evaluation of CL-1848C: A new dissociative
anesthetic in normal human volunteers. Anesth Analg 49:236-241,
1970.
Woolverton, W.L., and Balster, R.L. Tolerance to the behavioral
effects of phencyclidine: Importance of behavioral and pharma-
cological variables. Psychopharmacology (Berlin) 64:19-24,
1979.
Woolverton, W.L., and Balster, R.L. Effects of combinations of
phencyclidine and pentobarbital on fixed-interval performance in
rhesus monkeys. J Pharmacol Exp Ther 217:611-618, 1981.
Woolverton, W.L.; Martin, B.R.; and Balster, R.L. Modification of
the behavioral effects of phencyclidine by repeated drug admin-
istration and body weight changes. Pharmacol Biochem Behav
12:761-766, 1980.
Zimmerman, D.M.; Woods, J.H.; Hynes, M.D.; Cantrell, B.E.;
Reamer, M.; and Leander, J.D. Discovery and characterization of
the phencyclidine-like actions of a new series of benz(f)iso-
quinoline derivatives. In: Kamenka, J.M.; Domino, E.F.; and
Geneste, P., eds. Phencyclidine and Related Arylcyclohexyl-
amines: Ann Arbor: NPPPresent and Future Applications.
Books, 1983. pp. 59-81.
Zukin, S.R.; Brady, K.T.; Slifer, B.L.; and Balster, R.L. Behav-
ioral and biochemical stereoselectivity of sigma opiate/PCP
receptors. Brain Res 294:174-177, 1984.
161
ACKNOWLEDGEMENTS
My colleagues whose names appear as my co-authors on the papers
cited for this report are due a substantial portion of the credit
for most of the research described herein. The research has been
supported by National Institute on Drug Abuse Grant DA-01442.
AUTHOR
Robert L. Balster, Ph.D.
Department of Pharmacology and Toxicology







GENERAL TRENDS 1973 TO 1984
Phencyclidine (PCP), one of the arylcyclohexylamines. was devel-
oped and originally used as a general anesthetic for humans. Due
to psychotic and hallucinogenic reactions, use of the drug for
humans was discontinued. It is now used legally only in veter-
inary medicine as an animal immobilizing agent.
Currently, trends in PCP abuse are monitored through emergency
room visits, deaths, initiates entering drug abuse treatment pro-
grams, and surveys, as shown in table 1 and figures 1 and 2. The
years between 1973 and 1984 have been divided into three periods:
during the years between 1973 and 1978/1979, the indicators of PCP
use increased; the period 1978/1979 through 1981 marked a decline
in the PCP indicators; 1981 to the present time are years in which
PCP indicators have shown resurgence.
Indicators of PCP abuse, i.e., emergencies, deaths, and the number
of initiates entering treatment, increased between 1973 and 1978/
1979. Between 1973 and 1975, the rate of initiates, based on
treatment year-of-first-use records, increased more rapidly than
the number of emergencies. This phenomenon may be explained, in
part, by a change in the route of administration. Beginning about
1972, PCP users changed from administering the drug orally in tab-
let or capsule form to smoking the drug on leaf material, such as
marijuana, tobacco, or parsley. By smoking, PCP users were able
to control the dosage more effectively, thus decreasing the chance
of overdose.
By 1978/1979, indicators of PCP abuse leveled off and started to
decline. This trend is thought to be related to a variety of
activities initiated by health and law enforcement officials,
including a nationwide education campaign in which 18,000 letters
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were mailed to treatment programs, emergency rooms, health agen-
cies, and medical examiner/coroner offices describing the typical
reactions to PCP, and treatment procedures. In addition, PCP was
rescheduled from Schedule III to Schedule II of the Controlled
Substance Act, a highly restrictive category reserved for sub-
stances with limited legitimate use and/or significant abuse
potential. The PCP analogues, PCE, PHP, and TCP were placed in
Schedule I. Required reporting of production of the precursor,
piperidine, began in 1979. Penalties for possession of PCP with
intent to sell were increased at about the same time. As a result
of these and other efforts, the number of emergencies, deaths, and
PCP initiates entering treatment began to decline.
TABLE 1. PCP indicators
Number Percent Percent
PCP Emergencies PCP “Ever Use” 30-Day Use Age 12-17
PCP Related
National2
Initiate in "Ever Use"












1980 8.5 7.154 3.781
1981 9.4 5.840 2.722
1982 16.4 8.067 3.383
























1. Number of PCP related deaths x 10-1 reported to DAWN. Newark and New York ex-
eluded after 1981. The 1984 data are preliminary (National lnstitute on Drug
Abuse 1985c).
2. Number of PCP related emergencies x 10-3 reported to DAWN projected to the Na-
tion (Hinkley and Greenwood 1982).
3. Number of imputed PCP related emergencies x 10-3 reported to a consistent panel
of hospitals In DAWN (National lnstitute on Drug Abuse 1985a).
4. Number of PCP lnitiates x 10-2 starting use 1973-1983 admitted to a consistent
panel of 402 treatment programs In 1977 through 1981.
5. Number of persons in households x 10-6 having ever used PCP 1970, 1979, and
1982 (Miller et al. 1983).
6. Percent of high school seniors using PCP In the 30 days prior to the survey
(Johnston et al. 1985).
7. Percent ages 12 to 17 years In households reporting ever having used PCP
(Miller et al. 1983).
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KEY: = PCP ralated mortalities (NY and Newark excluded) x 10-1; = P C P
emergencies projected to nation x 10-3; = PCP emergencies reported to con-
sistent panel x 10-3.
FIGURE 1. The number of PCP-retated emergencies projected to the
Nation, and the number of PCP-related deaths, peaked
in 1978/1979, declined through 1980/1981, then
increased in 1981 through 1984
By 1981, some of the indicators of PCP abuse began to increase
again. The number of PCP-related emergencies projected to the
Nation from the Drug Abuse Warning Network (DAWN) data showed an
increase from 5,840 in 1981 to 9,782 in 1983 (Hinkley and
Greenwood 1984). Data from a consistent panel of reporting hospi-
tals indicate that the number of emergencies continued to increase
through 1983. The number of PCP-related deaths reported to DAWN
increased from 96 in 1981, to 154 in 1983 (National Institute on
Drug Abuse 1984). The estimated number of persons reporting ever
having used PCP increased from 7.01 million in 1979 to 8.28 mil-
lion in 1982 (Miller et al. 1983).
The recent increase, however, appears to be concentrated primarily
in the metropolitan areas of Los Angeles, Washington, D.C., and
New York City. These three areas accounted for 76.0 percent of
the emergencies reported to DAWN in 1983, while Los Angeles and
Washington, D.C. accounted for 81.8 percent of the PCP-related
deaths2. Rates of PCP emergencies per 100,000 total emergencies
are available for 26 major metropolitan areas in 1983, based on
DAWN data (National Institute on Drug Abuse 1985d). The areas of
Los Angeles, Washington, D.C., and New York City show the highest
rates at 2.52, 2.03 and 0.53 per 100,000 emergencies, respective-
ly, in 1984.
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KEY: = Percent of household residents ages 12 to 17 years reporting "ever use”
of PCP; = Percent of high school seniors using PCP In past 30 days; = PCP
lnitiates In treatment x 10-2, corrected for lag between first use and treatment.
FIGURE 2. The increase in PCP indicators starting in 1981 does
not reflect an increase for new or young users. The
number of PCP initiates first admitted to treatment,
the percent of high school seniors using the drug in
the 30 days prior to the survey, and the percent of
persons ages 12 to 17 years in households reporting
ever having used PCP declined in the late 1970s and
remained at low levels since the early 1980s.
Table 2 shows the number of PCP-related emergencies for the period
of 1982 to 1984 by quarter for New York, Los Angeles, and
Washington, D.C. For New York and Washington, D.C., the average
number of mentions increased significantly between 1983 and 1984.
The decline in Los Angeles between 1983 and 1984 cannot immediate-
ly be interpreted as a decline in PCP use for that city. In 1981,
during an investigation of PCP trends in Los Angeles, it was dis-
covered that many PCP emergencies were diverted to psychiatric
units, better equipped to handle the violent behavior sometimes
accompanying PCP reactions. These psychiatric units were not par-
ticipating in the DAWN network at that time (Kozel and Husson
1981). It is possible that similar systemic problems may have
occurred in 1984.
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TABLE 2. Number of PCP-related emergencies from a consistent
panel of emergency rooms in New York, Washington,
D.C., and Los Angeles, 1982-1984
Time Frame New York Washington, D.C. Los Angeles
1982 Q1 93 49 567
Q2 147 68 660
Q3 147 68 660
Q4 125 96 589
1983 Q1 142 104 568
Q2 173




1984 Q1 267 190 641
Q2 217 285 635
Q3 237 285 635
Q4 239 229 493
Mean 1982 121.6 70.0 600.6
Mean 1983 207.9 127.6 751.8
Mean 1984 240.0 241.4 621.0
SOURCE: National institute on Drug Abuse 1985b.
Potential problems in PCP abuse were also reported in New Orleans
and St. Louis (National Institute on Drug Abuse, in preparation),
although the quarterly frequencies of emergency room mentions in
those SMSAs were small compared to New York, Washington, D.C., and
Los Angeles.
NEW OR YOUNG USERS
Based on data from national surveillance systems, the increase
between 1981 and 1983 does not appear to reflect substantial in-
creased use among new or young users, as occurred during the early
and mid-1970s, although there may be regional variations. In gen-
eral, the number of initiates declined sharply after 1977 and
remained at low levels through 1981. Table 1 and figure 2 show
that there were 913 initiates starting use in 1978, first treated
in a panel of 402 consistently reporting treatment programs. The
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number of initiates in treatment declined to 127 by 1981. Prelim-
inary data from 1982 and 1983, corrected for the lag time between
first use of the drug and first entry into treatment, do not show
an increase. In addition, the percent of high school seniors
using PCP in the 30 days prior to an annually conducted survey de-
clined from 2.4 percent in 1979 to 1.0 percent in 1984 (Johnston
et al. 1985). There was also a smaller percent of emergency cases
ages 6 to 19 years in 1983 compared to 1979: 34 percent vs. 18
percent (National Institute on Drug Abuse 1984; Drug Enforcement
Administration 1981).
Consistent with the decline in use among youth in these indicators
is the decline in self-reported PCP use among youth and young
adults in the household population. The National Survey on Drug
Abuse showed a significant decline between 1979 and 1982 in the
percent of 12- to 17-year-olds and the percent of 18- to 25-year-
olds reporting ever having used PCP, from 3.9 percent to 2.2
percent, and from 14.5 percent to 10.5 percent, respectively
(Miller et al. 1983).
One exception was noted to the declining trend among youthful
users relative to other age groups. The number of 6- to 19-year-
old black and Hispanic PCP emergency patients increased in one
Harlem hospital from 14 in 1981, to 297 in 1984. However, since
90 percent of all PCP-related emergencies in that hospital in 1984
were ages 6 to 19 years, indicating a bias or specialized program,
the hospital was eliminated from all subsequent analysis.
CHARACTERISTICS OF USERS
According to data from emergency rooms reporting to the Drug Abuse
Warning Network (table 3), most users were male, black, and
between the ages of 20 and 29. Table 3 shows the distribution by
gender, showing 71.8 percent were male. Table 4, giving the char-
acteristics of emergency room patients over time, shows little
change in the gender of PCP emergency patients between 1976/1977
and 1983.
In contrast to the stable trends in gender, the age of emergency
room patients increased. As table 3 shows, in 1983 18.1 percent
were ages 6 to 19 years, 61.8 percent were ages 20 to 29 years,
and 19.6 percent were ages 30 years and older. Table 4 shows the
decline in the proportion of young users ages 6 to 19 years with
an emergency, from 51 percent in 1976/1977, to 18 percent in 1983.
This change in age can also be seen by SMSA, where New York and
Los Angeles both show significant change in the age distributions
between 1981 and 1984 toward older users (NY X2 =17.35, df=3,
p < .001; LA X2 =44.72, df=3, p < .001). No significant change in
age was noted for Washington, D.C.
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TABLE 3. Distribution of PCP-related emergency room visits by
age, race and 8ex, 1983
Age (Years) Percent Race Percent Sex Percent
10-19 18.1 Black 53.9 Male 71.8
20-29 61.8 White 29.3 Female 28.1
30 and older 19.6 Hispanic 13.7 Unknown 0.1
Other or
Unknown 0.5 Unknown 3.1
Total 100.0 Total 100.0 Total 100.0
SOURCE: National Institute on Drug Abuse 1984.
TABLE 4. Distribution of PCP-related emergency room visits by


















Jan 1983-Dec 1983g 18 54 72
SOURCES: aDrug enforcement Administration 1977; b
1978;
Drug Enforcement Administration
Drug Enforcement Administration 1979; Drug
Administration 1981; National Institute on Drug Abuse 1982;
Enforcement
National
lnstitute on Drug Abuse 1983; gNational Institute on Drug Abuse 1984.
The race distribution of emergency patients is also changing over
time in the direction of a larger proportion of black and Hispanic
patients. In 1983 (table 3), 53.9 percent of emergency room pa-
tients were black, 29.3 percent were white, and 13.7 percent were
Hispanic. Trends over time (table 4) indicate a change from 24
percent black in 1976/1977, to 54 percent by 1983. Within SMSA,
all three SMSAs showed significant changes between 1981 and 1984
toward a higher proportion of black and Hispanic patients in New
York and Los Angeles, and a higher proportion of black patients in
Washington, D.C. (NY X2=33.23, df=2, p < .001; DC X
2=116.68, df=2,
p < .001; LA X2 =29.32, df=2, p < .001).
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While most PCP emergencies involve patients ages 20 years and old-
er, the problem among 6- to 19-year-olds is nonetheless important.
Among young patients ages 6 to 19 years, PCP is more popular than
any other drug of abuse. In New York, 50.7 percent of young black
emergency room patients reported use of PCP, as did 19.9 percent
of the young Hispanic patients. In Washington, D.C., 35.4 percent
of the young black patients reported PCP abuse; in Los Angeles,
22.3 percent of the young black and 30.0 percent of the young
Hispanic patients did so.
PCP-RELATED DEATHS
More than 66 percent of PCP-related deaths reported to DAWN in
1983 involved at least one other drug. Table 5 shows a statisti-
cally significant relationship for
heroin combined with PCP (alcohol
alcohol combined with PCP and
X2=12.41, df=1, p < .001; heroin
X2 =29.13, df=1, p < .001).
The number of deaths associated with alcohol combined with PCP,
and for heroin combined with PCP has been increasing. Nationally,
the number of alcohol:PCP-related deaths was 21, 50, and 59, re-
spectively, for the three years 1981, 1982, and 1983, according to
the DAWN annual reports. The number of heroin:PCP-related deaths
increased from 11 in 1981, to 24 in 1982, and 58 in 1983.




PCP No PCP PCP No PCP
59 988 Heroin 58 761
144 4,189 No Heroin 145 4,416
SOURCE: National Institute on Drug Abuse 1984.
The higher than expected frequency of alcohol:PCP-, and her-
oin:PCP-related deaths may be the result of an interaction of
the combined substances. Balster (this volume) anticipated an
interaction of the combined substances when he reported "PCP
very markedly enhances the effects of classical depressant drugs,
including barbiturates and ethanol."
The higher than expected frequencies of alcohol:PCP- and her-
oin:PCP-related deaths also would have occurred if the combina-
tions were preferred by the users. The motivation may involve the
injection of heroin to moderate the adverse effects of PCP, or the
use of PCP to ease the pain of heroin withdrawal. Another expla-
nation assumes a stimulant effect of PCP. The use of stimulants,
especially cocaine, with heroin is increasingly popular among
heroin users (Kozel et al. 1982).
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Many of the PCP-related deaths were not the result of overdose or
drug interaction or reaction, but the direct result of some exter-
nal event. The percent of cases involving a manner of death of
"drug and external event" increased from 31.3 percent in 1976 to
43.4 percent in 1983 (National Institute on Drug Abuse 1984).
According to Kozel and Husson (1981), in a report on a series of
104 PCP-related deaths in Los Angeles, 54 were homicides, 29 were
accidents, and 14 were accidental drug overdoses; the remainder
were reported as suicides. The 54 homicides were not deaths re-
sulting from PCP, but were the result of some event, such as a
gunshot wound or strangling, in which the victim was found to have
been using PCP. Of the 29 accidents, 18 were drownings and 5 were
automobile accidents, while other accidents were the result of
various other causes, such as, a fall or cut. The various manners
of death reported in PCP-related deaths are consistent with ob-
served symptoms of disorientation and violent aggressive behavior.
CONCLUSION
In general, PCP indicators increased between 1973 and 1978/1979,
declined between 1978/1979 and 1981, then increased again through
1984. The increase is predominantly among older, over age 20
years, former users, rather than among young and new users. None-
theless, PCP is the most popular drug of abuse among 6- to 19-
year-old black and Hispanic youth with an emergency, in some
cities. The age of emergency room patients presenting for PCP-
related problems increased between 1976 and 1983, and there was an
increasing proportion of emergencies occurring among blacks during
the same period. Certain cities, such as Los Angeles, Washington,
D.C., and New York, have more PCP-related emergencies per 100,000
total emergencies than other metropolitan areas of the country.
The number of alcohol:PCP- and heroin:PCP-related deaths was
higher than expected. Users may prefer taking these drugs in
combination, or there may be an interaction in the effect of the
combinations. Many of the PCP-related deaths are the consequence
of some external event rather than a direct consequence of the
drug itself.
FOOTNOTES
1. DAWN is a morbidity and mortality information system, funded
by the National Institute on Drug Abuse, in which data are
collected from a sample of more than 800 hospitals located in
27 major metropolitan areas in the continental United States,
from a National panel of hospitals outside of these areas, and
from medical examiners/coroners located in 26 major metropoli-
tan areas.
2. Medical examiner data from New York City are not included be-
cause of incomplete reporting.
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The scientific literature on PCP use and crime is sparse and con-
sists mainly of case studies of persons who have committed vio-
lent, often bizarre acts after ingesting the drug (Siegel 1978;
Siegel 1980; Fauman and Fauman 1982). Death from drowning, often
in small amounts of water, has been a frequent cause of PCP-
related death in California, and the media's emphasis on such
extreme events has helped to increase the drug's notoriety.
PCP is easily synthesized and inexpensive. One should therefore
not expect to find the need for funds to purchase PCP to be the
strong motive for committing income-generating crimes that exists
for users of more expensive drugs like heroin and cocaine. A
potential link between PCP use and violent, impulsive crimes
against persons is often hypothesized, because some users appear
to become so disoriented from the drug that they commit extraordi-
nary aggressive acts. One study of drug use and crime, in 112
boys (mean age of 15 years) committed to a training school,
reported that abusers of PCP had a greater number of offenses
against persons (e.g. rape, assault, robbery) than did abusers of
any other drugs (Simonds and Kashani 1980). Level of PCP use was
not significantly related to rates of property offenses. However,
because many of these boys abused multiple drugs, and only 17
percent of the offenses against persons were preceded by use of
any drug within the prior 24 hours, it is not possible to attrib-
ute the violent acts directly to the use of any of these drugs,
including PCP.
The potential link between PCP use and violent crime is reflected
in the legal debate regarding the defense of diminished capacity
for crimes committed by persons intoxicated with PCP (Baxley
1980). It is argued that persons who have committed violent
crimes under the influence of PCP are not legally responsible for
their acts because they have an inability to have criminal intent.
One reviewer concluded:
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The PCP-intoxicated user's orientation toward the imme-
diate present and disregard for long range consequences
of his/her behavior would make it difficult for him/her
to premeditate criminal acts. But the tendency to re-
act strongly to sensory stimuli in the immediate envi-
ronment, the inclination to refer everything to oneself
that often develops into paranoia, and the need to do
something due to intense psychomotor stimulation can
all produce an aggression-prone individual. Once again
peopleit must be emphasized that emotionally stable
under the influence of low doses of PCP probably will
not act in a way very differently from their normal
behavior. (Siegel 1978, p. 285, emphasis added)
The percentage of all PCP users who become intoxicated and commit
violent acts is unknown. As the statement above implies, however,
one would suspect that only a small minority of disturbed users
reach such a stage, In a recent review of the literature concern-
ing PCP use and crime, the authors concluded that:
PCP is used by persons who tend to be multiple drug
users. PCP is one of the more common drugs found in
arrestee populations , although its prevalence varies
considerably by jurisdiction. An unknown, but probably
very small percentage of users suffer extreme PCP-
induced intoxication and disorientation and commit
bizarre, often violent acts. Much more research is
needed to identify the extent of these problems in
users, and to learn how personality, other drug use,
and the quality and quantity of PCP ingested contribute
to the occurrence of violent behavior. (Wish and
Johnson, in press)
PROBLEMS IN THE STUDY OF PCP AND CRIME
A principal reason for the paucity of rigorous studies of the
association between PCP use and crime is the quantity of method-
ological problems that must be surmounted. Researchers may not be
able to depend upon the accuracy of self-reported PCP use. First,
PCP is often sold under a variety of names and may be misrepre-
sented as other drugs. Thus, users may be unable to report
accurately whether they have taken the drug. Second, because
marijuana is sometimes laced with PCP, users may be unaware that
they have consumed the drug. Third, users of PCP may concurrently
use other illicit drugs. Disentangling the effects of each drug
on behavior is therefore difficult, if not impossible. Finally,
to assess the impact of the drug on individual criminal behavior,
one must have some idea whether PCP was present (or biologically
active) in the body near the time of the crime. In view of these
methodologic problems, the most basic questions regarding the
prevalence of PCP use in offender populations, the characteristics
of arrestees with the greatest risk of PCP use, and the types of
crimes they are charged with, have gone unanswered.
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Our current study of drug use and crime in arrestees in Manhattan
overcame some of these measurement problems and enabled us to
address some of these basic questions regarding PCP use and crime.
The recent use of PCP (as well as other drugs) in male arrestees
was measured by a urinalysis of a specimen obtained within hours
after arrest. We therefore did not have to rely on each person's
accurate report that he had taken PCP. We shall use the urinaly-
sis test results, with information from interviews with the
arrestees, and from their criminal records, to describe the preva-
lence of PCP use in arrestees, the demographic characteristics of
users and the types of offenses for which they are arrested. The
next section describes our study of drug use and crime in arrest-
ees in Manhattan.
STUDY OF ARRESTEES IN NEW YORK CITY
Since 1971, the District of Columbia has routinely used urinalysis
tests to detect recent drug use in all arrestees held in the D.C.
Superior Court lock-up prior to arraignment. This program has
been a valuable source of epidemiologic data regarding drug abuse
trends, and drugs and crime associations (Wish et al. 1980; Forst
and Wish 1983; Toborg 1984). Our current study was designed to
determine whether a similar program of urine testing of arrestees
could be established in New York City, and whether arrestees iden-
tified by urine tests to be current users of hard drugs are at
greater risk for pretrial rearrest and/or failure-to-appear (for
scheduled court appearances) than are arrestees not detected to be
using drugs. We approached 6,406 male arrestees processed in the
Manhattan Central Booking facility between March and October,
1984, and asked each to participate in the voluntary research.
All persons arrested anywhere in Manhattan for more than the most
minor crimes are brought to Central Booking for fingerprinting and
processing before they are arraigned in court. We did not have
the resources to approach all persons who appeared in Central
Booking during the study period. Because this research was
intended to focus on serious offenders who would have substantial
pretrial periods, priority was given to approaching persons
charged with Felony offenses. We also excluded persons charged
with offenses that were so minor that they were not detained in
Central Booking prior to their arraignment.
For these reasons, about three-quarters (77 percent) of the per-
sons in our sample were charged with felony offenses. A drug-
related offense (sale or possession) was the top charge at arrest
for 20 percent of the sample. Comparisons of the characteristics
of our sample members with those of all males processed in Central
Booking during the months that we collected data indicates that 58
percent of all males were charged with a felony, and 32 percent
with a drug-related offense. Thus, our findings apply to all male
arrestees processed in the Manhattan Central Booking facility,
overweighted for felony offenses and underweighted for drug-
related offenses.
176
Response rates for this voluntary, confidential research were
high. Approximately 95 percent of the eligible persons approached
answered the interview questions regarding their drug use and
treatment experiences. Of those interviewed, 84 percent agreed to
provide a urine specimen for analysis. The specimens were sent to
the New York State Division of Substance Abuse Services laboratory
in Brooklyn for analysis.
layer chromatography (TLC),
Each specimen was tested using thin
a widely used general screen for about
20 drugs. In addition, each specimen was tested for alcohol by
gas chromatography, and for opiates, PCP, cocaine, and methadone
using the more sensitive EMIT tests. Information regarding crim-
inal history and recent arrests was obtained from criminal justice
records. Additional information regarding the study methodology
and some preliminary findings may be found in Wish and Johnson (in
press).
FINDINGS
In this section we first describe some background and case charac-
teristics of the arrestees, and the types of drugs found in their
urine specimens. We next describe the persons found to have a
urine test positive for PCP and compare them with arrestees having
other urine test results.
Characteristics of the Sample Members
Because our subsequent analyses are based upon the urine test re-
sults, we present information here only from the subset of arrest-
ees who provided a urine specimen (n=4,847). Other analyses (not
presented here) indicate that the persons who provided a specimen
were virtually identical on these characteristics to the entire
group of persons approached in Central Booking (n=6,406).
As one might suspect, the modal age range of the arrestees was the
twenties. Almost one-half of the men (47 percent) were age 25 or
less, and only 19 percent were 36 or older. The majority of the
men (54 percent) were black, with a sizable minority (33 percent)
being of Hispanic descent. Ten percent of the sample members were
white. Education was limited in the men. More than one half (56
percent) never completed high school or its equivalent (GED).
Only 15 percent had received some education at the college level.
Larceny and robbery were the most common top arrest charges in the
sample. Each of these charges accounted for 14 percent of the
arrests. (Arrestees are often charged with multiple offenses, and
tend to plead guilty to, or be convicted of, a lesser offense.
The top charge is the crime the police officer thought the arrest-
ee had committed.) Possession of drugs was the top charge for
13 percent of the sample, and the sale of drugs accounted for an
additional 7 percent. As we noted earlier, the percentage of
arrestees charged with a drug-related offense would have been much
higher had we not limited their recruitment into the sample. Nine
percent of the sample were charged with possession of stolen
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property, 10 percent with assault, and 7 percent with burglary.
The remainder of the sample (about 26 percent) consisted of a
variety of charges, none of which was found in more than 5 percent
of the arrests.
Urinalysis Test Results
Table 1 provides the urinalysis test results for the 4,847 arrest-
ees. While PCP was tested for by an EMIT test only, cocaine, opi-
ates and methadone were tested for by both EMIT and thin layer
chromatography (TLC). (The EMIT test for opiates is not specific
to morphine, the metabolite of heroin, and can detect the recent
use of a variety of opiates. A specimen positive for opiates is
most likely to indicate the use of heroin in this population, how-
ever.) Our analyses will use only the results from the EMIT
tests, because we have learned that the TLC general drug screen is
less sensitive for detecting recent use of these illicit street
drugs (Wish et al. 1983; Wish et al. 1984).
TABLE 1. Drugs detected in the specimens of male arrestees
(n=4,847)





















A test positive for opiates, cocaine, or methadone probably indi-
cates that the drug was used within the prior 24 to 48 hours.
There is some possibility that PCP, like marijuana, may be detect-
ed in the urine days or weeks after the last use (Khajawall and
Simpson 1983). Thus, a test positive for PCP indicates that the
drug was present in the body at the time the specimen was ob-
tained, but does not necessarily mean that the arrestee last used
the drug near the time of the crime or the arrest. This may not
be too important, however, since the presence of the drug in the
body implies a potential effect upon the person.
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Cocaine was the drug most likely to be found in the arrestees; 42
percent had a test positive for cocaine. The next most frequently
detected drug was an opiate (21 percent), followed by PCP (12 per-
cent). Only 8 percent of the arrestees were positive for metha-
done. (The urine test could not, of course indicate whether the
methadone was obtained legally, by a prescription, or through
illegal channels.) The prevalence of PCP in the arrestees in
Manhattan contrasts with its prevalence in arrestees in Washing-
ton, D.C. In recent years, PCP has been the drug most frequently
detected in arrestees in Washington (found in more than 30 per-
cent), followed by cocaine. As-table 1 indicates, 56 percent of
the tested arrestees were positive for at least one drug. (This
percentage is similar to the statistics currently coming out of
the D.C. testing program, in which 55 to 65 percent of all male
and female arrestees were positive for a drug.) More than one
drug was detected in almost one-fourth (23 percent) of the
specimens.
Specimens containing PCP were somewhat less likely to contain
other drugs than were specimens containing any drugs other than
PCP. Forty-nine percent of the PCP-positive specimens contained
another drug, compared with 52 percent of the cocaine positives,
73 percent of the opiate-positive specimens, and 73 percent of the
methadone positive specimens. The drug found most frequently with
PCP was cocaine; 35 percent of the PCP-positive specimens con-
tained PCP and cocaine. The third most frequent combination found
in specimens containing PCP was PCP, cocaine, and an opiate (8
percent). Opiates and methadone were rarely detected in specimens
containing PCP, probably because PCP was most likely to be detect-
ed in younger arrestees, while opiates and methadone were concen-
trated in older arrestees. As figure 1 shows, PCP was most likely
to be detected in arrestees between the ages of 16 and 25. In
fact, PCP use was the only drug use that peaked for those in their
early twenties. Cocaine, and especially opiates and methadone,
tended to become more prevalent in arrestees above age 20, and to
peak for those in their thirties.
Arrest Charges Associated With a PCP-Positive Specimen
If PCP use were associated with a greater risk of violent, unpre-
meditated crimes, one would expect persons charged with assault,
murder, or public disorder to be most likely to be positive for
PCP. As table 2 shows, however, persons charged with robbery were
most likely to be detected to be PCP users. Persons charged with
drug-related offenses, larceny, and fare beating were next most
likely to be positive for PCP. Persons charged with assault,
sexual assault, public disorder, and murder actually were below
the average (12 percent) likelihood of a PCP-positive test for the
entire sample. PCP users appeared to be arrested for the more
goal-oriented, income-generating offenses rather than for bizarre,
unpremeditated  crimes.
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FIGURE 1. Percent of male arrestees with a positive urine test,
by age
TABLE 2. Percent of persons charged with each offense vho had a



























































We found that PCP use is concentrated in the younger arrestees and
that almost one-half of the PCP-positive arrestees were also posi-
tive for another drug. It is, therefore, possible that the PCP-
crime associations in table 2 could have been partially confounded
by the youthful ages and multiple drug use of PCP users. (For
example, PCP users, being predominantly young, may be more likely
to commit robbery merely because youths tend to specialize in this
crime.) The analyses in the remainder of this paper examine PCP
use and crime, taking into account these possible confounding
variables.
We divided our sample into four groups: (1) persons negative for
all drugs (D- , n=2,153); (2) persons positive for PCP only (PCP
only, n=309); (3) persons positive for PCP and another drug (PCP +
other, n=295); and (4) persons negative for PCP but positive for
another drug (D+, no PCP, n=2,090). As table 3 shows, both groups
of PCP-positive arrestees were younger than the other arrestees.





PCP Only PCP + Other D+, No PCP
(n=307) (n=294) (n=2,079)







27 28 25 13
22 37 42 24
17 17 22 25
34 8 11 38
100 100 100 100
28.4 22.9 24.3 29.2
Even the PCP-positive arrestees who were also positive for another
drug were rarely over age 30 (11 percent). The PCP-positive ar-
restees had average ages in their early twenties, while the other
arrestees had average ages in their late twenties. Age will
therefore continue to be a possible confounding factor to be al-
lowed for in comparisons of drug use and crime in the four groups
of arrestees. The remaining section of this paper examines the
drug use and crime patterns for these four groups of arrestees.
We will especially be looking at whether the two PCP-positive
groups of arrestees tend to resemble the D- arrestees or the other
hard drug users.
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Self-Reported Drug Use in the Four Groups of Arrestees
During the brief interview at Central Booking, we asked each
arrestee several questions about his prior use of drugs and his
treatment needs. Table 4 presents these results.
TABLE 4. Self-reported drug use and treatment, by urine test
result (n=4,847*)
Urine Test Results
D- PCP Only PCP + Other D+, No PCP
Ever used (percent)**
Marijuana 56 79 80 76
Cocaine 22 34 48 60
PCP 8 36 33 8
Heroin 10 11 24 48
Used PCP within 24 to
48 hours before
arrest (percent) 1 14 18 1
Mean age first felt
dependent on PCP 18.3 19.5 19.1 17.8
(Base N) (18) (26) (27) (9)
Needs any drug abuse
treatment now
(percent) 10 8 24 35
*Group n's vary slightly because of missing information.
**Percentages may add to more than 100 because of multiple drug use.
Lifetime use of illicit drugs varied considerably in the four
groups, but the nature of the differences depended on the drug.
For example, more than three-fourths of the arrestees in the three
drug positive (D+) groups reported having used marijuana, compared
with only about half (56 percent) of the D- arrestees. Cocaine
use was relatively rare in the D- arrestees (22 percent), more
prevalent in the two PCP-positive groups (34 to 48 percent), and
most prevalent (60 percent) in arrestees detected to be using
drugs other than PCP. The high level of reported cocaine use in
the latter group is probably related to our finding that these
persons were older; many had a urine test that was positive for
cocaine.
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The two groups of PCP-positive arrestees were four times more
likely to admit using PCP at least once than were persons who were
D- or positive for drugs other than PCP. Still, only about one-
third of the PCP-positive arrestees admitted to using PCP. One
reason for this discrepancy is intentional underreporting of PCP
use by the arrestees. (Underreporting of illicit drug use and
other deviant behaviors is common in persons interviewed in the
potentially threatening criminal justice environment. In contrast
to research conducted in relatively neutral research settings, it
is difficult to convince apprehended persons to disclose sensitive
information about themselves in Central Booking, even in a confi-
dential and independent research project such as ours.) The fact
that many persons are unaware that they have been given PCP is
another possible reason for this lack of concordance.Self-
reported heroin use was rare in the D- and PCP-only groups. Con-
sistent with the urine test results, heroin use was most frequent-
ly reported in the other two groups of arrestees.
Both groups of arrestees who were positive for PCP were more like-
ly to report using the drug in the 24 to 48 hours prior to arrest
than were arrestees in the other two groups (14 percent and 18
percent vs. 1 percent). Again, however, only a small minority of
the PCP positives reported recently using the drug. (Arrestees
are even more likely to underreport illicit behaviors that
occurred in the very recent past.) Fewer than 10 percent of the
arrestees in the four groups who reported using PCP at any time in
their lives reported ever feeling dependent on the drug. However,
of those who did report such feelings, it is clear that the aver-
age age of onset for feelings of dependency was in the late teens.
Few arrestees said that they currently needed drug abuse treat-
ment. There was a clear difference here between the two PCP-
positive groups. The PCP-only arrestees were as unlikely to
indicate a need for treatment as were the D- arrestees. The PCP +
other arrestees were three times more likely to report that they
needed treatment (24 percent vs. 8 percent). This was still less
than we found among the persons positive for drugs other than PCP
(35 percent). These findings are consistent with the fact that
drug dependence and treatment were more common in older persons
abusing cocaine and/or heroin, drugs that were detected in the
urine of the latter two groups of arrestees.
Our findings suggest that the arrestee who is detected by uri-
nalysis to be using only PCP is more involved with drugs than the
arrestee who is negative for all drugs, but is less seriously in-
volved than the arrestee detected to be using PCP and other hard
drugs. The arrestee who is detected by urinalysis to be using
only PCP is typically younger than hard drug use arrestees, and
may be an especially good candidate for interventions that may
prevent his progression to more serious drug abuse.
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Criminal Behavior in the Four Groups
Table 5 presents the top charge at arrest and other criminal back-
ground information (obtained from criminal justice records) for
the four groups of arrestees.
TABLE 5. Arrest charge and criminal history, by urine test result
(n=4,847*)
Urine Test Results (Percent)
D- PCP Only PCP + Other D+, No PCP
Top charge at arrest**
Robbery 14
Larceny 14



































conviction 15 28 27 29
Prior misdemeanor
conviction 34 47 59 55
Had 2+ arrests within
3 years*** 35 60 70 55
*Group n's vary slightly because of missing information.
**Specifies all charges applied to at least 5 percent of either PCP group.
***Counts arrests In a J-year period that extends before and after the index
arrest: excludes the index arrest at which the person was interviewed.
We found that the group of arrestees who were positive for PCP
only were most likely to be charged with robbery (22 percent).
While assault was the most common charge for D- arrestees, it was
the fourth most frequent charge for the PCP-only arrestees, and
was even less common in the arrestees detected to be using hard
drugs.
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Table 5 also presents information about PCP-positive arrestees'
involvement with the criminal justice system. The D- arrestees
were least likely to have had a prior felony or misdemeanor con-
viction, or two or more other arrests within 3 years of their
current arrest. The criminal records of the three drug-positive
groups tended to be quite similar, however, and indicated a great-
er level of prior criminal justice contacts. More than one-fourth
of these groups of D+ arrestees had a prior felony conviction,
one-half had a prior misdemeanor conviction, and over half had
multiple arrests within 3 years of their current arrest. Most im-
portant, the criminal backgrounds of the arrestees positive for
PCP alone were similar to those of persons found positive for the
harder drugs (opiates, cocaine, or methadone).
We were most interested in the PCP-using arrestees' apparent af-
finity for robbery. It occurred to us that there were two compet-
ing hypotheses that could explain this association: (1) our
findings could simply reflect the fact that youths tended to be
charged with robbery and that many of the PCP-positive arrestees
were younger; (2) perhaps many of the persons positive for PCP had
last used the drug weeks before the arrest (or crime). Would
robbery still be the most prevalent crime in persons known to have
used PCP in the day or two prior to arrest? To test for these
possibilities we first looked at the proportion of arrestees, by
age, in each group, who were charged with robbery. Figure 2
presents these findings (n varies from 38 to 790).
FIGURE 2. Percent of arrestees charged with robbery, by urine
test result and age
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Within each age group, at least one of the groups positive for PCP
was the most likely to be charged with robbery. On the other
hand, the size of the differences depended on age. Arrestees 16
to 17 years of age and positive for PCP only were more likely to
be charged with robbery than any other group of arrestees at any
age level. With increasing age, the PCP-only arrestees' higher
likelihood of robbery decreased. At the higher age levels, the
arrestees positive for PCP plus other hard drugs were those most
likely to be charged with robbery. Thus, although PCP users had
more arrests for robbery at all age levels, in the younger ages,
when PCP is most likely to be found in an arrestee, persons posi-
tive for PCP only are the most likely to be charged with robbery.
To examine the possibility that our findings might change if we
knew that the person had taken PCP within hours of the arrest, we
isolated the 96 persons who reported using PCP in the 24 to 48
hours prior to arrest and were positive for PCP by the urine test.
We found that robbery was still the most frequent offense charged.
Twenty-three percent of these persons were charged with robbery;
the percentage was identical for persons positive for PCP only,
and those positive for PCP plus other hard drugs. The next most
frequent offense charged was the possession of drugs (20 percent),
followed by larceny (14 percent). A charge of assault was found
for 12 percent. Thus, even in a group of PCP-positive persons who
admitted to using PCP shortly before arrest, we found that robbery
was the most frequent offense charged.
This information suggests that the PCP-positive arrestee in
Manhattan looks much like other drug-using arrestees. Far from
being charged with assaults or bizarre types of offenses, PCP-pos-
itive arrestees are most likely to be charged with robbery, lar-
ceny, and other drug offenses.
DISCUSSION
This section presents some of the implications of our findings.
Where possible, we will discuss comparable information from the
urine testing program in Washington, D.C., in order to provide a
larger context for our findings.
Perhaps of most significance, we have found that PCP use is rela-
tively common in an arrestee population. Twelve percent of the
male arrestees in Manhattan and about 30 percent of arrestees in
Washington, D.C. have a urine test positive for PCP. In New York,
this would translate into approximately 12,000 PCP-positive
persons arrested and processed in Manhattan Central booking each
year. Furthermore, these are probably minimum estimates of the
number of users, since the urine tests failed to detect the many
users who had not taken the drug soon before arrest.
The fact that PCP is the drug most frequently detected in the
urines of arrestees in Washington, D.C., but only the third most
frequently detected drug in Manhattan, implies that there may be
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considerable differences in the use of this drug in different
regions of the country. We cannot say whether these differences
are the result of fads in drug use, accessibility of the drug, or
some other factor.
Another implication of the large numbers of arrestees who use PCP
is that only a small percentage of users probably experience the
bizarre, violent behavior that is often attributed to PCP. If
more than one or two percent of the arrestees in New York City and
Washington, D.C. were to experience violent psychotic-like behav-
ior when they use PCP, the police and treatment resources in these
cities would be overburdened by the problem. Furthermore, these
estimates do not include the many users of PCP who are never
arrested.
PCP use is concentrated in young offenders under age 25. Since
opiates and methadone are largely found in older arrestees, it
would appear that PCP may be an excellent marker for identifying
the drug-involved offender before he progresses to other hard
drugs. Our findings indicate that the PCP-positive arrestee in
New York City is no stranger to the criminal justice system. He
is likely to have a history of prior arrests and convictions. By
identifying the young PCP-using arrestee at entry to the criminal
justice system and by applying suitable constructive interven-
tions, it may be possible to deter him from progressing to the
more serious hard drug habits found in older arrestees.
Far from finding a preponderance of charges for bizarre, violent
offenses in PCP-positive arrestees, we unexpectedly found that
their most frequent offense was robbery. This affinity for rob-
bery remained at all age levels, and was found even when we
selected out the few persons in our sample who were positive for
PCP and admitted taking the drug within hours of arrest. One
possible explanation for this association between robbery and PCP
use is that both behaviors require a willingness of the person to
risk his/her physical and/or mental well-being. If this is the
case, the PCP-using robber may be an especially dangerous
offender. A top charge of robbery accounted for only a minority
of the PCP-positive arrestees. Following the robbery charge,
larceny, drug offenses, and assault were the most frequent charges
for PCP-positive arrestees. Comparable analyses of information
from the testing program in Washington, D.C. confirm these
findings. Drug offenses, robbery, possession of stolen property,
and assault were the most frequent offenses charged for persons
positive for PCP only, in that city.
Our findings indicate that many PCP users are apprehended for
goal-oriented, income-generating crimes. We did not find a pre-
ponderance of the types of offenses one might expect from persons
commiting the bizarre, irrational acts ascribed to PCP users. One
possible explanation for these findings is that PCP use in these
offenders is so light that PCP intoxication is rare. It is prob-
ably true, as Siegel (1978) suggested, that emotionally stable
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persons taking low doses of PCP will behave the way they would
normally act. Because the criminal backgrounds and the drug abuse
histories of many PCP-positive arrestees were similar to those of
other drug-positive offenders in our sample, we suspect that the
detection of PCP use in an arrestee is the same indicator of in-
tense criminal activity that the presence of cocaine and heroin is
(Wish and Johnson, in press).
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James E. Lewis and Robert B. Hordan
The behavioral testing of phencyclidine (PCP) abusers by means of
neuropsychological (NP) assessment serves as a bridge between
neuroscience research into brain effects of PCP and the treatment
and rehabilitation of the drug abuser in the community. The sys-
tematic individual NP case study includes: (1) a critical review
of historical/developmental antecedents to an individual's drug
use; (2) observations pertaining to a mental status evaluation,
performance on full-scale intelligence, NP, and screening achieve-
ment tests; and (3) a diagnostic interview focusing on education-
al , occupational, and legal implications of the evaluation.
Due to the subtle and gross effects found in brain functioning of
the PCP abuser, assessment information can be critical to develop-
ing rehabilitation plans, successful psychotherapy and/or behav-
ioral treatment programs, and total treatment objectives. The
development of briefer screening assessment techniques, in lieu of
the 6- to 8-hour full NP evaluation, has been recommended for par-
ticular clinical populations, to provide a cost-effective service
while still obtaining important clinical information. Neverthe-
less, a significant amount of professional time and effort contin-
ues to be spent providing treatment to PCP and other polydrug
abusers: time and effort that prove unsuccessful, possibly due to
the lack of any form of objective assessment.
PURPOSES OF THE REVIEW
The purposes of this review are twofold: (1) to describe the con-
tents and rationale of an abbreviated (2- to 4-hour) NP evaluation
of PCP abusers; and (2) to explain the usefulness of this evalua-
tion in relating critical information concerning an individual's
pattern of higher cortical strengths and weaknesses to the thera-
pist's treatment and rehabilitation decisions. Specifically, we
discuss the nature of NP tests and their value in assessing PCP
abusers, and the relevance of history-taking of certain premorbid
developmental variables or factors pertinent to a drug abuse life-
style, e.g., toxicity-related transient organic brain syndromes,
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closed head injuries (CHI), etc. Further, this paper summarizes
patterns and trends in the predrug histories and NP test data
obtained in a pilot sample of PCP-polydrug abusers. Finally, four
case studies are presented to illustrate the diversity of effects
that PCP abuse may have on persons with varied predrug-use charac-
teristics and with varied patterns of drug abuse.
HISTORY OF THE NP EVALUATION IN CHEMICAL DEPENDENCY
In the early stages of clinical neuropsychology, Reitan (1955) and
others demonstrated the utility of NP tests as instruments sensi-
tive to subtle forms of brain dysfunction. Medical specialists,
particularly in neurology, have acknowledged the need to quantify
and elaborate on "soft signs" of brain dysfunction. Despite rapid
advances in radiological (e.g., computed tomography) and EEG tech-
nologies, the medical model approach alone has been insufficient
for full evaluation of impairment of higher cortical functions,
especially complex sensory, cognitive, and coordinated motor
behavior. Parsons and Farr (1981), in their review of research on
alcohol and polydrug abuse, illustrated that a careful NP evalua-
tion can provide valuable information on an abuser's verbal and
nonverbal intelligence, complex motor and sensory functions, and
adaptive "everyday functioning" skills (Heaton and Pendleton
1981). From these NP data, both subtle and gross impairment of
higher cortical functions can be inferred.
At this time, the most thorough and widespread use of NP tests, in
the field of chemical dependency, has been to evaluate effects of
alcohol abuse on higher cortical functions. Though similarities
exist between alcohol abusers and other drug abusers, there are
many ways in which these two groups differ. Grant et al. (1979),
Mider and Lewis (1981), and Parsons and Farr (1981) have applied
knowledge gained from research and clinical use of NP test results
obtained from evaluation of alcohol abusers, to the study of more
complex polydrug and PCP abusers.
COMPLICATIONS IN THE EVALUATION OF THE PCP ABUSER
Kolarik and Vayhinger (1983) implied that any neurological inves-
tigation into PCP abuse must begin by addressing drug identity and
purity problems inherent in the "street supply" of PCP. Analysis
of street samples of PCP reveal significant chemical differences,
with indications that one-third to one-half of all sampled PCP
illegally distributed is contaminated with chemical agents that
differ significantly from pharmaceutically manufactured PCP. The
issue of the chemical nature of the drug presumably ingested as
PCP is further complicated by street sales of chemicals that often
have little or no chemical resemblance to PCP, but may grossly
mimic PCP's physiological and psychological effects. Thus, NP
deficits identified in individual PCP abusers may be due to other
unknown substances that are toxic to the brain and central nervous
system (CNS). In addition to these pharmacologic issues, the vast
differences in patterns (frequency, amount, and types) of drugs
191
used by PCP abusers further complicates the evaluation of suspect-
ed PCP-induced toxic organic brain syndromes.
To date, nearly all published studies of human PCP use have shown
that most PCP abusers are not single-substance abusers. Specifi-
cally, PCP abuse is more often part of a larger pattern of poly-
drug abuse, which may include the abuse of alcohol, marijuana, and
cocaine. Other drugs of abuse, reported less frequently by PCP
abusers, are amphetamines, barbiturates, sedative/hypnotics, opi-
ates, and inhalants. Thus, clinical NP research on the CNS ef-
fects of PCP is complicated not only by differing characteristics
of the drug itself, but also by prior and concurrent patterns of
PCP and other drug use. This polydrug abuse produces indetermina-
ble, though suspected, potentiating and addictive effects.
Although many PCP abusers have histories of normal (before-drug
use) physical and psychological development, recognition of rele-
vant historical and developmental antecedents to PCP and polydrug
abuse are especially important in light of NP models that underlie
the interpretation of NP test results. Adolescence, in terms of
NP functioning, represents the "meeting point" of interpretive
models used to understand child versus adult brain dysfunction.
The child NP model presumes a developing, maturing brain in which
complex cognitive and perceptual skills are being acquired and
mastered. Childhood brain dysfunction is hypothesized as delaying
or impairing acquisition of verbal and nonverbal skills as well as
of psychological coping strategies used to deal with normal life
stresses. In contrast, the NP model of adult brain dysfunction
presumes a developed, mature brain, in which most skills have
"peaked" in terms of acquisition and mastery. Insult to the adult
brain may involve loss or impairment of previously acquired and
mastered cognitive and perceptual skills as well as loss or im-
pairment of other psychological mechanisms and coping strategies.
By the onset of puberty, many basic academic (and other) skills
and abilities have been acquired and mastered, but there continues
to be some "fine tuning" of complex psychological functions medi-
ated by the higher cortex.
Recent research (Mider and Lewis 1981) suggests the existence of a
large subsample of PCP abusers who have premorbid histories of
moderate to severe learning disabilities (LD). The genesis of LD
is often associated with prenatal, birth, and early childhood fac-
tors that are postulated to have influenced or delayed the devel-
opment of various higher cortical functions related to the
acquisition and mastery of specific academic skills. The General
Accounting Office Report to the Congress (1977) suggests a further
correlation between developmental LD and juvenile delinquency
(JD), a term often associated with drug abuse. The LD-JD hypothe-
sis derives from the observation that LD is estimated to be pres-
ent in 50 percent to 80 percent of the JD population, compared to
estimates of LD's presence in 8 percent to 12 percent of the
normal-IQ school-age population at large.
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The interpretation of NP test results, in adolescents and young
adults suspected of drug-induced brain dysfunction, can be a dif-
ficult task, since most NP and psychological evaluations represent
a first testing, or "baseline" situation. Inferences of predrug-
use levels of brain functioning often must be made using existing
educational data and/or by making a premorbid optimal estimate of
functioning from "best subtest" IQ scores. Thus, it becomes a
complex diagnostic issue to determine (1) whether observed defi-
cits on complex cognitive, sensory, and motor tasks represent a
pattern of loss or impairment of previously acquired functions due
to PCP and other associated drug abuse effects, or (2) whether the
observed deficits represent poorly developed learning and perform-
ance skills that were impaired prior to PCP and other drug abuse.
These complex diagnostic issues have important prognostic and
treatment implications. For example, an individual PCP abuser may
have no history of developmental learning or performance disor-
ders; however, the toxic effects of PCP on higher cortical func-
tions may contribute to the onset of learning disabilities
"acquired" as part of a toxic organic brain syndrome. Thus, PCP-
induced brain toxicity will impair skills involved in new learning
and directly influence academic and vocational success.
The examination of individual NP case studies by other investi-
gators, as well as summary results of our pilot research, suggest
at least two clinically distinct populations. One subsample of
PCP abusers has a developmental history of prenatal and birth
complications, e.g., prematurity, anoxia at birth, or low APGAR
scores, and of early childhood factors, e.g., CHI with loss of
consciousness, febrile illnesses with or without convulsions, or
chronic ear infections. These histories contribute to develop-
mental learning and performance disorders. In this group, LD
causes academic failure and frustrations, which in turn contribute
to the development of psychological and interpersonal problems.
The second subsample has little or no evidence of LD or impairment
of cognitive skills necessary for academic success, prior to PCP
abuse. However, this group does show evidence of impairment in
skills involved in new learning, following PCP and other drug
abuse. Socially, these adolescents have little or no history of
associating with a JD peer group but engage in experimental or
"recreational" drug use only. PCP-induced changes in personality
and behavior in these adolescents are anathema to their parents
and families, and sometimes even to the individual abuser.
RECOVERY OF FUNCTION
In working with PCP and polydrug abusers who have impaired every-
day functioning, counselors must be ultimately concerned with the
individual's ability to recover. Objective prediction of recovery
of function, using NP tests, involves a baseline evaluation and at
least one repeated assessment. Patterns of NP strengths and defi-
cits in the two or more assessments may then be compared. Clini-
cal inferences can be made, describing skills that show relative
permanence of deficit (with no change on repeated measurement), or
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skills that show relative recovery of function (with NP test score
improvement).
After drug abstinence has been established, the subgroup of PCP
abusers with no premorbid history of brain dysfunction or LD would
be expected to show the least impairment on NP tests and have the
best prognosis for recovery of lost or impaired functions. How-
ever, case study reports utilizing NP assessment in evaluating PCP
abusers find highly idiosyncratic effects of PCP, as measured on
higher cortical functions. Specifically, NP case studies have
shown moderate to severe impairment on NP tests in individuals
with histories of minimal use. Conversely, there is another group
of PCP abusers who show only borderline to mildly impaired NP
functioning subsequent to 1 or more years of chronic, moderate to
heavy PCP abuse.
Similar findings have been noted in NP case studies of PCP abusers
after 6 months or more of abstinence from all drugs of abuse. The
less frequent the PCP use, the better the prognosis usually is for
lost or impaired higher cortical functions to recover, following a
period of drug abstinence. However, there are instances of indi-
vidual PCP abusers who show moderately to severely impaired per-
formances on NP tasks after months of abstinence, following light
or "experimental" PCP use. As indicated above, these mixed find-
ings may be due to the actual chemical nature of what is presumed
to be PCP, as well as to additive and potentiating effects from
using PCP and other drugs. Other idiosyncratic differences in the
body's ability to metabolize PCP and related chemical contaminants
occur among individual PCP abusers. Human and animal neuroscience
research of PCP effects on neurotransmission may enhance the
understanding and interpretation of NP test results.
An analogue to drug-induced CNS dysfunction suggested by Parsons
and Farr (1981) is the dysfunction seen in aging. Reitan (1973)
first conceptualized the "brain age quotient" (BAQ), a combination
of Wechsler Adult Intelligence Scale-Revised (WAIS-R) and
Halstead-Reitan Battery (HRB) subtests as representing behavioral
manifestations of impaired brain functioning that occur as a nor-
mal consequence of aging. The BAQ pattern appears surprisingly
similar to deficits resulting from alcohol and polydrug abuse.
Because they reflect impairment in adaptive abilities necessary to
cope successfully with everyday functioning, BAQ test deficits may
be good prognostic indicators of diminished potential for complet-
ing treatment and/or of drug and alcohol recidivism. Serious
clinical and research consideration of this hypothesis may lead to
more revealing NP interpretations, especially since PCP abuse may
be far more devastating to NP functions than are alcohol and other
polydrug abuse.
RATIONALE FOR BRIEF NP ASSESSMENT WITH PCP ABUSERS
Due to drug treatment program budgetary constraints and the rela-
tive unavailability of clinicians having expertise in the use of
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NP assessment techniques, little or no psychological or NP evalu-
ation is currently employed. It is believed that the lack of
knowledge of the PCP abuser's pattern of higher cortical strengths
and deficits is responsible for a vast majority of current treat-
ment and program failures. This supposition is in marked contrast
to blaming the individual abuser or drug counselor for treatment
failures and recidivism. For an individualized treatment and
rehabilitation plan to be effective, both the PCP abuser and the
counselor should have a thorough understanding of that individ-
ual's pattern of higher cortical strengths and deficits. The
following sequence of events is not uncommon. First, many coun-
selors and therapists are predominantly trained in counseling
techniques that rely heavily on use of verbal concept formation.
However, results of NP case studies, as well as research into
"group" differences among PCP abusers, suggest that it is not un-
common for verbal abstraction skills to be moderately to severely
impaired as a result of PCP abuse. Regardless, the PCP abuser is
unwittingly placed into a treatment program where success in the
therapy or counseling session depends implicitly on reliance on an
impaired or defective skill. The subsequent treatment failure and
return of the PCP user to a drug-use lifestyle, away from achiev-
ing and maintaining abstinence, is frequently attributed to client
"resistance" or the therapist's lack of skills.
Historically, the HRB NP test, the most widely used and well-
validated of all NP test batteries, takes from 6 to 8 hours for
complete administration. Reducing an established test battery to
a 2- to 3-hour structured assessment procedure requires the use of
selected subtests: those most sensitive to PCP-induced brain dys-
function. The development and validation of briefer screening
batteries, which represent a reduction in the total number of sub-
tests used, professional time, and expense is an emergent trend
(Hartlage and Mains 1982, Reynolds et al. 1983). Based on our
literature review and results of a pilot sample study of 30 PCP
and polydrug abusers, the following subtests are recommended for
inclusion in a brief NP assessment battery.
Wechsler Intelligence Scales
Depending on the drug abuser's age, either the Wechsler Intelli-
gence Scale for Children-Revised (WISC-R) or WAIS-R should be used
to assess Verbal and Performance (nonverbal) IQ. These intelli-
aence scales contain subtests that have been documented. over a
20- to 30-year history of research, as being sensitive to discrete
types of brain dysfunction. The NP research with adults suggests
that WAIS-R Verbal IQ may estimate the efficiency of functioning
of the left cerebral hemisphere. Among the Verbal portions of the
WAIS-R, the Similarities subtest gives important information
regarding the client's ability for verbal abstract reasoning, an
important skill that underlies success in most forms of counseling
and psychotherapy. The Comprehension subtest estimates the indi-
vidual's knowledge of social conventions and expectations. This
subtest has specific treatment implications, and relates to an
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individual's capacity for understanding relationships between the
components and consequences of socially acceptable behavior.
Revised Wechsler Memory Scale (RWMS)
The RWMS is included to assess the PCP abuser when specific evi-
dence regarding verbal and nonverbal memory functions are neces-
sary for treatment and rehabilitation planning, or when other HRB
and WAIS-R performances suggest impairment of discrete memory
functions. Originally, age norms for this test were generally
inadequate, but Russell (1975, 1984) has developed scoring tech-
niques and criteria that improve the clinical utility of this
test.
Category Test
The Category Test involves nonverbal problem solving with complex
and novel stimuli where the skills of flexibility of thinking,
incidental memory, and nonverbal concept formation are implicit.
Since adequate performance on this test requires the brain to
function efficiently as a unified whole, the test tends to be
sensitive to any impairment of higher cortical functioning. The
research history of this subtest established it as the single best
indicator of comprehensive brain dysfunction when compared to all
other psychological and NP tests. Specific damage or impairment
to frontal lobe functions is inferred when performance on the
Category Test is impaired, but performances on other HRB subtests
are in the average range.
Speech-Sounds Perception (SSP) and Seashore Rhythm Test (SRT)
Presented in a recorded tape format, these HRB subtests give evi-
dence of efficiency of left and right temporal lobe functioning,
respectively. Individuals with specific LD impairment in acquir-
ing language-related academic skills, such as reading and spell-
ing, often perform poorly on SSP. Notably, SSP deficits among PCP
abusers may be due to developmentally-related as well as to PCP-
induced impairments. The SRT shows impairment when there is
damage or dysfunction associated with the right anterior temporal
lobe. Also, this subtest contains rather significant attention
and concentration components, skills often impaired as a result of
PCP-induced brain toxicity, especially when the NP assessment test
results are obtained with fewer than 30 days of PCP abstinence.
Trail-Making Test
Trails A is a timed task which requires graphomotor performance
with a random visual presentation of a numerical sequence. Trails
B, also a timed task, requires the individual to perform a similar
visual-motor task, but with an additional cognitive component of
alternating between a numerical and alphabetical sequence. The
presence of above-average times as well as number of errors gives
important information about the brain's capacity to function as a
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unified whole. Left, rather than right, hemisphere dysfunction is
suggested when performance on Trails B (alphabetic sequence) is
much more impaired than Trails A.
Hand Dynamometer and Finger Oscillation Tasks
These tasks provide reliable information and measurement of gross
and fine motor functions, respectively. It is important to real-
ize that psychomotor functions are the basis, and therein the
foundation, of all behavior. The measurement of intensity of
gross voluntary motor activity (grip strength in kilograms) has
been associated with the total functional efficiency of cerebral
hemisphere activity. Skills of finger oscillation have been asso-
ciated more specifically with the functional efficiency of the
primary motor cortex. In addition to comparing functional effi-
ciency of both sides of the body, the presence of below-average
performances on these tasks may indicate gross CNS disturbances
rather than specific and/or subtle functional deficits.
Test of Finger Agnosia
This subtest was included because it indicates the relative func-
tional efficiency of somatosensory-mediated brain functions.
Furthermore, difficulty with either the left or right hand on this
tactile finger recognition task has been associated with disturb-
ances of the angular gyrus, and associated with developmental
dyslexia. Significant differences between the preferred and non-
preferred hand also gives important lateralizing information
regarding differential PCP-induced toxic effects on left versus
right hemisphere parietal functions.
Wide Range Achievement Test (WRAT)
The WRAT (Jastak and Jastak 1978) provides grade equivalents and
standard scores on subtests of reading (word recognition), written
spelling, and written arithmetic calculations, and is included in
this brief assessment battery for several reasons. An objective
screening measure of academic achievement is needed to compare
with an individual's self-report of highest grade completed and
average report card grades. Further, functional illiteracy may
suggest evidence of either developmental or "acquired" LD. And,
finally, specific information on academic achievement in reading,
spelling, and arithmetic are critical for rehabilitation plans for
adolescent and young adult abusers, prior to recommending tutorial
(remedial) academic assistance and/or enrollment in General
Education Diploma (GED) classes.
SUMMARY OF PILOT FINDINGS
The above-described subtests were administered in part or in whole
to 30 adolescents and young adults referred either on a voluntary
or court-ordered basis for drug abuse counseling. Psychodiagnos-
tic and developmental histories were taken--additional information
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was obtained through family members when needed. These individ-
uals ranged in age from 18 to 32 with a mean age of 24.3 years.
Males outnumbered females in this sample by 3 to 1 (24 to 6).
Highest grade completed in school ranged from seventh grade to
college level work with a mean of 10.9 grades completed. Approx-
imately 25 percent of this sample reported having been identified
within the school system as LD and having been placed in special
education classes. Nearly 90 percent of the sample reported
predrug-use histories of one or more of the following: prematuri-
ty either by weight or by term, anoxia or low APGAR scores at
birth, febrile illnesses, early childhood seizures or convulsions
with no subsequent adolescent or adult seizure occurrences, chron-
ic ear infections, and CHI with or without loss of consciousness.
Subsequent to drug use, nearly 80 percent of the sample reported
histories of at least one of the following: CHI with or without
loss of consciousness, episodes of fainting and/or dizziness,
blackouts, seizures, and complaints of headaches or memory
difficulties.
Verbal, Performance, and Full-Scale IQ scores ranged from 67 (men-
tally deficient range) to 111 (bright normal range) with a mean
Full-Scale IQ score of 92.5, a mean Verbal IQ of 91.7, and a mean
Performance IQ of 96.2. On the whole, these results are similar
to past research findings (Mider and Lewis 1981), which suggest
that adolescents and young adults with histories of JD have
slightly higher Performance (nonverbal) IQ than Verbal IQ. The
extreme variation from individual to individual, in light of the
obtained prenatal and early childhood histories, suggests that
there have been impaired intellectual functions prior to drug use,
as well as loss of previously acquired intellectual capacity, sub-
sequent to PCP and other drug abuse. Furthermore, about 30 per-
cent of the sample showed above brain-damage cutoff scores on
Trails B while fewer than 10 percent showed above brain-damage
cutoff scores on Trails A. This may be due either to the fact
that Trails B is a much more sensitive indicator than Trails A to
impairment of the brain's functioning as a unified whole, or that
left hemisphere-mediated language dysfunction may occur somewhat
more among PCP abusers, a finding consistent with the lower Verbal
IQ than Performance IQ scores reported above.
Among the HRB subtests, the Category Test showed the most impair-
ment in terms of total number of individuals in the sample who
scored above the brain-damage cutoff score (50 errors) as recom-
mended by Reitan (1973). More than 70 percent of the sample were
in the mild, moderate, or severe impaired range on the Category
Test, a finding that suggests that PCP predominantly affects the
brain's capacity to function as an intact unified whole. These
findings suggest significant difficulty with flexibility of think-
ing, incidental memory, and the ability to formulate simple and
complex abstractions. These observed difficulties with changing
mental set and perseverating errors despite constructive feedback
form a pattern typically found with organic brain syndromes.
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Compared to the Category Test, SSP and SRT results show a rela-
tively mixed performance profile. This profile is indicative of
temporal lobe impairment and may explain the idiosyncratic charac-
ter of PCP-induced brain dysfunction. Other HRB subtest data
suggest that parietal lobe-mediated functions are less influenced
by PCP abuse, since approximately 30 percent of this sample had
error-free performances on a test sensitive to finger agnosia.
When finger agnosia was present, there were more errors with the
nonpreferred hand (2.05 mean errors) than with the preferred hand
(1.88 mean errors). Fewer than 10 percent of the sample showed
performances on the hand dynamometer below the normative
standards. Conversely, nearly 60 percent of the sample showed
below normal performances on the finger oscillation test, a find-
ing that suggests that fine motor dysfunction is more prevalent as
a result of PCP and other drug abuse than gross motor dysfunction.
The net results of our pilot study suggest that PCP-induced brain
dysfunction cannot be understood solely on the basis of the phar-
macological characteristics of PCP itself. There appear to be as
many individuals with histories of intermittent, light use as
there are chronic, moderate to heavy abusers of PCP who show sig-
nificant impairment on the NP tests.
CASE STUDIES
Case Study #1
This was a 31-year-old white married male with a 14-year history
of chronic, light to heavy PCP abuse and a late adolescent history
of heroin, cocaine, LSD, and marijuana abuse. Also, he drank beer
in moderate to heavy amounts, at times, to enhance the effects of
PCP. His wife also had a significant PCP abuse problem. Origi-
nally, both were self-referred with presenting concerns about the
obsessive-compulsive nature of their involvement with PCP, finan-
cial problems, an unproductive lifestyle, and a general deteriora-
tion of physical and mental health. The couple had recently had a
baby and were concerned for the child's welfare. Little progress
was made in reducing the amount of PCP abuse, and, after 2 weeks
and four marital counseling sessions, they did not return for
additional treatment. However, due to a criminal drug-related
charge, the court ordered him to obtain treatment. Child custody
and other marital/familial problems were additional reasons for
his compliance with drug counseling requirements and his rehabil-
itation plan.
The NP assessment was completed after 6 months of drug absti-
nence. Assessment of developmental (predrug-use history),
orientation, lateral preference , and sensory-perceptual exami-
nation provided significant evidence of mixed dominance. For
example, since age 5, he had played the guitar and was ambidex-
trous on many tasks requiring the coordination of fine motor
movements. This strongly suggested that, prior to drug abuse,
higher cortical functions were bilaterally mediated. Though he
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reported having great difficulty with mathematics in high school,
he graduated, and continued to be an avid reader. His history of
employment was primarily as an adept tradesman. He was a socially
uninhibited person and at times a very assertive communicator.
Diagnostic interview information revealed an inherent high energy
level with strong libido interests. He remembered sustaining two
CHI at age 17 and 24. Further, 1 month prior to our examination,
he sustained a broken jaw in a barroom altercation. Although
there was no indication of concussion-like symptoms, the shear/
strain effects of the injury may have caused an additional CHI.
Measures of intellectual functioning were in the average range and
showed little variability, except for poor performance on a test
designed to measure visual and inductive reasoning skills. How-
ever, this exception was incidental , as other Performance subtest
measures of visual-motor and perceptual skills requiring nonverbal
abstract reasoning were at or above his age group mean. The NP
tests designed to assess the brain's ability to discriminate audi-
tory speech and rhythmic-sound information were also in the aver-
age to above-average range. Actually, these latter test scores
may reflect in part avocational interests and practice in reading
and music. Scores on the memory and intelligence subtest as well
as a subtest of the Category Test (measuring incidental memory)
indicated a full range of at least average memory functions. In
contrast, his poorer performances on other NP tests and WAIS-R
visual-spatial tasks, considered the most sensitive general indi-
cators of brain impairment, suggested a mild diffuse organic brain
syndrome, probably transient in nature.
Though a recent facial impact injury may have caused additional
diffuse cerebral damage, the total performance seemed more indica-
tive of chronic PCP and alcohol abuse. Specifically, the NP
profile was characteristic of deficits in frontal lobe-mediated
adaptive abilities. While the severity of these deficits seemed
slight as compared with the mental status of others of similar
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histories of abuse, many higher cortical functions may have been
spared due to the premorbid bilateral representation of higher
cortical functions.
Case Study 12
This was a 23-year-old black male with a 5-year history of chron-
ic, moderate marijuana use and a 5-month history of moderate PCP
abuse ending 1 month prior to the NP assessment, as certified by
urinalysis reports. Further, he reported multiple personal and
legal problems as a result of PCP abuse, and complained of chronic
bilateral headaches, several times weekly during the last 5 years.
He described these headaches as caused by an undiagnosed "brain
tumor or brain cancer." Birth and prenatal history suggested that
he was the victim of Fetal Alcohol Syndrome (FAS). He was reared
by relatives and had minimal contact with his parents through
adolescence. He withdrew from vocational high school in the 12th
grade, then worked for 5 years as an attendant cashier in fast
food franchises, with dependable performance, until he began to
use PCP. His ambitions were to reestablish permanent employment
or to join the military to receive job skill training. Further,
he was ordered by the court to be on a 3-year probation with spe-
cial requirements to obtain a GED and to maintain full-time
employment, as contingencies in lieu of incarceration.
All NP and intelligence testing was accomplished in 1 day. The
client sustained good attention throughout the examination, but
was anxious about his failure to complete the more difficult
sections of particular subtests. He showed a strong preference
for lefthanded and ocular activity and mixed preference foot-leg
coordinated motor movement. His aggregate gross and fine motor
and perceptual-motor functions were characteristic of borderline-
normal intact performance. There were signs of mild impairment on
right-hand tactile-perceptual functions and diminished right-hand
motor speed. These deficits on the right side of the body sug-
gested some (contralateral) left cerebral hemisphere dysfunction,
possibly involving more primary motor and somatosensory cortex
dysfunction. Additionally, he showed test-taking behaviors often
associated with organicity, such as rotations of paper and diffi-
culty with organization of space on writing and copying tasks.
However, testing of all other left and right hemisphere-mediated
functions failed to identify any significant localized NP
deficits. Generally, the performance on other tests designed to
measure the integrity of coordinated brain functioning was in the
borderline impaired range. The "borderline range" interpretation
was based on a comparison of his test scores with those of stand-
ard scores of an adult normal population; his status was better
than average when these test scores were compared with standard
scores of an adult drug-abusing population. These NP deficits may
best be characterized as diffuse in nature and the result of both
developmental (predrug use) and PCP/polydrug abuse influences.
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Mastery level skills in WRAT Arithmetic revealed errors of sub-
traction, division, and multiplication, and little or no under-
standing of fractions, decimals, or percentiles. Fatigue was
assessed not to be a limiting factor in his performance because
this testing was performed early in the examination. The WAIS-R
yielded Verbal, Performance, and Full-Scale IQ scores in the low
dull to normal range. There were outstandingly low scores on
tests measuring verbal abstract reasoning and general knowledge
gained from experience (long-term attention and memory). However,
he scored better on tests measuring immediate recall (working
memory) of nonverbal and verbal information, and on tasks requir-
ing the application of basic mathematic processes (simple mental
addition). These intellectual strengths provided examples of
well-learned crystallized functions and were probably the direct
result of 5 years of skill development as an attendant cashier
with fast food franchises.
It was recommended that special attention be given to complaints
of headaches and a much delayed medical/neurological evaluation.
The NP test results suggested that observed deficits were probably
more likely to be residual deficits from congenital (prenatal or
neonatal) insulting factors, aggravated by developmental problems
and recent drug abuse, than attributable solely to a current or
degenerative organic brain condition. However, his belief that
his headaches were caused by a "tumor or cancer" suggested a
diseased self-concept and other basic self-assessment issues.
Depending on the final diagnostic outcome, these headaches may
need concurrent medical (pharmacologic) and psychological treat-
ment through counseling.
Diagnostic interview information revealed that a portion of his
interest in PCP was an attempt to self-medicate headache pain.
Notwithstanding the negative neurological test results, the con-
ceptualization of the presenting problems based on NP test results
helped formulate the direction and development of treatment goals
and subsequent counseling efforts. Over the next several months,
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his cognitive functioning showed improvement and drug counseling
centered more on preventing recidivism to marijuana abuse.
Concerning his ability to fulfill the court-ordered probationary
requirement to obtain a GED and literacy level academic skills, he
was an excellent candidate for individual and/or group tutorial
services. His reading and spelling skills were well established
and it was predicted that arithmetic skills would advance quickly.
His attitude toward treatment was positive, and he was motivated
to pursue educational study as a prerequisite to other vocational
goal developments. Therefore, formal vocational interest testing
and counseling was also strongly recommended. This additional
counseling attention reinforced other treatment objectives commen-
surate with his potential, and helped establish values and goals
appropriate to his physical and mental health status.
Case Study #3
This was a 19-year-old white single female with a 5-year history
of chronic, moderate PCP use and heavy marijuana/alcohol abuse.
She also had experimented with LSD and cocaine freebasing numerous
times within the past 2 years. Throughout her history of sub-
stance abuse she experienced an increasing frequency of periods of
dazed consciousness and blackouts multiple times yearly, while
under the influence of alcohol. Further, she reported that other
family members had chemical dependency problems, though her
parents never abused drugs/alcohol.
This young woman had 13 years of education with computer skills
training, and had just obtained an entrance level position in the
programming field. However, her job performance and her ability
to maintain satisfactory interpersonal relationships had deteri-
orated. Recently, she had been jilted by her boyfriend. She was
self-referred for treatment with additional complaints of anxiety,
paranoid thinking and behavior, problems with memory, headaches,
dizziness, and intermittent "after-image" visual hallucinations.
Though she failed to attend a formal psychiatric assessment inter-
view, she responded well to supportive psychotherapy with progress
in her mental status and general level of competency. Except for
several episodes of binge drinking, for the next 4 months she
remained drug abstinent while enhancing her performance at work,
sociability, and insight into her own behavioral and emotional
lifestyle. At this time, the purpose of the assessment was to
ascertain the presence, despite her response to treatment, of any
residual NP deficits.
All measures of gross and fine psychomotor coordinated activity,
as well as sensory-perceptual functions, were in the normal range,
with the exception of moderate left-handed finger agnosia.
latter finding suggested inefficient contralateral (
This
right) pari-
eta1 functioning. Subtest scores on Performance IQ tasks and
results of the figural memory section of the RWMS revealed intact
performance. Complex auditory verbal versus rhythm discrimination
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!test results further suggested anterior right cerebral hemisphere
dysfunction. This profile was characteristic of the early signs
and symptoms of an alcohol-related organic brain syndrome. How-
ever, based on the above mixed findings, recent psychotherapy
results, and her recently reduced drug/alcohol consumption, it
seemed likely that the mild but significant NP impairments
reflected residual NP deficits, while the intact performances
suggested the beginnings of recovery of function.
Diagnostic interview information confirmed WAIS-R Comprehension
subtest weaknesses in the use of practical judgment and common
sense in social situations. As such, the recommendation was for
future treatment sessions to focus on issues of reality testing,
decision making, interpersonal relations, and other expressive
psychological processes. The majority of IQ and NP performances
suggested a positive prognosis and good to excellent ability to
recover, assuming continuance of drug and alcohol abstinence.
Case Study #4
This was a 25-year-old black inner-city male with a history of
chronic, moderate levels of PCP abuse for 7 years, and inter-
mittent, moderate levels of whiskey drinking for several years.
All PCP and alcohol abuse ended 3 months prior to the NP assess-
ment, as determined by self-report and urinalysis results. He was
motivated to comply with all drug counseling requirements because
of an outstanding drug-related criminal charge. The major reason
for referral was to assess his current educational level, and his
memory and other neuropsychological functions. The drug counselor
also questioned whether complaints of recent memory problems were
symptomatic of a temporary (transient and reversible) condition,
or characteristic of a progressive or more permanent organic brain
dysfunction.
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During the examination he was quite cooperative, and concerned
about his performance. He used a cautious approach to the various
tasks and sustained good attention throughout the examination. He
reported receiving some minimal special education assistance in
junior high school, but he dropped out in his senior year owing to
scholastic problems, though he subsequently earned a GED. He
reported earlier, limited involvement in amateur boxing, which he
quit because of being "punched dizzy" on numerous occasions. This
suggested a history of CHI. Though at the time unemployed, he
participated in classroom study of the bricklaying trade, but had
difficulty maintaining good vocational school grades due to prob-
lems in sustaining attention and recalling learned material.
On NP tests of gross motor activity and fine motor speed, he was
mildly impaired in comparison to adult norms. However, he was
able to attain normal performance levels with practice and direct
encouragement. It is important to note that all other NP tests of
sensory, perceptual, and conceptual functions were in the normal
range; his minimal errors are often made by normal, nonimpaired
individuals.
Measures of academic achievement showed mastery skills just above
functional literacy levels, but well below the ninth grade-level
skill development often required to successfully complete a GED
examination, which had been obtained several years ago. Measures
of intellectual functioning showed problems with tasks requiring
expressive language and use of practical judgment and common sense
in social situations. These findings, in part, may be attribut-
able to cultural bias, lack of educational opportunity, and limit-
ed interpersonal or social experience. His major strengths were
his ability to analyze and synthesize abstract nonverbal informa-
tion, and to attend to a task under conditions designed to create
frustration and stress. Further, he scored well on tests requir-
ing inductive reasoning skills: both on the intelligence subtests
and on the NP measures.
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Considering the chronic history of PCP and alcohol abuse, the
anticipated finding was for more pronounced impairment of psycho-
logical functions. However, the NP and IQ scores reflected good
potential for recovery of function with sustained drug abstinence,
since there was little evidence of permanent deficit. An average
premorbid optimal estimate of intelligence was established, using
educational history, WAIS-R "best subtest" score, measures of re-
cent and remote cognitive-memory functions, and abstract reasoning
skills. Further, diagnostic interview information suggested in-
tact mental status prior to drug abuse. Collectively, these find-
ings supported a diagnosis of a transient (toxic) organic brain
syndrome in early stages of recovery. Therefore, the complaints
of memory loss and associative concerns seemed to be symptomatic
of a temporary disorder. The prognosis was good to excellent,
assuming continued drug and alcohol abstinence. Consequently, it
was recommended that he continue to receive probationary super-
vision and mandatory drug counseling, in conjunction with a random
schedule for urinalysis surveillance to ensure drug abstinence. A
6- to 9-month period of drug abstinence was estimated to be neces-
sary for more significant recovery of NP, IQ, and complex psycho-
motor functions. It was further recommended that he accept a more
active role in his own rehabilitation, to encourage the develop-
ment of psychological mechanisms and interpersonal skills comple-
mentary to the objectives of the treatment plan and personal
goals.
TREATMENT AND RESEARCH IMPLICATIONS
The clinical information obtained from NP assessment and struc-
tured history taking provides a basis for understanding the multi-
faceted nature of brain functions and their relation to human
behavior. The use of NP results, in conjunction with other diag-
nostic information, to develop rehabilitation plans for PCP abus-
ers can be invaluable in suggesting a prognosis. Thus, individual
treatment goals and expectations can better complement the cogni-
tive-behavioral strengths and weaknesses of an individual in need
of drug abuse consultation.
For many PCP abusers, a thorough NP examination, followed by a
review of assessment results with the PCP abuser, should be a
treatment policy. This debriefing strategy, when used as a
planned intervention. can have powerful therapeutic implications.
Foremost, discrepancies between-the clinical findings and an
individual's own assessment of level and pattern of functioning
can be addressed. This provides an opportunity for the PCP abuser
to receive objective feedback on mental status and can enhance the
therapeutic alliance and commitment to treatment. Due to the be-
havioral nature of many of the tasks comprising the NP assessment,
individuals frequently have an intuitive understanding of their
own performance prior to a formal debriefing. In practice, this
process of active participation and self-assessment reduces psy-
chological defensiveness and the tendency for denial.
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Estimates suggest that PCP abusers sustain a greater frequency and
severity of NP deficits than other drug and/or alcohol abusers.
These deficits are probably related to a combination of develop-
mental, toxicity, and idiosyncratic factors which differentially
affect CNS function. The complexity of NP diagnostic interpre-
tation is further compounded in developing a prognosis and pre-
dicting the ability to recover. Issues of brain plasticity and
recovery of function need extensive research in direct relation to
specific treatment objectives.
Forensic Use of NP Assessments
The PCP abuser poses unique problems for law enforcement agencies
and the judicial system. McCarron et al. (1981), in reviewing
medical and behavioral characteristics of 1,000 PCP episodes
observed in medical emergency rooms, have noted the extremely high
incidence (35 percent) of violence and rage reactions. Possibly
because of anesthetic effects, and/or PCP uptake in limbic-medi-
ated emotional centers, PCP abusers can sometimes behave with
superhuman strength, causing harm to self, others, and property.
Thus, it is not surprising that PCP abusers often incur criminal
charges ranging from simple possession and distribution to
homicide.
The NP evaluation of the PCP abuser may be useful in pretrial
investigation in a number of ways. In general, objective esti-
mates of intellectual functioning and NP status at the time of
criminal incident (projected from later assessment) can suggest
limited versus intact capacity of the PCP abusers for appreciating
the criminality of their actions or indicate similar capacity for
conforming their behavior to the requirements of the law. Perhaps
more important, from a standpoint of ultimate outcome, NP screen-
ing techniques can suggest a prognosis for rehabilitation versus a
risk for recidivism, and aid judicial decision making by providing
an objective basis for sentencing that is equitable to both socie-
ty and the PCP abuser.
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At the Los Angeles County/University of Southern California
(LAC/USC) Medical Center, phencyclidine (PCP) intoxication
accounts for more emergency department visits and hospitalizations
than any other drug of abuse. Most of the areas of the hospital
are called upon to treat PCP intoxication and related problems.
Emergency physicians, internists, and psychiatrists treat the
majority of cases, but orthopedists, neurosurgeons, and general
surgeons are well acquainted with the traumatic events often
accompanying PCP use. Pregnant women smoke PCP before entering
the hospital for delivery; babies are born with PCP intoxication.
Small children become intoxicated with PCP in the home, and older
children use the drug for "kicks." Since 1979, an average of five
patients per day have been arrested and brought to the Prison
Service because of illegal acts performed under the influence of
PCP.
PCP is usually smoked on "Sherman" or "More" cigarettes that have
thick brown wrappers that absorb PCP liquid and still allow the
cigarette to be smoked. Ingestion of partially smoked PCP ciga-
rettes can result in severe toxicity. About one hour from inges-
tion of such a cigarette, seizures may suddenly occur, followed by
coma, apnea, and hyperthermia.
Sometimes liquid PCP is ingested, often mixed with lemonade or
some alcoholic beverage. One man had eaten clams laced with PCP.
Solutions of PCP are also injected intravenously. Some patients
inject PCP two or three times a day for long periods of time.
Liquid PCP often contains volatile solvents that impart an "ether-
like" odor to the patient, although PCP itself is odorless. PCP
is nonvolatile at room temperatures, but ether is highly volatile.
Undoubtedly, some of the acute reactions that occur after exposure
to street "PCP fumes"' are due to the effects of the ether and not
to PCP. Several reactions of this type have been observed, such
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as a woman who became dizzy and nauseated and felt as if she were
about to faint when "PCP" fumes entered her apartment from a "PCP
laboratory" next door.
Another type of reaction that occurs when a person is inadvertent-
ly exposed to "PCP fumes" is acute anxiety. An example of this
was a policeman who smelled "PCP fumes" in the squad car while
transporting a person with PCP intoxication. The policeman was
examined and found to have a severe anxiety reaction with marked
hyperventilation and carpopedal spasms.
PCP can apparently be inhaled by a person working in a PCP labora-
tory when the laboratory catches fire. Eight acutely intoxicated
people were admitted to the LAC/USC Medical Center prison wards
with PCP toxicity and thermal burns incurred during explosions of
volatile chemicals in makeshift PCP laboratories (McCarron et al.
1981a).
PCP is also ingested in pill form , each tablet containing about 2
to 6 mg of PCP (Lundberg et al. 1976). PCP powder may be sniffed
or snorted, or incorporated into marijuana cigarettes.






Two or more routes 1.0
SOURCE: McCarron et al. 1981a.
In 42 percent of cases, PCP was used with another drug, usually
alcohol, marijuana, a barbiturate, or a narcotic.
Several analogues of PCP with similar pharmacological effects are
available on the streets. These include PCE (cyclohexamine), PHP
(phenyl-cyclohexyl-pyrrolidine, PCPP (phenyl-cyclo-pentyl-piperi-
dine), and TCP (thienyl-cyclohexyl-piperidine) (Baselt 1982).
DIAGNOSIS
In a series of 1,000 cases of PCP intoxication (McCarron et al.
1981a), 87 percent of patients were male: 45 percent were black,
36 percent Caucasian, and 19 percent Hispanic. The youngest
patient was 13  years old and the oldest was 65, with a median age
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of 23 years; however, 65 percent of patients were 18 to 25 years
old. One patient had seven episodes of PCP intoxication.
Unlike other drugs of abuse, the diagnosis of PCP intoxication is
often difficult because of the wide spectrum of clinical findings
that occurs with this drug. PCP toxicity sometimes can be mistak-
en for delirium tremens, acute psychiatric illness, sedative/
hypnotic overdosage, amphetamine intoxication, or sedative/
hypnotic withdrawal syndromes.
History
A description of the patient's actions before admission to the
hospital often provides valuable clues to the diagnosis. Since
PCP seems to diminish the user's ability to integrate sensory
input into meaningful behavior (Pender 1971), symptoms and find-
ings suggesting this problem should be sought. A demonstration of
sensory deprivation was provided by a patient who was found head
down in a dumpster filled with garbage. He was nude and the
weather was cold, but he didn't seem to be uncomfortable. He also
didn't mind the smell of garbage,
down position.
or the discomfort of the upside-
In one reported case, loss of pain sensation
resulted in an act of self-injury by biting of the forearms almost
to the bone (Grove 1979). Irrational acts, such as driving too
slowly on the freeway, or bizarre behavior, such as strolling down
the street nude or "standing in the park like a statue," may be
manifestations of PCP toxicity. Other general characteristics
include waxing and waning of the mental status or behavior and
evidence of increased strength.
Physical Findings
PCP affects the sensorium, behavior, and vital signs, and it may
affect motor and autonomic functions. Hypertension and nystagmus
are hallmarks of PCP intoxication. Nystagmus occurs in about 57
percent of patients, and hypertension occurs in about 48 percent.
Nystagmus may be horizontal, vertical, or rotary. The presence of
nystagmus, while helpful, does not provide the diagnosis because
all types of nystagmus may accompany other kinds of drug over-
dosage, such as sedative/hypnotic intoxication. The usual level
of blood pressure in patients with hypertension is 140-160/95-105
mm Hg (McCarron et al. 1981a) However, hypertensive crises may
occur with blood pressures as high as 200-300+/140+ nun Hg. Severe
hypertension may be accompanied by intracranial bleeding.
Sensorium. Patients with PCP intoxication can have a clear senso-
rium, or they can be disoriented, confused, stuporous, lethargic,
or comatose. Signs of cerebral stimulation, such as pressured
speech, verbigerations, and echolalia, may also occur.
chotic symptoms,
Frank psy-
including hallucinations, delusions, and paranoid
ideation, are not unusual.
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Behavior. Some patients with PCP toxicity display inappropriate
behavior. Behavioral effects include muteness, staring, violence,
and agitation. Violent behavior occurred in 35 percent of people
with PCP intoxication who were examined on the prison wards of the
LAC/USC Medical Center (McCarron et al. 1981a).
Motor Signs. PCP causes grimacing, localized dystonic reactions,
generalized rigidity, catalepsy, athetosis, tremors, twitching,
coarse jerky movements, and grand ma1 seizures. Status epilep-
ticus may occur. Deep tendon reflexes may range from hyperactive
to absent.
Autonomic Signs. The most common autonomic signs are profuse
diaphoresis, hypersalivation, bronchorrhea, and urinary retention.
Wheezing and severe bronchospasm occur occasionally. Pupils may
be any size.
Vital Signs. Although hypertension is common and may be severe,
hypotension can also occur. Tachycardia occurs in about 30 per-
cent of cases. Severe tachypnea with respiratory rates as high as
88/min or respiratory depression with rates of 10/min or less may
be seen. Respiratory arrest and cardiac arrest may occur. Hyper-
thermia with temperatures as high as 108.0 °F is a life-threaten-
ing event and may be associated with submassive liver necrosis
(Armen et al. 1984).
Numerous deaths have been reported in people under the influence
of PCP. Most of the fatalities resulted from various kinds of
trauma, but some have been attributed to the direct effects of
PCP (Burns and Lerner 1978; Caplan 1979; Armen et al. 1984).
PATTERNS OF INTOXICATION
In adult patients, the manifestations of PCP use can be grouped
into nine clinical patterns of intoxication. Four of these are
called major patterns because they may be associated with severe
toxicity and often necessitate hospitalization. Patients with
major patterns are usually unpredictable; symptoms wax and wane,
and the patient may abruptly change from one pattern of intoxica-
tion to another. Five other symptom complexes are designated as
minor patterns since toxicity is usually mild and of short dura-
tion. Major Patterns consist of: coma, catatonic syndrome, toxic
psychosis, and acute brain syndrome. Minor Patterns are lethargy,
bizarre behavior, violent behavior, agitation, and euphoria
(McCarron et al. 1981b).
In determining the pattern of intoxication, the manifestations of
toxicity obtained by history should be considered, since many
patients with severe intoxication improve considerably by the time
they are admitted to a hospital. Nontraumatic rhabdomyolysis
occurs almost exclusively in patients who have experienced a major
pattern of PCP intoxication.
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Major Patterns
Coma. Patients with PCP-induced coma are unresponsive to stimuli,
are nonverbal, and have closed eyes. Some patients may have no
other findings. Others may have any of the motor and autonomic
signs and disturbances of vital signs listed above. A triad of
coma-apnea-seizures occurs in this group.
Some comatose patients are unconscious for less than 2 hours, do
not show signs of severe toxicity, and have few complications. In
other patients, coma lasts from 2 to 24 hours, and symptoms are
more marked. Patients with severe toxicity, including status epi-
lepticus and malignant hyperthermia, may remain in coma for 1 day
to 3 weeks. These patients often have respiratory or metabolic
acidosis. Comatose patients are susceptible to aspiration pneu-
monia and rhabdomyolysis. Head injury and intracerebral bleeding
should be considered as the cause of the comatose state.
Catatonic Syndrome. The essential characteristics of the organic
catatonic syndrome are (1) central nervous system excitement
alternating with stupor, and (2) catalepsy. Many patients are
mute and staring, and have generalized muscle rigidity or local-
ized dystonic reactions. PCP catatonic syndrome often includes:
posturing, repetitive actions, grand ma1 seizures, nudism, agita-
tion, violence, hallucinations, delusions, and verbigerations.
The patient may be alert and oriented, withdrawn or lethargic, or
have an acute brain syndrome. There is a high incidence of
rhabdomyolysis and hyperthermia in PCP-induced catatonic syndrome.
Some patients have the neuroleptic malignant syndrome or develop
it after administration of haloperidol.
The neuroleptic malignant syndrome is characterized by hyper-
thermia (temperature over 103 °F without evidence of infection),
altered sensorium, muscle rigidity, and autonomic disturbances,
usually profuse diaphoresis, hypersalivation, bronchorrhea, and
urinary retention.
Toxic Psychosis. Any patient who is not catatonic but has hallu-
cinations, delusions, paranoid ideation, or other psychiatric
manifestations is classified as having toxic psychosis. These
patients are often difficult to differentiate from those with
acute agitated psychosis, and about 25 percent appear manic.
Motor and autonomic disturbances are less common in this group
than in any of the major patterns. Severe hypertension has been
noted. Rhabdomyolysis is unusual.
Acute Brain Syndrome. Any patient with disorientation, lack of
judgment, inappropriate affect, and loss of recent memory who was
not comatose or catatonic and has no discernible hallucinations,
delusions, or other psychiatric manifestations is included in this
pattern. Acute brain syndrome is the most common pattern of PCP
intoxication among patients brought to the emergency department at
LAC/USC Medical Center, accounting for 25 percent of the PCP
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cases. All of the manifestations and complications of PCP toxici-
ty can occur in this group. These patients are often misdiagnosed
as having delirium tremens.
Minor Patterns
Patients with the lethargy pattern of PCP toxicity may be clini-
cally indistinguishable from patient with mild sedative/hypnotic
intoxication, although hypertension and grand mal seizures which
may occur with PCP intoxication, are not expected with sedative/
hypnotic overdose. The remaining minor patterns are differenti-
ated as follows.
TABLE 2. Characteristics of minor PCP patterns
Pattern Sensorium Behavior
Bizarre behavior Alert & oriented Bizarre, violent or agitated
Violent behavior Alert & oriented Bizarre, violent or agitated
Agitation Alert & oriented Agitated
Euphoria Alert & oriented No behavioral disturbance
SOURCE: McCarron et al. 1981b.
Any of the motor or autonomic signs, and hypertension and/or
nystagmus may occur with any of the minor PCP patterns. Minor
patterns should not be diagnosed on physical examination in an
emergency department without adequate information about the pa-
tient's behavior and sensorium prior to admission. Many patients
with major patterns may be alert and oriented when they reach the
hospital. If no history is available, the patient is kept under
observation and rhabdomyolysis is ruled out.
Toxicology Tests
Urine concentrations of PCP determined by enzyme immunoassay did
not correlate with the state of intoxication at the time the urine
sample was taken. The test was negative in 15 percent of 1,000
patients with clinical evidence of PCP toxicity, many of whom
admitted taking PCP (McCarron et al. 1981a). Several of these
negative urines were analyzed for PCP analogues; none were found.
Serum concentrations of PCP determined by enzyme immunoassay in
405 patients also did not correlate with the state of intoxication
at the time the blood speciman was obtained, although the highest
PCP concentrations in the study were associated with major
patterns. However, some patients with major patterns had negative
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tests or lower concentrations of PCP than some patients with minor
patterns (Walberg et al. 1983).
A radioimmune assay for PCP in saliva and serum showed that saliva
could be used as a specimen for PCP analysis (McCarron et al.
1984). Of 79 patients with acute PCP intoxication clinically, 70
had positive tests in both serum and saliva, two had positive
serum tests and negative saliva tests, and seven had negative
tests on both serum and saliva.
TREATMENT
The treatment of acute PCP toxicity depends on the pattern of
intoxication and the physical findings. On the prison wards of
the LAC/USC Medical Center, approximately 60 percent of patients
are treated and released within 24 hours. Most of these patients
have minor patterns of intoxication and no medical complications.
Another 10 percent of patients have minor problems with medical
complications, usually trauma.
Treatment of Minor PCP Patterns
For the most part, patients with minor PCP patterns are treated
symptomatically. Abnormalities in the vital signs are treated
with supportive care. Patients with grand mal seizures are given
IV diazepam in doses of 5 to 20 mg. Bizarre, violent, and agitat-
ed patients are placed in restraints to protect themselves and
others. Haloperidol 5 to 10 mg is given IM as needed. Localized
dystonic reactions are treated with 50 mg diphenhydramine IV. Few
of these patients require gastric lavage and none are given syrup
of ipecac. Each patient has a Hemastix test performed on urine.
If the test is positive, the urine is examined microscopically for
red blood cells. If no red blood cells are found, a tentative
diagnosis of myoglobinuria is made, serum chemistries are ob-
tained, and the patient is held to rule out rhabdomyolysis. If
the uric acid and creatinine kinase (CK) values are normal, and
the patient is asymptomatic, he/she is discharged from the
hospital. Routine toxicology tests include urinary PCP, serum
alcohol, and hypnotic screen.
Treatment of Major PCP Patterns
All patients with major patterns of PCP intoxication are placed in
restraints. If the patient is comatose or catatonic, if multiple
intoxication is suspected, or if ingestion of PCP is suspected,
gastric lavage with activated charcoal is performed. If the pa-
tient is severely intoxicated, a nasogastric tube is inserted and
connected to suction in order to remove any PCP that is excreted
in the gastric juice, and arterial blood gases are obtained.
Metabolic acidosis is treated by administration of sodium bicar-
bonate. No attempt is made to acidify the urine. All patients
are given IV fluids. To combat hypoglycemia, 50 ml of 50 percent
215
dextrose solution IV is routinely administered. Status epilepti-
cus is controlled with IV diazepam; if diazepam is ineffective,
the patient is treated with neuromuscular blockade in the medical
intensive care unit. Severe hypertension is treated with sodium
nitroprusside. Agitation or violence is controlled with chlorpro-
mazine or haloperidol (Giannini et al. 1984), unless these drugs
are contraindicated by the presence of shock or hyperthermia, in
which case diazepam may be used. For temperatures above 105 °F,
dantrolene sodium in doses of 1 to 1.5 mg/kg is given in addition
to cooling measures.
All patients with major patterns are monitored for rhabdomyolysis
and renal failure. An early sign of rhabdomyolysis is an elevated
serum uric acid, associated with an increase in serum CK. Within
8 to 12 hours, the serum tests are repeated. If the uric acid
falls and the CK rises, rhabdomyolysis is likely. Renal function
tests may also be increased at this time. When the diagnosis of
rhabdomyolysis is made, the patient is treated with 40 mg furose-
mide IV once, and IV fluids. Urine myoglobin concentrations are
obtained. If the patient develops renal failure, hemodialysis or
peritoneal dialysis may be necessary. In all cases, multiple drug
intoxication, trauma, and rhabdomyolysis are ruled out or treated.
All patients are kept under observation until they are asympto-
matic.
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Diagnosis and Treatment of
Chronic Phencyclidine (PCP) Abuse
David A. Gorelick, Jeffrey N. Wilkins, and Carl Wong
INTRODUCTION
Phencyclidine (PCP) abuse remains a serious public health problem
in large urban areas of the United States, with recent trends sug-
gesting increased use after a period of decline (Crider, this
volume). Most clinical and research attention has focused on the
psychiatric and medical manifestations of acute or subacute PCP
intoxication, especially the organic mental disorders (toxic
delirium, psychosis, or depression) that PCP can induce (McCarron
et al. 1981; McCarron, this volume; Sioris and Krenzelok 1978).
Much less attention has been paid to chronic PCP use per se, i.e.,
the substance use disorder itself. Such issues as the effects of
chronic PCP use, and the diagnosis, clinical characterization, and
treatment of chronic PCP abusers are rarely discussed in the pub-
lished literature, even in detailed review articles (Davis 1982;
Pearlson 1981; Pradhan 1984). This paper reviews the literature
on inpatient and outpatient treatment of PCP abuse, outlines our
own experience with PCP users and abusers in one large, public,
urban hospital, and makes suggestions for future research based on
this information and animal research findings (Balster, this
volume).
We were able to find only five published studies on the inpatient
or residential treatment of PCP abusers (DeAngelis and Goldstein
1978; Fauman and Fauman 1980; Khajawall and Simpson 1981; Rawson
et al. 1981; Simpson et al. 1983), with a total sample size of 397
patients. Two of these studies are from the same 32-bed unit in a
large urban state hospital (Khajawall and Simpson 1981; Simpson et
al. 1983), and therefore may have included some of the same pa-
tients. Three are from residential therapeutic communities (RTC)
(DeAngelis and Goldstein 1978; Fauman and Fauman 1980; Rawson et
al. 1981). While all of these studies provide some sociodemo-
graphic and clinical data on their patients, only two give even
minimal short-term (i.e., during hospitalization) treatment out-
come results, and none give any long-term (i.e., after hospital
discharge) outcome results. Khajawall and Simpson (1981) found
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that only 6 percent of 182 consecutive adult PCP abusers completed
the entire rehabilitation program (minimum stay 45 days). The
average length of stay was 36 days. Most patients wanted only
detoxification treatment. DeAngelis and Goldstein (1978), study-
ing adolescent patients (mean age 16 years) in an RTC, found that
the 22 "chronic PCP users" (using at least 3 to 4 times weekly)
had a significantly longer length of stay than the 42 non-PCP
users (108 days vs. 68 days), but not longer than the 23 occasion-
al (once a week or less) PCP users (85 days). There was no dif-
ference between chronic and occasional PCP users in frequency of
aberrant behaviors or program rule infractions. Chronic users
were somewhat less likely than occasional users to show angry and
belligerent behaviors (46 percent vs. 80 percent occurrence), but
more likely to have sexual acting out (31 percent vs. 12 percent)
and delusions (12 percent vs. 0 percent).
All five published studies dealt with a young population, with
mean patient ages ranging from 16 years (DeAngelis and Goldstein
1978) to 23 years (Simpson et al. 1983). The oldest PCP patient
included was 46 years old (Khajawall and Simpson 1981). The
racial makeup of the study populations varied from 96 percent
white (Fauman and Fauman 1980) to 25 percent white (Khajawall and
Simpson 1981), presumably reflecting selection bias due to the
geographic location and funding mechanisms of the various treat-
ment programs. The majority of patients in all studies (where
data were given) were male (54 to 80 percent), unmarried (79 to 87
percent), unemployed, and with less than 12 years education. The
mean durations of regular PCP use (3+ times weekly) were 2.4 to 4
years.
We found only one published systematic study of outpatient treat-
ment for PCP abusers, involving 158 patients (73 percent male) of
a private clinic (Bolter et al. 1976). This study gave no treat-
ment outcome data, but the authors did comment that treatment was
difficult because of the patients' strong psychological dependence
on PCP.
METHODS
Our own studies were conducted at the Brentwood Division of the
West Los Angeles Veterans Administration Medical Center.
Brentwood is the 450-bed psychiatric division of the Medical
Center, which serves a large catchment area in the central and
western Los Angeles basin and includes general psychiatry programs
(230 beds), substance abuse inpatient (80 beds) and outpatient
programs, an involuntary locked ward (15 beds), and several other
specialty programs. The substance abuse wards on which studies
were done are voluntary rehabilitation programs with scheduled
admissions and 4- to 6-week lengths of stay. They do not accept
acutely psychotic, violent, or suicidal patients, nor patients
requiring specialized medical attention (e.g., IV therapy or
cardiac monitoring).
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PCP assays were performed in the hospital's Clinical Psychopharma-
cology Unit, using gas chromatography with nitrogen/phosphorus
detection after PCP was extracted from the raw samples by column
chromatography. The authenticity of PCP samples was occasionally
verified with gas chromatography/mass spectrography. (Assay
parameters had been adjusted to avoid false positive results from
substances known to be potentially interfering.) Assay sensitiv-
ity was 0.1 ng/ml, intraassay variability was 3 percent, and
interassay variability was 5 percent. Urine samples were refrig-
erated within 4 hours of collection and assayed within 4 days.
Sociodemographic and clinical data were collected by social worker
interview with the patient, usually within 2 days of admission.
It was rarely possible to confirm this data by contacting collat-
eral sources of information or reviewing old records (if any).
RESULTS
General Psychiatry Inpatients
All inpatients admitted through the hospital emergency room over a
15-month period (June 1982 through August 1983) had urine samples
collected in the emergency room for later PCP assay. This repre-
sented 1,550 admissions of 1,384 individual patients, but did not
include all hospital inpatients (i.e., excluded those who were ad-
mitted from outpatient status). PCP was detected in the urine of
16.5 percent (255) of the total admissions and 15.5 percent (215)
of individual patients. In the vast majority of cases, the PCP
levels were low (less than 30 ng/ml in 85.0 percent).
Clinical data on 1,454 admissions (1,128 individual patients) was
obtained from hospital records. The most common primary discharge
diagnosis among the PCP-positive patients was alcohol dependence
(27.5 percent), followed by drug dependence (26.6 percent), schiz-
ophrenia (20.0 percent), and drug-induced psychosis (7.8 percent).
In terms of the proportion of patients with positive PCP assays,
the diagnoses ranked as follows: drug-induced psychosis (63.0
percent), followed by drug dependence (33.3 percent), alcoholic
psychosis (23.1 percent), and schizophrenia (13.7 percent). Even
among patients with primary discharge diagnoses of affective dis-
order, personality disorder, and neurosis, 8 to 12 percent had
PCP-positive urine on admission. The PCP-using patients (as
reflected by PCP-positive urine on admission) were admitted
throughout the hospital. The proportion of discharges that had
PCP-posltive urine varied from 23.8 percent from a mixed substance
abuse ward (20 beds) and 22.5 percent from the involuntary ward,
to 17.6 percent from general psychiatry wards and 13.1 percent
from the alcohol treatment ward (40 beds), There was no signifi-
cant trend towards PCP-positive patients having a longer length of
stay in the hospital or more frequent admissions during the study
period.
A small pilot study was done to determine the clinical impact of
routine screening of urine for PCP on admission. Forty-one
220
inpatients on three different types of wards had their charts
reviewed 5 to 10 days after their admission to see whether the
result of their PCP urine assay, done on admission, was reflected
in their treatment plan (laboratory reports were sent to the wards
2 to 3 days after admission). In only 34 percent of cases was the
PCP assay result mentioned in the treatment plan. The substance
abuse wards did best, with 60 percent mention, followed by the
involuntary ward (21 percent), and general psychiatry wards (17
percent).
Substance Abuse Inpatients
Admission urine PCP assays were done on 155 consecutive males ad-
mitted over a g-month period (December 1982 to August 1983) to a
mixed abuse ward (20 beds). Forty-two patients (27 percent) had
PCP detected in their urine; another 14 (9 percent) gave a history
of PCP use. Of these, 14 (9 percent of the total sample) initial-
ly denied any PCP use, and 9 continued to deny use after they were
confronted with the laboratory results.
Patients were classified into PCP abusers or users by applying
DSM-III criteria to the history obtained from the admission inter-
view. The 42 PCP-positive patients broke down into 20 PCP abusers
and 22 PCP users. All 14 patients who gave a history of PCP use,
but had negative urine assays, were considered nonabusers. The
PCP abusers were sig
more prior arrests
nificantly younger (32 vs. 40 years) and had
(2 vs. 1) than the users, but did not differ in
race, education level, marital status, or employment status.
Abusers differed from users in having much higher urine PCP levels
and more recent PCP use, but did not differ significantly from
users in number of prior drug abuse treatments, time since last
treatment, or abuse of other drugs. There was also no difference
between abusers and users in immediate treatment outcome, as re-
flected by length of stay in the program or reason for discharge.
A high proportion of both groups reported abuse of other drugs,
including alcohol (61 percent), opiates (38 percent), and mari-
juana (29 percent). All the PCP abusers in the sample had used
PCP for at least 2 years (55 percent more than 5 years); 35
percent used it at least daily. All but one abuser smoked his
PCP; the exception used it by insufflation.
The immediate treatment outcome resulted in less than half (47
percent) of the PCP abusers completing the treatment program. The
mean length of stay was just under 4 weeks.
There was a significant negative correlation between (log) admis-
sion urinary PCP level and self-reported time since last PCP use
(r=-0.53, p<0.001). Visual inspection of a graph of these two
variables suggested a possible biphasic elimination curve, with
the initial phase having a half-life of 5 to 7 days, and the later
phase a half-life of about 30 days. However, formal curve fitting
of these data to standard pharmacokinetic models (using BMDP
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computer programs) showed the data to be equally consistent with a
monophasic elimination curve (i.e., with a one-compartment
pharmacokinetic model). The 42 patients with PCP-positive admis-
sion urines had weekly urine assays done thereafter, until a nega-
tive urine assay was obtained. No urine acidification treatment
was given to increase elimination. Thirty-seven patients showed a
monotonic decline in urine PCP levels, with negative assays by the
fourth or fifth week. The remaining five patients showed a sig-
nificant increase in PCP levels at one or more measurement points,
but PCP reuse was suspected on clinical grounds. When analyzed by
computer curve fitting, these data were also equally consistent
with either a one- or two-compartment pharmacokinetic model.
Substance Abuse Outpatients
The Substance Abuse Service at the hospital includes a weekly out-
patient therapy group for PCP abusers, run by psychiatric social
workers. The approach used is supportive, behavioral, and educa-
tional, with the goal of decreasing or eliminating drug-seeking
and drug-taking behavior, and increasing problem-solving skills.
Weekly urine samples for PCP assay and drug screen are required
for group membership, but patients are not automatically dis-
charged from the group because of a positive urine test. The
results presented here are based on 24 patients who attended at
least one group session after the group was formed in February,
1984. The majority of patients (54 percent) were self-referred to
the clinic; 16 percent attended only because of probation or
parole conditions.
Outpatient group members were very similar to the inpatient PCP
abusers in most sociodemographic and drug-use characteristics.
Their mean age was 29 years, educational level 12.6 years, and
number of prior arrests 1.5. The majority of outpatients were
black (83 percent), unmarried (67 percent), and unemployed (67
percent). Their mean duration of PCP use was almost 8 years,
with, usually, no prior or recent substance abuse treatment.
Thirty-seven percent used PCP at least daily, always by smoking.
Like the inpatient PCP abusers, outpatients frequently (87 per-
cent) reported abuse of other drugs: alcohol (46 percent), mari-
juana (46 percent), and cocaine (37 percent). Several outpatients
for whom cocaine was the preferred drug of abuse used PCP as a
"cheaper high" when cocaine was not affordable.
There was frequent group consensus on the psychological effects of
PCP and motivations for its use. The two main psychological ef-
fects often cited as maintaining PCP use were the feelings of
strength, power, and invulnerability it engendered; and a psychic
numbing that was used to self-medicate dysphoric affects, espe-
cially anger and rage ("I use PCP because I want to forget").
Some patients were attracted by the challenge of the risk in using
PCP, i.e., not knowing what would happen. Three types of acute
intoxication responses were described: stimulation, depression,
and hallucinogenic. Many patients reported being able to predict
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which response they would have by the concentration of the PCP
that they used. Almost all patients had had religious experiences
while intoxicated: feelings of meeting God, impending death, etc.
Whatever the experience , all patients reported liking PCP use and
having great psychological difficulty in giving it up. This was
despite common adverse effects such as legal problems, difficulty
in working regularly, transient depression following cessation of
use, and uncomfortably warm sensations in the extremities (some-
times prompting patients to feel like taking off their clothes).
The outcome of this specialized outpatient group therapy was
mixed. Patients stayed in treatment for a mean of 14 weeks (range
2 to 60 weeks), and attended 67 percent (range 25 to 100 percent)
of the scheduled group sessions. Urine samples were positive for
PCP 47 percent of the time; patients reported PCP use 24 percent
of the weeks they attended. Over the 14 months of the group's
existence, 75 percent of members have stopped participating: 42
percent to enter treatment elsewhere (60 percent residential, 40
percent outpatient); 8 percent to go to jail; and 25 percent to
drop out of treatment completely. Of those 6 patients currently,
remaining in the group, only one has become completely drug free
(and has returned to full-time employment).
DISCUSSION
We found that about 15 percent of patients admitted to a large,
public, urban hospital had PCP present in their urine. This is a
substantially lower prevalence than the 43 to 78 percent previous-
ly reported from another large, public hospital in Los Angeles
(Aniline et al. 1980; Yago et al. 1981), but still suggests that
PCP use is not rare among psychiatric patients. The PCP use oc-
curred in both substance abuse and general psychiatry patients and
in all diagnostic categories, not just identified substance abuse
patients. Therefore, routine screening for PCP might well detect
a significant number of unsuspected users in such a population.
For example, even on a voluntary inpatient substance abuse
program, admission urine screening detected 9 percent of newly
admitted patients who initially denied PCP use. It is tempting to
speculate on the clinical significance of PCP use in newly admit-
ted psychiatric patients, i.e., what role it plays, if any, in
precipitating the admission. Only future longitudinal and pro-
spective research can address this question. In any case, our
small pilot study suggests that specific training of clinical
staff may be necessary before results of PCP assays are incorpo-
rated into treatment planning for patients in whom PCP use is not
initially suspected.
The sociodemographic and clinical characteristics of our PCP abus-
ers were similar to those previously reported in the literature,
except for a somewhat older age range. This indicates that chron-
ic PCP use does occur outside the adolescent/young adult age
group, and suggests that future treatment and research efforts
should include older age groups.
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Our experience with inpatient and outpatient treatment of PCP
abuse was not very successful, similar to experiences reported in
the literature. A few authors have commented on the difficulties
in treating PCP abusers, citing their impaired attention span and
concentration, emotional lability, impulsiveness, poor group
interaction, and low tolerance for confrontation (Bolter 1980;
Bragg 1980). Systematic, controlled studies using appropriate
comparison groups are needed to validate these anecdotal obser-
vations and to determine whether they are effects of PCP use or
antecedent conditions (which perhaps might predispose to PCP use).
In particular, studies of the direct neuropsychological and
neurophysiological effects of chronic PCP use (over and above the
short-term effects of acute intoxication) would have important
treatment implications (Lewis and Hordan, this volume). Recent
studies of alcoholic patients suggest that neuropsychological
functioning at admission may be a significant predictor of treat-
ment outcome (Donovan et al. 1984). There is no a priori reason
why a similar phenomenon might not occur with PCP abusers.
There are currently no systematic data to guide a decision on
inpatient vs. outpatient treatment. However, the cheap and easy
availability of PCP reported by outpatients in their living envi-
ronments, and the frequent continued use of PCP by outpatients
suggest that a brief period of inpatient treatment might be useful
in initiating drug abstinence. There is clearly a strong need for
research on specific treatment modalities for PCP abuse.
Findings from psychopharmacological and neuropharmacological stud-
ies of PCP in animals suggest other potentially fruitful areas of
clinical research (Balster, this volume). The PCP drug stimulus
in animals does not generalize well to other drugs of abuse. This
has led to the hypothesis that PCP has a unique psychotropic
action, and that therefore PCP abusers would have a distinctive
pattern of drug use and tend to avoid use of other drugs. In
fact, clinical data from our own studies and the published liter-
ature show that the majority of PCP abusers regularly use other
drugs, either concurrently or sequentially. A possible explana-
tion for this lies in the variety of behavioral effects produced
by PCP in animals. Both stimulant and sedative effects of PCP
have been reported in various animal paradigms, analogous to the
variety of intoxication responses reported by patients. This sug-
gests that PCP may be considered at least somewhat interchangeable
with other drugs of the stimulant and CNS depressant classes.
Furthermore, PCP might be considered effective self-medication for
a variety of psychopathologic states, e.g., the stimulant effects
might be attractive to those with dysthymic symptoms, and the the
sedative effects to those with anxiety symptoms. Careful psychi-
atric studies of representative samples of PCP abusers in the
sober state (along with corroborative information about psychi-
atric history) are needed to test these hypotheses.
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Almost all the PCP abusers we studied had a "psychological depend-
ence" on PCP, i.e., an inability to give up drug use despite
serious adverse consequences, coupled with a conscious desire to
use the drug (craving). No patient described clear evidence of
physical (physiological) dependence, either in terms of tolerance
or a withdrawal syndrome. (However, we did not systematically
evaluate patients for these phenomena.) Anecdotal reports of
fourfold tolerance to PCP have been published (Burns and Lerner
1981). Animal studies have found moderate (two- to fourfold)
tolerance to PCP, probably involving metabolic, pharmacodynamic,
and behavioral adaptation processes (Balster and Woolverton 1981;
Freeman et al. 1984). There is also some animal evidence for a
PCP withdrawal syndrome. Balster and Woolverton (1980) noted a
marked syndrome occurring in rhesus monkeys who self-administered
very large IV doses (up to 10 mg/kg/day or more) for over a month.
Bruxism, oculomotor hyperactivity, tremor, diarrhea, and pilo-
erection appeared within 8 hours of drug cessation, and peaked at
24 hours. Slifer et al. (1984) found a much milder syndrome in
monkeys who received a continuous IV infusion of PCP (1.2 mg/kg/
day) for 10 days. The principal withdrawal effect was a disrup-
tion of conditioned lever pressing for food, which appeared within
8 hours of drug cessation and resolved over the next week. An
acute PCP dose temporarily reversed the behavioral disruption,
supporting its interpretation as a withdrawal phenomenon. These
findings suggest that, while physical dependence on PCP can exist,
it probably requires long-term regular exposure to relatively high
levels.
Tennant and colleagues (Tennant et al. 1981; Ayd 1981) studied 26
long-term (at least 3 months) daily PCP abusers and described the
following syndrome occurring within 1 day of drug cessation:
depression, anxiety, irritability, restlessness, anergia, sleep
disturbance, confused thoughts, and strong craving for PCP. It is
not clear how long this syndrome lasted, since none of the eight
untreated patients returned to the clinic for follow-up. The 18
patients treated with desipramine (50 to 150 mg/day open-label)
reported a rapid and substantial reduction in symptoms, which
helped 15 of them become drug free during a 2-week follow-up
period. Given the probable role of withdrawal symptoms and drug
craving in promoting continued drug use (and relapse from abstin-
ence), further systematic, controlled research in this area, in-
cluding double-blind medication trials with random assignment of
subjects to treatment groups, would appear very worthwhile.
Our pharmacokinetic data indicate that detectable PCP levels may
remain in the urine for 4 to 5 weeks after the last use, similar
to previous reports (Khajawall and Simpson 1983). The observed
elimination kinetics were equally consistent with a one- or two-
compartment model, but methodological problems with our data make
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any conclusions highly tentative. The time variable was based on
patient self-report, making its accuracy uncertain. Although the
PCP level itself was measured accurately, the PCP dose yielding
that level varied among patients in an unknown fashion (since no
data on dose could be collected).
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Legal Issues Associated With
PCP Abuse—The Role of the
Forensic Expert
Steven E. Lerner and Richard S. Burns
It is not uncommon for individuals under the influence of phency-
clidine to come to the attention of the criminal justice system.
Increasingly, there is a need for forensic experts to advise and
testify in cases involving PCP and other psychoactive drugs. With
the publication of a paper on acute intoxication and fatalities
from PCP use, we began to receive requests from attorneys to eval-
uate PCP-related cases (Burns et al. 1975). We have now consulted
in over 400 civil and criminal cases and have testified in munici-
pal, superior, and Federal courts from Hawaii to Washington, D.C.
In this chapter, we will examine some of the issues that are fre-
quently raised in both criminal and civil PCP-related litigation.
Most jurors and many courts have limited knowledge about psycho-
active drugs, including PCP. From our experience, it is not
uncommon for the average juror to believe that the effects pro-
duced by PCP are no different from those produced by other drugs.
For this reason, jurors must be educated if they are to be expect-
ed to make informed decisions about complex issues with which they
have little or no familiarity. It is possible, in a limited
amount of time, using visual aids, to provide a jury with a basic
understanding of PCP, through expert testimony. We have found
that a general discussion, prior to testimony, of the specifics of
a case, covering PCP's history, street pharmacology including
modes of administration, patterns of use, duration of effects,
signs and symptoms of intoxication, toxicological screening, and
effects on brain functioning provide an adequate foundation for
many issues that jurors must consider (Lerner and Burns 1978).
The following case histories illustrate some of the issues faced
by PCP abusers, law enforcement personnel, and the courts.
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CRIMINAL LITIGATION
Case 1. Determination of Implied Malice Associated With Driving
While Intoxicated
Prior to 1981, in California, the most serious charge possible for
death occurring as a result of alcohol- or drug-related vehicular
homicide was the crime of vehicular manslaughter with gross negli-
gence. That year, the California Supreme Court decided that sec-
ond degree murder could be charged when the facts surrounding a
vehicular homicide supported a finding of "implied malice." Under
California law, implied malice exists where the killing results
from an intentional act, the natural consequences of which are
dangerous to life, which act was deliberately performed by a per-
son who knows that his conduct endangers the life of another, and
who acts with conscious disregard for life. Under this defini-
tion, it is not necessary to prove that a defendant intended to
kill another. Proof of the subjective state of mind of the intox-
icated driver is critical in the determination of whether the
driver was acting with implied malice and therefore guilty of
murder. Elements of knowledge and cognitive thinking ability must
be proven.
In People vs. Ernesto Rangle Juarez1, the issue of PCP and its
effects upon a person's state of mind became the focal point of
the trial. The prosecution sought to prove that Juarez intention-
ally used PCP, was aware that using PCP and driving an automobile
was dangerous to human life, and acted with conscious disregard
for human life. The defense sought to prove that Juarez's use of
PCP was unintentional, and that the effect of the PCP was to
render him incapable of being aware of the consequences of his
conduct and unable to control his conduct; therefore, Juarez was
not guilty of murder.
Summary of facts. The factual situation was important in the
trial, for the resolution of the PCP issue, Evidence produced at
the trial revealed that around noon on March 6, 1982, Juarez was
driving his automobile in the City of South San Francisco, with
three of his friends as passengers. The men smoked what Juarez
claimed to be a joint of marijuana in his automobile, while parked
in a store parking lot. Juarez claimed that he took only one or
two inhalations from the joint. He then drove from the parking
lot and became involved in two minor traffic accidents within a
span of 30 seconds. Accelerating rapidly, he fled the scene. A
South San Francisco police officer on patrol in the area saw
Juarez's automobile and gave chase. Juarez took evasive action
when the officer activated his emergency lights and siren, and
Juarez's automobile reached speeds of 65 to 70 miles per hour. As
the automobile approached a curve in the roadway, Juarez failed to
control the automobile, which went into oncoming traffic lanes and
hit the victim's car head-on, killing the victim instantly. A
great deal of evidence was produced concerning Juarez's conduct
and action after the accident. Juarez was not significantly
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injured in the collision , although paramedics found him somewhat
dazed. Police officers and medical personnel testified that he
answered questions appropriately. His speech was slurred, and he
appeared to be extremely intoxicated or under the influence of
drugs. Approximately 1 hour after the accident, blood and urine
samples were obtained for toxicological screening. The analysis
revealed a PCP blood level of 30 ng/ml and a PCP urine level of
2.1 µg/ml. No alcohol was detected.
Prior to the collision, Juarez had been on probation for sales of
narcotics and had been reporting to an adult probation officer.
The officer testified concerning a 2-year period of probation
during which Juarez continually used PCP, as evidenced by toxico-
logical screening, a condition of probation. This information was
introduced by the prosecution to show Juarez's awareness of PCP
and its effect upon him.
Expert Testimony. Drug abuse experts testified on both sides.
The prosecution's expert used slides and a motion picture to in-
form the jury of the effects of PCP. He testified that a person
with a PCP blood level of 30 ng/ml would be considered under the
influence of this drug, and should display nystagmus and have dif-
ficulty with coordination. A person with this blood level would
be classified as being in an acute confusional state (Burns and
Lerner 1981). This level would not necessarily mean that an indi-
vidual would not be conscious of what he was doing, nor would he
be unable to control his conduct. Emphasis was placed on Juarez's
behavior on the day of the collision. Important factors presented
to the jury were his history of PCP abuse, his driving ability
throughout the entire incident, and his conduct and behavior after
the collision. In addition, testimony was given regarding the
substantial evidence of what was referred to as reality-oriented,
goal-directed behavior exhibited by Juarez both before and after
the collision. This testimony enabled the prosecution to argue
that, despite PCP intoxication, Juarez was aware of his conduct
and had the ability to make conscious decisions regarding his
conduct. Under the prosecution's theory, this reality-oriented,
goal-directed behavior was evidence of Juarez's state of mind of
implied malice.
On this issue, the defense called a drug abuse expert who testi-
fied to Juarez's state of mind. The defense expert testified that
for a person to be aware that his conduct is dangerous to another
and in order for him to make a conscious decision to refrain from
such activity, or to act without regard to such known danger, he
must be able to engage in abstract thinking. A PCP blood level of
30 ng/ml would result in a high likelihood that there would be
gross impairment of the ability of the defendant to think
abstractly.
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Outcome. After consideration by the jury, defense testimony was
rejected and Juarez was found guilty of second degree murder.
This was the first time in the history of the State that an indi-
vidual was convicted of murder based upon an automobile collision
while under the influence of PCP.
Case 2. Diminished Capacity Associated With PCP Intoxication
The diminished capacity defense associated with PCP intoxication
has frequently been used as an explanation of an individual's
conduct. In 1981, this explanation was the sentral issue in the
case of People vs. Richard Cavesuella et al. that became known as
the Mt. Madonna murders.
Summary of facts. In Watsonville, California, a town located near
the City of Santa Cruz, two youth gangs became embroiled in a turf
war that ended with the brother of Cavesuella receiving a shotgun
wound to the head, which resulted in a severe, permanent brain
injury. Gang and family pride led Cavesuella to seek to avenge
his brother's injury. With a friend, he ventured into so-called
neutral territory, to a party at a fairgrounds. There, they
encountered two young males (15 and 16 years of age) associated
with the rival gang. After drinking to the point of intoxication,
the youths were invited out for more beer.
During a ride to a nearby park called Mt. Madonna, the youths were
terrorized and one was stabbed. Very quickly, it became clear
that Cavesuella was interested in revenge for his brother's
shooting. Both youths protested that they were not in the other
gang, nor had they been involved in the shooting. Their protests
were to no avail. They were subsequently harrassed, interrogated,
and stabbed repeatedly. There were approximately 140 stab wounds
to the two bocies that were deposited by the side of a road.
Trial strategies. The defense described the killings as
"frenzied," so that they could attempt to use the manslaughter
instruction. In essence, a killing committed in the heat of
passion, or upon a sudden quarrel, that is not premeditated or
deliberated is manslaughter at most. The defense strategy was to
make the drug be the culprit in the case. PCP had been given wide
media attention and had been highlighted as causing indiscriminate
fits of rage and/or violence. Toxicological screening had not
been conducted at the time of Cavesuella's arrest. Nevertheless,
the defense attempted to prove that Cavesuella had taken PCP and
was under the influence of the drug at the time of the killings.
The prosecution's main trial issue was to counteract or show the
jury that, even assuming Cavesuella ingested PCP, his acts were
reality-oriented; goal-directed in such a way that the drug did
not prevent him from meditating, deliberating, or harboring
malice. This was accomplished by cross-examination of the de-
fense's drug expert and presentation of testimony by the prosecu-
tion's drug expert. The defense expert was questioned repeatedly
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about different facts in the case that showed the presence of
reality-oriented, goal-directed behavior on the part of
Cavesuella. In those areas, he indicated the presence of an
intellectual capacity to premeditate and deliberate. While the
expert still stuck with his opinion that Cavesuella was diminished
because of the use of PCP, he conceded that he had not read the
crime reports or much of the information that was utilized in
cross-examination of his testimony.
Testimony by the prosecution's expert was that it was possible
Cavesuella had taken PCP at some time. Whether or not he did on
the night of the killings could not be determined. However,
Cavesuella's actions were inconsistent with someone who, under the
influence of PCP, is significantly impaired.
Outcome. The jury deliberated for 2 weeks before deciding that
Cavesuella was guilty of first-degree murder with special circum-
stances. He was sentenced to life imprisonment without the
possibility of parole.
CIVIL LITIGATION
Case 3. Death Associated With Law Enforcement Intervention
It is not uncommon for civil actions to be brought against law
enforcement personnel who have come into contact with individuals
under the influence of PCP.
Honolulu et al.
Helen A. Burns vs. City and County of
represents an issue that is being brought before
the courts with increasing frequency.
Summary of facts. On the night of May 10, 1979, officers from the
Honolulu Police Department responded to a call that a disturbance
was taking place at a night club frequented by sailors as well as
by "locals." The first officers to arrive observed a group of
sailors in the parking lot. A shirtless young man in this group
was asked for some identification and gave one officer a card that
identified him as Richard Burns. One officer went into the club
to find out what had happened.
As the other officer approached, Burns yelled "Watch your back!"
causing the officer to turn around, but no one was there. Burns's
skin appeared to be covered with perspiration, and he appeared to
have been involved in a fight. He would occasionally spit on the
sidewalk and try to wipe it up with a handkerchief or rag. Once
in a while he would yell "Watch your back!" and/or "Is it over?"
The officer suspected that Burns was on drugs. Once Burns
attempted to run past the officer, who was just barely able to
restrain him. Although the officer was much larger, Burns pulled
away with such ease that the officer knew if he had to hold him
there was going to be a problem.
Additional officers arrived as the crowd grew, and Burns continued
his bizarre behavior. A decision was made to remove Burns and
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defuse the situation that seemed to be building; the supervising
officer ordered him arrested for disorderly conduct. Burns backed
into an officer who applied what was described as a neck hold as
the officers struggled to handcuff him. There was disagreement as
to whether Burns actually lost consciousness after this first
hold, although he did go limp, and handcuffs were placed on his
wrists. Burns was immediately back up on his feet, kicking wildly
in all directions. This time an officer managed to apply a carot-
id restraint hold. In addition, a belt was placed around his
feet. This hold was applied for not more than a fraction of a
minute by all accounts.
All three officers got up from Burns at the same time. The super-
vising officer stated that Burns looked like anybody who was un-
conscious; he saw nothing out of the ordinary. Several minutes
had passed after application of the second hold (there was a dis-
pute about how many holds had been applied), at which time the
officers discovered that Burns was not breathing and applied
cardiopulmonary resuscitation. Burns, however, was dead.
It was later learned that Burns had accosted two female employees
in a restroom. A struggle had ensued, during which a bouncer
applied a neck hold; he had been kicked in the head by someone
wearing a hard shoe; he was either bounced against or bounced
himself against a wall, and had slipped from the grasp of five or
six well-built men.
Issues at trial. The decedent's mother and his estate brought an
action that came to trial in Federal court against the City and
County of Honolulu for intentionally, recklessly, or negligently
causing his death. The propriety of the arrest was never ques-
tioned by the plaintiff, only the manner in which it had been
handled. Much of the plaintiff's case focused on attempting to
prove an alleged third choke hold. The third hold was supposedly
witnessed by a security guard, from a rooftop parking lot, who ob-
served one officer come back after the second hold and "strangle"
Burns for up to 14 seconds. No one else observed this, and testi-
mony from other witnesses was that this officer had gone back into
the bar after the second hold.
The medical examiner for the City and County of Honolulu ruled
that the cause of Burns's death was asphyxiation. Laboratory
analysis confirmed the presence of PCP in his body. However, it
was the medical examiner's opinion that PCP did not play a role in
the death. It was later learned that the medical examiner's
knowledge of PCP was limited to articles he had read that were
written by experts subsequently retained by the City and County of
Honolulu.
These experts had been requested to determine the cause of death
and to evaluate the officers' conduct in this matter. At trial,
they testified that the medical examiner was in error regarding
the cause of death. There were no statements made that anyone had
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cut off the decedent's air supply for the minimum time required
for asphyxiation. It was their opinion that Burns had died from
an idiosyncratic reaction from a combination of control hold(s)
and PCP (Burns and Lerner 1978). Testimony was also offered that,
under the circumstances, and with the absence of any knowledge by
police of the effects of PCP, the conduct of the officers was
appropriate. It was stressed that traditional control holds may
be ineffective in controlling someone under the influence of PCP.
For this reason, law enforcement training in signs and symptoms of
PCP intoxication and appropriate methods of control was extremely
important. However, in this case, it would not be reasonable to
expect officers to have this specialized training, since PCP had
not been recognized as a problem in Hawaii.
Outcome. After a week of deliberation, the jury returned a find-
ing of no improper conduct by the police in effecting the arrest.
They did find the City and County of Honolulu 20 percent negligent
in failing to discover sooner that Burns was not breathing, and
negligent in administering CPR. However, under Hawaii law, negli-
gence must be more than 51 percent for a cash award.
SUMMARY
These cases illustrate some of the complex issues associated with
PCP-related litigation. The concept that malice is implied when
an experienced drug user commits a crime while under the influence
of the drug is not held in most states, at the present time.
The authors have now reviewed in detail four cases of unexpected
death following the use of neck holds in PCP-intoxicated indi-
viduals. In all of the cases, multiple carotid compression holds
had been attempted, according to the history. Skin abrasions,
hemorrhage into the soft tissues of the neck, and fractures of the
hyoid bone and thyroid cartilage provide structural evidence of
the application of substantial force to the neck. On autopsy,
there has been no evidence of lethal injuries to the bronchial
tree, brain, or heart.
Drugs related to PCP are known to alter the carotid sinus reflex.
Mechanical stimulation of the carotid sinus in the neck normally
results in a slowing of heart rate and a decrease in blood
pressure. Carotid sinus stimulation, coupled with the effects of
PCP on blood vessels, might result in a marked fall in the blood
pressure that could lead, ultimately, to death. Individuals
intoxicated with PCP may be at a higher risk to complications of
carotid compression neck holds. Hence, additional cases would be
expected to become medicolegal issues.
FOOTNOTES
1. Charles J. Smith, Deputy District Attorney, County of San
Mateo, contributed case information.
235
2. Arthur Danner III, District Attorney, County of Santa Cruz,
contributed case information.
3. Adrienne Sepaniak King, former Deputy Corporation Counsel,
City and County of Honolulu, contributed case information.
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The Long-Term Effects on
Neurodevelopment in Infants
Exposed Prenatally to PCP
Judy Howard, Vickie Kropenske, and Rachelle Tyler
Abuse of phencyclidine hydrochloride (PCP) is a national problem
that has reached epidemic proportions in urban areas of the United
States. The drug is inexpensive, readily obtainable, and is usu-
ally used in combination with other drugs such as marijuana, hero-
in, cocaine, and alcohol (Golden et al. 1982). The routes of PCP
use include inhalation, ingestion and parenteral administration.
In Los Angeles County, the number of PCP abusers seen in emergency
rooms rose from 1,567 in 1980 to 3,001 in 1983, an increase of 92
percent. In addition, approximately 30 percent of these individu-
als were women of child-bearing age, who reported that their first
use of PCP was at the age of 20 years (Husson 1984).
With the increased use of PCP by young women, pediatricians have
begun to identify the newborn's neurobehavioral symptoms after in
utero exposure. In 1980, Golden et al. were the first to document
the placental transfer of PCP in humans and to describe the re-
sulting neurobehavioral symptoms. They reported on one infant
whose mother had smoked an average of six joints per day of mari-
juana dusted with PCP. The behaviors emerging shortly after birth
included extreme jitteriness , coarse flapping movements in re-
sponse to slight auditory or tactile stimuli, nystagmus, poor
visual tracking, and hypertonicity. At 2 months of age, the in-
fant continued to have coarse tremors, roving eye movements, and
hypertonicity. Furthermore, the infant had dysmorphic features.
Subsequent to this report, Strauss et al. (1981) described two
other infants who had been exposed prenatally to PCP. These in-
fants also displayed signs of irritability, tremulousness, and
increased muscle tone. However, no congenital anomalies were
noted.
More recently, Chasnoff et al. (1983) have described the behavior
of seven infants whose mothers used PCP daily throughout their
pregnancies as well as using various other drugs intermittently.
As compared to a control group of 27 infants, the PCP-exposed new-
borns had rapid changes in their levels of consciousness, with
lethargy alternating with irritability. Furthermore, these
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infants were very sensitive to auditory stimuli and had tremors
and facial grimacing.
The effects of PCP in its purest form, as a single drug, have been
studied in animals. In 1977, Cooper et al. noted the placental
transfer of PCP in pigs. In fact, they found that plasma levels
in the piglet were 10 times higher than in the sow. Other animal
studies support marked neurobehavioral changes in the newborn, but
have yet to incriminate PCP as a teratogen (Goodwin et al. 1980;
Tonge 1973; Tenor 1974). A more specific description of the
behavior of monkeys that had received PCP was given by Balster and
Chait in 1976. The monkeys had nystagmus and rhythmical limb
movements, and were unable to track visually.
While the aforementioned studies have described the manifestations
of in utero exposure to PCP by human and animal fetuses as well as
behaviors adult monkeys who had received only PCP, the long-
term consequences of prenatal abuse have not been described.
Therefore, this report will elaborate upon our observations of the
effects of PCP upon the growth and development of 12 neonates
between 2 and 18 months of age, whom we have followed from August
1983 to March 1985.
DESCRIPTION OF INFANTS
During an 18-month period the growth and development of eight male
and four female infants exposed prenatally to phencyclidine was
observed.
The Ballard Screening System (Ballard et al. 1977) was used to
determine the gestational ages for the five preterm and five full-
term neonates born at UCLA. Maternal dates and physical exam
established the gestational ages for the two full-term infants
born at community hospitals. The average gestational age for all
infants was 37.75 weeks with a range of 33 to 42 weeks. The five
preterm infants had a mean gestational age of 34.6 weeks with a
range of 33 to 36 weeks. The average gestational age for the
seven full-term infants was 40 weeks with a range of 38-42 weeks.
The 12 neonates included in this study had a mean birth weight of
2,481 grams (10 percent), a mean frontal-occipital head circum-
ference of 31.5 cm (10 percent), and a mean crown-to-heel length
of 47 cm (25 percent). Among preterm infants the respective mean
weight, head circumference, and length were 1,804 grams [referent
to the norms established by Lubchenco et al. (1966). this weight
fell at the 10th percentile], 29 cm (10th percentile), and 42 cm
(25th percentile). Full-term infants averaged a birth weight of
2,964 grams (25 percent), head circumference of 33 cm (10 per-
cent), and length of 49 cm (25 percent). Two of the preterm
neonates were small for gestational age. All infants were normo-
cephalic and no congenital anomalies were apparent.
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Urine toxicology screens from the mothers and infants were
obtained during the labor and delivery and/or postnatal periods.
All specimens were analyzed by EMIT (Enzyme Immunoassay Tech-
nique), an enzyme method based upon the competitive bonding of an
enzyme and an antibody. This method yields a positive result with
concentrations of 75 ng of PCP/ml or greater (Rubenstein et al.
1972).
For all 12 mother-infant pairs, either the mother or the infant's
toxicology report was subsequently positive for PCP. In nine
cases, the screens for both mother and infant were positive. In
two cases, the mother's results were positive and the infant's
were negative. In one case, the infant had a positive result
while the mother's test was negative. Test sensitivity, specimen
handling procedures, and delays in obtaining specimens undoubtedly
contributed to the inconsistency in paired results. Cocaine,
codeine, and glutethemide, in addition to phencyclidine, were
identified in the urine toxicology screens of two mothers and
their neonates.
All infants developed deviant neurobehavioral symptoms within the
first 24 hours of life. Most commonly, the neonates were found to
have symptoms of irritability, tremors, and hypertonicity. Bi-
zarre eye movements and staring spells were seen in 25 percent of
infants. Poor sucking, lethargy, diarrhea, and facial twitching,
symptoms commonly associated with prenatal opiate exposure, were
seen infrequently in these PCP-addicted infants.
In addition, the temperature, pulse, and respiratory rates for 10
infants were reviewed for evidence of drug effects on autonomic
nervous system function. However, no abnormal patterns were noted
during the course of hospitalization.
In 58 percent of cases, symptomatic treatment with Valium, pheno-
barbital, or paregoric, for a period ranging from 2 to 14 days,
was required to control drug effects. However, in 42 percent of
the cases, symptoms were successfully managed with more conserva-
tive measures such as swaddling, use of a pacifier, decreased
environmental stimulation and excessive handling, and modification
of feeding schedules and techniques. Although all infants re-
mained symptomatic, only two neonates continued to require medica-
tion at the time of discharge.
In addition to normal neurobehavioral symptoms, 67 percent of
infants were also noted to have one or more medical problems dur-
ing the perinatal period including respiratory distress, meconium-
stained amniotic fluid, hyperbilirubinemia, anemia, syphilis,
omphalitis, and electrolyte imbalances. Meconium staining and
respiratory distress were the most commonly observed problems for
both preterm and full-term infants. However, among preterm neo-
nates, respiratory problems were noted with much greater frequen-
cy, and the severity of the preterms' early respiratory problems
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continued to lower l-minute Apgar scores. Eighty percent of pre-
term Infants had Apgar scores below 7 at 1 minute, compared to 14
percent of full-term infants with low 1-minute scores. Among 43
percent of full-term infants, the sole identified medical problem
was abnormal neurobehavioral signs. In contrast, during the peri-
natal period, 80 percent of preterm infants experienced three or
more medical problems in addition to withdrawal symptoms.
TABLE 1. Incidence of neonatal medical problems
Medical Problem








































































The medical problems and slow weight gain of the preterm infants
contributed to their prolonged hospitalization. The five preterm
infants remained in the hospital an average of 24 days with a
range of 10 to 37 days. At UCLA, infants between 33 and 37 weeks'
gestational age routinely require 10 days of hospitalization. The
seven full-term infants had a mean hospital stay of 8 days with a
range of 4 to 14 days. While the average length of hospitaliza-
tion at UCLA is routinely 2 1/2 days for full-term infants, the
stay for these essentially healthy infants was extended to monitor
their neurological status, and to taper or stabilize medications.
At the time of discharge , all infants were placed in the homes of
relatives or foster parents. In the State of California, a child
born withdrawing from drugs or alcohol is considered to be abused
and must be reported to child protection agencies (Los Angeles
County 1982). Therefore, all the infants reported in this paper
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were identified as having been abused, were referred for court
supervision, and were placed in foster homes or with extended-
family members during the period of follow-up observation.


















Birth weight grams) 1,804 ± 170
Head circumference 29 ± 0.7
Birth length 42 ± 2.8
Apgar scores
1 minute 4.4 ± 2.9
5 minutes 6.8 ± 2.9
6 at 1 minute 4(80)
Withdrawal
Mild (no meds.) 2(40)
Moderate (meds. 2 weeks) 3(60)









7 ± 2.7 5.9 ± 2.9










The physical growth scales used are those published by the
National Center for Health Statistics: percentiles which are
based upon the work of Lubchenco et al. in 1966. The infant's
weight, height, and head circumference were adjusted for sex and
corrected for prematurity.
At an age of 35 weeks, the mean weight and head circumference were
at the 10th percentile and height was at the 25th percentile. By
18 months of age, five infants had a mean weight between the 25th
and 50th percentile, and a mean height at the 75th percentile.
The mean head circumference of the four males was at the 10th
percentile. The one female's head circumference was at the 50th
percentile.
DESCRIPTION OF MOTHERS
Maternal data were obtained during interviews with the mothers
following delivery and by review of the maternal and infant
medical records.
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The mean maternal age for the 12 mothers included in this study
was 25.8 years, with a range of 20 to 31 years. Mother's race
was: 75 percent black, 17 percent white, and 8 percent Hispanic.
All were low income. Eighty-three percent of the women were
multiparas with an average of 5.2 previous pregnancies and 2.7
live births.
TABLE 3. Summary of maternal demographic data
Maternal Status





















4.1 ± 1.3 5 ± 3.5 4.8 ± 2.7







Criteria developed in the National Institute of Medicine Study
(Gortmaker 1979) was used to establish the adequacy of prenatal
care. In 67 percent of our 12 cases, prenatal care during preg-
nancy was inadequate. However, among mothers of preterm infants,
care was inadequate in all cases. Thirty-three percent of all
mothers received no prenatal care.





















Mothers of preterm infants were also more likely than mothers of
full-term infants to have obstetrical complications at the time of
delivery. Eighty percent of mothers of preterm infants had three
or more obstetrical complications. Possible complications includ-
ed premature labor. oremature rupture of membranes, prolonged
rupture of membranes', Caesarean section, chorioamnionitis, and
marginal placenta abruption. In contrast, only one mother of a
full-term infant developed obstetrical complications during the
perinatal period.
However, the pregnancies of 67 percent of all mothers were compli-
cated by a variety of medical problems including anemia, hepatit
B, syphilis, and psychiatric emergencies. At the time of deliv-
ery, 57 percent of mothers of full-term infants and 80 percent of
mothers of preterm infants were noted to have had one or more
medical problems during the pregnancy. Seventy-five percent of
all mothers smoked.
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Premature rupture of 5(100)
membranes
Prolonged rupture of 3( 60)
membranes
Caesarean section 2( 40)




Hepatitis B 1( 20)
Syphilis 1( 20)















Maternal reports of drug use during pregnancies reflected a pat-
tern of polydrug exposure during the gestational period. In only
two cases was phencyclidine the sole reported drug of abuse.
Alcohol, marijuana, and cocaine were commonly used in varying com-
binations with PCP. The extent of reported maternal use of phen-
cyclidine ranged from daily smoking of PCP-laced cigarettes to
"one-time" use 3 months prior to delivery. Fifty-eight percent of
women reported smoking as the primary route of ingestion.
percent of cases, the method of use is unknown.
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Information regarding the long-term history of drug abuse was
available for eight mothers: four who delivered full-term infants
and four mothers of preterm infants. The average number of years
of drug use for this group of mothers was 7.4 years, with a range
of 3 to 15 years.
TABLE 6. Incidence of reported maternal drug use during
pregnancy
Drug Used













2( 29) 6( 50)
2( 29)





1( 20) - 1( 8)
- 1( 14) 1( 8)
Of the 10 mothers who delivered at UCLA Medical Center, one re-
turned for the scheduled 6-week follow-up appointment. Twenty-
five percent of all mothers have had repeat pregnancies.
DESCRIPTION OF THE INFANTS' POSTDISCHARGE ENVIRONMENT
Following their hospitalization , all infants were placed with
foster parents or in the care of extended-family members. Four
infants were discharged to relatives and eight infants were placed
in foster care. Later, two of the foster children were also
placed with extended families.
During the follow-up period, no infant was returned to the care of
the mother. In 25 percent of cases, the child was essentially
abandoned after delivery. While, in the remaining 75 percent of
cases, the mothers expressed a strong desire to care for their
infants, none of the parents was able to complete a drug rehabili-
tation program and/or successfully sustain a drug-free life style,
conditions stipulated by the court as the basis for reunification.
Furthermore, there was evidence from previous childrearing pat-
terns that the mothers who already had children would have diffi-
culty managing the caretaking responsibility for the new infant,
if the parents' drug use continued.
Of mothers who had older children (58 percent), 85 percent already
had one or more of their offspring in foster placement or in the
care of extended-family members. In addition, physical and
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developmental evaluations of six children who were living with two
of the mothers at the time of this delivery revealed significant
developmental delays in two of the children, and emotional and
school problems among the four siblings. Medical neglect was also
evident in all six children.
After discharge , all infants were followed by a team composed of a
pediatrician with subspecialty training in Child Development, a
public health nurse, and a social worker. In order to maintain
contact with the foster families and relatives who had responsi-
bility for the care of the infant, team members made regular home
visits and had frequent telephone contact with the infants' care-
takers. During the first 3 months of placement, infants were seen
(an average of twice per month) for follow-up visits at home or in
the UCLA Child Development Clinic. Phone conferences with care-
takers were held on a biweekly basis. During the following 3
months, clinic and home visits were tapered to once per month and
phone contacts were made biweekly.
Team members provided and coordinated referrals to a variety of
community agencies, and supported caretakers in learning about
normal infant development, sleep-wake patterns, and feeding sched-
ules and appropriate foods. Caretakers were also helped to under-
stand the infants' developmental strengths, what would effectively
soothe him/her, and what play activities were appropriate at
certain ages.
The team also assisted the infants' caretakers with obtaining
appropriate medical care and treatment. The primary health care
of 58 percent of the infants was received from physicians who
lived within the foster family's community; 42 percent of infants
returned to the UCLA Pediatric Clinic for routine pediatric
follow-up. In order to promote optimal medical care for all in-
fants, team members provided the primary physician with summaries
of the child's birth history, developmental progress, and informa-
tion regarding the medical treatment and management of the PCP-
exposed infant.
The intent of these specialized follow-up services to families was
to provide education, support, and anticipatory guidance in order
to maintain a nurturing and stable environment for the high-risk
infant. In 67 percent of the 12 cases, the infant did remain in
the same home environment throughout the follow-up period. There
were, however, four infants who had multiple changes in placement
following discharge. Among these four cases, three infants were
placed in two different homes within the first 2 months of life.
Thereafter their placements were stable. The fourth infant ex-
perienced four placements during the first 9 months, two place-
ments being with foster parents and two with relatives.
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DEVELOPMENTAL OUTCOME OF INFANTS
In order to determine the infants' behaviors in the areas of gross
motor, fine motor, adaptive, language, and personal-social devel-
opment, the standardized Gesell Developmental Evaluation (Gesell &
Amatruda 1954) was administered to them. This examination pro-
vides a developmental age (DA) and developmental quotient (DQ)
(ascertained by dividing the chronological age into the develop-
mental age) in each of the five areas of behavior, and an aggre-
gate DA and DQ. For those infants born preterm, correction for
their gestational age was made. The average DQ is 100.
The DQ's of eight infants who had a mean age of 34.5 weeks are
described in table 7. The DQ's of five infants who had a mean age
of 17.75 months are described in table 8.
TABLE 7. Gesell developmental evaluation of 8 infants at 34.5
weeks (±4.6)
Developmental Area Developmental Quotient
Gross motor 106 ± 32.9
Fine motor 81 ± 18.7
Adaptive 90 ± 20.1
Language 96 ± 14
Personal-social 103 ± 19
Aggregate score 96 ± 18
TABLE 8. Gesell developmental evaluation of 5 infants at 17.75
months (±1.1)
Developmental Area Developmental Quotient
Gross motor 114 ± 14
Fine motor 86 ± 12.9
Adaptive 93 ± 17.5
Language 86 ± 11.1
Personal-social 90 ± 8.4
Aggregate score 94 ± 11.3
The evaluation results are mildly worrisome; however, the quality
of the infants' behaviors are very worrisome. In the area of fine
motor development, the infants performed in the low normal range.
Furthermore, the items used to score fine motor behaviors do not
identify deviant movements required for the fine motor act. For
instance, each of these infants displayed abnormal movement
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patterns when attempting to grasp small objects. The movements of
the arms were awkward and the positioning of the hands was pecu-
liar in that the fingers were held in an extended, splayed
position. There was a palmar approach to the cube, with over-
extension of the mark and an overhand approach. When the infants
attempted to retrieve a small pellet, they would bat at the pellet
with their palms, and seemed to have difficulty flexing their
extended fingers. Some infants were very persistent in their
attempts to grab the objects, other were easily frustrated.
Paralyses and weaknesses were not seen. Tactile and/or proprio-
ceptive dysfunction are possible causes for these peculiar move-
ments of the arms and hands.
The infants' gross motor milestones were obtained well within the
normal range. However, observations of their early attempts to
walk independently revealed awkward leg movements and placement of
their feet. These movements improved over time as did the total
arm movements.
Eye movements were noted to be deviant in 25 percent of the
infants during the neonatal period. Nystagmus and darting eye
movements were seen. Also, a glazed stare associated with total
body stillness was frequently seen during the first 6 weeks.
The infants' adaptive or playing behaviors with the test objects
showed the infants to be spontaneous in their approach to the toys
and to demonstrate an interest in manipulating them. Some infants
were easily frustrated by their inability to manipulate the
objects due to their fine motor difficulties. However, there was
no evidence of gross retardation in the emerging cognitive areas.
Language skills were more difficult to evaluate. The infants'
caretakers reported age-appropriate vocalizations. However, at
clinic and home visits, we found the infants to be less vocal
during the 1-hour session than we would have anticipated.
A further area of concern is the infants' personal-social devel-
opment. During the latter half of the first year, we noted seem-
ingly appropriate eye contact with their primary caretakers as
well as joyful expressions. However, during the first half of the
second year, the primary caretakers expressed concern about the
infants' emerging interactive and affective behaviors. These
infants seem more prone to oppositional behavior demonstrated by
temper tantrums, and less enjoyment of social interaction with the
adults in their environment.
DISCUSSION
The clinical characteristics of newborns exposed prenatally to PCP
are similar to behavior patterns of infants born addicted to hero-
in and/or methadone. In 1973, Wilson et al. described the early
development of infants of heroin-addicted mothers. The neuro-
behavioral symptoms of the newborn included tremors, irritability,
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and hypertonia. Following discharge from the hospital, these
infants continued to be agitated and restless. By the second half
of the first year, the infants slept for longer periods of time
and became less irritable. However, between 1 and 2 years of age,
the authors noted increased activity levels and impaired attention
span.
Clinical experience with the infants exposed primarily to PCP pre-
natally is remarkably close to Wilson et al. These neonates are
difficult to console, have alternating periods of lethargy and
irritability, and are unable to control the tremors of their
extremities when unswaddled. Vasomotor instability, diarrhea, and
voracious sucking movements are infrequently seen in the PCP-
exposed infants who were followed. Chasnoff et al. (1983) com-
pared these behaviors in infants exposed prenatally to PCP to
those of adults who have acute intoxication.
McCarron's paper (this volume) describes the behaviors of 1,000
adults admitted to an inpatient service with acute symptoms of PCP
intoxication. She states that some of the patients have appropri-
ate behavior while many have mute and staring episodes, bizarre
facial grimacing, localized dystonic reactions, rigidity, tremors,
coarse jerky movements, and nystagmus. Thus, there is similarity
between the acutely intoxicated adult's behavior and that of the
newborn with a positive urine toxic screen for PCP.
Following the initial period of observation, the infants frequent-
ly continued to be highly irritable and sensitive to tactile and
auditory stimuli during the first half of the year. They were
also unable to adjust to a sleep-wake cycle that contained extend-
ed periods of sleep during the night (Parmelee 1977). In addi-
tion, some infants continued to demonstrate sudden changes in
motor tone, ranging from hypotonia during sleep to rigidity that
would awaken them and cause intense crying. By 9 months of age,
most infants had become easier to manage because of increasing
sleep periods and lessening of irritability.
As the infants were emerging into a more predictable pattern of
behavior, the deviant fine motor movements became apparent.
Central nervous system maturation progresses in a cephalo-caudal
manner, allowing for differentiation of fine motor movements, as
those seen in the pincer grasp by 9 months (Gesell et al. 1954).
Fair evaluation of the fine motor system was not possible until
the last quarter of the first year.
The observations of fine motor problems in infants born to heroin
addicts has also been described by Wilson et al., in 1973. She
notes the discrepancy between the gross motor skills of the
infants and fine motor abilities during the first year. Further-
more, in 1979, Wilson et al, described the development of
preschool children between 3 and 6 years of age, born to heroin-
addicted mothers. They performed poorer on measures of visual,
tactile, and auditory perception, were more active, and had
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greater difficulties in the process of organization than the
children born to mothers who did not use drugs. The poor fine
motor abilities of these preschoolers were attributed to their
poor attention span and persistence rather than to a central
nervous system dysfunction. Unfortunately, these preschoolers'
fine motor movements were not described.
The most recent studies addressing the outcome of infants exposed
to drugs prenatally tend to stress the importance of the perinatal
problems and the poor environment. Lifschitz et al. (1985) stud-
ied the effects of prenatal exposure to heroin and methadone on
head growth and neurodevelopmental performance in preschool chil-
dren. They found that the factors associated with postnatal head
growth were birth weight, interpartum risk, and race. Further-
more, the increased incidence of low-average and mildly retarded
intellectual performance in the drug-exposed children was related
to the amount of prenatal care, prenatal risk, and the home
environment. The amount of narcotics used by the mother during
her pregnancy was not a significant factor. The narcotic index
used in their data analysis was solely based upon the mothers'
report of drugs taken during their pregnancies. Experience
indicates that these reports are not reliable and, in addition,
the quality of the street drugs is notoriously uneven.
Chasnoff et al. (1984) have reported on the developmental outcome
of three groups of children, from birth until 2 years of age. The
methadone, polydrug, and control groups demonstrated a downward
trend in scores in the Bayley Scales of Infant Development. Their
interpretation is that the infants' environment and subsequent
lack of stimulation has a more direct influence on long-term
development than does maternal use of drugs during pregnancy.
These findings are in contrast to the developmental outcome of the
PCP infants reported in this paper. In spite of the consistent,
nurturing environments, these infants have consistently demon-
strated borderline abilities in fine motor, adaptive, language and
personal-social development.
The effects of PCP, heroin, and methadone upon the developing
fetus may indeed be different. We have found that the PCP infants
are more deviant in their development than the reported develop-
ment of the heroin and methadone infants. Our concerns about
stating that drug use by the mothers during pregnancy does not
affect developmental outcome are great.
Information from well-controlled animal studies that focus on the
effects of prenatal exposure to single and polydrug use will be of
great value. Further evaluation of the fine motor movements that
appear to be clearly neurologically deviant in the PCP-exposed
infants is essential. The emerging socialization skills during
the second year of life also need more detailed evaluations.
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Future effort:; in this area of study must be collaborative.
Psychopharmacologists, biochemists, neurologists, psychiatrists,
pediatricians, psychologists, and other health care providers need
to share their observations about the effects of drugs upon the
various organ systems as well as upon the behavior of the species
studied. Clinically, we recognize that drug levels in most
instances cannot be detected in the urine for more than 3 days
after last use (Baumgartner et al., in press). Furthermore, with-
in this 3-day period, we cannot determine when or how much of the
drug(s) was taken. Thus, we have a difficult time defining the
groups we are to study. Attrition of subjects is another problem.
However, it has been our experience that an intensive service
program incorporated in the research design lessens this problem.
By combining the knowledge gained about drugs from animal studies,
quantifying the drugs in the system, carefully assessing the
neurobehavioral activities of the developing infant through video-
tape analysis, and stabilizing the infants' environments, we will
learn about the effects of the drugs upon the developing fetus.
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Clinical Observations in the
Treatment of Adolescent and
Young Adult PCP Abusers
David H. Fram and Nancy Stone
INTRODUCTION
Over the past 20 to 25 years, drug abuse has become a major public
health issue in this country. An "epidemic" of abuse commenced in
the sixties that had not been seen before (Wilford 1981). Drug
abuse has, however, always been pandemic. People have always
sought out psychoactive substances for their euphoriant proper-
ties. Individuals impaired by the excessive use of such sub-
stances have always been a concern. Our society has taken both
therapeutic and law enforcement approaches to dealing with the
problems of drug abuse. Our country's unsuccessful experiment
with Prohibition in the twenties and early thirties demonstrated
the difficulties of legislatively attempting to change culturally
accepted ways of handling psychoactive substances. More recently,
the disregard for laws regulating the use of marijuana and other
substances have demonstrated the continuing difficulty of legis-
lating contraculturally.
The concern over most substances of abuse arises from the effect
of the drug use on the individual's health or social functioning.
Negative attitudes toward the use of substances may be founded
upon a desire to limit the damage done to individuals, or to limit
the burden on society of supporting chronically intoxicated indi-
viduals, who have diminished ability to care for themselves.
Antisocial activities engaged in during illegal procurement of
drugs, or behavior resulting from impaired judgment while intoxi-
cated may present a hazard to persons other than the drug abuser.
The illegal distribution system for drugs provides, of course, a
significant danger to the community from both individual and or-
ganized illegal activities that such a system fosters. It is
generally accepted that the primary impetus for antisocial activi-
ty is the procurement of drugs, rather than the effect of drugs.
The problem of phencyclidine (PCP) abuse has an added dimension.
In addition to the antisocial activities involved in procurement,
PCP has effects on the user that may evoke dangerous, bizarre, or
252
deviant behavior. These effects may be considered undesirable by
the user, or may be sought after. Our understanding of this drug
needs to take into account not only the PCP user's desire for eu-
phoria, but also the user's acceptance of, often seeking of, the
behavioral effects.
The work of the Psychiatric Institute of Washington and the
Metropolitan Psychiatric Group provides considerable opportunity
for clinical observations of PCP users. Much of the author's
professional time and nearly all of mine is spent evaluating and
treating disturbed individuals with severe drug dependence prob-
lems, or supervising the work of our staff members, who collabo-
rate with us. Our programs and practices treat about 150
patients, of whom approximately 20 are PCP abusers. There are
about 500 admissions per year including approximately 75 who use
PCP. Psychiatric Institute of Washington is a private psychiatric
hospital in Washington, D.C., which has clinical services for both
adolescent and adult substance abusers. Metropolitan Psychiatric
Group is the group practice that conducts much of the treatment at
Psychiatric Institute. While the Psychiatric Institute has main-
tained drug treatment services for more than 10 years (Capodonno
et al. 1984), recently it became necessary to organize a special
admissions service to treat PCP users, because of the particular
difficulties in engaging these patients in treatment.
PCP has been a drug of abuse in Washington, D.C. for the entire 15
years that this author have been working with drug abusers. Until
the past few years, it tended to be used either unknowingly, as an
adulterant of other drugs, or as one of many drugs used by poly-
drug users. A few disturbed young people may have used it as the
drug of preference to enhance their disturbances. It was, ini-
tially, a drug primarily used by young, white, middle-class users.
Recently there has been a marked change in the patterns of its use
in the District of Columbia. PCP has become the drug of choice
for many users. Its use has become more widespread, and it is now
used in the black community, where it had not been seen much
before.
CLINICAL OBSERVATIONS--YOUNG ADULTS
When asked why they use PCP, young people frequently answer, "to
get high." Drug users want "to get high" for the easily obtain-
able pleasure that is, for the young, worth the adverse effects
and other costs. Young people also use drugs to be part of the
group. The term "peer pressure" is often used to describe this
phenomenon. I think that "peer example" or "following the crowd"
describes the phenomenon better. I have rarely heard of anyone
being forced or pressured to use drugs. Rather, being a member of
the drug culture is highly valued, and the use of drugs, including
PCP, comes as a result.
We need to understand better why being a member of the drug
culture became so highly valued. Until the sixties, drug abuse
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was mostly the domain of the "inner city" and the criminal sub-
culture. At that time, however, a major social change commenced,
in which the recreational use of illicit substances, especially
marijuana and cocaine, eventually became a part of the dominant
culture. In addition, we saw the development of the subculture of
heavy drug users, made up of individuals often exhibiting markedly
deviant behavior. Both of these developments had their roots in
the disaffection of the sixties, with its widespread rejection of
traditional "establishment" values by youth, often focused around
a rejection of our country's involvement in the Vietnam War.
I think that it is important to attempt to understand these socio-
cultural aspects of drug abuse. Perhaps we can then better under-
stand why a drug like PCP, after being around for a time, suddenly
becomes fashionable. Perhaps also, as we understand these phenom-
ena of social change better, we can develop more effective means
of primary prevention, and perhaps foster social change that might
discourage the use of such drugs.
Another important problem is why some drug users prefer PCP, while
others avoid it. The answers are probably found in biological and
psychological variations in individuals, and also in the constitu-
ents of different mixtures of PCP available on the street. I have
found it instructive to discuss this point with drug abusers who
avoid PCP. Some have never used it because of the horror stories
they have heard. I have worked with several dozen young drug
abusers who tried PCP and did not like it. Some reported experi-
encing paranoia, frightening hallucinations, or dysphoria, which
they did not want to repeat. Others described an intense loss of
control, far in excess of what they could tolerate. They felt
that they would be dominated by the use of PCP, if they continued
to use it.
Other drug abusers, however, who continued to use PCP, described
experiences that they intentionally sought. For many, the experi-
ence appears to be a relatively mild one, in which the user has a
pleasant intoxication that lasts several hours and then wears off.
Such users, although often aware of the bizarre or violence-
producing experiences of others, have never experienced such epi-
sodes themselves. Some report having used PCP repeatedly, for
many years, without experiencing any effects other than a simple
high. Clinical observation of these people, furthermore, does not
demonstrate deterioration of intellectual functioning or obvious
personality change. For these users, PCP offers an inexpensive,
pleasant high. It is often the discovery of their use of sub-
stances by someone else, such as an employer in the case of an
adult, or a parent in the case of an adolescent, that brings such
individuals into treatment.
Another group of users appears to seek the bizarreness and lack of
control that PCP offers. These individuals, who are likely to
manifest much psychopathology apart from the drug abuse, are often
threatening and violent. They perceive the actions of others as
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being threatening, and deny the significance of their own actions.
Two cases are instructive. Both were PCP users in late adoles-
cence who came for treatment after getting in trouble with the
law. One had wrecked his truck after hearing PCP-induced voices
commanding him to do so. He spoke of how much he loved to be vio-
lent and hurt others. He did have some inhibitions about expres-
sing violence, so found PCP the optimal drug for "putting him in
the mood" to be violent.
The second patient, a 19-year-old, was, upon entering my office,
immediately suspicious, irritable, irrational, and showed charac-
teristic decreased psychomotor activity and intense staring
expression. As the person who does most of the outpatient intake
evaluations for the adult drug program, I have become very wary of
new patients who enter with characteristics of PCP use. When the
patient casually mentioned, early in the interview, that he had
just been released from jail on a charge of assaulting a police
officer, I wondered to myself if he had a weapon in the umbrella
he was carrying--on a warm, sunny day. He became agitated and
threatening in the course of the interview, and eventually had to
be escorted from my office by the police. The following morning
he called, apologetic, but not comprehending why I and my staff
responded to him the way we had. He remembered everything, but
lacked an appreciation of the emotional impact of his actions.
Later the same day, intoxicated again, he called to scream threats
and profanity over the phone.
Both of these young men appeared to use PCP to enhance a desired
loss of control. PCP-induced loss of control also raises forensic
considerations. A few years ago, I received a call from a lawyer
defending a young man accused of assault during a robbery. At
issue was the question of possible diminished criminal responsi-
bility, as the defendant acknowledged using PCP before the alleged
incident. He had been noted to be more brutal in his treatment of
the victims of the assault than his nonintoxicated cohorts. The
lawyer was trying to build an insanity defense. I declined to
become involved in the case, as I believe that individuals should
be held responsible for actions committed while intoxicated. I
have been pleased to note the legal trend away from considering
the altered states of mind induced by drugs as grounds for dimin-
ished criminal responsibility for acts committed while in a drug-
induced condition.
Another important area for consideration is that of the addiction-
and dependence-producing potential of PCP. Our observations are
that PCP does not produce classical physical addiction in the
sense of the development of tolerance and withdrawal symptoms. It
does, however, produce drug craving, although to a lesser degree
than does heroin. Users apparently develop a compulsion to repeat
the PCP experience, but do not seem to organize their lives around
drug-seeking behavior as do heroin users.
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CLINICAL OBSERVATIONS--ADOLESCENTS
Some of the same factors that apply to all adolescents with chem-
ical abuse dependency problems contribute to the use of PCP. A
principal developmental task of adolescence is that of separating
from parents and consolidating one's identity as a separate per-
son, who will be able to cope with independence. Adolescents will
often engage in activities of which parents disapprove, to assert
their independence and protect themselves from a felt need to re-
turn to emotional dependency. Furthermore, adolescents rely on
peers, who may also be using street drugs, for information about
the world as well as for support for their self-esteem. The capa-
city for denial and for risk-taking, and the need for excitement,
all make experimentation with illicit drugs attractive to adoles-
cents. Adolescents have a remarkable capacity for denial. The
argument often goes that "drugs won't hurt me," "I know lots of
people that use drugs all the time and make good grades, play on
the football team," and so forth. Adolescent drug users will fre-
quently maintain that the real problem is that adults are trying
to scare them, that parents are gullible and believe everything
they hear about drugs. Thus, the early adolescent's egocentric
and immature sense of the world, the initial pleasurable effects
of drug use, and the possible biological vulnerability to chemical
dependence implement the use of street drugs as an attempt to
solve some of the problems of adolescence. Biological vulnerabil-
ity to chemical dependence, which may account for the progression
in some adolescents from experimentation to dependence, is an area
for further research.
A personality type that leads to a preference for PCP as the drug
of choice has not been identified. Experience has shown that dis-
turbed adolescents for whom PCP is a drug of choice have histories
indicating significant depression, feelings of hopelessness, pow-
erlessness, and dysphoria, prior to the use of PCP. The feelings
of power and invulnerability obtained from PCP use seem to be
sought by some, while others appear to seek the feeling of "numb-
ness" that this drug provides. Many adolescents with PCP psycho-
sis who have been admitted to Psychiatric Institute have charac-
teristics like those described in PCP users admitted to
psychiatric facilities elsewhere (DeAngelis and Goldstein 1978).
They exhibit minimal coping skills, including lack of employable
skills, limited academic skills, and minimal meaningful interper-
sonal relationships. Depression, and a sense of alienation and
hopelessness about themselves and the future are also observed.
This profile, however, does not distinguish PCP-using adolescents
from many other adolescents seen, who do not use PCP. As yet,
there is no satisfactory explanation for why some adolescents with
this profile abuse PCP and others do not.
TREATMENT CONSIDERATIONS
The literature regarding treatment of PCP users is not encouraging
(Graeven and Sharp 1981; Russ and Wang 1979). Our experience has
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been similar to others in that the percentage of patients who re-
main only for detoxification, then leave the hospital against med-
ical advice, is discouragingly high. This pattern is particularly
seen in patients over 17, who are legally adults and make their
own decisions about treatment.
Treatment of the Intoxicated Patient
An initial evaluation of the intoxicated patient is needed to de-
termine the level of care indicated. Some patients, although
frequent users, may have sufficient ego strength, behavioral con-
trol, and capacity to form a treatment alliance to commence treat-
ment in an outpatient setting. Their repeated PCP intoxications
may continue for a time, but the intoxication picture is
sufficiently benign to allow an outpatient program to be conducted
safely, and with a reasonable chance of success.
Other patients require hospitalization. Some present with a psy-
chotic picture: paranoia, irritability, agitation, and a tendency
to violent behavior. The diagnosis of this condition is often not
too difficult to make. Patients tend to readily acknowledge their
use of PCP. Moreover, the irritable, easily angered, suspiciously
staring, rigid person with impaired reasoning is not hard to spot.
Urine testing for drugs can be done to verify the diagnosis when
there is doubt.
Psychoses, when they occur, appear to be due to drug effect inter-
acting with a vulnerable personality organization (Luisada 1978).
Our experience has been that some adolescents with borderline
personality disorders, as well as adolescents at risk of schizo-
phrenic decompensation, may have this vulnerability. Although we
do not have hard data to support the hypothesis that patients with
PCP psychoses that are most resistant to treatment have the poor-
est long-term prognosis (Erard et al. 1980), our observations have
been that persistence of symptoms of psychosis after the first 2
to 3 weeks of treatment often correlates with extended periods of
impairment.
When hospital treatment is indicated, we have found that a closed,
highly structured, intensely staffed setting is required. Until
recently, when we started getting greater numbers of referrals of
PCP abusers, we treated those who came on our general drug-depend-
ence services. The PCP abusers were very difficult to manage,
resistant to treatment, and frequently left treatment early. We
established, on our locked intensive care unit, a separate admis-
sions service with therapy sessions and educational sessions
focused on PCP problems. Following this 2-week program of evalu-
ation and acute treatment, the patient is then sent to continuing
treatment, either in a residential/hospital setting for general
drug patients or to our outpatient PCP-specialized program.
Pharmacotherapy for PCP-intoxicated patients is delayed. For the
first 48 hours of admission we avoid all psychotropic medication,
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if possible, and try to manage the patient by placing him in a
quiet, secure environment with a few people to relate to. After 
this period, we encourage the patient to take haloperidol in order
to ameliorate the psychotic process as much as possible.
Although it has not been proven that acidification of the urine to
increase PCP excretion alters the duration of the symptoms of psy-
chosis, it appears appropriate to facilitate excretion of PCP from
the adipose tissue in which it is stored in any PCP user (Done
1980). Maintaining the urine pH at an acid level for several
weeks, even though the mental status is normal, is advised. It is
important to test the pH of the urine to ensure compliance with
the acidification. We have found that PCP becomes detectable in
acidified urine for a time, even after being undetectable in alka-
line urine, in previously intoxicated individuals. We have not
found a change in mental status to result from such acidification
treatment and resultant enhanced PCP excretion.
Finding ways to enhance the treatment alliance and decrease denial
are major tasks of the hospital phase of treatment. One method
used to engage the patient is to engage the family actively.
Staff spend a lot of their time talking with families, educating
them, increasing their understanding of what has happened to their
ill family members, and also helping the family to change habitual
ways of relating to the patient, patterns that have facilitated or
"enabled" rather than discouraged drug use. Often a change in
family interaction can make the difference in success or failure
of treatment. For example, families are often very tolerant of
deviation or irresponsible behavior. Members will continue to
support or cover for their family members, fearing that patients
will be hurt if held accountable for their actions. In fact, the
family members' tolerance has often reinforced the deviant
behavior. The family sessions help the family members understand
this and also provide support for behavioral change.
Narcotics Anonymous (NA)
Another important focus in developing a workable treatment plan
for these patients is promoting their involvement with Narcotics
Anonymous, or NA. The phenomenal growth of NA in the Washington,
D.C. area over the past 2 to 3 years may be the most hopeful thing
that has happened with regard to the drug problem in recent years.
Good hospital programs, good detoxification techniques, talented
therapists and counselors are weak forces, compared to the pres-
sures that reinforce drug use in the outside community. In our
experience, Alcoholics Anonymous has been useful in the past for
only a limited number of drug abusers, as many drug-dependent
individuals do not identify sufficiently with the dominant alco-
holic group, therefore do not remain involved in Alcoholics
Anonymous. Narcotics Anonymous is an organization of people who
have experienced the drug-use lifestyle, rejected that lifestyle,
and are developing another. NA provides a drug-free model for the
recovering person, a social milieu, and a value system that
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promotes continued abstinence. NA members state their beliefs
loudly and publicly, and provide needed support for each other,
especially at times of weakness. Membership in and identification
with NA provides, for many, the counterforce needed to withstand
the lure of the drug-abusing peer group. Consequently, a major
thrust in the PCP admissions service, as well as the other compo-
nents of the drug-dependence services, is to acquaint the patient
with NA and persuade him of the importance of membership and
participation.
Aftercare Treatment
The outpatient aftercare phase of the program is where the diffi-
cult long-term changes in the individual's relation to drugs take
place. Changes commenced in the protective inpatient environment
are tested in the outside environment. We recommend that our pa-
tients attend a group therapy program for recovering PCP abusers,
which meets twice weekly and includes regular monitored urine
testing and family involvement. We recommend this program be
attended for no less than 6 months. We further recommend daily
attendance at NA initially, and continued involvement with NA
indefinitely.
Even with the intense involvement of the inpatient program and a
carefully devised treatment plan, many drop out of outpatient
treatment and return to drug use. Nevertheless, we have found
various psychotherapeutic strategies and methods worthwhile.
An educational, behavior modification approach should be taken
with the patient. Education about chemical dependency is most
important. Expected behavioral changes must be clearly conceived
and communicated to the patient. Evaluation of vocational status
and skill development require attention.
The patient can be taught to recognize the impulsiveness and sense
of powerlessness that leads to the return of use of this drug.
The patient can be introduced to alternatives to a chemically-
induced sense of invulnerability, and encouraged to practice these
alternatives.
The treatment staff must be aware of countertransference issues,
and anticipate relapses and failures. For both patient and staff,
it helps to define and accept limited goals. Appropriate security
measures are necessary, so that staff can feel safe; also, staff
need to be educated about not taking unnecessary risks in handling
these patients. Staff frustration has to be recognized and
managed.
CONCLUSION
Treating the PCP abuser remains a dangerous and frustrating
business. To date, our therapeutic measures have less effect than
they do with abusers of other drugs. Part of the solution to the
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problem of PCP abuse may be an understanding of why drug abuse has
become acceptable in our society. It may then be possible to
devise appropriate primary prevention measures, so that the abuse
of other drugs will not develop as has that of PCP.
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